0001213900-24-059190.txt : 20240705 0001213900-24-059190.hdr.sgml : 20240705 20240703195927 ACCESSION NUMBER: 0001213900-24-059190 CONFORMED SUBMISSION TYPE: POS AM PUBLIC DOCUMENT COUNT: 81 FILED AS OF DATE: 20240705 DATE AS OF CHANGE: 20240703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NutriBand Inc. CENTRAL INDEX KEY: 0001676047 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 811118176 STATE OF INCORPORATION: NV FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: POS AM SEC ACT: 1933 Act SEC FILE NUMBER: 333-259833 FILM NUMBER: 241101382 BUSINESS ADDRESS: STREET 1: 121 S. ORANGE AVE. STREET 2: SUITE 1500 CITY: ORLANDO STATE: FL ZIP: 32801 BUSINESS PHONE: 407 377-6695 MAIL ADDRESS: STREET 1: 121 S. ORANGE AVE. STREET 2: SUITE 1500 CITY: ORLANDO STATE: FL ZIP: 32801 FORMER COMPANY: FORMER CONFORMED NAME: Nutriband Inc. DATE OF NAME CHANGE: 20160601 POS AM 1 ea0205970-posama4_nutri.htm POST-EFFECTIVE AMENDMENT NO. 4 TO FORM S-1

As filed with the Securities and Exchange Commission on July 3, 2024

Registration No. 333-259833

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

POST-EFFECTIVE AMENDMENT NO. 4

TO

FORM S-1

REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933

 

Nutriband Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   2834   81-1118176
(State or jurisdiction of
incorporation or organization)		   (Primary Standard Industrial
Classification Code Number)		   (I.R.S. Employer
Identification No.)

 

121 South Orange Ave., Suite 1500

Orlando, Florida 32801

(407) 377-6695

(Address and telephone number of principal executive offices)

 

Gareth Sheridan, Chief Executive Officer

Nutriband Inc.

121 South Orange Ave., Suite 1500

Orlando, Florida 32801

(407) 377-6695

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

Copies to:

 

Michael Paige

Michael Paige Law PLLC

3508 Lowell Street, NW

Washington, DC 20016

(202) 363-4791

Fax: (202)364-8795

 

APPROXIMATE DATE OF PROPOSED SALE TO PUBLIC:

As soon as practicable after this registration statement becomes effective.

 

If any securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non- accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☒

 

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a) may determine.

 

 

 

 

 

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

 

PRELIMINARY PROSPECTUS, SUBJECT TO COMPLETION, DATED July 3, 2024

 

Warrants to Purchase 959,005 Shares of Common Stock

 

Nutriband Inc.

 

Nasdaq trading symbol for the common stock: NTRB

 

This prospectus covers the issuance by Nutriband Inc. (the “Company”) of 959,005 shares of common stock, par value $0.001 per share (“common stock”)’ upon the exercise of warrants (the “Warrants”), issued in a public offering on October 1, 2021 of 1,232,000 units (each a “Unit”) of common stock and warrants that were offered in the IPO on The Nasdaq Capital Market, each Unit consisting of one share of common stock and one warrant (each a “Warrant”) at a price of $5.36 per Unit. The underwriters received 184,800 warrants. Each Warrant is immediately exercisable, entitles the holder to purchase one share of common stock at an exercise price of $6.43 and expires five (5) years from the date of issuance, As of July 2, 2024, 457,795 Warrants issued in the IPO have been exercised, with net proceeds to the Company of $2,942,970, and 959,005 Warrants are unexercised and outstanding. However, there is no assurance that the holders of our Warrants will elect to exercise any or all of such Warrants.

 

A prospectus supplement may also add, update, or change information included in this prospectus. You should rely only on the information contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. See “Where You Can Find More Information.”

 

Our common stock and Warrants are traded on the NASDAQ Capital Market under the symbols “NTRB” and “NTRBW,” respectively. On July 2, 2024, the last reported sale price of our common stock was $5.89 per share, and the last reported sale price for the Warrants was $1.04 per Warrant.

 

Investing in our common stock involves risks. See “Risk Factors” beginning on page 4.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this prospectus is       , 2024.

 

 

 

 

TABLE OF CONTENTS

 

    Page
Prospectus Summary   1
The Offering    
Selected Consolidated Financial Data   3
Risk Factors   4
Use of Proceeds   22
Capitalization   22
Market for Common Stock and Related Stockholder Matters    
Management’s Discussion and Analysis of Financial Condition and Results of Operations   23
Business   32
Management   42
Executive Compensation   47
Principal Stockholders   50
Certain Relationships and Related Party Transactions   51
Description of Securities   52
Shares Eligible for Future Sale   55
Underwriting    
Legal Matters    
Experts   55
Where You Can Find More Information   55
Index to Consolidated Financial Statements   F-1

 

You should rely only on the information contained in this prospectus and in any free writing prospectus prepared by or on behalf of us and delivered or made available to you. Neither we nor the underwriters have authorized anyone to provide you with additional or different information. We are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or a free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, operating results, and prospects may have changed since that date, and neither the delivery of this prospectus nor any sale made in connection with this prospectus shall, under any circumstances, create any implication that there has been no change in our affairs since the date of this prospectus or that the information contained by reference to this prospectus is correct as of any time after its date.

 

References to “we,” “us,” “our” and words of like import refer to us and our subsidiaries, including 4P Therapeutics LLC following our acquisition of 4P Therapeutics on August 1, 2018, and certain assets of Pocono Coated Products, LLC, on August 31, 2020, unless the context indicates otherwise. References to 4P Therapeutics or Pocono Coated Products, LLC refer to the business and operations of 4P Therapeutics or Pocono Coated Products, LLC, as the case may be, prior to acquisition by us unless the context indicates otherwise.

 

Industry and Market Data

 

The market data and certain other statistical information used throughout this prospectus are based on independent industry publications, government publications and other published independent sources. Some data is also based on our good faith estimates. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in the section entitled “Risk Factors.” These and other factors could cause results to differ materially from those expressed in these publications.

 

i

 

 

PROSPECTUS SUMMARY

 

This summary highlights information contained elsewhere in this prospectus. This summary does not contain all the information you should consider before investing in the securities. However, you should read the entire prospectus carefully, including the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and our financial statements, including the notes thereto, appearing elsewhere in this prospectus.

 

This summary highlights information contained elsewhere in this prospectus This summary does not contain all the information you should consider before investing in the securities. However, you should read the entire prospectus carefully, including the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and our financial statements, including the notes thereto, appearing elsewhere in this report.

 

Overview

 

Nutriband Inc. (the “Company”, “Nutriband”, “we” or “us”), was incorporated in Nevada in January 2016. Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our development pipeline consists of transdermal products that are based on our proprietary AVERSA™ abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs.

 

The Company’s revenues are based on providing services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics. Pocono Pharmaceuticals provides contract manufacturing services for health, wellness and over-the-counter pharmaceutical customers and 4P Therapeutics performs contract research and development related services for pharmaceutical and medical devices customers. We manage and evaluate our operations, and report our financial results, through these two separate subsidiaries.

 

Our principal offices are located in Orlando, Florida, and our subsidiary, Pocono Pharmaceuticals, has a manufacturing facility in Cherryville, North Carolina. We primarily operate and derive most of our revenues in the United States.

 

Selected Risks Associated with our Business and Operations

 

Our business is subject to significant risks, which are disclosed in more detail under “Risk Factors,” which begins on page 4, as a result of which an investment in our common stock is highly speculative and could result in the loss of your entire investment. Significant risks include, but are not limited to, the following:

 

  ● The FDA regulatory process may take longer and be more expensive than we anticipate without any assurance that we will obtain FDA approval.
     
  ● If we are not able to obtain FDA approval for our lead product, we may not have the resources to develop any other product, and we may not be able to continue in business.
     
  ● We may not be able to launch any products for which we receive FDA marketing approval.

  

1

 

  ● We may not be able to establish a distribution network for the marketing and sale of any products for which we receive FDA approval.

  

  ● We may not be able to establish manufacturing facilities in compliance with FDA good manufacturing practices or to enter into manufacturing agreements for the manufacture of our products in an FDA approved manufacturing facility.
     
  ● It will be necessary to us to enter into a joint venture or other strategic relationship in order to develop, perform clinical testing for, manufacture or market any of our proposed products. We may not be able to enter into such a relationship, and any relationship may not be successful, and the other party may have business interests and priorities that are different from ours.
     
  ● We may not be able to protect our rights in our intellectual property, and we may be subject to intellectual property litigation which would be expensive and disruptive of our operations even if we eventually prevail on the merits.
     
  ● Unanticipated side effects or other adverse events resulting from the use of our product could require a recall of our products and, even if no recall is required, our reputation could be impaired by side effects.
     
  ● We may fail to comply with all applicable laws and regulations relating to our product. We may have to change or adapt our operations in the event of changes in national, regional and local government regulations, taxation, controls and political and economic developments that affect our products and the market for our products;
     
  ● We may be unable to accurately estimate anticipated expenses, capital requirements and needs for additional financing;
     
  ● The terms of our recent financing, including the antidilution provisions of the warrants, may impair our ability to raise funds for our operations during the term of the warrants.

 

Our Organization

 

We are a Nevada corporation, incorporated on January 4, 2016. In January 2016, we acquired Nutriband Ltd, an Irish company which was formed by Gareth Sheridan, our chief executive officer, in 2012 to enter the health and wellness market by marketing transdermal patches. Our corporate headquarters are located at 121 S. Orange Ave. Suite 1500, Orlando, Florida 32765, telephone (407) 377-6695. Our website is www.nutriband.com. Information contained on or available through our website or any other website does not constitute a portion of this prospectus.

 

Recent Financings

 

On October 5, 2021, the Company consummated a public offering (the “IPO”) of units (the “Units”), of common stock and warrants that were offered in the IPO on The Nasdaq Capital Market, which included 1,231,200 (each a “Unit”), each Unit consisting of one share of common stock and one warrant (each a “Warrant”) at a price of $5.36 per Unit. Each Warrant is immediately exercisable, entitles the holder to purchase one share of common stock at an exercise price of $6.43 and expires five (5) years from the date of issuance. The underwriters’ over-allotment option was exercised for 184,800 warrants to purchase shares of common stock bringing the total net proceeds to the Company from the IPO to $5,836,230. The shares of common stock and Warrants were separately transferable immediately upon issuance. As of April 30, 2024, 457,795 warrants issued in the IPO have been exercised, with net proceeds to the Company of $ 2,942,970, and 959,005 warrants are unexercised and outstanding.

 

Recent Development

 

On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, each Unit consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock. The Warrants have an initial exercise price of $6.43, are exercisable by payment of the exercise price in cash only and expire April 19, 2029, five years from the date of issuance. The Offering was made solely to investors resident outside the United States and was not registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any jurisdiction, including any jurisdiction outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act.

 

2

 

SELECTED CONSOLIDATED FINANCIAL DATA

 

The following information as of January 31, 2024 and 2023, and for years then ended, has been derived from our audited consolidated financial statements which appear elsewhere in this prospectus. The following information as of and for the three months ended April 30, 2024 and 2023, has been derived from our unaudited consolidated financial statements which appear elsewhere in this prospectus.

 

Statement of Operations Information:

 

   Three Months Ended
April 30,		   Year Ended
January 31,		 
   2024   2023   2024   2023 
   (Unaudited)         
Revenue  $408,532    476,932   $2,085,314   $2,079,609 
Cost of revenue   243,746    254,648    1,223,209    1,329,200 
Selling, general and administrative expenses   1,079,728    839,732    3,773,606    3,916,041 
Net (loss)   (1,898,077)   (1,015,229)   (5,485,314)   (4,483,474)
Net (loss) per share of common stock (basic and diluted)  $(0.21)   (0.13)   (0.69)   (0.53)
Weighted average shares of common stock outstanding (basic and diluted)   9,159,869    7,833,150    7,954,105    8,459,547 

 

Balance Sheet Information:

 

   April 30,   January 31, 
   2024   2024   2023 
   (Unaudited)         
Current assets  $8,729,940   $1,021,863   $2,693,745 
Working capital surplus (deficiency)   7,313,082    22,770    1,945,132 
Accumulated deficit   (29,878,096)   (27,980,019)   (22,494,705)
Stockholders’ equity   13,363,113    6,438,235    8.572,990 

  

3

 

RISK FACTORS

 

An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below together with all of the other information included in this prospectus before making an investment decision with regard to our securities. The statements contained in this prospectus include forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. The risks set forth below are not the only risks facing us. Additional risks and uncertainties may exist that could also adversely affect our business, prospects or operations. If any of the following risks actually occurs, our business, financial condition or results of operations could be harmed. In that case, the trading price of our common stock could decline, and you may lose all or a significant part of your investment.

 

Risks Concerning our Business

 

Because we are an early-stage company with minimal revenue and a history of losses and we expect to continue to incur substantial losses for the foreseeable future, we cannot assure you that we can or will be able to operate profitably.

 

We are subject to the risks common to start-up, pre-revenue enterprises, including, among other factors, undercapitalization, cash shortages, limitations with respect to personnel, financial and other resources and lack of revenues. Drug development companies typically incur substantial losses during the product development and FDA testing phase of the business and do not generate revenues until after the drug has received FDA approval, which cannot be assured, and until the company has started to sell the product. We can give no assurance that we can or will ever be successful in achieving profitability and the likelihood of our success must be considered in light of our early stage of operations. We cannot assure you that we will be able to operate profitably or generate positive cash flow. If we cannot achieve profitability, we may be forced to cease operations and you may suffer a total loss of your investment. 

 

Because we do not have a product we can market in the United States, we cannot predict when or whether we will operate profitably.

 

Our lead product, which is our abuse deterrent fentanyl transdermal system, is currently in development and is not yet approved by the FDA in the United States or by any other regulatory agency in any other country. Because of the numerous risks and uncertainties associated with product development, we cannot assure you that we will be able to develop and market any products or achieve or attain profitability. If we are able to obtain financing for our operations, we expect that we will incur substantial expenses as we continue with our product development programs and clinical trials. Further, if we are required by applicable regulatory authorities, including the FDA as well as the comparable regulatory agencies in other countries in which we may seek to market product, to perform studies in addition to those we currently anticipate, our expenses will increase beyond expectations and the timing of any potential product approval may be delayed. As a result, we expect to continue to incur substantial losses and negative cash flow for the foreseeable future.

 

A number of factors, including, but not limited to the following, may affect our ability to develop our business and operate profitably:

 

  ● our ability to obtain necessary funding to develop our proposed products;

 

  ● the success of clinical trials for our products;

 

  ● our ability to obtain FDA approval for us to market any proposed product in our pipeline in the United States;

 

  ● any delays in regulatory review and approval of product in development;

 

  ● if we obtain FDA approval to market our product, our ability to establish manufacturing and distribution operations or entering into manufacturing and distribution agreements with qualified third parties;

 

  ● market acceptance of our products;

 

  ● our ability to establish an effective sales and marketing infrastructure;

 

  ● our ability to protect our intellectual property;

 

  ● competition from existing products or new products that may emerge;

 

  ● the ability to commercialize our products;

 

  ● potential product liability claims and adverse events;

 

  ● our ability to adequately support future growth; and

 

  ● our ability to attract and retain key personnel to manage our business effectively.

 

4

 

Our failure to develop our abuse deterrent fentanyl transdermal system will impair our ability to continue in business.

 

Our lead product is our abuse deterrent fentanyl transdermal system, and we are devoting our resources primarily to developing this product to enable us to obtain FDA approval and to market the product. If we are not able to obtain necessary financing to develop, obtain FDA marketing approval and market this product successfully, we may not have the resources to develop additional products, and we may not be able to continue in business. 

 

Before we can market in the United States any product which is classified by the FDA as a drug, we must obtain FDA marketing approval.

 

Our proposed transdermal products are drug-device combinations that are considered by the FDA to be drugs, which require approval by the FDA. In order to obtain FDA approval, it is necessary to conduct a series of preclinical and clinical tests to confirm that the product is safe and effective. Even though the medication that is being delivered through our transdermal patch may have already received FDA approval, because we are changing the dosage form or route of administration, we will need to complete, to the FDA’s satisfaction, all of the studies required to demonstrate safety and efficacy. At any point, the FDA could ask us to perform additional tests or to refine and redo a test that we had previously completed. The process of obtaining FDA approval could take many years, with no assurance that the FDA will approve the product. The FDA also will need to approve the manufacturing process and the manufacturing facility.

 

We may need to rely on a contract research organization to conduct our preclinical and clinical trials.

 

Although we believe that we, through 4P Therapeutics, have the capabilities to conduct certain preclinical studies and early-stage clinical studies in house, we may need to rely on third party contract research organizations to conduct our pivotal preclinical and clinical trials. Our failure or the failure of the contract research organization to conduct the trials in compliance with FDA regulations could possibly derail our obtaining FDA approval and could require us to redo any preclinical or clinical trials which we or the contract research organization administered.

 

We may encounter delays in completing clinical trials, which would increase our costs and delay market entry.

 

We may experience delays in completing the clinical trials necessary for FDA approval. These delays may result from a number of factors which could prevent us from starting the trial on time or completing the study in a timely manner, which may include factors out of our control. Since we may need to rely on third parties for supplying us with the drug and transdermal patches used in the trials, there may be various reasons for us to experience a delay in obtaining the clinical materials required to start each clinical trial, which may include factors out of our control. Clinical trials can be delayed or terminated for a number of reasons, including delay or failure to:

 

  ● obtain necessary financing;

 

  ● obtain regulatory approval to commence a trial;

 

  ● reach agreement on acceptable terms with prospective contract research organizations, investigators and clinical trial sites, the terms of which may be subject to extensive negotiation and vary significantly among different research organizations and trial sites;

 

  ● obtain institutional review board approval at each site;

 

  ● enlist suitable patients to participate in a trial;

 

  ● have patients complete a trial or return for post-treatment follow-up;

 

  ● ensure clinical sites observe trial protocol or continue to participate in a trial;

 

  ● address any patient safety concerns that arise during the course of a trial;

 

  ● address any conflicts with new or existing laws or regulations;

 

  ● add a sufficient number of clinical trial sites; or

 

  ● manufacture sufficient quantities of the product candidate for use in clinical trials.

 

5

  

Patient enrollment is also a significant factor in the timely completion of clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages of the drug being studied in relation to available alternatives, including any new drugs or treatments that may be approved for the indications we are investigating.

 

We may also encounter delays if a clinical trial is suspended or terminated by us, by the independent review boards of the institutions in which such trials are being conducted, by the trial’s data safety monitoring board, or by the FDA. Such authorities may suspend or terminate one or more of our clinical trials due to a number of factors, including our failure to conduct the clinical trial in accordance with relevant regulatory requirements or clinical protocols, inspection of the clinical trial operations or trial site by the FDA resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.

 

If we experience delays in carrying out or completing clinical trials for any product candidates, the commercial prospects of our product candidates may be harmed, and our ability to generate revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down the product development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business and financial condition. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.

 

Our ability to finance our operations and generate revenues depends on the clinical and commercial success of our abuse deterrent fentanyl transdermal system and our other related product candidates and failure to achieve such success will negatively impact our business.

 

Our prospects, including our ability to finance our operations and generate revenues, depend on the successful development, regulatory approval and commercialization of our abuse deterrent fentanyl transdermal system, which itself requires substantial financing, as well as our other product candidates. The clinical and commercial success of our product candidates depends on a number of factors, many of which are beyond our control, including:

 

  ● the FDA’s acceptance of our parameters for regulatory approval relating to our product candidates, including our proposed indications, primary endpoint assessments, primary endpoint measurements and regulatory pathways;

 

  ● the FDA’s acceptance of the number, design, size, conduct and implementation of our clinical trials, our trial protocols and the interpretation of data from preclinical studies or clinical trials;

 

  ● the FDA’s acceptance of the sufficiency of the data we collect from our preclinical studies and pivotal clinical trials to support the submission of a New Drug Application, known as an NDA, without requiring additional preclinical or clinical trials;

 

6

 

  ● the FDA’s acceptance of our abuse deterrent labelling relating to our products, including our abuse deterrent fentanyl transdermal system;

 

  ● when we submit our NDA upon completion of our clinical trials, the FDA’s willingness to schedule an advisory committee meeting, if applicable, in a timely manner to evaluate and decide on the approval of our NDA;

 

  ● the recommendation of the FDA’s advisory committee, if applicable, to approve our application without limiting the approved labelling, specifications, distribution, or use of the products, or imposing other restrictions;

 

  ● our ability to satisfy any issued raised by the FDA in response to our test data;

 

  ● the FDA’s satisfaction with the safety and efficacy of our product candidates;

 

  ● the prevalence and severity of adverse events associated with our product candidates;

 

  ● the timely and satisfactory performance by third party contractors of their obligations in relation to our clinical trials;

 

  ● if we receive FDA approval, our success in educating physicians and patients about the benefits, administration and use our product candidates;

 

  ● our ability to raise additional capital on acceptable terms in order to achieve conduct the necessary clinical trials;

 

  ● the availability, perceived advantages and relative cost of alternative and competing treatments;

 

  ● the effectiveness of our marketing, sales and distribution strategy and operations;

 

  ● our ability to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing practices;

  

  ● our ability to obtain, protect and enforce our intellectual property rights;

 

  ● our ability to bring an action timely for patent infringement arising out of the filing of ANDAs by generic companies seeking approval to market generic versions of our products, if applicable, before the expiry of our patents; and

 

  ● our ability to avoid third party claims of patent infringement or intellectual property violations.

 

If we fail to achieve these objectives or to overcome the challenges presented above, many of which are beyond our control, in a timely manner, we could experience significant delays or an inability to successfully commercialize our product candidates. Accordingly, even if we obtain FDA approval to market our products, we may not be able to generate sufficient revenues through the sale of our products to enable us to continue our business.

 

7

 

Since we do not have commercial manufacturing capability, if we are unable to establish manufacturing facilities, we may have to enter into a manufacturing agreement with a manufacturer that has been approved by the FDA.

 

Any commercial manufacturer of our products and the manufacturing facilities where we make our commercial products will be subject to FDA inspection. Part of the process of seeking FDA approval to market our products is the FDA’s approval of the manufacturing process and facility. Although we may establish our own manufacturing facilities, the establishment of a manufacturing facility is very costly, and, unless we obtain funding for that purpose, it would be necessary for us to engage a contract manufacturer who has experience is manufacturing FDA-approved transdermal products. By relying on a contract manufacturer, we will be dependent upon the manufacturer, whose interests may be different from ours. Any contract manufacturer will be responsible for product quality and for meeting regulatory requirements. If the manufacturer does not meet our quality standards and delivers products that do not meet our specifications, we may both incur liability for breach of our warranty to our customer, as well as liability for any adverse events, including death, that may result from the use, abuse or accidental misuse of the product. Regardless of whether we are able to make a claim against the contract manufacturer, our reputation may be harmed and we may lose business as a result. Further, the contract manufacturer may have other customers and may allocate its resources based on the contract manufacturer’s interest rather than our interest. Furthermore, we may not be able to assure ourselves that we will get favorable pricing.

 

If we or any third-party manufacturer fails to comply with FDA current good manufacturing practices, we may not be able to sell our products until and unless the manufacturer becomes compliant.

 

All FDA approved drugs, including our proposed transdermal products, must be manufactured in accordance with good manufacturing practices. All manufacturing facilities are inspected by the FDA as a matter of routine inspection or for a specific cause. If a manufacturer fails to comply with all applicable regulations, the FDA can prohibit us from distributing products manufactured in those facilities, whether they are a contract manufacturer or own facility. Failure to be in compliance with good manufacturing practices could result in the FDA closing the facilities or limiting our use of the facilities.

 

If the FDA implements Risk Evaluation and Mitigation Strategies policies for any of our proposed products, we will need to comply with such policies before we can obtain FDA approval or the product.

 

The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks. If one of our proposed product candidates does receive regulatory approval, the approval may be limited to specific conditions and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. The FDA may require a REMS, which can include a medication guide, patient package insert, a communication plan, elements to assure safe use and implementation system, and include a timetable for assessment of the REMS. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. In addition, the FDA may require post-approval testing which involves clinical trials designed to further assess a drug product’s safety and effectiveness after the NDA.

 

Depending on the extent of the REMS requirements, any U.S. launch may be delayed, the costs to commercialize may increase substantially and the potential commercial market could be restricted. Furthermore, risks that are not adequately addressed through the proposed REMS program may also prevent or delay its approval for commercialization.

 

Our products will continue to be subject to FDA review after FDA approval is given.

 

Discovery of previously unknown problems with our products or unanticipated problems with the manufacturing processes and facilities, even after FDA and other regulatory approvals of the product for commercial sale, may result in the imposition of significant restrictions, including withdrawal of the product from the market.

 

The FDA and other regulatory agencies continue to review products even after the products receive agency approval. If and when the FDA approves one of our products, its manufacture and marketing will be subject to ongoing regulation, which could include compliance with current good manufacturing practices, adverse event reporting requirements and general prohibitions against promoting products for unapproved or “off-label” uses. We are also subject to inspection and market surveillance by the FDA for compliance with these and other requirements. Any enforcement action resulting from the failure, even by inadvertence, to comply with these requirements could affect the manufacture and marketing of our products. In addition, the FDA or other regulatory agencies could withdraw a previously approved product from the market upon receipt of newly discovered information. The FDA or another regulatory agency could also require us to conduct additional, and potentially expensive, studies in areas outside our approved indicated uses. 

 

8

 

We must continually monitor the safety of our products once approved and marketed for potential adverse events which could jeopardize our ability to continue marketing the products.

 

As with all medical products, the use of our products could sometimes produce undesirable side effects or adverse reactions or events (referred to cumulatively as adverse events). For the most part, we expect these adverse events to be known and occur at some predicted frequency based on our experience in the clinical development program. When adverse events are reported to us, we are required to investigate each event and the circumstances surrounding it to determine whether it was caused by our product and whether a previously unrecognized safety issue exists. We will also be required to periodically report summaries of these events to the applicable regulatory authorities. If the adverse effects are significant, we may be required to recall our product. We cannot assure you that our transdermal products will not cause skin irritation or other adverse events. Our ability to market our products may be impaired by unanticipated adverse events and any recall of our product. Because we are an early-stage company, our reputation, and our ability to market products, could be affected more severely than a major pharmaceutical company.

 

In addition, the use of our products could be associated with serious and unexpected adverse events, or with less serious reactions at a greater than expected frequency. Such issues may arise when our products are used in critically ill or otherwise compromised patient populations. When unexpected events are reported to us, we are required to make a thorough investigation to determine causality and the implications for product safety. These events must also be specifically reported to the applicable regulatory authorities. If our evaluation concludes, or regulatory authorities perceive, that there is an unreasonable risk associated with the product, we would be obligated to withdraw the impacted lot(s) of that product or recall the product and discontinue marketing until all problems are satisfactorily resolved. Furthermore, an unexpected adverse event of a new product could be recognized only after extensive use of the product, which could expose us to product liability risks, enforcement action by regulatory authorities and damage to our reputation and public image.

 

A serious adverse finding concerning the risk of any of our products by any regulatory authority could adversely affect our reputation, business and financial results.

 

If we obtain FDA approval to market our products, we expect to spend considerable time and money complying with federal and state laws and regulations governing their sale, and, if we are unable to fully comply with such laws and regulations, we could face substantial penalties.

 

Health care providers, physicians and others will play a primary role in the recommendation and prescription of our proposed products. Further, if we use third-party sales and marketing providers, they may expose us to broadly applicable fraud and abuse and other health care laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products. Applicable federal and state health care laws and regulations are expected to include, but not be limited to, the following:

 

●The federal anti-kickback statute is a criminal statute that makes it a felony for individuals or entities knowingly and willfully to offer or pay, or to solicit or receive, direct or indirect remuneration, in order to induce the purchase, order, lease, or recommending of items or services, or the referral of patients for services, that are reimbursed under a federal health care program, including Medicare and Medicaid;

 

●The federal False Claims Act imposes liability on any person who knowingly submits, or causes another person or entity to submit, a false claim for payment of government funds. Penalties include three times the government’s damages plus civil penalties of $5,500 to $11,000 per false claim. In addition, the False Claims Act permits a person with knowledge of fraud, referred to as a qui tam plaintiff, to file a lawsuit on behalf of the government against the person or business that committed the fraud, and, if the action is successful, the qui tam plaintiff is rewarded with a percentage of the recovery;

 

●Health Insurance Portability and Accountability Act, known as HIPAA, imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;

 

●The Social Security Act contains numerous provisions allowing the imposition of a civil money penalty, a monetary assessment, exclusion from the Medicare and Medicaid programs, or some combination of these penalties; and

 

●Many states have analogous state laws and regulations, such as state anti-kickback and false claims laws. In some cases, these state laws impose more strict requirements than the federal laws. Some state laws also require pharmaceutical companies to comply with certain price reporting and other compliance requirements.

 

9

 

Our failure to comply with any of these federal and state health care laws and regulations, or health care laws in foreign jurisdictions, could have a material adverse effect on our business, financial condition, result of operations and cash flows.

 

Before we can market our products outside of the United States, we will need to obtain regulatory approval in each country in which we propose to sell our products.

 

In order to market and sell our products in jurisdictions other than the United States, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA and can involve additional testing.

 

In addition, in many countries worldwide, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Even if we were to receive approval in the United States, approval by the FDA for marketing in the United States does not ensure approval by regulatory authorities in other countries. Similarly, approval by one regulatory authority outside the United States would not ensure approval by regulatory authorities in other countries. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of our product candidates by regulatory authorities in foreign jurisdictions, the commercial prospects of those product candidates may be significantly diminished and our business prospects could be impaired.

 

Outside the United States, particularly in member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations or the successful completion of health technology assessment procedures with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Certain countries allow companies to fix their own prices for medicines but monitor the pricing.

 

In addition to regulations in the United States, if we market outside of the United States, we will be subject to a variety of regulations governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries.

 

If we do not have sufficient product liability insurance, we may be subject to claims that are in excess of our net worth.

 

Before we market any pharmaceutical product, we will need to purchase significant product liability insurance. However, in the event of major claims from the use of our products, it is possible that our product liability insurance will not be sufficient to cover claims against us. We cannot assure you that we will not face liability arising out of the use of our products which is significantly in excess of the limits of our product liability insurance. In such event, if we do not have the funds or access to the funds necessary to satisfy such liability, we may be unable to continue in business.

 

10

 

Because some of the patches we are developing, such as our abuse deterrent fentanyl patch, have potential severe side effects, we may face liability in the event patients suffer serious, possibly life-threatening, side effects from our products.

 

Fentanyl patches have known side effects and may cause serious or life-threatening breathing problems due to opioid-induced respiratory depression. In addition, taking certain medications with fentanyl may increase the risk of serious or life-threatening breathing problems, sedation or coma. Because of the seriousness of the side effects, fentanyl patches should only be used in accordance labelling approved by the FDA or by the applicable regulatory authorities outside of the United States. Fentanyl patches are only indicated for the treatment of people who are tolerant to opioid medications because they have taken this type of medication for at least one week and should not be used to treat mild or moderate pain, short-term pain, pain after an operation or medical or dental procedure, or pain that can be controlled by medication that is taken on an as-needed basis. Although we will include all warnings on the packaging that are required by the FDA or foreign regulatory authorities, claims may be made against us in the event that death or serious side effects result from the use of our abuse deterrent fentanyl transdermal system, even if prescribed for a patient for whom fentanyl patches should not be prescribed. We cannot assure you that we will not face significant liability as a result of such side effects and we may not have sufficient product liability insurance to cover any damages that may be assessed against us.

 

We may decide not to continue developing or commercializing any products at any time during development or after approval, which would reduce or eliminate our potential return on investment for those product candidates.

 

We may decide to discontinue the development of our abuse deterrent fentanyl transdermal system or any other product in our pipeline or not to continue to commercialize any potential product for a variety of reasons, such as the appearance of new technologies that make our product less commercially viable, an increase in competition, changes in or failure to comply with applicable regulatory requirements, changes in the regulatory or public policy environment, the discovery of unforeseen side effects during clinical development or after the approved product has been marketed or the occurrence of adverse events at a rate or severity level that is greater than experienced in prior clinical trials. If we discontinue a program in which we have invested significant resources, we will not receive any return on our investment.

 

If any of our potential products are approved for marketing but fail to achieve the broad degree of physician or market acceptance necessary for commercial success, our operating results and financial condition will be adversely affected.

 

If any of the products in our pipeline receives FDA approval thereby allowing us to market the product in the United States, it will be necessary for us to generate acceptance of our product for the indications covered by the FDA approval. In order to generate acceptance in the marketplace, we will need to demonstrate to physicians, patients and payors that our product provides a distinct advantage or better outcome at a price that reflects the value of our product as compared with existing products. We will need to develop and implement a marketing program directed at both physicians and the general public. Since we do not presently have the resources necessary to develop or implement an in-house marketing program and we may not have the funds to do so if and when we obtain FDA approval to market our product, we will need to establish a distribution network though license and distribution agreements with third parties who have the capability to market our product to physicians, and we will be dependent upon the ability of these third parties to market our products effectively. We cannot assure you that we will be able to negotiate license and distribution agreements with terms that are acceptable to us. Since we do not have an established track record and our product pipeline is relatively small, we may be at a disadvantage in negotiating the terms of license and distribution agreements. Further, we may have little control over the development and implementation of our licensee’s marketing program, and our licensees may have interests that are inconsistent with ours with respect to the allocation of resources and implementation of the marketing program. We cannot assure you that a marketing program for any of our products can or will be implemented effectively or that we will be successful in developing physician and emergency service acceptance of our products.

 

11

 

The drug delivery industry is subject to rapid technological change and, our failure to keep up with technological developments may impair our ability to market our products.

 

Our products use technology which we developed for the transdermal delivery of drugs. The field of drug delivery is subject to rapid technological changes. Our future success will depend upon our ability to keep abreast of the latest developments in the industry and to keep pace with advances in technology and changing customer requirements. If we cannot keep pace with such changes and advances, our proposed products could be rendered obsolete, which would result in our having to cease its operations.

 

If we obtain FDA approval, we will face significant competition from better known and better capitalized companies.

 

If we obtain FDA approval for any of our products, we expect to face significant competition from existing companies, which are better known and already have developed relationships with physicians within the healthcare system. Any product we may develop will compete with existing medications performing the same medicinal functions, which may include transdermal patches. We cannot assure you that we will be able to compete successfully. In addition, even if we are able to commercialize our product candidates, we may not be able to price them competitively with current standard of care products or their price may drop considerably due to factors outside our control. If this happens or the price of materials and manufacture increases dramatically, our ability to continue to operate our business would be materially harmed and we may be unable to commercialize any products successfully. In addition, other pharmaceutical companies may be engaged in developing, patenting, manufacturing and marketing products that compete with those that we are developing. These potential competitors may include large and experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities.

 

Healthcare reforms by governmental authorities, court decisions affecting health care policies and related reductions in pharmaceutical pricing, reimbursement and coverage by third-party payors may adversely affect our business.

 

We expect the healthcare industry to face increased limitations on reimbursement, rebates and other payments as a result of healthcare reform, which could adversely affect third-party coverage of our proposed products and how much or under what circumstances healthcare providers will prescribe or administer our products, if approved.

 

In both the U.S. and other countries, sales of our products, if approved for marketing, will depend in part upon the availability of reimbursement from third-party payors, which include governmental authorities, managed care organizations and other private health insurers. Third-party payors are increasingly challenging the price and examining the cost effectiveness of medical products and services.

 

12

 

Increasing expenditures for healthcare have been the subject of considerable public attention in the United States. Both private and government entities are seeking ways to reduce or contain healthcare costs. Numerous proposals that would effect changes in the United States healthcare system have been introduced or proposed in Congress and in some state legislatures, including reducing reimbursement for prescription products and reducing the levels at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products.

 

Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products, which in turn would affect the price we can receive for those products. Any reduction in reimbursement that results from federal legislation or regulation may also result in a similar reduction in payments from private payors, since private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates.

 

Significant developments that may adversely affect pricing in the United States include the enactment of federal healthcare reform laws and regulations, including the Affordable Care Act, or ACA, which is popularly known as Obamacare, and the Medicare Prescription Drug Improvement and Modernization Act of 2003.  A recent district court decision which struck down Obamacare, if upheld, could have a material adverse effect upon reimbursement and payment for products such as our proposed products. Changes to the healthcare system enacted as part of any healthcare reform in the United States, as well as the increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, may result in increased pricing pressure by influencing, for instance, the reimbursement policies of third-party payors. Regulatory changes which have the effect of decreasing the use of opioids has resulted in a decrease in the size of the market for opioid products, including fentanyl, could impact the market for our abuse deterrent fentanyl transdermal system or any other opioid-based transdermal product we may develop.

 

It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection.

 

Our commercial success will depend in part on obtaining and maintaining patent protection and trade secret protection for our technology which is incorporated in our products as well as successfully defending these patents against third-party challenges, should any be brought. 4P Therapeutics originally filed an international patent application under the Patent Cooperation Treaty for worldwide prosecution of the abuse deterrent transdermal technology intellectual property used in our lead product, the abuse deterrent fentanyl transdermal system.

 

The AVERSA abuse deterrent technology utilized in our AVERSA product pipeline is covered by an international intellectual property portfolio with patents issued in 45 countries including the United States, Europe, Japan, Korea, Russia, Mexico, Canada and Australia. Patent prosecution is still pending in China and Hong Kong. These patents provide patent coverage to 2035. We continue to build on our proprietary positions in the United States and internationally for our product candidates AVERSA Fentanyl, AVERSA buprenorphine and AVERSA methylphenidate as well as other products and technology that we may have in development. Our policy is to pursue, maintain and defend patent rights developed internally or acquired externally and to protect the technology, inventions and improvements that are commercially important to the development of our business. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology. We also rely on trade secrets to protect our commercial products and product candidates. Our commercial success also depends in part on our non-infringement of the patents or proprietary rights of third parties.

 

13

 

Our ability to stop third parties from making, using, selling, offering to sell or importing products utilizing our proprietary or patented technology is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. The patent positions of pharmaceutical and biopharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in biopharmaceutical patents has emerged to date in the United States. The biopharmaceutical patent situation outside the United States varies from country to country and is even more uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in any patents we may be granted. Further, if any patents are granted and are subsequently deemed invalid and unenforceable, it could impact our ability to license our technology and, as noted previously, fend off competitive challenges. Patent litigation is very expensive and we may not have sufficient funds to defend our proprietary technology from infringement, either as a plaintiff in an action seeking to stop infringers from using our technology, or as a defendant in an action against us alleging infringement by us.

 

The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:

 

●others may be able to make compositions or formulations that are similar to our product s but that are not covered by the claims of our patents;

 

●other persons may have filed patents covering inventions, technology or processes that we use, with the result that we may infringe upon the prior patents;

 

●others may independently develop similar or alternative technologies or duplicate any of our technologies;

 

●our pending patent applications may not result in the grant of patents;

 

●any patents which may be issued may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges by third parties;

 

●our inability to fund any litigation to defend our proprietary rights, either in defense of an action against us or a plaintiff to seek to prevent infringement.

 

●our failure to develop additional proprietary technologies that are patentable.

 

If we seek to expand our business through acquisition, we may not be successful in identifying acquisition targets or integrating their businesses with our existing business.

 

We have expanded our business by acquisition, and we may make acquisitions in the future. In 2017, we issued 1,458,333 shares of common stock, valued at $2,500,000, in connection with our proposed acquisition of Advanced Health Brands, Inc., but the stock of Advanced Health Brands was never transferred to us and the value of the intellectual property we were to have acquired did not have the value we anticipated, with the result that we incurred a $2,500,000 impairment loss in the year ended January 31, 2018. In September 2018, we entered into an agreement to acquire Carmel Biosciences Inc., and in November 2018, we terminated the agreement. We previously entered into another acquisition agreement which was rescinded shortly after the agreement was executed. We cannot assure you that any acquisition we complete will be successful or that any acquisition agreement we may enter into will result in an acquisition. An acquisition can be unsuccessful for a number of reasons, including the following:

 

●We may incur significant expenses and devote significant management time to the acquisition and we may be unable to consummate the acquisition on acceptable terms.

  

●The integration of any acquisition with our existing business may be difficult and, if we are not able to integrate the business successfully, we may not only be unable to operate the business profitably, but management may be unable to devote the necessary time to the development of our existing business;

 

●The key employees who operated the acquired business successfully prior to the acquisition may not be happy working for us and may resign, thus leaving the business without the necessary continuity of management.

 

14

 

●Even if the business is successful, our senior executive officers may need to devote significant time to the acquired business, which may distract them from their other management activities.

 

●If the business does not operate as we expect, we may incur an impairment charge based on the value of the assets acquired.

 

●The products or proposed products of the acquired company may have regulatory problems with the FDA or any other regulatory agency, including the need for additional and unanticipated testing or the need for a recall or a change in labeling.

 

●We may have difficulty maintaining the necessary quality control over the acquired business and its products and services.

 

●To the extent that an acquired company operates at a loss prior to our acquisition, we may not be able to develop profitable operations following the acquisition.

  

●The acquired company may have liabilities or obligations which were not disclosed to us, or the acquired assets, including any intellectual property, may not have the value we anticipated.

 

●The assets, including intellectual property, of the acquired company may not have the value that we anticipated.

 

●We may require significant capital both to acquire and to operate the business, and the capital requirements of the business may be greater than we anticipated. Our failure to obtain funds on reasonable terms may impair the value of the acquisition.

 

●The acquired company may not operate at the revenue level or with the gross margin shown in the financial statements or projections.

 

●Patents may not be granted for patent applications which the acquired company filed or patents may be successfully challenged.

 

●There may be conflicts in management styles that prevent us from integrating the acquired company with us.

 

●The business of the acquired company may have problems of which management was unaware and which do not become evident until after the acquisition and we may require significant funding to remedy the problem.

 

●The indemnification obligations of the seller under the purchase agreement, if any, may be inadequate to compensate us for any loss, damage or expense which we may sustain, including undisclosed claims or liabilities.

 

●To the extent that the acquired company is dependent upon its management to maintain relationships with existing customers, we may have difficulty in retaining the business of these customers if there is a change in management.

 

●Government agencies may seek damages after we make the acquisition for conduct which occurred prior to the acquisition and we may not have adequate recourse against the seller.

 

If any of the foregoing or any other events which we do not contemplate happen, we may incur significant expenses, which we may not be able to cover, and the development of our business can be impaired. We cannot assure you that any acquisition we will make will be successful.

 

We are dependent on third party distributors for the international marketing of our consumer products and complying with applicable laws.

 

We do not currently sell or market our consumer transdermal products domestically, or for our international sales, directly to international consumers, and we rely on distributors to sell and market these products. We cannot market our consumer transdermal patch products in the United States without first obtaining FDA approval. We do not plan to seek FDA approval or market these products in the United States at this time. We plan to sell our transdermal consumer products to distributors in those countries in which the products can be sold in compliance with all applicable regulations without our spending significant monies for preclinical and clinical studies to obtain regulatory approval.

 

15

 

We are dependent upon our chief executive officer, our president and our chief operating officer.

 

We are dependent upon Gareth Sheridan, our chief executive officer, Serguei Melnik, our president and Dr. Alan Smith, our chief operating officer who is president of 4P Therapeutics. Although Mr. Sheridan and Mr. Melnik have employment agreements with us, the employment agreements do not guarantee that the officer will continue with us. We do not have an employment agreement with Dr. Smith. The loss of Mr. Sheridan, Mr. Melnik or Dr. Smith would materially impair our ability to conduct our business.

 

If we are unable to attract, train and retain technical and financial personnel, our business may be materially and adversely affected.

 

Our future success depends, to a significant extent, on our ability to attract, train and retain key management, technical, regulatory and financial personnel. Recruiting and retaining capable personnel with experience in pharmaceutical product development is vital to our success. There is substantial competition for qualified personnel, and competition is likely to increase. We cannot assure you we will be able to attract or retain the personnel we require. Our financial condition is likely to impair our ability to attract qualified candidates. If we are unable to attract and retain qualified employees, our business may be materially and adversely affected.

 

Risks Concerning our Securities

 

Our lack of internal controls over financial reporting may affect the market for and price of our common stock.

 

Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to file a report by our management on our internal control over financial reporting. Our disclosure controls and our internal controls over financial reporting are not effective. We do not have the financial resources or personnel to develop or implement systems that would provide us with the necessary information on a timely basis so as to be able to implement financial controls The absence of internal controls over financial reporting may inhibit investors from purchasing our stock and may make it more difficult for us to raise capital or borrow money. Implementing any appropriate changes to our internal controls may require specific compliance training of our directors and employees, entail substantial costs in order to modify our existing accounting systems, take a significant period of time to complete and divert management’s attention from other business concerns. These changes may not, however, be effective in developing or maintaining internal control.

 

The market price for our common stock may be volatile and your investment in our common stock could suffer a decline in value.

 

The trading volume in our stock is low, which may result in volatility in our stock price. As a result, any reported prices may not reflect the price at which you would be able to sell shares of common stock if you want to sell any shares you own or buy if you wish to buy shares. Further, stocks with a low trading volume may be more subject to manipulation than a stock that has a significant public float and is actively traded. The price of our stock may fluctuate significantly in response to a number of factors, many of which are beyond our control. These factors include, but are not limited to, the following, in addition to the risks described above and general market and economic conditions:

 

●the market’s perception as to our ability to generate positive cash flow or earnings;

 

●changes in our or any securities analysts’ estimate of our financial performance;

 

●the perception of our ability to raise the necessary financing to complete the product development activities including preclinical and clinical testing required for FDA approval and our ability to generate revenue and cash flow from our products;

  

●the anticipated or actual results of our operations;

 

●changes in market valuations of other companies in our industry;

 

●litigation or changes in regulations and insurance company reimbursement policies affecting prescription drugs;

 

●concern that our internal controls are ineffective;

 

●any discrepancy between anticipated or projected results and actual results of our operations;

 

●actions by third parties to either sell or purchase stock in quantities which would have a significant effect on our stock price; and

 

●other factors not within our control.

 

16

 

Raising funds by issuing equity or convertible debt securities could dilute the net tangible book value of the common stock and impose restrictions on our working capital.

 

We anticipate that we will require funds for our business. If we were to raise capital by issuing equity securities, either alone or in connection with a non-equity financing, the net tangible book value of the then outstanding common stock could decline. If the additional equity securities were issued at a per share price less than the market price, which is customary in the private placement of equity securities, the holders of the outstanding shares would suffer dilution, which could be significant. Further, if we are able to raise funds from the sale of debt securities, the lenders may impose restrictions on our operations and may impair our working capital as we service any such debt obligations.

 

Stockholders may experience significant dilution as a result of future equity offerings and other issuances of our common stock or other securities.

 

We will need to raise substantial funds in order to develop our products. In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not which is less than the market price and which may be based on a discount from market at the time of issuance. Stockholders will incur dilution upon exercise of any outstanding stock options, warrants or upon the issuance of shares of common stock under our present and future stock incentive programs. In addition, the sale of shares and any future sales of a substantial number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or the availability of those shares of common stock for sale will have on the market price of our common stock. 

 

Our failure to meet the continued listing requirements of Nasdaq could result in a de-listing of our common stock.

 

If we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to de-list our securities. Such a de-listing would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our Common Stock when you wish to do so. In the event of a de-listing, we would take actions to restore our compliance with Nasdaq’s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq’s listing requirements.

 

We and our senior executive officers settled an SEC investigation, which may affect the market for and the market price of our common stock and our ability to list on a stock exchange.

 

Following an investigation into the accuracy of statements in our Form 10 registration statement filed June 2, 2016, as amended, and our Form 10-K annual report filed May 8, 2017 that did not accurately reflect the FDA’s jurisdiction over our consumer products and did not disclose that we could not legally market these products in the United States, a Wells notice which we, our chief executive officer and our chief financial officer received on August 10, 2017 and a Wells submission which we and the officers submitted in response to the Wells notice, the SEC, on December  26, 2018, announced that it has accepted our settlement offer and instituted settled an administrative cease-and-desist proceeding against us and our chief executive officer and chief financial officer. The SEC’s administrative order, dated December 26, 2018, finds that we and the officers consented – without admitting or denying any findings by the SEC — to cease-and-desist orders against them for violations by us of Sections 12(g) and 13(a) of the Securities Exchange Act of 1934 and Rules 12b-20 and 13a-1 thereunder, which require issuers to file accurate registration statements and annual reports with the Commission; violations by the officers for causing our violations of the above issuer reporting provisions; and violations by the officers of Rule 13a-14 of the Exchange Act, which requires each principal executive and principal financial officer of issuers to attest that annual reports filed with the SEC do not contain any untrue statements of material fact. In addition to consenting to the cease-and-desist orders, the officers have each agreed to pay a $25,000 civil penalty to resolve the investigation. The administrative order does not impose a civil penalty or any other monetary relief against us. The settlement may affect the market for and the market price of our common stock.

 

17

 

The market price for our common stock may be volatile and your investment in our common stock could suffer a decline in value.

 

The trading volume in our stock is low, which may result in volatility in our stock price. As a result, any reported prices may not reflect the price at which you would be able to sell shares of common stock if you want to sell any shares you own or buy if you wish to buy shares. Further, stocks with a low trading volume may be more subject to manipulation than a stock that has a significant public float and is actively traded. The price of our stock may fluctuate significantly in response to a number of factors, many of which are beyond our control. These factors include, but are not limited to, the following, in addition to the risks described above and general market and economic conditions:

 

●concern about the effects of our settlement with the SEC;

 

●the market’s reaction to our financial condition and its perception of our ability to raise necessary funding or enter into a joint venture, as well as its perception of the possible terms of any financing or joint venture;

 

●the market’s perception as to our ability to generate positive cash flow or earnings;

 

●changes in our or any securities analysts’ estimate of our financial performance;

 

●the perception of our ability to raise the necessary financing to complete the product development activities including preclinical and clinical testing required for FDA approval and our ability to generate revenue and cash flow from our products;

  

●the anticipated or actual results of our operations;

 

●changes in market valuations of other companies in our industry;

 

●litigation or changes in regulations and insurance company reimbursement policies affecting prescription drugs;

 

●concern that our internal controls are ineffective;

 

●any discrepancy between anticipated or projected results and actual results of our operations;

 

●actions by third parties to either sell or purchase stock in quantities which would have a significant effect on our stock price; and

 

●other factors not within our control.

 

Because of our executive officers’ stock ownership and stock ownership of certain other stockholders that have invested in the company, these stockholders have the power to elect all directors and to approve any action requiring stockholder approval.

 

Our officers and directors as a group beneficially own approximately 46% of our common stock as of July 2, 2024. As a result, they have the effective power using their contacts with a limited number of other shareholders to elect all of our directors and to approve any action requiring stockholder approval.

 

18

 

Raising funds by issuing equity or convertible debt securities could dilute the net tangible book value of the common stock and impose restrictions on our working capital.

 

We anticipate that we will require funds for our business. If we were to raise capital by issuing equity securities, either alone or in connection with a non-equity financing, the net tangible book value of the then outstanding common stock could decline. If the additional equity securities were issued at a per share price less than the market price, which is customary in the private placement of equity securities, the holders of the outstanding shares would suffer dilution, which could be significant. Further, if we are able to raise funds from the sale of debt securities, the lenders may impose restrictions on our operations and may impair our working capital as we service any such debt obligations.

 

We may issue preferred stock whose terms could adversely affect the voting power or value of our common stock.

 

Our articles of incorporation authorize us to issue, without the approval of our stockholders, one or more classes or series of preferred stock having such designations, preferences, limitations and relative rights, including preferences over our common stock respecting dividends and distributions, as our board of directors may determine. The terms of one or more classes or series of preferred stock could adversely impact the voting power or value of our common stock. For example, we might grant holders of preferred stock the right to elect a number of our directors in all events or on the happening of specified events or the right to veto specified transactions. Similarly, the repurchase or redemption rights or liquidation preferences we might assign to holders of preferred stock could affect the residual value of the common stock.

 

We do not intend to pay any cash dividends in the foreseeable future.

 

We have not paid any cash dividends on our common stock and do not intend to pay cash dividends on our common stock in the foreseeable future.

 

19

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus contains “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, all of which are subject to risks and uncertainties. Forward-looking statements can be identified by the use of words such as “expects,” “plans,” “will,” “forecasts,” “projects,” “intends,” “estimates,” and other words of similar meaning. One can identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address our growth strategy, financial results and product and development programs. One must carefully consider any such statement and should understand that many factors could cause actual results to differ from our forward-looking statements. These factors may include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.

 

These risks and uncertainties, many of which are beyond our control, include, and are not limited to:

 

  ● Our ability to raise the necessary financing for the development of our business and the terms of any financing which we are able to raise;

 

  ● Our ability to receive FDA marketing approval for any products we may develop;

 

  ● Our ability to obtain and enforce any United States and foreign patent we may seek;

 

  ● Our ability to design and execute clinical trials to the satisfaction of regulatory authorities;

 

  ● Our ability to engage, if and when necessary, an independent preclinical or clinical testing organization to design and implement our trials;

 

  ● Our ability to launch any products for which we receive FDA marketing approval;

 

  ● Our ability to generate sufficient revenue from our contract services to cover our operating expenses;

 

  ● Our ability to establish a distribution network for the marketing and sale of any products for which we receive FDA approval;

 

  ● Our ability to establish manufacturing facilities in compliance with FDA good manufacturing practices or to enter into manufacturing agreements for the manufacture of our products in an FDA approved manufacturing facility;

 

  ● Our ability to enter into joint venture or other strategic relationship with respect to any of our proposed products;

 

  ● The ability of the other party to any joint venture or strategic relationship to implement successfully any plans for the development, clinical testing, manufacturing and marketing of the products subject to the joint venture or strategic relationship;

 

  ● Our ability to evaluate potential acquisitions, and the consequences of our failure to accurately evaluate the acquisitions;

 

  ● Our ability to integrate any business we acquire with our business;

 

20

 

  ● Changes in national, regional and local government regulations, taxation, controls and political and economic developments that the market for our products;

 

  ● Our ability to develop and market products with the most current technology;

 

  ● Our ability to obtain and maintain any permits or licenses necessary for our business;

 

  ● Our ability to identify, hire and retain qualified executive, administrative, regulatory, research and development, and other personnel;

 

  ● Our ability to negotiate licenses on favorable terms with companies that have experience in marketing products such as ours;

 

  ● The costs associated with defending and resolving pending and potential legal claims, even if such claims are without merit;

 

  ● The effects of the SEC settlement;

 

  ● The effects of competition on our and our licensee’s ability to price, market and sell our product;

 

  ● Our ability to achieve favorable pricing for our products with third party reimbursement parties with respect to our products;

 

  ● Our ability to accurately estimate anticipated expenses, capital requirements and needs for additional financing;

 

  ● Our ability to accurately estimate the timing, cost or other aspects of the commercialization of our product candidates;

 

  ● Actions by third parties to either sell or purchase our common stock in quantities that would have a significant effect on our stock price;

 

  ● Risks generally associated with pre-revenue development stage companies in the pharmaceutical industry;

 

  ● Current and future economic and political conditions;

 

  ● The impact of changes in accounting rules on our financial statements;

 

  ● Other assumptions described in this prospectus; and

 

  ● Other matters that are not within our control.

 

Information regarding market and industry statistics contained in this prospectus is included based on information available to us that we believe is accurate. It is generally based on industry and other publications that are not produced for purposes of securities offerings or economic analysis. We have not reviewed or included data from all sources. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. We do not assume any obligation to update any forward-looking statement. As a result, you should not place undue reliance on these forward-looking statements.

 

The forward-looking statements in this prospectus speak only as of the date of this prospectus and you should not to place undue reliance on any forward-looking statements. Forward-looking statements are subject to certain events, risks, and uncertainties that may be outside of our control. When considering forward-looking statements, you should carefully review the risks, uncertainties and other cautionary statements in this prospectus as they identify certain important factors that could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. These factors include, among others, the risks described under in this prospectus, including those described under “Business,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as in other reports and documents we file with the SEC. We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements.

 

21

 

USE OF PROCEEDS

 

Any proceeds that we receive upon exercise of Warrants will be used for working capital. There is no assurance that the holders of our Warrants will elect to exercise any or all of such Warrants.

 

CAPITALIZATION

 

The following table sets forth our capitalization as of April 30, 2024.

 

   April 30,
2024		 
Common stock  $10,960 
Additional paid-in capital   43,263,194 
Accumulated other comprehensive loss   (304)
Treasury Stock   (32,641) 
Accumulated deficit   (29,878,096)
Stockholders’ equity   13,363,113 

 

You should read the foregoing table in connection with “Prospectus Summary — Selected Consolidated Financial Data,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and our consolidated financial statements and related notes.

 

Common Stock and Warrants Listing and Trading

 

Since our initial public offering on October 1, 2021, our common stock has traded on The NASDAQ Capital Market under the symbol “NTRB”, and our Warrants are traded on that exchange under the symbol “NTRBW”.

 

As of July 2, 2024, we had approximately 110 holders of record of our common stock.

 

The transfer agent for the common stock is Equiniti Trust Company, LLC, 6201 15th Ave, Brooklyn, NY, telephone (800) 937-5449.

 

22

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The following discussion and analysis of financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. See “Note Regarding Forward-Looking Statements.” Our actual results could differ materially from those anticipated in the forward-looking statements as a result of certain factors discussed in “Risk Factors” and elsewhere in this prospectus.

 

Overview

 

AVERSA™ Abuse Deterrent Transdermal Products

 

Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is AVERSA Fentanyl, our abuse deterrent fentanyl transdermal system which will require approval from the Food and Drug Administration (“FDA”) and substantial capital for research and development. AVERSA Fentanyl has the potential to provide clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy combined with properties designed to deter the abuse and misuse of fentanyl patches. In addition, we believe that our abuse deterrent technology can be broadly applied to various other transdermal products and our strategy is to follow the development of our abuse deterrent fentanyl transdermal system with the development of abuse deterrent transdermal products for pharmaceuticals that have a risk of abuse, misuse or accidental exposure.

 

On September 19, 2023, the United States Patent and Trademark Office (USPTO) granted US Patent No. 11,759,431 for Nutriband’s proprietary AVERSA abuse deterrent technology utilizing taste aversion to address the primary routes of abuse of opioid based transdermal patches. The issuance of this patent, entitled, “Abuse and Misuse Deterrent Transdermal Systems,” further expands Nutriband’s intellectual property protection in the United States for its portfolio of AVERSA abuse deterrent transdermal products.

 

Transdermal Pharmaceutical Products

 

Through October 31, 2018, our business was the development of a line of consumer and health products that are delivered through a transdermal or topical patch. Following our acquisition of 4P Therapeutics on August 1, 2018, our focus expanded to include prescription pharmaceuticals, and we are seeking to develop and seek FDA approval on a number of transdermal pharmaceutical products under development by 4P Therapeutics.

 

Most of our planned consumer products require FDA approval for sale in the United States, and we have not sought to obtain, and we do not plan to seek to obtain, FDA approval to market these products in the United States at this time. Following our acquisition of selected assets from Pocono Coated Products, LLC (“Pocono”), we are primarily focused on providing contract manufacturing services and consulting services to third party brands with no intention at this time to launch our own consumer products.

 

4P Therapeutics has not generated any revenue from any of its products under development. Rather, prior to our acquisition, 4P Therapeutics generated revenue to provide cash for its operations through contract research and development and related services for a small number of clients in the life sciences field on an as-needed basis. We are, for the near term, continuing this activity, although we do not anticipate that it will generate significant revenues and, since our acquisition, it has generated minor gross margins. We have no long-term contractual obligations, and either party can terminate at any time.

 

With the change in our focus, our capital requirements increased substantially. The process of developing pharmaceutical products and submitting them for FDA approval is both time consuming and expensive, with no assurance of obtaining approval from the FDA to market our product in the United States. We will require approximately $13 million for research and development of our abuse deterrent fentanyl transdermal system, including clinical manufacturing and clinical trials that need to be completed in order to obtain FDA approval. However, the total cost could be substantially in excess of that amount.

 

23

 

On August 31, 2020, the Company entered into a Purchase Agreement (“Agreement”), with Pocono Coated Products (“PCP”), pursuant to which PCP agreed to sell the Company all of the assets associated with its Transdermal, Topical, Cosmetic and Nutraceutical business (the “Assets”). PCP was the manufacturer of our transdermal consumer products, and we bought that business from them. The purchase price for the Assets was (i) $6,000,000 paid in shares of the Company’s common stock at a value of the average price of the previous 90 days at the date of Closing (the “Shares”); (ii) a promissory note of the Company in the principal amount of $1,500,000, which is due upon the earlier of (a) twelve (12) months from issuance, or (b) immediately following a capital raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. The note was repaid in full in October 2021. Subsequent to the repayment of the note, the Shares were released from escrow.

 

On November 1, 2021, The Board of Directors adopted the 2021 Employee Stock Option Plan (the “Plan”). The Company has reserved 408,333 shares to issue and sell upon the exercise of stock options issued under the Plan. On November 3, 2021, the Company filed a Registration Statement on Form S-8, to register under the Securities Act of 1933, as amended, the 408,333 shares of common stock reserved for issuance under the Plan, and on October 12, 2022, a Post-Effective Amendment to the Form S-8 was filed with the SEC.

 

Forward Split of our Common Stock.

 

On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7 for 6 forward stock split (the “Stock Split”) of our outstanding common stock. We filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7:6 forward split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share of common stock for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of authorized shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250,000,000 authorized shares to 291,666,666 authorized shares.

 

On December 15, 2023, the Company filed the Proxy Statement with the SEC for its Annual Meeting of Stockholders, held January 21, 2024, in Orlando, Florida. This Proxy Statement is available on our website at HTTPS://Nutriband.com/proxy.

 

On March 20, 2024, our Board of Directors adopted an amendment to the Company’s 2021 Employees Stock Option Plan (the “Plan”) increasing the number of shares of common stock subject to the plan (as of March 20, 2024 875,000 shares) to 1,400,00 shares (the “Amendment”). The plan adopted by the Board on November 1, 2021, provided for an initial 350,000 shares to issue and sell upon the exercise of stock options issued under the Plan. The Plan provides for an automatic annual increase to be added on February 1 of each year equal to the lesser of (i) 250,000 shares of Common Equity or (ii) five percent (5%) of the total shares of Common Stock outstanding on such date (including for this purpose any shares of Common Stock issuable upon conversion of any outstanding capital equity of the Company) or (iii) such lesser number as determined by the Board. We will submit the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting. If the Amendment is not approved by stockholders within one year of adoption by the increase in shares subject to the Plan will be void, together with any options issued following March 20, 2024 in the period pending approval of the Plan by our stockholders.

 

On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, each Unit consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock, the Warrants having an initial exercise price of $6.43, are exercisable by payment of the exercise price in cash only and expire April 19, 2029, five years from the date of issuance (“Warrants”). The Offering was made solely to investors resident outside the United States and was not registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any jurisdiction, including any jurisdiction outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act.

 

24

 

Results of Operations

 

Years Ended January 31, 2024 and 2023

 

For the year ended January 31, 2024, we generated revenue of $2,085,314 and our costs of revenue were $1,223,209. For the year ended January 31, 2023, we generated revenue of $2,079,609 and our costs of revenue were $1,329,200. Our revenue for the year ended January 31, 2024, included sales of $1,920,280 from contract manufacturing services performed in our Pocono Pharmaceuticals (Active Intelligence) segment and $165,034 from contract research and development services from our 4P Therapeutics segment. The revenue from the Transdermal Patches segment remained relatively constant from the prior year. An increase in demand is expected in the subsequent year.   Our cost of revenue for our contract research and development services represents our labor cost plus a modest amount of material costs which we passed on to the client. Our cost of sales during the year for our contract services in comparison to the prior year as our main contract has been completed and the balance of the contract is being recognized with limited additional costs.

  

For the year ended January 31, 2024, our selling, general and administrative expenses were $3,773,606, primarily legal, accounting, administrative salaries non-cash compensation from the issuance of warrants and employee stock options, compared to $3,916,041 for the year ended January 31, 2023. The decrease from 2023 is primarily due to a decrease in salaries and wages to executives of the Company.

 

During the years ended January 31, 2024 and 2023, the Company recorded an impairment expense of $-0- and $327,326, respectively, due to a write down of Goodwill in connection with its Pocono acquisition. The write down of goodwill for the year ended January 31, 2023, was attributable primarily to the effects of the pandemic. As of January 31, 2024, the valuation of the reporting unit exceeds the carrying amount of goodwill using the value in use or the going concern premise.

 

During the year ended January 31, 2024, the Company incurred research and development expenses for its Aversa Fentanyl product of $1,960,425, primarily due to labor and material costs incurred at our contract manufacturer, Kindeva Drug Delivery, as compared to $982,227 for the year ended January 31, 2023.

 

During the year ended January 31, 2024, the Company incurred a loss on extinguishment of debt of $554,423, consisting primarily of the loss on the conversion of $2,000,000 of credit line note into 1,026,750 shares of the Company’s common stock. There was no gain or loss on extinguishment of debt during the year ended January 31, 2023.

 

We incurred interest expense of $75,815 for the year ended January 31, 2024, as compared to $6,289 for the year ended January 31, 2023. The increase is primarily due to interest on the Company’s related party credit line note.

 

As a result of the foregoing, we sustained a net loss of $5,485,314, or $(0.69) per share (basic and diluted) for the year ended January 31, 2024, compared with a loss of $4,483,474, or $(0.53) per share (basic and diluted) for the year ended January 31, 2023.

 

25

Liquidity and Capital Resources January 31, 2024

 

As of January 31, 2024, we had $492,942 in cash and cash equivalents and working capital of $22,770, as compared with cash and cash equivalents of $1,985,440 and working capital of $1,945,132 as of January 31, 2023. During the year ended January 31, 2024, the Company on March 19, 2023, entered a three-year Credit Line Note facility for $2 million, to fund its research and development of its Aversa Fentayl product and an amendment thereto on July 13, 2023, increasing the amount under the credit line to $5 million. During 2024, the Company drew down a total of $2,000,000 under the credit line. In December 2023, the $2,000,000 was converted into shares of the Company’s common stock. On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, each Unit consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock.

 

For the year ended January 31, 2024, we used cash of $3,527,509 in our operations. The principal adjustments to our net loss of $5,485,314 were depreciation and amortization of $287,722, net loss on extinguishment of debt of $554,423 and stock-based compensation of $742,696.

 

For the year ended January 31, 2024, we used cash in investing activities of $51,761 primarily for the purchase of equipment.

 

For the year ended January 31, 2024, we provided cash in financing activities of $2,086,772, primarily from the proceeds of $2,000,000 from the proceeds of $2,000,000 from its line of credit and $106,528 from a factoring arrangement, offset from the payment on notes of $19,756. For the year ended January 31, 2023, we had cash flows of $160,074 from financing activities, primarily of $296,875 from the exercise of warrants, offset by a payment on notes and the repurchase of treasury stock.

 

Off Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Three Months Ended April 30, 2024 and 2023

 

For the three months ended April 30, 2024, we generated revenue of $408,532 and our costs of revenue were $243,746. For the three months ended April 30, 2023, we generated revenue of $478,942 and our costs of revenue were $254,648. Our revenue for April 30, 2024, was derived from sales from contract manufacturing services performed in our Pocono Pharmaceuticals (Active Intelligence) segment $-0- from contract research and development services from our 4P Therapeutics segment. The revenue from the Transdermal Patches segment remained relatively constant from the prior year. An increase in demand is expected in the balance of the current year. The Company’s contract with Sorrento Therapeutics was completed and 4P Therapeutics devoted most of its time to the development of its Aversa product, our cost of revenue for our contract research and development services represents our labor cost plus a modest amount of material costs which we passed on to the client.

 

For the three months ended April 30, 2024, our selling, general and administrative expenses were $1,078,728 primarily legal, accounting and administrative salaries and non-cash compensation from the issuance of employee stock options compared to $422,955 for the three months ended April 30, 2024.The increase from 2023 is primarily attributable to increases in non-cash equity-based expenses.

 

During the three months ended April 30, 2024, the Company incurred research and development expenses of its Aversa Fentanyl product of $974,535, primarily of salaries and increases in development costs from Kindeva as compared to $400,430 for the three months ended April 30, 2023.

 

We incurred interest expense of $8,618 for the three months ended April 30, 2024, as compared to $3,166 for the three months ended April 30, 2023. The increase is primarily due to interest in the Company’s related party loans.

 

As a result of the foregoing, we sustained a net loss of $1,898,077 or $(0.21) per share (basic and diluted) for the three months ended April 30, 2024, compared with a loss of $1,015,235, or $(0.13) per share (basic and diluted) for the three months ended April 30, 2023.

 

Liquidity and Capital Resources April 30, 2024

 

As of April 30, 2024, we had $8,347,740 in cash and cash equivalents and working capital of $7,313,072, as compared with cash and cash equivalents of $492,942 and working capital of $22,870 as of January 31, 2024.

 

For the three months ended April 30, 2024, we used cash of $833,926 in our operations. The principal adjustments to our net loss of $1,898,077 were depreciation and amortization of $69,101, and the issuance of employee stock options for services in the amount of $422,955.

 

For the three months ended April 30, 2024, we used cash in investing activities of $6,195 primarily for the purchase of equipment.

 

For the three months ended April 30, 2024, we provided cash in financing activities of $8,694,919. During the three months ended April 30, 2024, the Company entered into an equity financing agreement with European investors and received proceeds of $8,400,00, of which $7.12 million is from related parties, to fund its research and development of its Aversa Fentanyl product. The Company also received proceeds of $300,000 from its Credit Line Promissory Note.

 

Off Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

26

 

Critical Accounting Policies

 

Going Concern Assessment

 

Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look-forward period.

 

As of April 30, 2024, the Company had cash and cash equivalents of $8,347,740 and working capital of $7,313,082. For the three months ended April 30, 2024, the Company incurred a net loss from operations of $1,898,077 and used cash flow from operations of $833,926. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third-party and related-party debt to support cash flow from operations. The Company has used these proceeds from the sales of securities and issuance of third-party and related party debt to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 13, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. On April 19, 2024, the Company received proceeds of $8,400,000 from equity financing with European investors, of which $7.12 million is from related parties.

 

Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern.

 

Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.

 

Principles of Consolidation

 

The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020 under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows:

 

Nutriband Ltd.

4P Therapeutics LLC

Pocono Pharmaceuticals Inc.

 

27

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

 

Revenue Recognition

 

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

  

Revenue Types

 

The following is a description of the Company’s revenue types, which include professional services and sale of goods:

 

  ● Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods.

 

  ● Product revenues derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods.

 

  ● Contract research and development services for pharmaceutical and medical devices for life sciences customers with revenues listed under services.

 

Contracts with Customers

 

A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

 

Contract Liabilities

 

Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

 

Performance Obligations

 

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.

 

All revenue recognized in the income statement is considered to be revenue from contracts with customers.

 

28

 

Cash and cash equivalents.

 

Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short-term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of April 30, 2024, the Company had $7,879,000 that exceeded federally insured limits.

 

Accounts receivable

 

Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make required payments. The Company determines its allowances by both specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the three months ended April 30, 2024, and 2023, the Company recorded bad debt expenses of $1,200 and $-0-, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $106,528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of April 30, 2024, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10%. The Company adopted ASU 2016-13 during 2013, and implemented the guidance on expected credit losses.

 

Inventories

 

Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of April 30, 2024, total inventory was $168,505, consisting of work-in-process of $27,447, finished goods of $26,751 and raw materials of $114,307. As of January 31, 2024, total inventory was $168,605, consisting of work-in-process of $7,466, finished goods of $8,707 and raw materials of $134,691.

 

Property, Plant and Equipment

 

Property and equipment represent an important component of the Company’s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:

 

Lab Equipment   5-10 years
Furniture and fixtures   3 years
Machinery and equipment   10-20 years

 

29

 

Intangible Assets

 

Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisitions have also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.

 

Goodwill

 

Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. During the years ended January 31, 2024, and 2023, the Company recorded an impairment charge of $-0- and $327,326, respectively, reducing the Active Intelligence LLC Goodwill to $3,302,478. As of April 30, 2024, and January 31, 2024, Goodwill amounted to $5,021,713 and $5,021,713, respectively.

 

Long-lived Assets

 

Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value.

 

Earnings per Share

 

Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of April 30, 2024, and 2023, there were 6,747,873 and 1,783,373 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.

 

Stock-Based Compensation

 

ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.

 

30

 

Business Combinations

 

The Company recognizes the assets acquired, the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value.

 

Leases

 

In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.

 

The Company applies the guidance for right-of-use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.

 

Research and Development Expenses

 

Research and development costs are expensed as incurred.

 

Income Taxes

 

Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland.

 

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

 

The Company records net deferred tax assets to the extent they believe these assets will more-likely-than-not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.

 

31

 

Business

 

Nutriband Inc. (the “Company”, “Nutriband”, “we” or “us”), was incorporated in Nevada in January 2016. Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our development pipeline consists of transdermal products that are based on our proprietary AVERSA™ abuse deterrent transdermal technology that we believe can be incorporated into existing transdermal patches that contain drugs that are susceptible to abuse and misuse such as opioid and stimulant drugs.

 

The Company’s revenues are based on providing services through our subsidiaries Pocono Pharmaceuticals operating as Active Intelligence and 4P Therapeutics. Pocono Pharmaceuticals provides contract manufacturing services for health, wellness and over-the-counter pharmaceutical customers and 4P Therapeutics performs contract research and development related services for pharmaceutical and medical devices customers. We manage and evaluate our operations, and report our financial results, through these two separate subsidiaries.

 

Our principal offices are located in Orlando, Florida, and our subsidiary, Pocono Pharmaceuticals, has a manufacturing facility in Cherryville, North Carolina. We primarily operate and derive most of our revenues in the United States.

 

Recent Development

 

On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, each Unit consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock, the Warrants having an initial exercise price of $6.43, are exercisable by payment of the exercise price in cash only and expire April 19, 2029, five years from the date of issuance (“Warrants”). The Offering was made solely to investors resident outside the United States and was not registered under the Securities Act, or the securities laws of any jurisdiction, including any jurisdiction outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act.

 

Our Business

 

AVERSA Abuse Deterrent Transdermal Products

 

Our lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with our AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. We believe that our AVERSA technology can be broadly applied to various transdermal products, and our plan is to follow the development of AVERSA Fentanyl with the development of additional abuse deterrent transdermal products for pharmaceuticals that have a risk or history of abuse, misuse or accidental exposure. Specifically, we have expanded our development pipeline to include AVERSA Buprenorphine and AVERSA Methylphenidate. In addition, we are developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery.

 

In January 2024, we signed a commercial development and clinical supply agreement with Kindeva Drug Delivery, formerly 3M Drug Delivery (“Kindeva”), for the development of AVERSA Fentanyl using Kindeva’s FDA-approved fentanyl patch. This agreement replaced the previous feasibility agreement between the two companies which was focused on establishing the feasibility of incorporating our AVERSA abuse deterrent transdermal technology into Kindeva’s commercial transdermal manufacturing process. The commercial development and clinical supply agreement is focused on developing the commercial manufacturing process for AVERSA Fentanyl.

 

The product development program for AVERSA Fentanyl includes performing preclinical and clinical studies to demonstrate the abuse deterrent properties of the product. The development program is based on the fact that the fentanyl transdermal system is already approved and the only change to the approved product will be to incorporate the AVERSA technology into the patch design with no change being made to the fentanyl drug matrix or its demonstrated safety, patch performance or drug release characteristics. Preclinical studies to be performed consist of laboratory-based in vitro manipulation and chemical extraction studies per FDA guidance. Clinical evaluation consists of a Phase 1 human abuse potential study to demonstrate the abuse potential of the product per FDA guidance. The regulatory path to FDA approval is planned to be a 505(b)(2) NDA submission to access the safety and efficacy information on file for the Duragesic® fentanyl transdermal system as the reference-listed drug and to be able to obtain approval for abuse deterrent claims as a branded pharmaceutical product.

 

The product development program for the additional AVERSA pipeline products, AVERSA Buprenorphine and AVERSA Methylphenidate, are similar to that of AVERSA Fentanyl, assuming that the AVERSA technology is incorporated into an already approved transdermal patch.

 

32

 

Acquisition of 4P Therapeutics

 

Pursuant to an acquisition agreement dated April 5, 2018 between us and 4P Therapeutics, on August 1, 2018, we acquired all of the equity interest in 4P Therapeutics from Steven Damon, the owner of 4P Therapeutics. The purchase price of $2,250,000, consisting of 62,500 shares of common stock, valued at $1,850,000, and cash of $400,000, and are to pay Mr. Damon a 6% royalty on any revenue we receive or derive from our utilization or sale of the abuse deterrent intellectual property that we acquired as a part of the assets 4P Therapeutics, including partner license milestones and development payments. The royalty is payable pursuant to the acquisition agreement and continues as long as we generate revenue from our utilization or sale of the abuse deterrent intellectual property we acquired as part of the acquisition of 4P Therapeutics. The 62,500 shares were issued to Mr. Damon (41,750 shares pre-split) and Dr. Alan Smith (20,750 shares pre-split). In connection with the acquisition, Mr. Damon retained any cash and accounts receivable and assumed any liabilities other than those relating to the ongoing business. Pursuant to the acquisition agreement, we appointed Mr. Damon to our board of directors in April 2018, when we signed the acquisition agreement. Mr. Damon resigned as a director in January 2022.

 

As a result of the acquisition, the focus of our business changed from the development and marketing outside of the U.S. of consumer transdermal products to the development of 4P Therapeutics’ portfolio of pharmaceutical transdermal products. Our lead product under development is AVERSA® Fentanyl (abuse deterrent fentanyl transdermal system) which we plan to develop to deter the abuse and accidental misuse of fentanyl transdermal patches. Fentanyl is a potent synthetic opioid that is marketed as a transdermal patch for chronic pain management. There are currently several generic fentanyl patches on the market but none of them have abuse deterrent properties. We believe that AVERSA Fentanyl, once approved by the US FDA will significantly deter the abuse and accidental misuse of fentanyl transdermal patches.

 

With the acquisition of 4P Therapeutics, we acquired a research pipeline of other transdermal products, including novel transdermal products that involve delivery of peptides and proteins through the skin. These drugs are off patent but are currently only available as injections, and we are evaluating the possibility of developing a transdermal delivery system for these drugs as an alternative to injection but with improved compliance and safety. In addition, we may develop certain generic passive transdermal products where we think we can make an improvement to existing patches and where we believe we can take significant market share with good profit margins. The prioritization of our portfolio product candidates will be reviewed on an ongoing basis and will take into account technical progress, market potential and R&D funding available. We cannot assure you that we will be able to develop and obtain FDA approval for any of these potential products or that we can be successful in marketing any such products. The FDA approval process can take many years to complete successfully, and we will require substantial funding for each product that goes through the process. We cannot assure you that we will obtain FDA marketing approval for any of our products.

 

In addition to performing research and development for its own products, 4P Therapeutics performs contract research and development services for a small number of clients in the life sciences field to help support its ongoing operations. The work includes conducting early-stage drug and device clinical and preclinical studies and providing clinical-regulatory and formulation/analytical consulting services. Neither we nor current clients have any long-term commitments, and either party can terminate at any time. We do not expect to generate significant revenues from these services.

 

Acquisition of Pocono Coated Products

 

On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc.(“Pocono”), a wholly owned subsidiary of the Company. Effective August 31, 2020, the Company entered into a Purchase Agreement (“Agreement”) with Pocono Coated Products (“PCP”), a manufacturer of topical and transdermal products, pursuant to which PCP agreed to sell the Company certain of the assets and liabilities associated with its Transdermal, Topical, Cosmetic and Nutraceutical business (the “Business”), including all related equipment, intellectual property and trade secrets, cash balances, receivables, bank accounts and inventory. The net assets were contributed to Pocono. Included in the transaction, the Company acquired 100% of the membership interests of Active Intelligence LLC (“Active Intelligence”). The purchase price for the assets of the Business is (i) $6,000,000 paid in 608,519 shares of the Company’s common stock, based on the average price for the Company’s common stock for the previous 90 days as of the date of Closing; (ii) a promissory note of the Company in the principal amount of $1,500,000, which has been paid in full as of October 1, 2021.

 

Our Organization

 

We are a Nevada corporation, incorporated on January 4, 2016. In January 2016, we acquired Nutriband Ltd, an Irish company which was formed by Gareth Sheridan, our chief executive officer, in 2012, to enter the health and wellness market by marketing transdermal patches. Our corporate headquarters are located at 121 S. Orange Ave. Suite 1500, Orlando, Florida 32801, telephone (407) 377-6695. Our website is www.nutriband.com. Information contained on or available through our website or any other website does not constitute a portion of this annual report.

 

33

 

Pharmaceutical Products in Development

 

We have a pipeline of transdermal pharmaceutical products that are primarily in the early stages of development. Our current focus is on developing our AVERSA abuse deterrent transdermal patch products. Our lead product is AVERSA Fentanyl for which we have a commercial development agreement with Kindeva Drug Delivery, a contract development and manufacturing organization. We plan to follow on from this with the development of additional products utilizing the AVERSA abuse deterrent transdermal technology, namely, AVERSA Buprenorphine and AVERSA Methylphenidate.

 

Transdermal patches containing opioid and stimulant drugs are designed to provide an alternative route of administration for treatment of conditions such as chronic pain, opioid use disorder or attention deficit/hyperactivity disorder. Although transdermal versions offer improved pharmacokinetic delivery as well as patient convenience with wear times of up to 7 days, they contain an increased drug payload which can often be a target for recreational drug abusers or subject to accidental pediatric exposure, particularly with infants and toddlers. Abuse of opioids in general, and in particular fentanyl abuse and overdose, continues to be an epidemic which can lead to the abuse of prescription transdermal fentanyl and other opioid containing transdermal products.

 

AVERSA Fentanyl is an abuse deterrent fentanyl patch for the treatment of chronic pain. As the United States faces an epidemic of opioid abuse, fentanyl transdermal patches have become an attractive target for recreational drug abusers due to the high potency of fentanyl, the high drug content contained in patches designed for delivery over three days, and its ease of abuse by the oral route. We are looking to utilize our proprietary approach to incorporate aversive agents into the transdermal patch to deter the abuse of fentanyl patches by the oral, buccal and inhaled routes, which represent as much as 70% of all transdermal fentanyl abuse. The technology is based on the incorporation of taste and sensory aversive agents into the patch that are intended to make abuse a very unpleasant experience thereby deterring the recreational abuse of fentanyl patches. These aversive agents have high potency, established safety, and the potential to prevent accidental misuse by children and pets. The aversive agents are coated onto the backing of the transdermal patch in a controlled release formulation that provides immediate and sustained release of aversive agents. This provides several advantages including having a physical separation of the aversive agents from the drug matrix, availability of aversive agents even after the patch is used and making it difficult to separate the aversive agents from the drug by extraction. The aversive agents are not contained in the drug matrix and are not delivered to the skin during patch wear. In addition to the fentanyl patch, this technology has broad applicability to any patch where deterring abuse as well as accidental misuse by children and pets are valuable attributes.

 

According to the FDA1, accidental exposure to medication is a leading cause of poisoning in children. Young children, in particular, have died or become seriously ill after being exposed to a skin patch containing fentanyl, a powerful opioid pain reliever. Children can overdose on new and used fentanyl patches by putting them in their mouth or sticking the patches on their skin. This can cause death by slowing the child’s breathing and decreasing the levels of oxygen in their blood.

 

We believe that our abuse deterrent technology can be broadly applied to various transdermal products and our strategy is to follow the development of our AVERSA Fentanyl with the development of additional products for pharmaceuticals that have a risk or history of abuse, misuse or accidental exposure. For example, we believe that our technology can be utilized in other transdermal products to deter the abuse of other drugs such as buprenorphine, an opioid, and methylphenidate, a central nervous system stimulant. Buprenorphine is an opioid used to treat opioid addiction, acute pain and chronic pain. It can be used under the tongue, by injection, as a skin patch, or as an implant. For opioid addiction, it is typically only started when withdrawal symptoms have begun and for the first two days of treatment under direct observation of a health care provider. For longer term treatment of addiction, a combination formulation of buprenorphine/naloxone is recommended to prevent misuse by injection. Methylphenidate, sold under various trade names, such as Ritalin in oral form, and in transdermal patch form known as Daytrana, is a central nervous system stimulant that is used in the treatment of attention deficit hyperactivity disorder and narcolepsy. We plan to develop transdermal delivery systems for buprenorphine and methylphenidate after we make significant progress on our abuse deterrent fentanyl transdermal system.

 

Our research pipeline consists primarily of drug compounds which have been previously approved by the FDA and are now off-patent. In some cases, we are developing a non-injectable version of the drug utilizing our transdermal technology which represents a new route of administration. We believe that transdermal delivery has the potential to improve compliance, which can lead to improved therapeutic outcomes associated with these treatments. In most cases, we plan to utilize the 505(b) (2) NDA regulatory pathway provided by the FDA which allows us to reference the safety information on file at FDA for the approved drug or to reference the published literature instead of having to generate new safety information that would typically be required for new chemical entities. However, we cannot assure you that the FDA will concur with our approach or that we will be able to receive FDA approval to market any of products that we develop.

 

1 https://www.fda.gov/consumers/consumer-updates/accidental-exposures-fentanyl-patches-continue-be-deadly-children

 

34

 

In addition, we may seek to develop certain generic transdermal products where we think we can efficiently make an improvement to existing patches and potentially take significant market share with good profit margins.

 

The prioritization of our portfolio of product candidates will be reviewed on an ongoing basis and will take into account technical progress, market potential, available funding and commercial interest. Our ability to take any meaningful steps to the development of any of these products is determined by our ability to provide sufficient funding for such activities.

 

Pharmaceutical Manufacturing and Supply

 

Manufacturing of our pharmaceutical transdermal products in development will be performed in compliance with FDA current Good Manufacturing Practices (cGMP) and all applicable local regulations by contract manufacturers. All manufacturing processes and facilities will be subject to review by the FDA during development, prior to approval and during subsequent routine FDA inspections. We plan to continue to rely on contract manufacturers and, potentially, collaboration partners to manufacture commercial quantities of our products, if and when approved for marketing by the FDA.

 

Government Regulation and Regulatory Path

 

United States

 

The pharmaceutical business is subject to extensive government regulation. In the United States, we must comply with the rules and regulations of the FDA. In other countries, we must comply with the laws and regulations of each country to legally market and sell our products. Obtaining FDA approval does not mean that the product will be approved in other countries. Each country may require that additional clinical and nonclinical studies be conducted prior to approval.

 

The process required by the FDA to receive approval prior to marketing and distributing a drug in the United States generally involves a preclinical phase followed by three phases of clinical trials. The definition of drug is broadly defined and includes the pharmaceutical products we have in development. Even though the drug used in each of our proposed products is currently approved by the FDA in other dosage forms, we will still need to conduct a development program that will include preclinical and clinical trials before we receive FDA marketing approval. The FDA also has a number of abbreviated approval pathways which, if we are eligible, could shorten the time for approval. For example, the regulatory path for the AVERSA products in development is intended to follow a 505(b)(2) NDA regulatory pathway which may reduce the amount of clinical work that needs to be performed to a single trial to evaluate the abuse potential of the product as the safety and efficacy of the drug has already been established. However, we cannot be certain that we will be able to use any abbreviated approval pathway, in which event we will need to comply with the full regulatory pathway as described below.

 

In general, the full NDA product development program required for new drugs for FDA approval consists of the following phases of development listed below. The full NDA pathway is not expected to be required for products incorporating AVERSA technology into an already approved transdermal patch.

 

●Preclinical phase. Before a drug company can test an experimental treatment in humans, it must prove the drug is safe and effective in animals. Scientists run tests in various animals before presenting the data to the FDA as an investigational new drug application. For already approved drugs, an animal study may not be required prior to testing in humans. In most cases, the company must file an Investigational New Drug (IND) submission to get clearance to test the product in humans.

 

●Phase one clinical trial. In the first round of clinical trials, the drug company attempts to establish the drug’s safety in humans. Drug researchers administer the treatment to healthy individuals — instead of patients suffering from the disease or condition the drug is intended to treat — and gradually increase the dose to see if the drug is toxic at higher levels or if any possible side effects occur. These drug trials are usually small, containing about 20 to 80 participants, according to the FDA. For drug delivery products incorporating already approved drugs, Phase 1 studies involve measuring blood levels of the drug to understand the pharmacokinetics for a new route of administration.

 

●Phase two clinical trial. In the second round of clinical trials, researchers give the treatment to patients who have the disease to assess the drug’s efficacy. The trial is randomized, meaning half of the study participants receive the drug and half receive a placebo. These trials usually contain hundreds of participants, according to the FDA. There is about a 30 percent chance of a drug moving on to a phase three clinical trial, according to data from the biotech trade organization BIO. For already approved drugs, as is the case with drug delivery products, a Phase 2 trial may not be necessary as the therapeutic drug doses and blood concentrations are already known. However, a Phase 2 may be conducted to inform the design of the Phase 3 clinical trial in regards to the safety and efficacy of the product when used by patients.

 

35

 

●Phase three clinical trial. In the third phase of clinical trials, researchers work with the FDA to design a larger trial to test the drug’s ideal dosage, patient population and other factors that could decide whether the drug is approved, according to the report. These trials usually contain a few hundred to thousands of participants. In the case of drug delivery products that utilize an approved drug, Phase 3 trials will typically include a comparison to the already approved reference product. For example, a transdermal patch may be compared to an injection.

 

●New drug application (NDA). Once a drug company collects and analyzes all data from the clinical trials, it submits a new drug application to the FDA. The application includes trial data, preclinical information and details on the drug’s manufacturing process. If the FDA accepts the application for review, the agency typically has ten months, or six months if the drug has priority review status, to make a decision whether to approve the drug or not. The FDA can hold an advisory committee meeting where independent experts assess the data and recommend whether to approve the drug. From there, the FDA will either approve the drug or give the applicant a complete response letter, which explains why the drug did not get approved and what steps the applicant must take before resubmitting the application for approval.

 

Before approving an NDA, the FDA may inspect the facilities where the product is being manufactured or facilities that are significantly involved in the product development and distribution process and will not approve the product unless they determine that compliance with current good manufacturing practices is satisfactory. The FDA may deny approval of an NDA if applicable statutory or regulatory criteria are not satisfied, or may require additional testing or information, which can delay the approval process. In pursuing FDA approval there may be various delays and it is possible that approval may never be granted. In addition, new government requirements may be established that could delay or prevent regulatory approval of our product candidates under development.

 

If a product is approved, the FDA may impose limitations on the indications for use for which the product may be marketed, may require that warning statements be included in the product labeling, may require that additional studies or trials be conducted following approval as a condition of the approval, may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a risk management plan, or impose other limitations.

 

Once a product receives FDA approval, marketing the product for other indicated uses or making certain manufacturing or other changes related to the product will require FDA review and approval of a supplemental NDA or a new NDA, which may require additional clinical safety and efficacy data and may require additional review fees. In addition, further post-marketing testing and surveillance to monitor the safety or efficacy of a product may be required. Also, product approvals may be withdrawn if compliance with regulatory standards is not maintained or if safety or manufacturing problems occur following initial marketing.

 

With respect to the labeling for our abuse deterrent transdermal fentanyl system or any other opioid transdermal patch we develop, it is likely that the FDA will require us to disclose the risks of improper use or abuse using language required by the FDA upon approval.

 

FDA Approval Pathways

 

The FDA has several pathways that can be followed to obtain FDA approval.

 

●A stand-alone NDA is an application submitted under Section 505(b)(1) of the Food, Drug and Cosmetic Act (“FD&C Act”) and approved under Section 505(c) of the FD&C Act that contains full reports of investigations of safety and effectiveness that were conducted by or for the applicant or for which the applicant has a right of reference or use. This is typically the pathway used for new chemical entities.

 

●A 505(b)(2) application is a limited NDA submitted under Section 505(b)(1) and approved under Section 505(c) of the FD&C Act that contains full reports of investigations of safety and effectiveness, where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. This is the pathway typically taken for off-patent drugs that are being development into alternate dosage forms or routes of administration.

 

36

 

●An ANDA is an application for a duplicate of a previously approved drug product that was submitted and approved under Section 505(j) of the FD&C Act. An ANDA relies on the FDA’s finding that the previously approved drug product is safe and effective. An ANDA generally must contain information to show that the proposed generic product (1) is the same as the drug with respect to the active ingredients, conditions of use, route of administration, dosage form, strength and labeling (with certain permissible differences) and (2) is bioequivalent to the referenced drug. An ANDA may not be submitted if studies are necessary to establish the safety and effectiveness of the proposed product. This is the pathway taken for generic drugs.

 

Nutriband plans to utilize the 505(b)(2) New Drug Application (NDA) regulatory pathway which limits the development required for products that contain drugs that have already been approved, and allows applicants to reference data already on file at the FDA. As a result, the NDA application will be primarily based on a single Phase 1 human abuse potential clinical study with no Phase 2 or 3 clinical trials needed. A clinical abuse potential study is typically performed in recreational drug abusers and is designed to demonstrate that the abuse-deterrent product is less preferable to recreational drug abusers than conventional fentanyl patches which contain no abuse-deterrent technology.

 

Following a successful Phase 1 clinical abuse potential study, Nutriband intends to file a 505(b)(2) NDA to the FDA for marketing approval of AVERSA™ Fentanyl, which has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The AVERSA™ Fentanyl NDA has the potential to receive an expedited review by FDA as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

 

Combined, the clinical development and regulatory path for AVERSA Fentanyl is substantially limited compared to conventional pharmaceutical product development, requiring only a single clinical trial and, following a limited NDA pathway, undergoing an expedited review by the FDA.

 

We cannot assure you that we will be able to take advantage of any of the available abbreviated approval pathways for any of our proposed products.

 

Post-approval requirements

 

Any drug products for which we receive FDA approval will be subject to continuing regulation by the FDA. Certain requirements include, among other things, record-keeping requirements, reporting of adverse events with the product, providing the FDA with updated safety and efficacy information on an annual basis or more frequently for specific events, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements. These promotion and advertising requirements include, among others, standards for direct-to-consumer advertising, prohibitions against promoting drugs for uses or patient populations that are not described in the drug’s approved labeling, known as “off-label use,” and other promotional activities, such as those considered to be false or misleading. Failure to comply with FDA regulations can have negative consequences, including the immediate discontinuation of noncomplying materials, adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Such enforcement may also lead to scrutiny and enforcement by other government and regulatory bodies.

 

Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not encourage, market or promote such off-label uses. As a result, “off-label promotion” has formed the basis for litigation under the Federal False Claims Act, violations of which are subject to significant civil fines and penalties. In addition, manufacturers of prescription products are required to disclose annually to the Center for Medicaid and Medicare any payments made to physicians and teaching hospitals in the U.S. under the federal Physician Payment Sunshine Act. Reportable payments may be direct or indirect, in cash or kind, for any reason, and are required to be disclosed even if the payments are not related to the approved product. Failure to fully disclose or not in time reporting could lead to penalties up to $1.15 million per year.

 

The manufacturing of any of our products will be required to comply with the FDA’s current Good Manufacturing Practices (cGMP) regulations. These regulations require, among other things, quality control and quality assurance, as well as the corresponding maintenance of comprehensive records and documentation. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are also required to register with the FDA their establishments and list any products they make and to comply with related requirements in certain states. These entities are further subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with current good manufacturing practices and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.

 

Discovery of problems with a product after approval may result in serious and extensive restrictions on a product, manufacturer or holder of an approved NDA, as well as lead to potential market disruptions. These restrictions may include recalls, suspension of a product until the FDA is assured that quality standards can be met, and continuing oversight of manufacturing by the FDA under a “consent decree,” which frequently includes the imposition of costs and continuing inspections over a period of many years, as well as possible withdrawal of the product from the market. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.

 

37

 

The FDA also may require post-marketing testing, or Phase IV testing, as well as risk minimization action plans and surveillance to monitor the effects of an approved product or place conditions on an approval that could otherwise restrict the distribution or use of our products.

 

Other Government Regulations

 

We may be subject to government regulations that are applicable to businesses generally, including those relating to workers’ health and safety, environmental and waste disposal, wage and hour and labor practices, including sexual harassment laws and regulations, and anti-discrimination laws and regulations.

 

In addition, we must comply with the laws and regulations governing the research and manufacture of products containing controlled substances such as fentanyl and other opioids. We or our contract manufacturer must be licensed by the Drug Enforcement Agency (DEA) and the state(s) in which we conduct research and development activities.

 

Europe and Other Countries

 

If we market our products in any countries other than the United States, we would be subject to the laws of those countries. To obtain market access for our products in other countries we must comply with numerous and varying regulatory requirements of such countries regarding the demonstration of safety and efficacy for authorization and governing, among other things, clinical trials and commercial sales, pricing and distribution of our products.

 

The European medicines regulatory system is based on a network of around 50 regulatory authorities from the 31 countries in the European Economic Area, the European Commission and the European Medicines Agency. All medicines must be authorized before they can be placed on the market in the European Union. The European system offers different routes for authorization. A centralized procedure allows the marketing of a medicine on the basis of a single European Union assessment and marketing authorization which is valid throughout the European Union. However, a majority of medicines authorized in the European Union do not fall within the scope of the centralized procedure, and we do not know whether our proposed products will fall within the centralized authorization. We also do not know how the withdrawal of Great Britain from the European Union will affect the procedure for approval of medicines in the United Kingdom. If we are not able to use the centralized procedure, we would need to use one of the following procedures. One method is the decentralized procedure where we would apply for simultaneous authorization in more than one European Union member. The second method is the mutual-recognition procedure where we would have a medicine authorized in one European Union country apply for authorization to be recognized in other European Union countries. In either case, we would be required to complete clinical trials to demonstrate the safety and efficacy of the medicine and show that the medicine is manufactured in accordance with good manufacturing practices based upon European Union standards.

 

In countries other than the United States and the European Union, we would be required to comply with the applicable laws of those countries, which may require us to perform additional clinical testing.

 

Failure to obtain regulatory approval in any country would prevent our product candidates from being marketed in those countries. In order to market and sell our products in jurisdictions other than the United States and the European Union, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The regulatory approval process outside the United States and the European Union generally includes all of the risks associated with obtaining FDA and European Union approval but can involve additional testing.

 

In addition, in many countries worldwide, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Even if we were to receive approval in the United States or the European Union, approval by the FDA or the European Medicines Agency does not ensure approval by regulatory authorities in other countries or jurisdictions. Similarly, approval by one regulatory authority outside the United States would not ensure approval by regulatory authorities in other countries or jurisdictions. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of our product candidates by regulatory authorities in other foreign jurisdictions, the commercial prospects of those product candidates may be significantly diminished and our business prospects could decline.

 

38

 

Outside the United States, particularly in member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations or the successful completion of health technology assessment procedures with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures.

 

In addition to regulations in the United States, if we market outside of the United States, we will be subject to a variety of regulations governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries.

 

Intellectual Property

 

The AVERSA abuse deterrent technology utilized in our AVERSA product pipeline is covered by an international intellectual property portfolio with patents issued in 45 countries including the United States, Europe, Japan, Korea, Russia, Mexico, Canada, and Australia and pending in China and Hong Kong. These patents provide patent coverage to 2035. We continue to build on our proprietary positions in the United States and internationally for our product candidates AVERSA Fentanyl, AVERSA Buprenorphine and AVERSA Methylphenidate as well as other products and technology that we may have in development. Our policy is to pursue, maintain and defend patent rights developed internally or acquired externally and to protect the technology, inventions and improvements that are commercially important to the development of our business. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology. We also may rely on trade secrets to protect our commercial products and product candidates. Our commercial success also depends in part on our non-infringement of the patents or proprietary rights of third parties.

 

On September 19, 2023, the United States Patent and Trademark Office (USPTO) granted US Patent No. 11,759,431 for Nutriband’s proprietary AVERSA abuse deterrent technology utilizing taste aversion to address the primary routes of abuse of opioid based transdermal patches. The issuance of this patent, entitled, “Abuse and Misuse Deterrent Transdermal Systems,” further expands Nutriband’s intellectual property protection in the United States for its portfolio of AVERSA abuse deterrent transdermal products.

 

Further, we plan to seek trademark protection in the United States and internationally where available and when appropriate. We have registered the name Nutriband in the United States. We have filed an intent to use Trademark application for AVERSA. The USPTO will require us to show the mark used in commerce prior to fully registering the trademark.

 

Publications

 

On March 8, 2024, Nutriband presented data on the incidence of transdermal patch abuse and accidental pediatric exposure as a scientific poster at the 2024 American Academy of Pain Medicine (AAPM) Annual Meeting2. The American Academy of Pain Medicine (AAPM) is dedicated to advancing multidisciplinary pain care, education, advocacy, and research.

 

The company engaged Rocky Mountain Poison & Drug Safety (RMPDS), a division of Denver Health and Hospital Authority, Denver, Colorado, to determine the incidence of abuse and accidental pediatric exposure of transdermal patches containing drugs of abuse (fentanyl, buprenorphine, and methylphenidate) in the United States based on poison center data for the surveillance period 2018-2022. RMPDS utilized the Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS®) System, a surveillance system that collects real-world safety and effectiveness data about prescription drugs (https://www.radars.org/).

 

2 Olsen, H, Mogusu, E, Black, JC, Sumbundu, K, Dart, RC. Poison center exposure calls involving fentanyl, buprenorphine, and methylphenidate transdermal patches in the United States. Poster presented at the 40th Annual Meeting of the American Academy of Pain Medicine; 2024 Mar 7-10; Scottsdale, Arizona. https://www.radars.org/system/publications/39.%20Olsen.pdf

 

39

 

The data indicate that transdermal patch abuse and accidental pediatric exposures to patches continues to be a serious problem resulting in major medical outcomes and death, suggesting an unmet need for safer abuse-deterrent versions of transdermal patches containing drugs with a risk of abuse, misuse or accidental exposure. Key findings from the study showed that major medical outcome or death resulted from a notable proportion of fentanyl and buprenorphine patch intentional and accidental pediatric exposures with two deaths reported due to abuse of fentanyl transdermal patches. The oral route accounted for the majority of fentanyl patch abuse with 62.5% of all intentional abuse/misuse event reports for fentanyl patches (85.3% of non-dermal routes of abuse). Furthermore, there was a notable proportion of accidental pediatric exposures to transdermal formulations that resulted in major medical outcomes (fentanyl patches: 10.1%, buprenorphine patches: 16.7%). Abuse and overdose are a real problem with transdermal fentanyl as well as other transdermal opioid and stimulant products. In addition, there continues to be an alarming amount of accidental pediatric exposures, resulting in major negative health outcomes. We believe our AVERSA abuse-deterrent technology will have a substantial impact on both of these unfortunate and preventable situations and will help reduce the risk of harm from opioid and stimulant patches by providing taste aversion agents in every patch.

 

Market Assessment

 

The company engaged leading healthcare consulting company Health Advances to assess the market opportunity and commercial strategy for AVERSA Fentanyl and AVERSA Buprenorphine.

 

AVERSA Fentanyl is the lead AVERSA product under development and has the potential to be the world’s first fentanyl transdermal systems with abuse deterrent properties. Once approved by the United States FDA, Aversa Fentanyl will be priced competitively with the non-abuse deterrent patch and has the potential to reach peak annual US sales of $80-200 million according to the assessment performed by Health Advances in January 2022. This assessment did not include the impact of the revised CDC Opioid Prescribing Guidelines which were published in November 2022 that encouraged prescribers to implement comprehensive and holistic pain management including responsible opioid use particularly for patients with moderate to severe chronic pain. Health Advances was able to confirm the significant unmet patient need for AVERSA Fentanyl based on rigorous primary and secondary market research accompanied with deep experience in the abuse deterrence pain space. Nutriband is also considering developing the product for strategic international markets as protected by its global abuse deterrent patent portfolio.

 

AVERSA Buprenorphine is the second AVERSA product under development and has the potential to be the world’s first buprenorphine transdermal systems with abuse deterrent properties. Once approved by the United States FDA, Aversa Buprenorphine will be priced competitively with non-abuse deterrent options and has the potential to reach peak annual US sales of $70-130 million according to the assessment performed by Health Advances in October 2023. Health Advances was able to confirm the significant unmet patient need for Aversa™ Buprenorphine based on rigorous primary and secondary market research accompanied with deep experience in the abuse deterrence pain space. Nutriband is also considering developing the product for strategic international markets as protected by its global abuse deterrent patent portfolio.

 

Competition

 

The pharmaceutical industry is highly competitive and subject to rapid change as new products are developed and marketed. Potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, and medical technology companies. We believe the key competitive factors that will affect the development and commercial success of our products are product performance including safety and efficacy, level of patient compliance, healthcare professional acceptance, and the extent of insurance reimbursement of our products.

 

40

 

As our development pipeline includes products that contain opioids (AVERSA Fentanyl and AVERSA Buprenorphine), we continually monitor the market for opioid products, particularly in the United States. Pharmaceutical companies engaged in the distribution and sale of opioids, in particular for the treatment of chronic pain, are promoting responsible opioid use. In 2022, the CDC revised its clinical practice guideline for prescribing opioids to ease the restrictions on prescribers and encourage responsible opioid use particularly for patients with moderate to severe pain. Our abuse deterrent opioid products potentially offer a unique proposition to meet the unmet needs of patients by deterring the abuse and misuse of opioids while making opioids accessible to those patients who need them. If approved, our AVERSA pipeline products will compete with the currently marketed products that do not contain abuse deterrent features as well as other products that may employ different abuse deterrent technology. We may also have to compete with products that do not contain opioids or other drugs that are susceptible to abuse. We are not aware of any abuse deterrent transdermal products that are in development or being marketed at this time. If we obtain regulatory approval to market our products, we cannot assure you that we will be successful in the marketplace.

 

Properties

 

We do not own any real property. We lease under a one year lease an office for $ 2,500 per month at 121 South Orange Street, Orlando, Florida. With the office lease, we have access to boardrooms, kitchen facilities and administrative support services. We lease manufacturing space in Cherryville, North Carolina, for $3,000 per month under a three-year lease entered into on February 1, 2022, with a renewal option.

 

Legal Proceedings

 

The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (“Gunnar”) and Lucosky Brookman LLP (“LB”) in the Supreme Court of the State of New York, New York County, under Index No.654633/2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company’s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $500,000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees.

 

In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $1,000,000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims.

 

Currently, there are no pending hearings or motions as both parties are engaged in discovery and are attempting to resolve the matter amicably.

 

41

 

MANAGEMENT

 

Set forth below are the name, age, position of and biographical information about each nominee, all of whom are currently directors and compromise our entire Board as of the record date.

 

Name   Age   Position
Gareth Sheridan   34   Chief Executive Officer and Director
Serguei Melnik   51   Chairman of the Board, President and Secretary
Sergei Glinka   58   Director
Mark Hamilton(1)(3)   37   Director
Radu Bujoreanu(1)(2)(3)   54   Director
Stefani Mancas(2)(3)   47   Director
Irina Gram(2)(1)   36   Director
Gerald Goodman   76   Chief Financial Officer
Alan Smith, Ph.D.   57   Chief operating officer and president of 4P Therapeutics
Jeff Patrick, Pharm.D.   55   Chief scientific officer

 

(1) Member of the Audit Committee.

 

(2) Member of the Compensation Committee.

 

(3) Member of the Nominating and Corporate Governance Committee.

 

Gareth Sheridan, our founder, has been chief executive officer and a director since our organization in 2016. In 2012, Mr. Sheridan founded Nutriband Ltd., an Irish company which we acquired in 2016. Mr. Sheridan was named Ireland’s ‘Young Entrepreneur of the Year’ in 2014 in the National Bank of Ireland Startup Awards for establishing Nutriband Ltd. Mr. Sheridan has further business awards from S. Dublin’s Best Young Entrepreneur and Nutriband Ltd as S. Dublin’s Best Startup Company. Mr. Sheridan has also worked as a Business Mentor with 100 Minds, a social enterprise founded in 2013, that brings together some of Ireland’s top college students and connects them with one cause to achieve large charitable goals in a short space of time. Mr. Sheridan is also a past Nissan Generation Next Ambassador, receiving the acknowledgement in 2015 by Nissan Ireland as one of Ireland’s future generational leaders. In 2019 Mr. Sheridan served on the Board of the St. James Hospital foundation, the charitable foundation for Ireland’s largest public hospital. Mr. Sheridan received a B.Sc. in Business and Management from Dublin Institute of Technology in 2012 where he concentrated on international economics, venture creation and entrepreneurship.

  

Serguei Melnik, who was elected by the Board as President on October 8, 2021, serves as a member of the board of directors and is a co-founder of Nutriband Inc. Mr. Melnik has previously served as our chief financial officer and a director since January 2016. Mr. Melnik has been involved in general business consulting for companies in the U.S. financial markets and setting up a legal and financial framework for operations of foreign companies in the U.S. Mr. Melnik advised UNR Holdings, Inc. with regard to the initiation of the trading of its stock in the over-the-counter markets in the U.S. and has provided general advice with respect to the U.S. financial markets for companies located in the U.S. and abroad. From February 2003 to May 2005, he was the Chief Operations Officer and a Board member of Asconi Corporation, Winter Park, Florida, with regard to restructuring the company and listing it on the American Stock Exchange. Mr. Melnik from June 1995 to December 1996 was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,”, Chisinau, Moldova, and prior thereto practiced law in Moldova in various positions. Mr. Melnik is fluent in Russian, Romanian, English and Spanish.

 

42

 

Sergei Glinka, an investor in our April 17, 2024 private offshore financing, joined our Board of Directors on May 15, 2024. Mr. Glinka has been the Commercial Manager of TG Biochemicals Limited, Cyprus. since 2019. He has been a shareholder and member of the Board of GST Investments OÜ, Estonia since 2019. From 2000 to 2019, Mr. Glinka was a shareholder and member of the Board of Transgroup Invest AS, Commencing in 1973 Mr. Glinka attended secondary school in Moldova, graduating in 1981, and graduated from the Tallinn Merchant Marine School, Estonia, in 1986.

 

Mark Hamilton, an independent director since July 2018, is an experienced director level professional who joined global consulting firm, Korn Ferry in 2020 as a Managing Consultant. Prior to moving into organizational consulting, Mark qualified as a Chartered Accountant in global advisory firm, BDO, where he spent 12 years advising some of Ireland’s most successful businesses. His work originated in corporate finance/corporate recovery and more recently, he spent 5 years leading BDO’s client management and sales function, as Head of Business Development.

 

Mr. Hamilton is a Member of the Association of Chartered Accountants (ACA), since 2012. Mr. Hamilton’s accounting/consulting background and experience in corporate finance, restructuring, sales and talent assists us in his role as an independent Board member and Committee Chair. Mr. Hamilton has a very strong presence in the business community across jurisdictions, along with an accomplished track record in project management and business development. Educated at Terenure College, Mark went on to study a B.Sc. degree in Business & Management at Dublin Institute of Technology and subsequently received First Class Honours in his postgraduate degree, for which he specialized in Accountancy in 2009. In addition to his ACA qualification, Mark has also recently completed a diploma in Corporate Governance and is now a member of the Corporate Governance Institute which will assist him in his role as Independent Director, alongside his recent approval by the Central Bank of Ireland to act as an Independent Director to regulated entities.

 

Radu Bujoreanu has been a director since June 2019. Mr Bujoreanu is a real estate agent and investor since 2019 and currently he is with Samson Properties LLC.  Mr. Bujoreanu has been the owner and executive director of Consular Assistance, Inc., which provided assistance in obtaining visas, travel documents, other national and foreign documents and related services since December 2002 to December 2020. From 2003 to 2005 he served as an independent director and member of the Board of Directors of Asconi Corporation. From August 1999 to August 2002 Mr. Bujoreanu worked as a consular officer at the Embassy of the Republic of Moldova to the United States. Before that from May 1994 to August 1999 he was Chief of Bilateral Treaties section in the International Law and Treaties Department of the Ministry of Foreign Affairs of the Republic of Moldova.  Mr. Bujoreanu received his bachelor degree in international public law from the University of Moldova.

 

Dr. Stefani Mancas graduated Summa cum Laude from the Military Navy College in Constanta, Romania. After attending the faculty of Cybernetics from the Academy of Economic Studies in Bucharest, Stefani transferred to University of Central Florida, and graduated with a dual B.Sc. in Mathematics/ Aerospace Engineering, a Master’s Degree in Applied Mathematics, and a Ph.D. in Mathematical Sciences from the Department of Mathematics. The Ph.D. dissertation topic was “Dissipative solitons in the cubic-quintic complex Ginzburg-Landau equation: Bifurcations and Spatiotemporal Structure”, for which Stefani received the UCF Outstanding Dissertation Award.

 

Currently, Stefani is a tenured full Professor, and a researcher in the Department of Mathematics at Embry-Riddle Aeronautical University in Daytona Beach, Florida. Stefani’s research areas deal with finding analytical solutions to nonlinear dissipative equations that can be reduced through Darboux transformations to Riccati or Abel equations. The main focus is on Schrödinger equation, for which Stefani is using methods based on factorization, and variational formulation together with ansatz reduction with global minimizers of objective functions, applied to supersymmetric quantum mechanics. Another important area of interest is the theory of elliptic functions with applications to nonlinear optics, soliton theory, general relativity, as well as optimization of the blockchain, and quantum cryptography.

 

Irina Gram was elected as a director of the Company at the January 21, 2022 stockholders meeting. Irina is a Senior Financial Analyst at Thales IFEC, Melbourne, Florida. There she is responsible for financial planning, analysis and risk and opportunities reviews of multiple development and customer programs. From 2016 to 2017, she was a Project Engineering Coordinator at Thales IFEC, where she executed budgeting and forecasting activities with specialized focus on SFRD spending, interfaced with engineering team to monitor and report the performance of the financial impact of projects. From 2013 to 2016, she held various project management, accounting and reporting positions with Siemens Building Technology, Inc., Winter Park, Florida. She received a Bachelor’s Degree in Finance from the University of Central Florida, Orlando, Florida, where she graduated in May 2015, with honors, and received a Masters Degree in business administration from the University of Central Florida, Orlando, Florida, in May 2019.

 

43

 

Gerald Goodman has been our chief accounting officer since July 31, 2018 and was elected our Chief Financial Officer on November 12, 2020. Mr. Goodman is a certified public accountant and, since 2014, has practiced with his own firm, Gerald Goodman CPA P.C. From January 1, 2010 until December 31, 2014, Mr. Goodman practiced with Madsen & Associates, CPA’s Inc., Murray, Utah, and was a non-equity partner and managed the firm’s SEC practice. Mr. Goodman is a director of Lifestyle Medical Network, Inc., which provides management services to healthcare providers. From 1971 to 2010, Mr. Goodman was a partner in the accounting firm of Wiener, Goodman & Company P.C. Mr. Goodman is a 1970 graduate of Pennsylvania State University where he received a B.S. Degree in Accounting.

 

Alan Smith, Ph.D., serves as Chief Operating Officer of Nutriband and President of 4P Therapeutics, a wholly owned subsidiary of Nutriband. He joined the Company after Nutriband acquired 4P Therapeutics in 2018. Dr. Smith co-founded 4P Therapeutics in 2011 to develop drug-device and biologic-device combination products to meet the needs of patients, physicians, and payers, and was Vice President, Clinical, Regulatory, Quality and Operations at the time of the acquisition. Dr. Smith is co-inventor of the Company’s Aversa™ abuse deterrent transdermal system technology. Dr. Smith has over 20 years of experience in the research and development of drug and biologic delivery systems, diagnostics and medical devices for treatment and management of chronic pain, diabetes, and cardiovascular disease. Previously, he was with Altea Therapeutics, a venture capital funded company focused on novel transdermal drug and biologic delivery, most recently serving as Vice President, Product Development and Head of Clinical R&D, Regulatory Affairs, and Project Management. Prior to joining Altea Therapeutics, he led the development of transdermal glucose monitoring systems at SpectRx, Inc., a publicly traded noninvasive diagnostics company. Dr. Smith received Ph.D. and M.S. degrees in Biomedical Engineering from Rutgers University and the University of Medicine and Dentistry of New Jersey. He currently serves on the Editorial Advisory Board of Expert Opinion on Drug Delivery. 

 

Jeff Patrick Pharm.D. currently serves as Director of Drug Development Institute at the Ohio State University Comprehensive Cancer Center. Dr. Patrick most recently serving as Chief Scientific Officer for New Haven Pharmaceuticals. Prior roles included global vice president of professional affairs at Mallinckrodt Pharmaceuticals, Inc.; and roles with ascending responsibilities at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo, Inc. Dr. Patrick is a residency-trained clinical pharmacist with approximately 20 years of pharmaceutical industry experience. He brings expertise in executive leadership, scientific and medical strategy, drug development and commercialization to the company. Prior to pursuing a career in research and development, Patrick was an ambulatory care clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy, where he earned his doctorate in pharmacy. He also completed the Wharton School of Business Pharmaceutical Executive Program. Dr. Patrick works for us on a part-time basis.

 

44

 

CORPORATE GOVERNANCE AND THE BOARD OF DIRECTORS

 

Board Leadership Structure and Risk Oversight

 

Gareth Sheridan serves as Chief Executive Officer and Serguei Melnik is serving as our Chairman and President. Our Chairman leads the Board of Directors in its discussions and has such other duties as are prescribed by the Board. As Chief Executive Officer, Mr. Sheridan is responsible for implementing the Company’s strategic and operating objectives and day-to-day decision-making related to such implementation.

 

The Board of Directors currently has three standing committees (audit, compensation, and nominating and corporate governance) that are chaired and composed entirely of directors who are independent under Nasdaq and SEC rules. Given the role and scope of authority of these committees, and that a majority of the members of the Board are independent, the Board of Directors believes that its leadership structure is appropriate. We select directors as members of these committees with the expectation that they will be free of relationships that might interfere with the exercise of independent judgement.

 

Our Board of Directors is our Company’s ultimate decision-making body, except with respect to those matters reserved to the stockholders. Our Board of Directors selects our senior management team, which is charged with the conduct of our business. Our Board of Directors also acts as an advisor and counselor to senior management and oversees its performance.

 

Board Composition

 

Our business and affairs are managed under the direction of our Board of Directors. The number of directors is determined by our board of directors, subject to the terms of our certificate of incorporation and bylaws. Our board of directors currently consists of six members, four of which are independent directors.

 

Meetings

 

Our Board of Directors held two meetings and acted by written consent eight times during fiscal 2024.

 

Committees of the Board of Directors

 

The board of directors has created three committees — the audit committee, the compensation committee and the nominating and corporate governance committee. Each of the committees has a charter which meets the Nasdaq Stock Market requirements and is composed of three independent directors.

 

Audit Committee

 

The audit committee is comprised of Mr. Hamilton, as chairman, Mr. Bujoreanu and Irina Gram. We believe that Mark Hamilton qualifies as an “audit committee financial expert” under the rules of the Nasdaq Stock Market. The audit committee oversees, reviews, acts on and reports on various auditing and accounting matters to the board, including: the selection of our independent accountants, the scope of our annual audits, fees to be paid to the independent accountants, the performance of our independent accountants and our accounting practices, all as set forth in our audit committee charter. The Audit Committee met three times in fiscal 2024.

 

Compensation Committee

 

The compensation committee is comprised of Irina Gram, Chairperson, Mr. Bujoreanu and Dr. Mancas. The compensation committee oversees the compensation of our chief executive officer and our other executive officers and reviews our overall compensation policies for employees generally as set forth in the audit committee charter. If so authorized by the board, the compensation committee may also serve as the granting and administrative committee under any option or other equity-based compensation plans which we may adopt. The compensation committee will not delegate its authority to fix compensation; however, as to officers who report to the chief executive officer, the compensation committee will consult with the chief executive officer, who may make recommendations to the compensation committee. Any recommendations by the chief executive officer are accompanied by an analysis of the basis for the recommendations. The committee will also discuss with the chief executive officer and other responsible officers the compensation policies for employees who are not officers. The compensation committee has the responsibilities and authority relating to the retention, compensation, oversight and funding of compensation consultants, legal counsel and other compensation advisers. The compensation committee members will consider the independence of such advisors before selecting or receiving advice from such advisors. The compensation committee met three times in fiscal 2024.

 

45

 

Nominating and Corporate Governance Committee

 

The nominating and corporate governance committee, which is comprised of Dr. Mancas, Mark Hamilton and Mr. Bujoreanu, will identify, evaluate and recommend qualified nominees to serve on our board; develop and oversee our internal corporate governance processes, and maintain a management succession plan. The nominating and corporate governance committee met two times in fiscal 2024.

 

Risk Management

 

The Board has an active role, as a whole and also at the committee level, in overseeing the management of our risks. The Compensation Committee of our Board is responsible for overseeing the management of risks relating to our executive compensation plans and arrangements. The Audit Committee of our Board oversees management of financial risks, under its charter it is to meet periodically and at least four times per year with management to review and assess the Company’s major financial risk exposures and the manner in which such risks are being monitored and controlled. The Nominating and Corporate Governance Committee of our Board is responsible for the management of risks associated with the independence of the Board members and potential conflicts of interest. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board of Directors is informed about such risks.

 

Independent Directors

 

Five of our directors, Sergei Glinka, Mark Hamilton, Radu Bujoreanu, Stefani Mancas and Irina Gram are independent directors based on the NASDAQ definition of independent director.

  

Family Relationships

 

There are no family relationships among our directors and executive officers.

 

Compensation Committee Interlocks and Insider Participation

 

None of our executive officers serve on the board of directors or compensation committee of a company that has an executive officer who serves on our Board or compensation committee. No member of our Board is an executive officer of a company in which one of our executive officers serves as a member of the board of directors or compensation committee of that company.

 

Conflicts of Interest

 

Certain conflicts of interest exist and may continue to exist between the Company and its officers and directors due to the fact that each has other business interests to which they devote their primary attention. Each officer and director may continue to do so notwithstanding the fact that management time should be devoted to the business of the Company.

 

Certain conflicts of interest may exist between the Company and its management, and conflicts may develop in the future. The Company has not established policies or procedures for the resolution of current or potential conflicts of interest between the Company, its officers and directors or affiliated entities. There can be no assurance that management will resolve all conflicts of interest in favor of the Company, and conflicts of interest may arise that can be resolved only through the exercise by management their best judgment as may be consistent with their fiduciary duties. Management will try to resolve conflicts to the best advantage of all concerned.

 

Compliance with Section 16(a) of the Securities Exchange Act of 1934

 

Section 16(a) of the Exchange Act requires our officers and directors, and persons who beneficially own more than ten percent of our Common Stock, to file reports of ownership and changes of ownership of such securities with the SEC. Mr. Goodman, Dr. Smith, Dr. Patrick, Mr. Bujoreanu, and Ms. Gram have not yet filed their Form 3 reports.

 

Gareth Sheridan and Serguei Melnik have not filed Form 4’s reporting receipt of compensation in fiscal years 2024 and 2025; With the exception of Gerald Goodman, who has filed Form 5’s to catch up on Form 4’s due over the past three fiscal years. Mr. Goodman is late with respect to Form 4’s required to be filed for stock option compensation issuances for fiscal 2024 and 2025. No other officer or director has filed any ownership reports.

 

46

 

EXECUTIVE COMPENSATION

 

The table below shows the compensation for services in all capacities we paid during the years ended January 31, 2024 and 2023 to the individuals serving as our principal executive officers during the last completed fiscal year and our other two most highly paid executive officers at the end of the last completed fiscal year (whom we refer to collectively as our “named executive officers”);

 

Name and Principal Position  Year   Salary
$		   Bonus
Awards
$		   Stock
Awards
$		   Option/
Awards(1)
$		   Incentive
Plan
Compensation
$		   Nonqualified
Deferred
Earnings
$		   All Other
Compensation
$		   Total
$		 
Gareth Sheridan,  2024    150,000              82,110                      25,000    257,110 
CEO(1)  2023    200,000         38,000    140,672                   378,672 
                                             
Serguei Melnik  2024    150,000              82,110              25,000    257,110 
President  2023    200,000              146,672                   346,672 
                                             
Alan Smith  2024    154,000              42,720              5,000    201,720 
Chief Operating Officer  2023    179,000              57,490                   236,490 
                                             
Gerald Goodman  2024    110,000              52,866              30,000    192,866 
Chief Financial Officer  2023    160,000    —         114,976    —         —    274,976 

 

(1) During the year ended January 31, 2023, we issued to Gareth Sheridan, our CEO, 11,667 shares of common stock valued at $38,000, representing compensation for the year ended January 31, 2023.

 

   Directors Compensation 
   Fees Earned
or Paid in
Cash		   Stock
Awards		   Option
Awards		   Non-Equity
Incentive
Plan
Compensation’		   Change in
Pension
Value and
NonQualified Deferred
Compensation
Earnings		  

All Other

Compensation

   Total 
Name  ($)   ($)   ($)   ($)   ($)   ($)   ($) 
(a)  (b)   (c)   (d)   (e)   (f)   (g)   (h) 
Mark Hamilton  $5,000   $      -   $10,146   $           -   $         -   $          -   $15,146 
Radu Bujorneau  $5,000   $-   $11,214   $-   $-   $-   $16,214 
Stefani Mancas  $5,000   $-   $10,146   $-   $-   $-   $15,146 
Irina Gram  $5,000   $-   $10,146   $-   $-   $-   $15,146 

 

Employment Agreements with Company Officers

 

The Company entered into a three-year employment agreement with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as a director. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $250,000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance Pbonus of 3.5% of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $150,000.

 

47

 

The Company entered into a three-year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $210,000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $110,000.

 

The Employment Agreements provide for incentive payments as established by the Board of Directors, and the Employment Agreements with Mr. Sheridan and Mr. Melnik provide for a performance bonus as follows:

 

Net Operating Profit Before Income Taxes  Performance
Bonus		 
On the First $10 Million   3.5%
On the Next $40 Million   3.5%
On the Next $50 Million   3.5%
On all Amounts Over $100 Million   3.5%

 

Each of the Employment Agreements contains similar provisions for discharge for “cause”, including breach of the Employment Agreement or specified detrimental conduct by the employee, in which cases accrued compensation would payable as provided in the Employment Agreements.  The Agreements also provide for termination by the executives for “good reason”, comprising events such as breach of the Agreement by the Company, assignment of duties inconsistent with the Executive’s position, , or in the event of a change in control of the Company. In the event of a termination by the Company without cause, or by the executive for “good reason”, the Company is required to pay to the Executive in a lump sum in cash within 30 days after the date of termination the aggregate of the following amounts:

 

  A. the sum of (1) the executive’s annual minimum salary through the date of termination to the extent not theretofore paid, (2) any annual incentive payment earned by the executive for a prior period to the extent not theretofore paid and not theretofore deferred, (3) any annual performance bonus payment earned by the executive for a prior period to the extent not theretofore paid and not theretofore deferred,(4) any accrued and unused  vacation pay and (5) any business expenses incurred by the executive that are unreimbursed as of the date of termination;

 

  B. The product of (1) the performance bonus payment and (2) a fraction, the numerator of which is the number of days that have elapsed in the fiscal year of the Company in which the date of termination occurs as of the date of termination, and the denominator of which is 365;

 

  C. the amount equal to the sum of (1) three (3) times the executive’s annual minimum  salary; (2) one (1) times the performance bonus payment and (3) one (1) times the incentive payment;

 

  D. In the event executive is not fully vested in any retirement benefits with the Company from pension, profit sharing or any other qualified or non-qualified retirement plan, the difference between the amounts executive would have been paid if he or she had been vested on the date his/her employment was terminated and the amounts paid or owed to the executive pursuant to such retirement plans;

  

  E. The product of (1) the incentive payment and (2) a fraction, the numerator of which is the number of days that have elapsed in the fiscal year of the Company in which the date of termination occurs as of the date of termination, and the denominator of which is 365; and

 

  F. If applicable, the present value of the amount equal to the sum of five (5) years’ Performance Bonus pay with such amount being calculated based on the Performance Bonus paid to the Employee the year prior to Termination.

 

In addition, all stock options and warrants outstanding as of the date of termination and held by the executive shall vest in full and become immediately exercisable for the remainder of their full term; all restricted stock shall no longer be restricted to the extent permitted by law, and the Company will use its best efforts, at its sole cost to register such restricted stock as expeditiously as possible.

 

Gross-up Reimbursement on Excise Taxes Paid by Employee on Certain Payments received from Company

 

The Employment Agreements of Mr. Sheridan and Mr. Melnik provide that, to the extent any payment under the Employment Agreement to the executive is subject to the excise tax imposed by section 4999 of the Internal Revenue Code, the executive is entitled to a gross-up payment from the Company to reimburse the executive for additional federal, state and local taxes imposed on executive by reason of the excise tax and the Company’s payment of the initial taxes on such amount. The Company is also required to bear the costs and expenses of any proceeding with any taxing authority in connection with the imposition of any such excise tax.

  

48

 

Employment Agreement with Alan Smith

 

The Company entered into a three-year employment agreement with Alan Smith, our Chief Operating Officer, effective October 1, 2021, for an initial term of three years through September 30, 2024. For his services to the Company during the term of the agreement, Mr. Smith receives a fixed base salary of $204,000 per year, payable no less frequently than monthly. This base salary is reviewed not later than the end of each calendar year that Mr. Smith is employed by the Company. As of July 31, 2022, the Company and Mr. Smith mutually agreed to reduce his annual salary to $154,000.

 

Pension Benefits

 

We currently have no plans that provide for payments or other benefits at, following, or in connection with retirement of our officers.

 

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END

 

   Option Awards      Stock Awards 
   Number of
Shares of
Common Stock
Underlying
Unexercised
Options
Exercisable		   Number of
Securities
Underlying
Unexercised
Options
Unexercisable		   Equity
Incentive Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned Options		   Options Exercise
Price		   Options
Expiration
Date		  Number of
Shares or
Units of
Stock
that
Have
Not
Vested		   Market
Value of
Shares or
Units of Stock
That
Have
Not
Vested		   Equity
Incentive Plan
Awards:
Number of
Unearned
Shares, Units
or Other Rights That
Have
Not Vested		   Incentive
Plan
Awards:
Market or
Payout
Value of
Unearned
Shares, Units or
Other
Rights That		 
Name  (#)   (#)   (#)   ($)   ($)  (#)   ($)   (#)   ($) 
(a)  (b)   (c)   (d)   (e)   (f)  (g)   (h)   (i)   (j) 
Gareth Sheridan, CEO   23,333           -            -   $4.58   January 21, 2025             -          -              -               - 
    29,167    -    -   $4.50   August 2, 2025   -    -    -    - 
    25,000    -    -   $4.12   December 8, 2025   -    -    -    - 
    70,000    -    -   $2.12   October 27, 2026   -    -    -    - 
                                            
Serguei Melnik, President   23,333    -    -   $4.58   January 21, 2025   -    -    -    - 
    29,167    -    -   $4.50   August 2, 2025   -    -    -    - 
    25,000    -    -   $4.12   December 8, 2025   -    -    -    - 
    70,000    -    -   $2.12   October 27, 2026   -    -    -    - 
                                            
Alan Smith, COO   11,667    -    -   $4.16   January 21, 2025   -    -    -    - 
    11,667    -    -   $4.09   August 2, 2025   -    -    -    - 
    10,000    -    -   $3.75   December 8, 2025   -    -    -    - 
    40,000    -    -   $1.93   October 27, 2026   -    -    -    - 
                                            
Gerald Goodman, CFO   11,667    -    -   $4.16   January 21, 2025   -    -    -    - 
    23,333    -    -   $4.09   August 2, 2025   -    -    -    - 
    20,000    -    -   $3.75   December 8, 2025   -    -    -    - 
    49,500    -    -   $1.93   October 27, 2026   -    -    -    - 
    87,500(1)   -    -   $1.93   October 27, 2026   -    -    -    - 

 

(1) This option held by Mr. Goodman is in the form of a common stock purchase warrant.

 

Bonuses

 

Any bonuses granted in the future will relate to meeting certain performance criteria that are directly related to areas within the named executive’s responsibilities with the Company. As we continue to grow, more defined bonus programs may be established to attract and retain our employees at all levels.

 

Other Director Compensation

  

There are no agreements or arrangements by which any directors or nominees are to receive compensation or other payments from third parties in return for serving on the Board of Directors.

 

49

 

PRINCIPAL STOCKHOLDERS

 

The following table provides information concerning the beneficial ownership of the Company’s common Stock by each director, certain executive officers, by all directors and officers of the Company as a group as of July 2, 2024. In addition, the table provides information concerning the current beneficial owners, if any, known to the Company to hold more than five percent (5%) of the outstanding common stock of the Company.

 

The amounts and percentage of stock beneficially owned are reported based on regulations of the SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a “beneficial owner” of a security if that person has or shares “voting power,” which includes the power to dispose of or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities of which that person has a right to acquire beneficial ownership within 60 days after July 2, 2024. Under these rules, more than one person may be deemed a beneficial owner of the same securities and a person may be deemed a beneficial owner of securities in which he has no economic interest. The percentage of common stock beneficially owned is based on 11,106,185 shares of common stock outstanding as of July 2, 2024.

 

Name and Address(1) of Beneficial Owner
(Management and Directors)		   Shares of
Common
Stock
Owned
Directly		     Shares of
Derivative
Securities
Owned
Beneficially		     Total
Beneficial
Ownership
Including
Option
Grants		     Percentage of
Issued and
Outstanding
Common
Stock		  
Gareth Sheridan     1,761,667       245,000       2,006,667       17.68 %
Serguei Melnik(2)     820,418       245,000       1,065,418       9.39 %
Stefani Mancas     14,125       25,583       39,708       *  
Mark Hamilton     17,208       28,500       45,708       *  
Radu Bujoreanu     15,750       29,333       45,083       *  
Irina Gram     1,167       18,000       19,167       *  
Dr. Jeff Patrick     36,612       160,000       196,612       1.75 %
Alan Smith     41,908       143,334       185,242       1.65 %
Gerald Goodman(3)     86,335       179,500       265,835       2.36 %
Sergei Glinka(5)     825,000       1,650,000       2,475,000       19.40 % 
All officers and directors as a group (10 individuals)     3,627,175       2,724,250       6,351,425       45.928 %
Other Beneficial Owners                                
Vitalie Botgros(4)     2,370,774       1,808,288       4,179,002       32.36 %

 

*Less than One (1%) Percent.

 

(1) The address for each director and officer, unless indicated otherwise, is c/o Nutriband, Inc., 121 South Orange Ave., Suite 1500, Orlando, FL 32801.

 

(2) Includes 29,167 shares owned by Mr. Melnik’s wife, as to which Mr. Melnik disclaims beneficial ownership, and 58,334 shares held under the UGMA for the benefit of his minor children.

 

(3) Gerald Goodman holds 86,335 shares directly and has been granted three-year options under the Company’s 2021 Employee Stock Option Plan to purchase an aggregate of 179,500 shares of common stock at exercise prices ranging from $1.93 per share to $4.16 per share.

 

(4)

Mr. Botgros, to the knowledge of the Company, is the ultimate beneficial owner of (1) 1,323,177 shares of common stock held by TII Jet Services Ltd. (“Jet Services”), and (2) 1,047,597 shares of common stock held by Nociata Holdings. Jet Services holds warrants to purchase 547,095 shares of common stock (of which warrants 134,635 are the publicly-traded Company warrants (NTRB).

 

Jet Services is 100% owned by Nociata Holding Limited, a Cyprus company (“Nociata”). Nociata is 100% owned by Mr. Botgros and holds owns 100% of the equity in Jet Services, so that Mr. Botros is the ultimate beneficial owner of all securities held by Jet Services and Nociata received 525,000 of its shares held, and 1,050,000 warrants from its investment in the Company’s private offshore financing closed April 19, 2024. Nociata holds 211,133 of the Nutriband publicly-traded warrants.

 

Mr. Botgros’ address is c/o Nociata Holding Limited, 1Apriliou, 47 Demetriou Bldg., 2,1st Floor, Flat/Office 12, 3117 Limassol, Cyprus.

 

(5) Mr. Glinka purchased 825,000 shares of common stock and 1,650,000 warrants in Nutriband’s equity financing that was completed April 19, 2024. Mr. Glinka’s address is 13 Morfu Str., Matina Court FL 402, 3012 Limassol, Cyprus. Mr. Glinka’s son, Daniil Glinka, purchased 125,000 shares of common stock at the offering price of $4.00 per share with warrants to purchase 250,000 shares of common stock in the Company’s April 19, 2024 private offshore financing.

 

To our knowledge, all beneficial owners named in this table have sole voting and investment power with respect to all shares shown as beneficially owned by them.

 

50

 

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

 

On February 1, 2023, the Board of Directors ratified and authorized the issuance of Option Award Agreements with respect option grants approved February 1, 2023, by the Compensation Committee, to officers and directors as set forth in the table below.

 

Name  No. of Shares        
Jeff Patrick, Chief Scientific Officer   30,000   $3.98   Services Rendered in fiscal 2024

 

On September 18, 2023, the Board of Directors ratified and authorized the issuance of Option Award Agreements with respect option grants approved September 18, 2023, by the Compensation Committee, to officers and directors as set forth in the table below.

 

Name  No. of Shares        
Jeff Patrick, Chief Scientific Officer   20,000   $2.65   Services Rendered in fiscal 2024

 

On October 19, 2023, the Board of Directors ratified and authorized the issuance of Option Award Agreements with respect option grants approved October 19, 2023, by the Compensation Committee modified a common stock purchase warrant issued to Gerald Goodman, as set forth in the table below.

 

Name  No. of Shares   No. of Warrants
Gareth Sheridan, CEO   70,000    -   $2.12   Services Rendered in fiscal 2024
Serguei Melnik, Chairman & President   70,000    -   $2.12   Services Rendered in fiscal 2024
Gerald Goodman, CFO   49,500    -   $1.93   Services Rendered in fiscal 2024
Alan Smith, Chief Operating Officer   40,000    -   $1.93   Services Rendered in fiscal 2024
Jeff Patrick, Chief Scientific Officer   40,000    -   $1.93   Services Rendered in fiscal 2024
Gerald Goodman, CFO   -    87,500   $1.93   Services Rendered in fiscal 2024

 

On March 20, 2024, our Board of Directors authorized the issuance of stock option award agreements to the following options to Board members and officers, and a consultant.

 

Date     Title and Amount (1)   Purchaser   Principal
Underwriter		   Total Offering Price/
Underwriting
Discounts
March 20, 2024     Option to purchase 97,500 shares of common stock.   Gareth Sheridan, Chief Executive Officer   NA   $2.61 per share/NA
March 20, 2024     Option to purchase 97,500 shares of common stock.   Serguei Melnik, President   NA   $2.61 per share/NA
March 20, 2024     Option to purchase 75,000 shares of common stock.   Gerald Goodman, Chief Financial Officer   NA   $2.37 per share/NA
March 20, 2024     Option to purchase 70,000 shares of common stock.   Alan Smith, Chief Operating Officer   NA   $2.37 per share/NA
March 20, 2024     Option to purchase 25,000 shares of common stock.   Jeff Patrick, Chief Scientific Officer   NA   $2.37 per share/NA
March 20, 2024     Option to purchase 2,500 shares of common stock.   Dianna Mather   NA   $2.37 per share/NA
March 20, 2024     Option to purchase 12,500   Olet Burea, consultant   NA   $2.37 per share/NA

 

On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors which included related parties. The related parties invested a total of $7,120,000 and received 1,780,000 shares of common stock and warrants to purchase 3,560,000 shares of common stock @ $6.43 per share. One related party, a director of the Company, invested $4.5 million which included $500,000 from his son and $700,000 from an entity he controls. The other related party invested $2.62 million from entities controlled by the investor.

 

The Company agreed on May 14, 2024, to convert $300,000, which as of that date of all the outstanding principal on the Credit line Promissory Note of the Company held by TII Jet Services LDA, a related party, (the “Holder”). The conversion was made pursuant to the terms of a Conversion Agreement dated May 14, 2024, which provided that the conversion of $300,000 of principal and $4,922 of accrued interest would be made at a price of $4.00 per share, resulting in the Company issuing on May 14, 2024, a total of 76,230 shares of common stock at the conversion price of $4.00 per share. On May 22, 2024, the Conversion Agreement was amended allowing the lender to purchase an additional 152,460 shares of common stock at a rate of two warrants per converted share, with an exercise price of $6.43 per share and a term of five years from the conversion date (May 14, 2024).

 

Independent Directors

 

Five of our directors, Sergei Glinka, Mark Hamilton, Radu Bujoreanu, Stefani Mancas and Irina Gram are independent directors based on the NASDAQ definition of independent director.

 

51

 

DESCRIPTION OF SECURITIES

 

Our authorized capital stock consists of 10,000,000 shares of preferred stock, par value $0.001 per share, none of which have been issued, and 291,666,666 shares of common stock, par value $0.001 per share, of which 11,106.185 shares are issued and outstanding. Holders of our common stock are entitled to equal voting rights, consisting of one vote per share on all matters submitted to a stockholder vote. Holders of common stock do not have cumulative voting rights. Therefore, holders of a majority of the shares of common stock can elect all of our directors. The presence, in person or by proxy duly authorized, of the holders of a majority of the outstanding shares of stock entitled to vote are necessary to constitute a quorum at any meeting of our stockholders. A vote by the holders of a majority of our outstanding shares is required to effectuate certain fundamental corporate changes such as liquidation, merger or an amendment to our articles of incorporation. In the event of liquidation, dissolution or winding up of our company, either voluntarily or involuntarily, each outstanding share of the common stock is entitled to share equally in our assets.

 

Holders of our common stock have no pre-emptive rights, no conversion rights and there are no redemption provisions applicable to our common stock. They are entitled to receive dividends when and as declared by our board of directors, out of funds legally available therefore. We have not paid cash dividends in the past and do not expect to pay any within the foreseeable future.

 

The board of directors has broad powers to create one or more series of preferred stock and to designate the voting powers, designations, preferences, limitations, restrictions and relative rights of each series.

 

Warrants

 

Warrants Issued in the Public Offering

 

The following summary of certain terms and provisions of the warrants (“Warrants”) included in the Units offered sold in our October 1, 2021 public offering (“IPO”) is not complete and is subject to, and qualified in its entirety by, the provisions of the warrant agent agreement between us and Equinity Trust Company, LLC, as warrant agent. As of June 28, 2024, 457,795 Warrants issued in the IPO have been exercised, with net proceeds to the Company of $2,942,970, and 959,005 Warrants are unexercised and outstanding.

 

Exercisability. The Warrants are exercisable at any time after their original issuance and at any time up to the date that is five years after their original issuance. The Warrants are exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice and, at any time a registration statement registering the issuance of the shares of common stock underlying the Warrants under the Securities Act is effective and available for the issuance of such shares, or an exemption from registration under the Securities Act is available for the issuance of such shares, by payment in full in immediately available funds for the number of shares of common stock purchased upon such exercise. If a registration statement registering the issuance of the shares of common stock underlying the Warrants under the Securities Act is not effective or available and an exemption from registration under the Securities Act is not available for the issuance of such shares, the holder may, in its sole discretion, elect to exercise the Warrant through a cashless exercise, in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the formula set forth in the Warrant. No fractional shares of common stock will be issued in connection with the exercise of a Warrant. In lieu of fractional shares, we will pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price.

 

Exercise Limitation. A holder does not have the right to exercise any portion of the warrant if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Warrants. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days following notice from the holder to us.

 

52

 

Exercise Price. The exercise price per whole share of common stock purchasable upon exercise of the Warrants is $6.43 per share, which is 120% of public offering price of the common stock adjusted for the August 12, 2022 forward stock split. The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting our common stock and also upon any distributions of assets, including cash, stock or other property to our stockholders.

 

Transferability. Subject to applicable laws, the Warrants may be offered for sale, sold, transferred or assigned without our consent.

 

Exchange Listing. We were approved for listing of our common stock and the Warrants on The NASDAQ Capital Market under the symbols “NTRB,” and “NTRBW,” respectively. 

 

Warrant Agent. The transfer agent for the common stock and warrant agent for the warrants is Equinity Trust Company, LLC (“Equiniti”), 6201 15th Ave, Brooklyn, NY 11219, telephone (800) 937-5449.

 

The Warrants have been issued in registered form under a warrant agent agreement between AST, as warrant agent, and us. The Warrants were initially be represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf of The Depository Trust Company (DTC) and registered in the name of Cede & Co., a nominee of DTC, or as otherwise directed by DTC.

  

Fundamental Transactions. In the event of a fundamental transaction, as described in the Warrants and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the warrants will be entitled to receive upon exercise of the warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the warrants immediately prior to such fundamental transaction.

 

Rights as a Stockholder. Except as otherwise provided in the Warrants or by virtue of such holder’s ownership of shares of our common stock, the holder of a Warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the Warrant.

 

Governing Law. The Warrants and the warrant agent agreement are governed by Delaware law.

 

Representative’s Warrants

 

As additional compensation to the underwriters in the public offering, upon consummation of our 2021 public offering, we issued to the designees of the underwriters warrants to purchase an aggregate of 123,200 shares of our common stock (the “Underwriters’ Warrants”). The Underwriters’ Warrants are exercisable, in whole or in part, and will expire on the fifth anniversary of the effective date of that registration statement. 

 

53

 

Warrants Issued in Recent Private Offshore Financing

 

On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, each Unit consisting of one share of common stock (“Shares”) and a warrant to purchase two shares of common stock (the “warrants”). The warrants are exercisable by payment of the exercise price in cash only and expire April 19, 2029, five years from the date of issuance. In this Offering, 4,200,000 warrants were issued to the investors, which have an exercise price of $6.43, The Offering was made solely to investors resident outside the United States and was not registered under the Securities Act, or the securities laws of any jurisdiction, including any jurisdiction outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act.

 

Nevada Law Provisions Relating to Certain Transactions

 

Sections 78.378 through 78.3793 of the Nevada Revised Statutes contains voting limitations on certain acquisitions of control shares. Sections 78.411 through 78.444 contain restrictions of combinations with interested stockholders. The Nevada law defines an interested stockholder as a beneficial owner (directly or indirectly) of 10% or more of the voting power of the outstanding shares of the corporation. In addition, combinations with an interested stockholder remain prohibited for three years after the person became an interested stockholder unless (i) the transaction is approved by the board of directors or the holders of a majority of the outstanding shares not beneficially owned by the interested party, or (ii) the interested stockholder satisfies certain fair value requirements.

 

Limitation on liability of officers and directors

 

Nevada law provides that subject to certain very limited statutory exceptions, a director or officer is not individually liable to the corporation or its stockholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a director or officer, unless it is proven that the act or failure to act constituted a breach of his or her fiduciary duties as a director or officer and such breach of those duties involved intentional misconduct, fraud or a knowing violation of law. The statutory standard of liability established by NRS Section 78.138 controls even if there is a provision in the corporation’s articles of incorporation unless a provision in the corporation’s articles of incorporation provides for greater individual liability.

 

Indemnification

 

Nevada law permits broad provisions for indemnification of officers and directors.

 

Our bylaws provide that each person who was or is made a party or is threatened to be made a party to or is involved (including, without limitation, as a witness) in any threatened, pending, or completed action, suit or proceeding, whether formal or informal, civil, criminal, administrative or investigative (hereinafter a “proceeding”), by reason of the fact that he or she is or was a director of or who is or was serving at our request as a director, officer, employee or agent of this or another corporation or of a partnership, joint venture, trust, other enterprise, or employee benefit plan (a “covered person”), whether the basis of such proceeding is alleged action in an official capacity as a covered person shall be indemnified and held harmless by us to the fullest extent permitted by applicable law, as then in effect, against all expense, liability and loss (including attorneys’ fees, costs, judgments, fines, ERISA excise taxes or penalties and amounts to be paid in settlement) reasonably incurred or suffered by such person in connection therewith, and such indemnification shall continue as to a person who ceased to be a covered person and shall inure to the benefit of his or her heirs, executors and administrators.

 

However, no indemnification shall be provided hereunder to any covered person to the extent that such indemnification would be prohibited by Nevada state law or other applicable law as then in effect, nor, with respect to proceedings seeking to enforce rights to indemnification, shall we indemnify any covered person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person except where such proceeding (or part thereof) was authorized by our board of directors, nor shall we indemnify any covered person who shall be adjudged in any action, suit or proceeding for which indemnification is sought, to be liable for any negligence or intentional misconduct in the performance of a duty.

 

SEC Policy on Indemnification for Securities Act liabilities

 

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

 

Transfer Agent and Warrant Agent

 

The transfer agent for the common stock and warrant agent for the warrants is Equiniti Trust Company, LLC, 6201 15th Ave, Brooklyn, NY 11219, telephone (800) 937-5449.

 

54

 

SHARES ELIGIBLE FOR FUTURE SALE

 

Sale of Restricted Securities

 

We have 11,106185 shares of common stock outstanding. Of these shares, approximately 4,250,000 shares are freely tradable, except that any shares purchased by our affiliates or by investors in the Company in a private offering may generally only be sold in compliance with Rule 144, which is described below. Of the remaining outstanding shares, the shares beneficially owned by our officers and directors and by recent investors in the Company will be deemed “restricted securities” under the Securities Act.

 

Rule 144

 

Any shares of our common stock held by an “affiliate” of ours may not be resold publicly except in compliance with the registration requirements of the Securities Act or under an exemption under Rule 144 or otherwise. Rule 144 permits our common stock that has been acquired by a person who is an affiliate of ours, or has been an affiliate of ours within the three months of the date of sale, to be sold into the market in an amount that does not exceed, during any three-month period, the greater of:

 

  ● 1% of the total number of shares of our common stock outstanding; or

 

  ● the average weekly reported trading volume of our common stock for the four calendar weeks prior to the sale.

 

Such sales are also subject to specific manner of sale provisions, a six-month holding period requirement, notice requirements and the availability of current public information about us.

 

Approximately We estimate that approximately 4,700,000 shares of our common stock are eligible for sale under Rule 144.

 

Rule 144 also provides that a person who is not deemed to have been an affiliate of ours at any time during the three months preceding a sale, and who has for at least six months beneficially owned shares of our common stock that are restricted securities, will be entitled to freely sell such shares of our common stock subject only to the availability of current public information regarding us. A person who is not deemed to have been an affiliate of ours at any time during the three months preceding a sale, and who has beneficially owned for at least one year shares of our common stock that are restricted securities, will be entitled to freely sell such shares of our common stock under Rule 144 without regard to the current public information requirements of Rule 144.

 

EXPERTS

 

Our financial statements included in this prospectus as of January 31, 2024 and 2023, have been included in reliance on the reports of Sadler, Gibb & Associates, LLC, an independent registered public accounting firm, given on the authority of such firm as experts in accounting and auditing.

 

WHERE YOU CAN FIND MORE INFORMATION

 

The Securities and Exchange Commission maintains an Internet site which contains reports, proxy and information statements, and other information regarding registrants that file electronically with the Commission at the address: sec.gov.

 

55

 

NUTRIBAND INC.

January 31, 2024

 

Index to Consolidated Financial Statements

 

Report of Independent Registered Public Accounting Firm (PCAOB ID: 3627) F-2
Consolidated Balance Sheet as of January 31, 2024 and 2023 F-3
Consolidated Statements of Operations for the years ended January 31, 2024 and 2023 F-4
Consolidated Statements of Changes in Stockholder’s Equity for the years ended January 31,2024 and 2023 F-5
Consolidated Statements of Cash Flows for the years ended January 31, 2024 and 2023 F-6
Notes to Consolidated Financial Statements F-7

 

F-1

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Shareholders of Nutriband Inc.:

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Nutriband Inc. (“the Company”) as of January 31, 2024 and 2023, the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the years in the two-year period ended January 31, 2024 and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of January 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the two-year period ended January 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) related to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgements. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

 

Long-Lived Asset Impairment Assessment

 

Critical Audit Matter Description

 

As described in note 2 to the consolidated financial statements, the Company performs impairment testing for its long-lived assets when events or changes in circumstances indicate that its carrying amount may not be recoverable and exceeds its fair value. Due to challenging industry and economic conditions, the Company tested its long-lived assets during the year ended January 31, 2024. The Company’s evaluation of the recoverability of these long-lived asset groups involved comparing the undiscounted future cash flows expected to be generated by these long-lived asset groups to their respective carrying amounts. The Company’s recoverability analysis requires management to make significant estimates and assumptions related to cash flows over the remaining useful life of these long-lived asset groups.

 

We identified the evaluation of the recoverability analysis for the long-lived assets in the 4P Therapeutics asset group as a critical audit matter because of the significant estimates and assumptions management used in the related cash flow analysis. Performing audit procedures to evaluate the reasonableness of these estimates and assumptions required a high degree of auditor judgment and an increased extent of effort.

 

How the Critical Audit Matter was Addressed in the Audit

 

Our audit procedures related to the following:

 

●Testing management’s process for developing the undiscounted cash flow model.
●Evaluating the appropriateness of the undiscounted cash flow models used by management.
●Testing the completeness and accuracy of underlying data used in the undiscounted cash flow model.
●Evaluating the significant assumptions used by management, including assumptions related to current and planned costs, future revenues, gross margin and other operating expenses to discern whether they are reasonable considering (i) the current and past performance of the entity; (ii) the consistency with external market and industry data; and (iii) whether these assumptions were consistent with evidence obtained in other areas of the audit.
●Professionals with specialized skill and knowledge were utilized by the Firm to assist in the evaluation of the undiscounted cash flow model and underlying assumptions.

 

/s/ Sadler, Gibb & Associates, LLC

 

We have served as the Company’s auditor since 2016.

 

Draper, UT

April 30, 2024

F-2

 

 

NUTRIBAND INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   January 31, 
   2024   2023 
ASSETS        
CURRENT ASSETS:          
Cash and cash equivalents  $492,942   $1,985,440 
Accounts receivable   148,649    113,045 
Inventory   168,605    229,335 
Prepaid expenses   211,667    365,925 
Total Current Assets   1,021,863    2,693,745 
           
PROPERTY & EQUIPMENT-net   774,924    897,735 
           
OTHER ASSETS:          
Goodwill   5,021,713    5,021,713 
Operating lease right of use asset   31,374    62,754 
Intangible assets-net   667,280    780,430 
           
TOTAL ASSETS  $7,517,154   $9,456,377 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
CURRENT LIABILITIES:          
Accounts payable and accrued expenses  $680,132   $534,679 
Deferred revenue   157,502    162,903 
Operating lease liability-current portion   34,276    31,291 
Notes payable-current portion   127,183    19,740 
Total Current Liabilities   999,093    748,613 
           
LONG-TERM LIABILITIES:          
Note payable-net of current portion   79,826    100,497 
Note payable-related party   
-
    
-
 
Operating lease liability-net of current portion   
-
    34,277 
Total Liabilities   1,078,919    883,387 
           
Commitments and Contingencies   
-
    
-
 
           
STOCKHOLDERS’ EQUITY:          
Preferred stock, $.001 par value, 10,000,000 shares authorized, -0- outstanding   
-
    
-
 
Common stock, $.001 par value, 291,666,666 shares authorized; 8,869,870 and 7,843,150 shares issued at January 31,2024 and 2023, respectively, 8,859,870 and 7,833,150 shares outstanding as of January 31, 2024 and 2023, respectively   8,860    7,833 
Additional paid-in-capital   34,442,339    31,092,807 
Accumulated other comprehensive loss   (304)   (304)
Treasury stock, 10,000 and 10,000 shares at cost, respectively   (32,641)   (32,641)
Accumulated deficit   (27,980,019)   (22,494,705)
Total Stockholders’ Equity   6,438,235    8,572,990 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $7,517,154   $9,456,377 

 

See notes to consolidated financial statements 

 

F-3

 

 

NUTRIBAND INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

 

   For the Years Ended
January 31,		 
   2024   2023 
         
Revenue  $2,085,314   $2,079,609 
           
Costs and expenses:          
Cost of revenues   1,223,209    1,329,200 
Research and development   1,960,425    982,227 
Goodwill impairment   
-
    327,326 
Selling, general and administrative   3,773,606    3,916,041 
Total Costs and Expenses   6,957,240    6,554,794 
           
Loss from operations   (4,871,926)   (4,475,185)
           
Other income (expense):          
Interest income   16,850    
-
 
Loss on extinguishment of debt   (554,423)   
-
 
Interest expense   (75,815)   (8,289)
Total other income (expense)   (613,388)   (8,289)
           
Loss before provision for income taxes   (5,485,314)   (4,483,474)
           
Provision for income taxes   
-
    
-
 
           
Net loss  $(5,485,314)  $(4,483,474)
           
Net loss per share of common stock-basic and diluted
  $(0.69)  $(0.53)
          
Weighted average shares of common stock outstanding - basic and diluted
   7,954,105    8,459,547 

 

See notes to consolidated financial statements 

 

F-4

 

 

NUTRIBAND INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

 

                   Accumulated         
       Common Stock   Additional   Other         
       Number of       Paid In   Comprehensive   Accumulated   Treasury 
Year Ended January 31, 2024  Total   shares   Amount   Capital   Income(Loss)   Deficit   Stock 
Balance, February 1, 2023  $8,572,990    7,833,150   $7,833   $31,092,807   $(304)  $(22,494,705)  $(32,641)
                                    
Warrants issued for services   242,840              242,840                
                                    
Options issued for services   499,856    -    
-
    499,856    
-
    
-
    
-
 
                                    
Issuance of common stock for note payable and interest   2,607,863    1,026,720    1,027    2,606,836                
                                    
Net loss for the year ended January 31, 2024   (5,485,314)   -    
-
    
-
    
-
    (5,485,314)   
-
 
                                    
Balance, January 31, 2024  $6,438,235    8,859,870   $8,860   $34,442,339   $(304)  $(27,980,019)  $(32,641)

 

                   Accumulated         
       Common Stock   Additional   Other         
       Number of       Paid In   Comprehensive   Accumulated   Treasury 
Year Ended January 31, 2023  Total   shares   Amount   Capital   Income(Loss)   Deficit   Stock 
Balance, February 1, 2022  $11,859,285    9,154,846   $9,155   $29,966,132   $(304)  $(18,011,231)  $(104,467)
                                    
Exercise of warrants   296,875    55,417    56    296,819    -    -    - 
                                    
Common stock returned in settlement   -    (1,400,000)   (1,400)   1,400    -    -    - 
                                    
Treasury stock issued for services   113,155    33,471    32    3,746    -    -    109,377 
                                    
Treasury stock and warrants issued for termination agreement   174,025    25,000    25    92,545              81,455 
                                    
Treasury stock repurchased   (119,006)   (35,584)   (35)   35    -    -    (119,006)
                                    
Options issued for services   732,130              732,130                
                                    
Net loss for the year ended January 31, 2023   (4,483,474)   -    -    -    -    (4,483,474)   - 
                                    
Balance, January 31, 2023  $8,572,990    7,833,150   $7,833   $31,092,807   $(304)  $(22,494,705)  $(32,641)

 

See notes to consolidated financial statements 

 

F-5

 

 

NUTRIBAND INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   For the Years Ended
January 31,		 
   2024   2023 
Cash flows from operating activities:        
Net loss  $(5,485,314)  $(4,483,474)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   287,722    330,143 
Operating lease expense   31,380    38,813 
Loss on extinguishment of debt   554,423    
-
 
Reserve for doubtful accounts   118,365    
-
 
Treasury stock issued for services   
-
    113,155 
Treasury stock and warrants issued for termination agreement   
-
    174,025 
Goodwill impairment   
-
    327,326 
Stock-based compensation-warrants   242,840    
-
 
Stock-based compensation-options   499,856    732,130 
Changes in operating assets and liabilities:          
Accounts receivable   (153,969)   (41,665)
Prepaid expenses   154,258    4,547 
Inventories   60,730    (97,687)
Deferred revenue   (5,401)   56,636 
Operating lease liability   (31,292)   (36,287)
Accounts payable and accrued expenses   198,893    (104,860)
Net Cash Used In Operating Activities   (3,527,509)   (2,987,198)
           
Cash flows from investing activities:          
Purchase of equipment   (51,761)   (79,304)
Net Cash Used in Investing Activities   (51,761)   (79,304)
           
Cash flows from financing activities:          
Proceeds from note payable-related party   2,000,000    
-
 
Proceeds from secured borrowing liability   106,528    
-
 
Proceeds from exercise of warrants   
-
    296,875 
Payment on note payable   (19,756)   (17,795)
Purchase of treasury stock   
-
    (119,006)
Net Cash Provided by Financing Activities   2,086,772    160,074 
           
Net change in cash   (1,492,498)   (2,906,428)
Cash and cash equivalents - Beginning of period   1,985,440    4,891,868 
Cash and cash equivalents - End of period  $492,942   $1,985,440 
           
Supplementary information:          
           
Cash paid for:          
Interest  $7,352   $4,266 
Income taxes  $
-
   $
-
 
           
Supplemental disclosure of non-cash investing and financing activities:          
Adoption of ASC 842 Operating lease asset and liability  $
-
   $94,134 
Promissory note on equipment purchase  $
-
   $22,794 
Common stock returned in settlement  $
-
   $1,400 
Issuance of common stock for extinguishment of debt  $2,607,863   $
-
 

 

See notes to consolidated financial statements

 

F-6

 

 

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

as of and for the Years Ended January 31, 2024 and 2023

 

1.ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Organization

 

Nutriband Inc. (the “Company”) is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was formed by the Company’s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.

 

On August 1, 2018, the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics. The former owner resigned as a director in January 2022.

 

4P Therapeutics is engaged in the development of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics, the Company’s business was the development and marketing of a range of transdermal consumer patches. Most of these products are considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration (the “FDA”). The Company entered a feasibility agreement as an initial step to seek FDA approval of its consumer transdermal products and its consumer products which are not being marketed in the United States.

 

With the acquisition of 4P Therapeutics, 4P Therapeutics’ drug development business became the Company’s principal business. The Company’s approach is to use generic drugs that are off patent and incorporate them into the Company’s transdermal drug delivery system. Although these medications have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products.

 

On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc. (“Pocono Pharmaceuticals”), a wholly owned subsidiary of the Company. On August 31, 2020, the Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono Coated Products LLC (“PCP”). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction, Pocono Pharmaceuticals also acquired 100% of the membership interests of Active Intelligence LLC (“Active Intelligence”).

 

Pocono Pharmaceuticals is a contract development and manufacturing organization with unique process capabilities and experience focused on coated product manufacturing. Pocono helps their customers with product design and development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical’s competitive edge is a low-cost manufacturing base: a result of its unique processes and state-of-the-art material technology. Active Intelligence manufactures activated kinesiology tape for transdermal or topical use.

 

F-7

 

 

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Forward Stock Split

 

On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the “Stock Split”) of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250,000,000 authorized shares to 291,666,666 authorized shares.

 

All share and per share information in these financial statements retroactively reflect the forward stock split.

 

Going Concern Assessment

 

Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look-forward period.

 

As of January 31, 2024, the Company had cash and cash equivalents of $492,942 and working capital of $22,770. For the year ended January 31, 2024, the Company incurred a loss from operations of $4,871,926 and used cash flow from operations of $3,527,509. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third-party and related-party debt to support cash flow from operations. In October 2021, the Company consummated a public offering and received net proceeds of $5,836,230. The Company has also received to date $3,239,845 in proceeds from the exercise of warrants. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 13, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. The Company was advanced $2,000,000, all of which was settled by the issuance of common stock during the year ended January 31, 2024. The $2,000,000 debt and accrued interest was converted into 1,026,720 shares of the Company’s common stock. On April 19, 2024, the Company received proceeds of $8,400,000 from a private placement of its common stock.

 

Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern.

 

Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.

 

F-8

 

 

Principles of Consolidation

 

The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020 under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows:

 

Nutriband Ltd.

4P Therapeutics LLC

Pocono Pharmaceuticals Inc.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

 

Revenue Recognition

 

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

 

Revenue Types

 

The following is a description of the Company’s revenue types, which include professional services and sale of goods:

 

●Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods

 

●Product revenues derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods

 

●Contract research and development services for pharmaceuticals and medical devices for life sciences customers with revenues listed under services

 

Contracts with Customers

 

A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

 

Contract Liabilities

 

Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

 

F-9

 

 

Performance Obligations

 

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.

 

All revenue recognized in the income statement is considered to be revenue from contracts with customers.

 

Disaggregation of Revenues

 

The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:

 

   Years Ended 
   January 31, 
   2024   2023 
Revenue by type        
Sale of goods  $1,920,280   $1,785,507 
Services   165,034    294,102 
Total  $2,085,314   $2,079,609 

 

   Years Ended 
   January 31, 
   2024   2023 
Revenue by geographic location:        
United States  $2,085,314   $2,079,609 
Foreign   
-
    
-
 
   $2,085,314   $2,079,609 

 

Cash and cash equivalents.

 

Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short-term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of January 31, 2024, the Company has no balances that exceed federally insured limits.

 

Accounts receivable

 

Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both the specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the years ended January 31, 2024, and 2023, the Company recorded bad debt expenses of $118,364 and $-0-, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $106,528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of January 31, 2024, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10%. The Company adopted ASU 2016-13 during 2023 and implemented the guidance on expected credit losses.

 

F-10

 

 

Inventories

 

Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of January 31, 2024, total inventory was $168,605, consisting of work-in-process of $7,466, finished goods of $8,707 and raw materials of $134,691. As of January 31, 2023, total inventory was $229,335, consisting of work-in-process of $11,021 and raw materials of $218,334.

 

Property, Plant and Equipment

 

Property and equipment represent an important component of the Company’s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:

 

Lab Equipment   5-10 years 
Furniture and fixtures   3 years 
Machinery and equipment   10-20 years 

 

Intangible Assets

 

Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisitions have also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.

 

Goodwill

 

Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. During the years ended January 31, 2024, and 2023, the Company recorded an impairment charge of $-0- and $327,326, respectively, reducing the Active Intelligence LLC Goodwill to $3,302,478. As of January 31, 2024, and 2023, Goodwill amounted to $5,021,713 and $5,021,713, respectively.

 

Long-lived Assets

 

Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value.

 

F-11

 

 

Earnings per Share

 

Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period.  Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of January 31, 2024, and 2023, there were 2,157,873 and 1,778,006 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.

 

Stock-Based Compensation

 

ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.

 

Business Combinations

 

The Company recognizes the assets acquired, the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value.

 

Leases

 

In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.

 

The Company applies guidance for right-of-use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.

 

Research and Development Expenses

 

Research and development costs are expensed as incurred.

 

Income Taxes

 

Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland.

 

F-12

 

 

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

 

The Company records net deferred tax assets to the extent they believe these assets will more-likely-than-not be realized.  In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.  In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.

 

Fair Value Measurements

 

FASB ASC 820, “Fair Value Measurements and Disclosure” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value.

 

The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:

 

  Level 1 -Observable inputs such as quoted market prices in active markets.
     
  Level 2 -Inputs other than quoted prices in active markets that are either directly or indirectly observable.
     
  Level 3 -Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

The carrying value of the Company’s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments.

 

Recent Accounting Standards

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (“CECL”), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016-13 during the year ended January 31, 2024. The adoption of ASU 2016-13 did not have a material impact on the Company’s balance sheet or statement of operations.

 

F-13

 

 

The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.

 

3.PROPERTY AND EQUIPMENT

 

   January 31, 
   2024   2023 
Lab equipment  $144,585   $144,585 
Machinery and equipment   1,292,389    1,240,628 
Furniture and fixtures   19,643    19,643 
    1,456,617    1,404,856 
Less: Accumulated depreciation   (681,693)   (507,121)
Net Property and Equipment  $774,924   $897,735 

 

Depreciation expenses amounted to $174,572 and $183,660 for the years ended January 31, 2024, and 2023, respectively. During the years ended January 31, 2024, and 2023, depreciation expenses of $131,360 and $139,689, respectively, have been allocated to cost of goods sold.

 

4.INCOME TAXES

 

The Company adopted the provisions of ASC 740, “Income Taxes, (“ASC 740”). As a result of the implementation of ASC 740, the Company recognized no adjustment in the net liability for unrecognized income tax benefits. The Company believes there are no potential uncertain tax positions, and all tax returns are correct as filed. Should the Company recognize a liability for uncertain tax positions, the Company will separately recognize the liability for uncertain tax positions on its balance sheet. Included in any liability or uncertain tax positions, the Company will also set up a liability for interest and penalties. The Company’s policy is to recognize interest and penalties related to uncertain tax positions as a component of the current

provision for income taxes.

 

There is no U.S. tax provision due to losses from U.S. operations for the years ended January 31, 2024 and 2023. Deferred income taxes are provided for the temporary differences between the financial reporting and tax basis of the Company’s assets and liabilities. The principal item giving rise to deferred taxes is the net operating loss carryforward in the U.S. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has set up a valuation allowance for losses for certain carryforwards that it believes may not be realized.

 

F-14

 

 

The provision for income taxes consists of the following:

 

    Years Ended
January 31,		 
    2024    2023 
Current          
Federal  $
          -
   $
           -
 
Foreign   
-
    
-
 
           
Deferred          
Federal   
-
    
-
 
Foreign   
-
    
-
 

 

A reconciliation of taxes on income computed at the federal statutory rate to amounts provided is as follows:

 

   Years Ended
January 31,		 
   2024   2023 
Book Income (loss from operations)  $(1,151,916)  $(941,530)
Common stock issued for services   155,966    168,768 
Impairment expense   
-
    68,738 
Unused operating losses   995,950    704,024 
Income tax expense  $
-
   $
-
 

 

As of January 31, 2024, the Company recorded a deferred tax asset associated with a net operating loss (“NOL”) carryforward of approximately $15,800,000 that was fully offset by a valuation allowance due to the determination that it was more likely than not that the Company would be unable to utilize those benefits in the foreseeable future. The Company’s NOL expires in 2041. The tax effect of the valuation allowance increased by approximately $1,151,916 during the year ended January 31, 2024. On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) significantly revised U.S. corporate income tax law by, among other things, reducing the corporate rate from 34% to 21%. Because the Company recognizes a valuation allowance for the entire balance, there is no net impact on the Company’s balance sheet or results of operations.

 

F-15

 

 

The types of temporary differences between tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax asset and their approximate tax effects are as follows:

 

   January 31, 
   2024   2023 
Net operating loss carryforward (expire through 2040)  $(3,312,698)  $(2,316,748)
Stock issued for services  $(1,455,848)   (1,299,882)
Intangible impairment expense  $(1,051,714)   (1,051,714)
Valuation allowance  $5,820,260    4,668,344 
Net deferred taxes  $
-
   $
-
 

 

5.NOTES PAYABLE

 

Notes Payable

 

Active Intelligence, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due October 16, 2028, with interest of 5% per year. The amount assumed was $139,184. The loan requires monthly payments of principal and interest of $1,697. During the year ended January 31, 2024, the Company made $15,378 of principal payments. As of January 31, 2024, the amount due was $85,249, of which $16,129 is current. As of January 31, 2023, the amount due was $100,627.

 

On April 3, 2022, the Company entered into a retail installment agreement for the purchase of an automobile. The contract price was $32,274, of which $22,795 was financed. The agreement is for five years bearing interest at 2.95% per annum with payments of $410 per month. The loan is secured by automobile. As of January 31, 2024, the amount due was $15,232 of which $4,456 is current. As of January 31, 2023, the amount due was $19,610.

 

Note payable-related party.

 

On July 17, 2023, the Company entered an amended Credit Line Note agreement, for an increased $5,000,000 credit line facility Note, with TII Jet Services LDA, a shareholder of the Company (replacing the $2,000,000 facility with the same lender that the Company entered on March 17, 2023). Outstanding advances under the Note bears interest at 7% per annum. The promissory note is due and payable in full on March 19, 2026. Interest is payable annually on December 31 of each year during the term of the note. During the year ended January 31, 2024, the Company received $2,000,000 on the Note. In December 2023, the Company converted the balance of the credit facility of $2,000,000 and $53,476 of accrued interest into 1,026,520 shares of common stock. The fair value of the common stock was $2,554,423 resulting in a $554,423 loss on extinguishment. As of January 31, 2024, the balance due was $-0-. The Company recorded interest expense of $60,453 for the year ended January 31, 2024.

 

Secured borrowing liability.

 

The Company entered into an accounts receivable sale agreement for one of its subsidiaries in connection with a bankruptcy claim. The Company received $106,528 and recorded the transaction as a secured loan payable against the account receivable. The sale of the account receivable balance was to an outside third party, whereby if the bankruptcy court does not pay the balance in full, the Company will owe back the unpaid portion. The loan is classified as a current liability as the Company expects the bankruptcy will be resolved in the next twelve months. The loan bears interest at 10%. For the year ended January 31, 2024, the Company recorded interest expense of $5,470.

 

Interest expenses for the year ended January 31, 2024, and 2023, were $75,815 and $6,289, respectively.

 

F-16

 

 

6.INTANGIBLE ASSETS

 

As of January 31, 2024, and 2023, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:

 

   January 31, 
   2024   2023 
Customer base  $314,100   $314,100 
Intellectual property and trademarks   817,400    817,400 
           
Total   1,131,500    1,131,500 
           
Less: Accumulated amortization   (464,220)   (351,070)
           
Net Intangible Assets  $667,280   $780,430 

 

In February 2021, the Company acquired an IP license from Rambam Med-Tech Ltd. for $50,000. The value of the intangible assets, consisting of intellectual property, license agreement and customer base has been recorded at their fair value by the Company and are being amortized over a period of three to ten years. The Company terminated the license agreement in October 2022. The Company issued 25,000 shares of its common stock from its treasury shares held by the Company and warrants to purchase 25,000 shares at an exercise price of $7.50 per share as part of the termination agreement. The Company recorded a termination expense of $174,025 during the year ended January 31, 2023. Which is included in selling, general and administrative expenses. The Company expensed the balance of the agreement of $33,334 during the year ended January 31, 2023, which is included in selling, general and administrative expenses. Amortization expenses for the years ended January 31, 2024, and 2023 amounted to $113,150 and $146,483, respectively.

 

Year Ended January 31,    
2025  $113,109 
2026   113,109 
2027   113,109 
2028   113,109 
2029   113,109 
2030 and thereafter   101,735 
   $667,280 

 

7.RELATED PARTY TRANSACTIONS

 

Activity during the year ended January 31, 2024

 

a)On February 1, 2023, options to purchase 30,000 shares of the Company’s common stock were issued to an executive of the Company at a price of $3.975 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $75,030 and was expensed during the year ended January 31, 2024.

 

F-17

 

 

b)In September and October 2023, options to purchase 374,500 shares of common stock to executives and directors of the Company at a price of $1.93, $2.12 and $2.65 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $424,826 and was expensed during the year ended January 31, 2024.
   
c)On October 26, 2023, warrants to purchase 87,500 shares of the Company’s common stock were issued to the Chief Financial Officer at a price of $1.93 per share. The warrant expires in three years. The fair value of the warrants issued amounted to $93,450 and was expensed during the year ended January 31, 2024.
   
d)On July 17, 2023, the Company entered an amended Credit Line Note facility with TII Jet Services LDA, a shareholder of the Company, for a credit facility of $5 million (replacing the $2,000,000 facility with the same lender that the Company entered on March 17, 2023). See Note 5 for further information. TII Jet Services LDA is owned 100% by a shareholder of the Company. During the year ended January 31, 2024, the Company received $2,000,000 from the credit facility. In December 2023, TII Jet Services LDA converted the balance of the credit facility of $2,000,000 and $53,436 of accrued interest into 1,026,520 shares of the Company’s common stock.

 

Activity during the year ended January 31, 2023

 

a)In May 2022, the Company issued stock awards to the Company’s CEO and the independent members of the Board of Directors. The CEO received 11,667 shares and the four directors received 1,167 shares each. The Company recorded a compensation expense of $53,200 in connection with the issuance of the shares.
   
b)On August 2, 2022, 137,084 options to purchase shares of the Company’s common stock were issued to executives of the Company at prices of $4.09 and $4.50 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $399,075 and was expensed during the year ended January 31, 2023.
   
c)On September 30, 2022, 35,000 options to purchase shares of the Company’s common stock were issued to the independent directors of the Company at a price of $3.59 per share. The options vest immediately and expire in five years. The fair value of the options issued for services amounted to $85,995 and was expensed during the year ended January 31, 2023
   
d)On December 7, 2022, options to purchase 107,500 shares of the Company’s common stock were issued to executives of the Company at prices of $3.53 and $3.88 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $245,170 and was expensed during the year ended January 31, 2023.

 

8.STOCKHOLDERS’ EQUITY

 

Preferred Stock

 

On January 15, 2016, the board of directors of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share.

 

On May 24, 2019, the board of directors created a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock (“Series A Preferred Stock”). On June 20, 2019, the Series A preferred Stock was terminated, and the 2,500,000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the board of directors.

 

F-18

 

 

Common Stock

 

On June 25, 2019, the Company effected a one-for-four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0.25 shares of common stock, and the Company decreased its authorized common stock in the same ratio from 100,000,000 to 25,000,000 shares.

 

On January 27, 2020, the Company amended its Articles of Incorporation to increase its authorized common shares from 25,000,000 authorized shares to 250,000,000 authorized shares.

 

On July 26, 2022, the Board of Directors of the Company approved a 7-for-6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. Pursuant to the operation of the amendment providing for the forward stock split filed with the Secretary of State of Nevada on August 4, 2022, the authorized common stock of the Company was increased from 250,000,000 shares to 291,666,666 shares in connection with the forward split.

 

Activity during the Year Ended January 31, 2024

 

(a)As of January 31, 2024, the Company holds 10,000 of its shares comprising $32,641 of treasury stock. There was no activity during the year ended January 31, 2024.
   
(b)In December 2024, TII Jet Services LDA converted $2,000,000 of its outstanding credit facility and $53,436 of accrued interest into 1,026,720 shares of the Company’s common stock. The fair value of the common stock at the date of issuance was $2,554,423, resulting in a $554,423 loss on extinguishment.

 

Activity during the Year Ended January 31, 2023

 

(a)In March and May 2022, the Company purchased 35,584 shares of its common stock for $119,006 and recorded the purchase as Treasury Stock. In May and December 2022, the Company issued 33,397 shares of stock awards to management, directors and employees from the treasury shares and recorded compensation expense of $113,155 In December 2022, the Company issued 25,000 shares from the treasury shares to non-employees in connection of the termination of the Rambam license agreement. As of January 31, 2023, the Company held 10,000 of its shares comprising $32,641 of treasury stock.
   
(b)On July 29, 2022, the Company received proceeds of $296,875 from the exercise of warrants and issued 55,417 shares of common stock.
   
(c)In July 2022, the Company cancelled 1,400,000 shares received in connection with the settlement of a lawsuit. See Note 11 for further information.

 

F-19

 

 

9.OPTIONS and WARRANTS

 

Warrants

 

The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company’s common stock issued to non-employees of the Company during the year ended January 31, 2024. On March 7, 2023, the Company issued 30,000 warrants to purchase the Company’s common shares to Barandnic Holdings Ltd. for services provided. The warrants are exercisable at a price of $4.00 per share and expire five years from the date of issuance. On October 27, 2023, the Company issued 145,833 warrants to purchase the Company’s common shares to management (87,500 warrants were issued to the Chief Financial Officer) and non-employees of the Company. The warrants are exercisable at a price of $1.93 per share and expire in three years from the date of issuance. These warrants replace previously issued warrants that have now been cancelled. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 152.10-174.45%; and a risk-free rate of 4.31%-4.84%. Non-cash compensation for the year ended January 31, 2024, amounted to $242,840.

 

       Exercise   Remaining   Intrinsic 
   Shares   Price   Life   Value 
Outstanding, January 31, 2022   1,435,622   $6.91     3.93 years    $
-
 
                     
Granted   25,000    7.50     5.00 years     
-
 
                     
Expired/Cancelled   (97,534)   5.36    
-
    
-
 
                     
Exercised   (55,417)   5.36    
-
    
-
 
                     
Outstanding, January 31, 2023   1,307,671    6.43    3.34 years    
-
 
                     
Granted   175,833    2.28    2.97 years    
-
 
                     
Expired/Cancelled   (200,466)   6.33    
-
    
-
 
                     
Exercised   
-
    
-
    
-
    
-
 
                     
Outstanding - January 31, 2024   1,283,038   $5.88     2.97 years    $99,166 
                     
Exercisable - January 31, 2024   1,283,038   $5.88     2.97 years    $99,166 

 

The following table summarizes additional information relating to the warrants outstanding as of January 31, 2024: 

 

Range of Exercise
Prices		   Number
Outstanding		   Weighted Average
Remaining
Contractual
Life(Years)		   Weighted Average
Exercise Price for
Shares
Outstanding		   Number
Exercisable		   Weighted Average
Exercise Price for
Shares
Exercisable		   Intrinsic
Value		 
$4.00    30,000    4.10   $4.00    30,000   $4.00   $
-
 
$6.43    1,082,205    2.68   $6.43    1,082,205   $6.43   $
-
 
$1.93    145,833    2.74   $1.93    145,833   $1.93   $99,166 
$7.50    25,000    3.77   $7.50    25,000   $7.50   $
-
 

 

F-20

 

 

Options

 

The following table summarizes the changes in options outstanding and the related price of the shares of the Company’s common stock issued to employees of the Company. See Note 7 for the issuance of related party options.

 

On November 1, 2021, the Board of Directors adopted the 2021 Employee Stock Option Plan (the “Plan”). The Company has reserved 408,333 shares for issuance and sale upon the exercise of stock options. In accordance with the Plan, on February 1, 2022, the Company reserved an additional 233,333 shares and on February 1, 2023, the Company reserved an additional 233,333 shares. The options vest immediately and expire in three years. Under the Plan, options may be granted which are intended to qualify as Incentive Stock Options (“ISO’s”) under Section 422 of the Internal Revenue Code of 1986 (the “Code”) or which are not (“non-ISO’s”) intended to qualify as Incentive Stock Options thereunder. The Plan also provides for restricted stock awards representing shares of common stock that are issued subject to such restrictions on transfer and other incidents of ownership and such forfeiture conditions as the Board of Directors, or the committee administering the Plan composed of directors who qualify as “independent” under Nasdaq rules, may determine. On November 3, 2021, the Company filed a Registration Statement on Form S-8, to register under the Securities Act of 1933, as amended the 408,333 shares of common stock reserved for issuance under the Plan. As of January 31, 2024, 166 shares remain available and issuance under the Plan.

 

During the year ended January 31, 2024, 404,500 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $1.93-$3.975 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $499,856 and was recorded during the year ended January 31, 2024. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 121.52-143.54%; and a risk-free rate of 3.00-4.5%.

 

During the year ended January 31, 2023, 279,584 options to purchase shares of the Company’s common stock were issued to executive officers and directors of the Company at prices of $3.59 to $4.50 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $732,130 and was recorded during the year ended January 31, 2023. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rate of 152.10-174.45%; and a risk-free rate of 3%.

 

The following table summarizes additional information relating to the options outstanding as of January 31, 2024.

 

   Shares   Exercise
Price		   Remaining
Life		   Intrinsic
Value		 
Outstanding, January 31, 2022   190,751   $4.26     2.97 years     
 
 
                     
Granted   279,584    3.93     3.00 years     
-
 
                     
Expired/Cancelled   
-
    
-
    
-
    
 
 
                     
Exercised   
-
    
-
    
-
    
 
 
                     
Outstanding, January 31, 2023   470,335    4.13     2.53 years     
 
 
                     
Granted   404,500    2.18     2.68 years     
-
 
                     
Expired/Cancelled   
-
    
-
    
-
    
 
 
                     
Exercised   
-
    
-
    
-
    
 
 
                     
Outstanding- January 31, 2024   874,835   $3.23    2.31 years    $214,460 
                     
Exercisable - January 31, 2024   874,835   $3.23    2.31 years    $214,460 

 

F-21

 

 

The following table summarizes additional information relating to the options outstanding as of January 31, 2024:

 

Prices   Outstanding   Life(Years)   Shares Outstanding   Exercisable   Shares Exercisable   Value 
                          
$1.93    214,500    2.74   $1.93    214,500   $1.93   $145,860 
$2.12    140,000    2.74   $2.12    140,000   $2.12   $68,600 
$2.65    20,000    2.63   $2.65    20,000   $2.65   $
-
 
$3.59    35,000    3.67   $3.59    35,000   $3.59   $
-
 
$3.75    57,500    1.85   $3.75    57,500   $3.75   $
-
 
$3.98    30,000    2.01   $3.98    30,000   $3.98   $
-
 
$4.09    78,750    1.50   $4.09    78,750   $4.09   $
-
 
$4.12    50,000    1.85   $4.12    50,000   $4.12   $
-
 
$4.16    144,083    0.97   $4.16    144,083   $4.16   $
-
 
$4.50    58,334    1.50   $4.50    58,334   $4.50   $
-
 
$4.58    46,668    0.97   $4.58    46,668   $4.58   $
-
 
                                 
      874,835    2.06   $3.23    874,835   $3.23   $214,460 

 

10.SEGMENT REPORTING

 

We organize and manage our business by the following two segments which meet the definition of reportable segments under ASC280-10, Segment Reporting: Sales of Goods and Services. These segments are based on the type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief officer decision maker, in making resource allocation decisions for our segments. Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit.

 

   Years Ended January 31, 
   2024   2023 
Net sales        
Pocono Pharmaceuticals  $1,920,280   $1,785,597 
4P Therapeutics   165,034    294,102 
    2,085,314    2,079,699 
Gross profit          
Pocono Pharmaceuticals   744,391    726,702 
4P Therapeutics   117,714    23,702 
    862,105    750,404 
Operating expenses          
Selling, general and administrative-Pocono Pharmaceuticals   606,275    577,930 
Selling, general and administrative-4P Therapeutics   236,953    103,181 
Selling, general and administrative-Corporate   2,930,378    3,234,930 
Research and development-4P Therapeutics   1,960,425    982,227 
Goodwill impairment-Pocono Pharmacueticals   
-
    327,326 
    5,734,031    5,225,594 
Depreciation and Amortization          
Pocono Pharmaceuticals  $222,159   $264,156 
Corporate   13,986    
-
 
4P Therapeutics   51,577    65,987 
   $287,722   $330,143 

 

F-22

 

 

The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.

 

   Years Ended
January 31,		 
   2024   2023 
Net sales        
United States  $2,085,314   $2,079,699 
Outside the United States   
-
    
-
 
   $2,085,314   $2,079,699 

 

    January 31,    January 31, 
    2024    2023 
Property and equipment, net of accumulated depreciation          
United States  $774,924   $897,735 
Outside the United States   
-
    
-
 
   $774,924   $897,735 
Assets          
Corporate  $344,192   $1,745,731 
Pocono Pharmaceuticals   5,079,293    5,400,814 
4P Therapeutics   2,093,369    2,309,832 
   $7,516,854   $9,456,377 

 

11.COMMITMENTS AND CONTIGENCIES

 

Employment Agreements

 

The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as directors and officers of the Company for the respective terms thereof. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $250,000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance bonus of 3.5% of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $150,000.

 

The Company entered into a three-year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $210,000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $110,000.

 

Kindeva Drug Delivery Agreement

 

On January 4, 2022, the Company signed a feasibility agreement with Kindeva Drug Delivery, L.P. (“Kindeva”) to develop Nutriband’s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system). The feasibility agreement provides for adapting Kindeva’s commercial transdermal manufacturing process to incorporate AVERSA technology in the fentanyl transdermal system.

 

F-23

 

 

The agreement will remain in force until the earlier of: (1) the completion of the work and deliverables under the Workplan; or (2) two (2) years after the Effective Date, after which time the agreement will expire. The feasibility Workplan was completed in February 2024.

 

The estimated cost to complete the feasibility Workplan was approximately $2.5 million. Nutriband made an advance deposit of $250,000 in January 2022, to be applied against the final invoices. As of January 31, 2024, Nutriband has incurred expenses of $2,369,508 and the net deposit of $138,250 after application to final invoices is included in prepaid expenses.

 

In January 2024, Nutriband signed a commercial development and clinical supply agreement with Kindeva Drug Delivery for development of AVERSA Fentanyl using Kindeva’s FDA-approved fentanyl patch. Kindeva will perform commercial manufacturing process development and clinical supplies manufacturing for the human abuse potential clinical study required by the FDA in support of a New Drug Application. The agreement replaces the previous feasibility agreement between the two companies which was focused on adapting Kindeva’s commercial transdermal manufacturing process to incorporate AVERSA abuse deterrent transdermal technology. The estimated cost to complete the commercial process development and clinical supplies manufacturing is approximately $8.1 million and the expected timing of FDA submission is twelve to eighteen months.

 

Lease Agreement

 

On February 1, 2022, Pocono Pharmaceuticals entered into a lease agreement with Geometric Group, LLC for 12,000 square feet of warehouse space currently occupied by Active Intelligence. The monthly rental is $3,000 and the lease expires on January 31, 2025. The lease can be extended for an additional three years at the same monthly rental. The Company recorded a Right of Use asset in the amount of $94,134 in connection with the valuation.

 

MDM Worldwide Agreement

 

In September 2022, the Company entered into a public relations agreement with MDM Worldwide. In connection with the agreement, the Company agreed to issue 20,000 options to MDM Worldwide. In October 2023, the contract was mutually terminated, and no options were issued. For the year ended January 31, 2024, the Company paid MDM Worldwide $190,000.

 

Money Channel Agreement

 

On March 13, 2023, the Company entered into a media advertising agreement with Money Channel Inc. The Company will pay a monthly fee and after ninety days can cancel the agreement. The Company, after 90 days, will also issue options to purchase 50,000 shares of common stock to Money Channel Inc. at an exercise price of $4.00 per share. In June 2023, the parties agreed to terminate the agreement by mutual consent. No options were issued. For the year ended January 31, 2024, the Company paid the Money Channel $100,000.

 

Sorrento Therapeutics, Inc. Agreement

 

4P Therapeutics had unpaid account receivables related to a contract clinical research services agreement in place with Sorrento Therapeutics. On February 13, 2023, Sorrento declared Chapter 11 bankruptcy. On July 25, 2023, 4P Therapeutics assigned its claim under the bankruptcy proceedings from Sorrento Therapeutics Inc. and received proceeds of $106,528. The amount due under the claim was $118,675 and 4P Therapeutics recorded a reserve for bad debts of $118,675 during the year ended January 31, 2024. Under the agreement with the buyer of the claim, 4P Therapeutics will make proportional restitution and/or repayment of the purchase amount to the extent the claim is disallowed, reduced or not paid at the same time or distribution rate as other general unsecured claims against the Debtor are paid. The Company has recorded the amount of the proceeds as a secured loan payable to the factor as of January 31, 2024.

 

F-24

 

 

Upstream Termination

 

On May 24, 2023, the Company sent notice of the termination of the Securities Facility Services Agreement, dated January 3, 2023, by and between MERJ DEP Ltd. And the Company (“Agreement”), which provided for the dual listing of the Company’s common stock on the MERJ Upstream exchange (“Upstream”), which is operated as a fully registered and licensed integrated securities exchange, clearing system and depository for digital and non-digital securities under the Seychelles security laws. The termination was effective May 31, 2023.

 

Legal Proceedings

 

The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (“Gunnar”) and Lucosky Brookman LLP (“LB”) in the Supreme Court of the State of New York, New York County, under Index No.654633/2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company’s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $500,000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees.

 

In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $1,000,000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims.

 

Currently, there are no pending hearings or motions as both parties are engaged in discovery and are attempting to resolve the matter amicably.

 

12.SUBSEQUENT EVENTS

 

(a)In February and April 2024, the Company received proceeds of $300,000 from its Credit Line Facility.
   
(b)On March 20, 2024, 390,000 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $2.37-$2.61 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued amounted to $450,000.
   
(c)On March 20, 2024, our Board of Directors adopted an amendment to the Company’s Employee Stock Option Plan (the “Plan”) increasing the number of shares of common stock subject to the Plan (as of March 20, 2024, 875,000 shares) to 1,400,000 shares (the “Amendment”). The Company will submit the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting. If the Amendment is not approved by stockholders within one year of adoption, the increase in shares subject to the Plan will be void, together with any options issued following March 20,2024, in the period pending approval of the Plan by our stockholders.
   
(d)On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, each Unit consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock, the Warrants having an initial exercise price of $6.43, are exercisable by payment of the exercise price in cash only and expire April 19,2029, five years from the date of issuance (“Warrants”). The Offering was made solely to investors residing outside the United States and was not registered under the Security Act of 1933, as amended, (the “Security Act”), or the securities law of any jurisdiction, including outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act.

 

F-25

 

 

Unaudited Financial Statements for the Three and Six Months Ended April 30, 2024

 

Condensed Consolidated Balance Sheets as of April 30, 2024 (unaudited) and January 31, 2024 F-27
Condensed Consolidated Statements of Operations for the three months ended April 30, 2024, and 2023 (unaudited) F-28
Consolidated Statements of Stockholders’ Equity for the three months ended April 30, 2024, and 2023 (unaudited) F-29
Condensed Consolidated Statements of Cash Flows for the nine months ended April 30, 2024, and 2023 (unaudited) F-30
Notes to Unaudited Condensed Consolidated Financial Statements F-31

 

F-26

 

 

NUTRIBAND INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

   April 30,   January 31, 
   2024   2024 
   (Unaudited)     
ASSETS        
         
CURRENT ASSETS:        
Cash and cash equivalents  $8,347,740   $492,942 
Accounts receivable   85,144    148,649 
Inventory   168,505    168,605 
Prepaid expenses   128,551    211,667 
Total Current Assets   8,729,940    1,021,863 
           
PROPERTY & EQUIPMENT-net   740,305    774,924 
           
OTHER ASSETS:          
Goodwill   5,021,713    5,021,713 
Operating lease right of use asset   23,529    31,374 
Intangible assets-net   638,993    667,280 
           
TOTAL ASSETS  $15,154,480   $7,517,154 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
CURRENT LIABILITIES:          
Accounts payable and accrued expenses  $994,106   $680,132 
Deferred revenue   269,345    157,502 
Operating lease liability-current portion   25,988    34,276 
Notes payable-current portion   127,419    127,183 
Total Current Liabilities   1,416,858    999,093 
           
LONG-TERM LIABILITIES:          
Note payable-net of current portion   74,509    79,826 
Note payable-related party   300,000    
-
 
Total Liabilities   1,791,367    1,078,919 
           
Commitments and Contingencies   
-
    
-
 
           
STOCKHOLDERS’ EQUITY:          
Preferred stock, $.001 par value, 10,000,000 shares authorized, -0- outstanding   
-
    
-
 
Common stock, $.001 par value, 291,666,666 shares authorized; 10,969,870 and 8,869,870 shares issued at April 30, 2024 and January 31,2024, respectively, 10,959,870 and 8,859,870 shares outstanding as of April 30, 2024 and January 31, 2024, respectively   10,960    8,860 
Additional paid-in-capital   43,263,194    34,442,339 
Accumulated other comprehensive loss   (304)   (304)
Treasury stock, 10,000 and 10,000 shares at cost, respectively   (32,641)   (32,641)
Accumulated deficit   (29,878,096)   (27,980,019)
Total Stockholders’ Equity   13,363,113    6,438,235 
           
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $15,154,480   $7,517,154 

 

See notes to unaudited consolidated financial statements

 

F-27

 

 

NUTRIBAND INC. AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

 

   For the Three Months Ended 
   April 30, 
   2024   2023 
         
Revenue  $408,532   $476,932 
           
Costs and expenses:          
Cost of revenues   243,746    254,648 
Research and development   974,535    400,430 
Selling, general and administrative   1,079,728    839,732 
Total Costs and Expenses   2,298,009    1,494,810 
           
Loss from operations   (1,889,477)   (1,017,878)
           
Other income (expense):          
Interest income   18    5,815 
Interest expense   (8,618)   (3,166)
Total other income (expense)   (8,600)   2,649 
           
Loss  before provision for income taxes   (1,898,077)   (1,015,229)
           
Provision for income taxes   -    - 
           
Net loss  $(1,898,077)  $(1,015,229)
           
Net loss per share of common stock-basic and diluted
  $(0.21)  $(0.13)
           
Weighted average shares of common stock outstanding          
- basic and diluted
   9,159,869    7,833,150 

 

See notes to unaudited consolidated financial statements

 

F-28

 

 

NUTRIBAND INC. AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

 

Three Months Ended April 30, 2024

 

                   Accumulated         
       Common Stock   Additional   Other         
       Number of       Paid In   Comprehensive   Accumulated   Treasury 
   Total   shares   Amount   Capital   Income(Loss)   Deficit   Stock 
Balance, February 1, 2024  $6,438,235    8,859,870   $8,860   $34,442,339   $(304)  $(27,980,019)  $(32,641)
                                    
Options issued for services   422,955    -    -    422,955    -    -    - 
                                    
Proceeds from sale of common stock and warrants   8,400,000    2,100,000    2,100    8,397,900    -    -    - 
                                    
Net loss for the three months ended April 30, 2024   (1,898,077)   -    -    -    -    (1,898,077)   - 
                                    
Balance, April 30, 2024  $13,363,113    10,959,870   $10,960   $43,263,194   $(304)  $(29,878,096)  $(32,641)

 

Three Months Ended April 30, 2023

 

                   Accumulated         
       Common Stock   Additional   Other         
       Number of       Paid In   Comprehensive   Accumulated   Treasury 
   Total   shares   Amount   Capital   Income(Loss)   Deficit   Stock 
Balance, February 1, 2023  $8,572,990    7,833,150   $7,833   $31,092,807   $(304)  $(22,494,705)  $(32,641)
                                    
Warrants issued for services   87,090    -    -    87,090    -    -    - 
                                    
Options issued for services   75,030    -    -    75,030    -    -    - 
                                    
Net loss for the three months ended April 31, 2023   (1,015,229)   -    -    -    -    (1,015,229)   - 
                                    
Balance, April 30, 2023  $7,719,881    7,833,150   $7,833   $31,254,927   $(304)  $(23,509,934)  $(32,641)

 

See notes to unaudited consolidated financial statements

 

F-29

 

 

NUTRIBAND INC. AND SUBSIDIARIES

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   For the Three Months Ended 
   April 30, 
   2024   2023 
Cash flows from operating activities:        
Net loss  $(1,898,077)  $(1,015,229)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   69,101    75,201 
Operating lease expense   7,845    7,845 
Stock-based compensation-warrants   -    87,090 
Stock-based compensation-options   422,955    75,030 
Changes in operating assets and liabilities:          
Accounts receivable   63,505    (51,596)
Prepaid expenses   84,631    (3,354)
Inventories   (1,415)   47,838 
Deferred revenue   111,843    25,794 
Operating lease liability   (8,288)   (7,557)
Accounts payable and accrued expenses   313,974    9,074 
Net Cash Used In Operating Activities   (833,926)   (749,864)
           
Cash flows from investing activities:          
Purchase of equipment   (6,195)   (2,624)
Net Cash Used in Investing Activities   (6,195)   (2,624)
           
Cash flows from financing activities:          
Proceeds from note payable-related party   300,000    50,000 
Proceeds from sale of common stock and warrants   8,400,000    - 
Payment on note payable   (5,081)   (4,877)
Net Cash Provided by Financing Activities   8,694,919    45,123 
           
Net change in cash   7,854,798    (707,365)
           
Cash and cash equivalents - Beginning of period   492,942    1,985,440 
           
Cash and cash equivalents - End of period  $8,347,740   $1,278,075 
           
Supplementary information:          
           
Cash paid for:          
Interest  $611   $1,725 
           
Income taxes  $-   $- 

 

See notes to unaudited consolidated financial statements

 

F-30

 

 

NUTRIBAND INC. AND SUBSIDIARIES

Notes to Unaudited Consolidated Financial Statements

as of and for the Three Months Ended April 30, 2024 and 2023

 

1.ORGANIZATION AND DESCRIPTION OF BUSINESS

 

Organization

 

Nutriband Inc. (the “Company”) is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was formed by the Company’s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.

 

On August 1, 2018, the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics. The former owner resigned as a director in January 2022.

 

4P Therapeutics is engaged in the development of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics, the Company’s business was the development and marketing of a range of transdermal consumer patches. Most of these products are considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration (the “FDA”). The Company entered a feasibility agreement as an initial step to seek FDA approval of its consumer transdermal products and its consumer products which are not being marketed in the United States.

 

With the acquisition of 4P Therapeutics, 4P Therapeutics’ drug development business became the Company’s principal business. The Company’s approach is to use generic drugs that are off patent and incorporate them into the Company’s transdermal drug delivery system. Although these medications have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products.

 

On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc. (“Pocono Pharmaceuticals”), a wholly owned subsidiary of the Company. On August 31, 2020, the Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono Coated Products LLC (“PCP”). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction, Pocono Pharmaceuticals also acquired 100% of the membership interests of Active Intelligence LLC (“Active Intelligence”).

 

Pocono Pharmaceuticals is a coated products manufacturing entity organized to take advantage of its unique process capabilities and experience. Pocono helps their customers with product design and development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical’s competitive edge is a low-cost manufacturing base: a result of its unique processes and state-of-the-art material technology. Active Intelligence manufactures activated kinesiology tape. The tape has transdermal and topical properties. This tape is used the same as traditional kinesiology tape.

 

F-31

 

 

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Unaudited Financial Statements

 

The consolidated balance sheet as of April 30, 2024, and the consolidated statements of operations, stockholders’ equity, and cash flows for the periods presented have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to prepare fairly the financial position, results of operations, changes in stockholders’ equity and cash flows for all periods presented have been made. The results for the three months ended April 30, 2024, are not necessarily indicative of the results to be expected for the full year. The consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in Nutriband’s Annual Report on Form 10-K for the year ended January 31, 2024.

 

Certain information and footnote disclosures required under generally accepted accounting principles in the United States of America (U.S. GAAP”) have been condensed or omitted from these consolidated financial statements pursuant to the rules and regulations, including interim reporting requirements of the U.S. Securities and Exchange Commission (“SEC”). The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosures of contingent amounts in our consolidated financial statements and accompanying footnotes. Actual results could differ from estimates.

 

The Company’s significant accounting policies in Note 2 in the Company’s Annual Report on Form 10-K for the year ended January 31, 2024. There were no significant changes to these accounting policies during the three months ended April 30, 2024.

 

Forward Stock Split

 

On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the “Stock Split”) of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250,000,000 authorized shares to 291,666,666 authorized shares.

 

All share and per share information in these financial statements retroactively reflect the forward stock split.

 

Going Concern Assessment

 

Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look-forward period.

 

F-32

 

 

As of April 30, 2024, the Company had cash and cash equivalents of $8,347,740 and working capital of $7,313,082. For the three months ended April 30, 2024, the Company incurred a net loss from operations of $1,898,077 and used cash flow from operations of $833,926. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third-party and related-party debt to support cash flow from operations. The Company has used these proceeds from the sales of securities and issuance of third-party and related party debt to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 13, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. On April 19, 2024, the Company received proceeds of $8,400,000 from equity financing with European investors, of which $7.12 million is from related parties.

 

Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern.

 

Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.

 

Principles of Consolidation

 

The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020 under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows:

 

Nutriband Ltd.

4P Therapeutics LLC

Pocono Pharmaceuticals Inc.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

 

Revenue Recognition

 

In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

 

F-33

 

 

Revenue Types

 

The following is a description of the Company’s revenue types, which include professional services and sale of goods:

 

●Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods.

 

●Product revenues derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods.

 

●Contract research and development services for pharmaceutical and medical devices for life sciences customers with revenues listed under services.

 

Contracts with Customers

 

A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

 

Contract Liabilities

 

Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

 

Performance Obligations

 

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.

 

All revenue recognized in the income statement is considered to be revenue from contracts with customers.

 

F-34

 

 

Disaggregation of Revenues

 

The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:

 

   Three Months Ended 
   April 30, 
   2024   2023 
Revenue by type        
Sale of goods  $408,532   $401,057 
Services   
-
    75,875 
Total  $408,532   $476,932 

 

   Three Months Ended 
   April 30, 
   2024   2023 
Revenue by geographic location:          
United States  $408,532   $476,932 
Foreign   
-
    
-
 
   $408,532   $476,932 

 

Cash and cash equivalents.

 

Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short-term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of April 30, 2024, the Company had $7,879,000 that exceeded federally insured limits.

 

Accounts receivable

 

Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both the specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the three months ended April 30, 2024, and 2023, the Company recorded bad debt expenses of $1,200 and $-0-, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $106,528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of April 30, 2024, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10%. The Company adopted ASU 2016-13 during 2013 and implemented the guidance on expected credit losses.

 

Inventories

 

Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of April 30, 2024, total inventory was $168,505, consisting of work-in-process of $27,447, finished goods of $26,751 and raw materials of $114,307. As of January 31, 2024, total inventory was $168,605, consisting of work-in-process of $7,466, finished goods of $8,707 and raw materials of $134,691.

 

F-35

 

 

Property, Plant and Equipment

 

Property and equipment represent an important component of the Company’s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:

 

Lab Equipment  5-10 years
Furniture and fixtures  3 years
Machinery and equipment  10-20 years

 

Intangible Assets

 

Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisitions have also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.

 

Goodwill

 

Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. During the years ended January 31, 2024, and 2023, the Company recorded an impairment charge of $-0- and $327,326, respectively, reducing the Active Intelligence LLC Goodwill to $3,302,478. As of April 30, 2024, and January 31, 2024, Goodwill amounted to $5,021,713 and $5,021,713, respectively.

 

Long-lived Assets

 

Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value.

 

Earnings per Share

 

Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period.  Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of April 30, 2024, and 2023, there were 6,747,873 and 1,783,373 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.

 

F-36

 

 

Stock-Based Compensation

 

ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.

 

Business Combinations

 

The Company recognizes the assets acquired, the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value.

 

Leases

 

In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.

 

The Company applies the guidance for right-of-use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.

 

Research and Development Expenses

 

Research and development costs are expensed as incurred.

 

Income Taxes

 

Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland.

 

The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

 

The Company records net deferred tax assets to the extent they believe these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.  In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.

 

F-37

 

 

Fair Value Measurements

 

FASB ASC 820, “Fair Value Measurements and Disclosure” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value.

 

The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:

 

  Level 1 - Observable inputs such as quoted market prices in active markets.
       
  Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable.
       
  Level 3 - Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.

 

The carrying value of the Company’s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments.

 

Recent Accounting Standards

 

In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (“CECL”), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016-13 during the year ended January 31, 2024. The adoption of ASU 2016-13 did not have a material impact on the Company’s balance sheet or statement of operations.

 

The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.

 

F-38

 

 

3.PROPERTY AND EQUIPMENT

 

   April 30,   January 31, 
   2024   2024 
Lab equipment  $144,585   $144,585 
Machinery and equipment   1,298,584    1,292,389 
Furniture and fixtures   19,643    19,643 
    1,462,812    1,456,617 
Less: Accumulated depreciation   (722,507)   (681,693)
Net Property and Equipment  $740,305   $774,924 

 

Depreciation expenses amounted to $40,814 and $46,914 for the three months ended April 30, 2024, and 2023, respectively. During the three months ended April 30, 2024, and 2023, depreciation expenses of $30,242 and $36,179, respectively, have been allocated to cost of goods sold.

 

4.NOTES PAYABLE

 

Notes Payable

 

Active Intelligence, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due October 16, 2028, with interest of 5% per year. The amount assumed was $139,184. The loan requires monthly payments of principal and interest of $1,697. During the three months ended April 30, 2024, the Company made $3,959 of principal payments. As of April 30, 2024, the amount due was $81,290, of which $16,331 is current. As of January 31, 2024, the amount due was $85,249.

 

On April 3, 2022, the Company entered into a retail installment agreement for the purchase of an automobile. The contract price was $32,274, of which $22,795 was financed. The agreement is for five years bearing interest at 2.95% per annum with payments of $410 per month. The loan is secured by automobile. As of April 30, 2024, the amount due was $14,860 of which $4,560 is current. As of January 31, 2024, the amount due was $15,232.

 

Note payable-related party.

 

On July 17, 2023, the Company entered an amended Credit Line Note agreement, for an increased $5,000,000 credit line facility t the Company entered on March 17, 2023). Outstanding advances under the Note bears interest at 7% per annum. The promissory note is due and payable in full on March 19, 2026. Interest is payable annually on December 31 of each year during the term of the note. During the year ended January 31, 2024, the Company received $2,000,000 on the Note. In December 2023, the Company converted the balance of the credit facility of $2,000,000 and $53,476 of accrued interest into 1,026,520 shares of common stock. The fair value of the common stock was $2,554,423 resulting in a $554,423 loss on extinguishment. The Company received advances of $300,000 during the three months ended April 30, 2024. As of April 30, 2024, the balance due was $300,000. The Company recorded interest expense of $4,163 for the three months ended April 30, 2024.

 

F-39

 

 

Secured borrowing liability.

 

The Company entered into an accounts receivable sale agreement for one of its subsidiaries in connection with a bankruptcy claim. The Company received $106,528 and recorded the transaction as a secured loan payable against the account receivable. The sale of the account receivable balance was to an outside third party, whereby if the bankruptcy court does not pay the balance in full, the Company will owe back the unpaid portion. The loan is classified as a current liability as the Company expects the bankruptcy will be resolved in the next twelve months. The loan bears interest at 10%. For the three months ended April 30, 2024, the Company recorded interest expense of $2,578.

 

Interest expenses for the three months ended April 30, 2024, and 2023, were $8,618 and $3,166, respectively.

 

5.INTANGIBLE ASSETS

 

As of April 30, 2024, and January 31, 2024, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:

 

   April 30,   January 31, 
   2024   2024 
Customer base  $314,100   $314,100 
Intellectual property and trademarks   817,400    817,400 
           
Total   1,131,500    1,131,500 
           
Less: Accumulated amortization   (492,507)   (464,220)
           
Net Intangible Assets  $638,993   $667,280 

 

Amortization expenses for the three months ended April 30, 2024, and 2023 amounted to $28,287 and $28,287, respectively.

 

Year Ended January 31,    
2025  $84,863 
2026   113,148 
2027   113,148 
2028   113,148 
2029   94,226 
2030 and thereafter   120,460 
   $638,993 

 

6.RELATED PARTY TRANSACTIONS

 

Activity during the year ended April 30, 2024

 

a)In March 2024, options to purchase 390,000 shares of common stock to executives and employees of the Company at a price of $2.37 and $2.61 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $422,955 and was expensed during the three months ended April 30, 2024.

 

F-40

 

 

b)

On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors which included related parties. The related parties invested a total of $7,120,000 and received 1,780,000 shares of common stock and warrants to purchase 3,560,000 shares of common stock @ $6.43 per share. One related party, a director of the Company, invested $4.5 million which included $500,000 from his son and $700,000 from an entity he controls. The other related party invested $2.62 million from entities controlled by the investor.
   
c)During the three months ended April 30, 2024, the Company received $300,000 from the credit line facility with TII Jet Services LDA. See Note 4 for further information.

 

Activity during the three months ended April 30, 2023

 

a)On February 1, 2023, options to purchase 30,000 shares of the Company’s common stock were issued to an executive of the Company at a price of $3.975 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $75,030 and was expensed during the three months ended April 30, 2023.

 

7.STOCKHOLDERS’ EQUITY

 

Preferred Stock

 

On January 15, 2016, the board of directors of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share.

 

On May 24, 2019, the board of directors created a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock (“Series A Preferred Stock”). On June 20, 2019, the Series A preferred Stock was terminated, and the 2,500,000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the board of directors.

 

Common Stock

 

On June 25, 2019, the Company effected a one-for-four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0.25 shares of common stock, and the Company decreased its authorized common stock in the same ratio from 100,000,000 to 25,000,000 shares.

 

On January 27, 2020, the Company amended its Articles of Incorporation to increase its authorized common shares from 25,000,000 authorized shares to 250,000,000 authorized shares.

 

On July 26, 2022, the Board of Directors of the Company approved a 7-for-6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. Pursuant to the operation of the amendment providing for the forward stock split filed with the Secretary of State of Nevada on August 4, 2022, the authorized common stock of the Company was increased from 250,000,000 shares to 291,666,666 shares in connection with the forward split.

 

Activity during the Three Months Ended April 30, 2024

 

(a)As of April 30, 2024, the Company holds 10,000 of its shares comprising $32,641 of treasury stock. There was no activity during the three months ended April 30, 2024.
   
(b)

On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors, of which $7.12 million is from related parties, (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock, the Warrant having an exercise price of $6.43, are exercisable by payment of the exercise price in cash only and expire April 19, 2029, five years from the date of issuance (“Warrants”). The offering was made solely to investors residing outside the United States and was not registered under the Security Act of 1933, as amended, (the “Security Act”), or the security law of any jurisdiction, including outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act. See Note 6 for further information.

 

Activity during the Three Months Ended January 31, 2023

 

(a)As of April 30, 2023, the Company held 10,000 of its shares comprising $32,641 of treasury stock. There was no activity during the three months ended April 30, 2023.

 

F-41

 

 

8.OPTIONS and WARRANTS

 

Warrants

 

The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company’s common stock issued to non-employees of the Company during the year ended January 31, 2024. On March 7, 2023, the Company issued 30,000 warrants to purchase the Company’s common shares to Barandnic Holdings Ltd. for services provided. The warrants are exercisable at a price of $4.00 per share and expire five years from the date of issuance. On October 27, 2023, the Company issued 145,833 warrants to purchase the Company’s common shares to management (87,500 warrants were issued to the Chief Financial Officer) and non-employees of the Company. The warrants are exercisable at a price of $1.93 per share and expire in three years from the date of issuance. These warrants replace previously issued warrants that have now been cancelled. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 152.10-174.45%; and a risk-free rate of 4.31%-4.84%. Non-cash compensation for the year ended January 31, 2024, amounted to $242,840.

 

On April 19, 2024, in connection with a private placement of the Company’s common stock, the Company issued 4,200,000 warrants. The warrants are exercisable at a price of $6.43 per share and expire five years from the date of issuance.

 

   Shares   Exercise
Price		   Remaining
Life		  Intrinsic
Value		 
Outstanding, January 31, 2023   1,307,671   $6.43   3.34 years  $
-
 
                   
Granted   175,833    2.28   2.97 years   
-
 
                   
Expired/Cancelled   (200,466)   6.33  
-
   
-
 
                   
Exercised   
-
    
-
  
-
   
-
 
                   
Outstanding, January 31, 2024   1,283,038    5.88   2.97 years   
-
 
                   
Granted   4,200,000    6.43   5.00 years   
-
 
                   
Expired/Cancelled   
-
    
-
  
-
   
-
 
                   
Exercised   
-
    
-
  
-
   
-
 
                   
Outstanding- April 30, 2024   5,483,038   $6.30   4.25 years  $233,125 
                   
Exercisable - April 30, 2024   5,483,038   $6.30   4.25 years  $233,125 

 

The following table summarizes additional information relating to the warrants outstanding as of April 30, 2024: 

 

Range of Exercise
Prices		   Number
Outstanding		   Weighted
Average
Remaining
Contractual
Life(Years)		   Weighted
Average
Exercise Price
for Shares
Outstanding		   Number
Exercisable		   Weighted
Average
Exercise Price
for Shares
Exercisable		   Intrinsic Value 
                          
$4.00    30,000    4.10   $4.00    30,000   $4.00   $
-
 
$6.43    5,282,205    2.68   $6.43    5,282,205   $6.43   $
-
 
$1.93    145,833    2.74   $1.93    145,833   $1.93   $233,125 
$7.50    25,000    3.77   $7.50    25,000   $7.50   $
-
 
      5,483,038              5,483,038        $233,125 

 

F-42

 

 

Options

 

The following table summarizes the changes in options outstanding and the related price of the shares of the Company’s common stock issued to employees of the Company. See Note 7 for the issuance of related party options.

 

On November 1, 2021, the Board of Directors adopted the 2021 Employee Stock Option Plan (the “Plan”). The Company has reserved 408,333 shares for issuance and sale upon the exercise of stock options. In accordance with the Plan, on February 1, 2022, the Company reserved an additional 233,333 shares and on February 1, 2023, the Company reserved an additional 233,333 shares. The options vest immediately and expire in three years. Under the Plan, options may be granted which are intended to qualify as Incentive Stock Options (“ISO’s”) under Section 422 of the Internal Revenue Code of 1986 (the “Code”) or which are not (“non-ISO’s”) intended to qualify as Incentive Stock Options thereunder. The Plan also provides for restricted stock awards representing shares of common stock that are issued subject to such restrictions on transfer and other incidents of ownership and such forfeiture conditions as the Board of Directors, or the committee administering the Plan composed of directors who qualify as “independent” under Nasdaq rules, may determine. On November 3, 2021, the Company filed a Registration Statement on Form S-8, to register under the Securities Act of 1933, as amended the 408,333 shares of common stock reserved for issuance under the Plan.

 

On March 20, 2024, our Board of Directors adopted an amendment to the Company’s Employee Stock Option Plan (the “Plan”) increasing the number of shares of common stock subject to the Plan (as of March 20, 2024, 875,000 shares) to 1,400,000 shares (the “Amendment”). The Company will submit the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting. If the Amendment is not approved by stockholders within one year of adoption, the increase in shares subject to the Plan will be void, together with any options issued following March 20, 2024, in the period pending approval of the Plan by our stockholders. As of April 30, 2024, 135,165 shares remain available for issuance of options under the Plan.

 

During the three months ended April 30, 2024, 390,000 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $2.37- $2.61 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $422,955 and was recorded during the three months ended April 30, 2024. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rate of 97.83%; and a risk-free rate of 4.87%.

 

During the year ended January 31, 2024, 404,500 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $1.93-$3.975 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $499,856 and was recorded during the year ended January 31, 2024. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 121.52-143.54%; and a risk-free rate of 3.00-4.5%.

 

   Shares   Exercise
Price		   Remaining
Life		  Intrinsic
Value		 
Outstanding, January 31, 2023   470,335   $4.13   2.53 years   
 
 
                   
Granted   404,500    2.18   2.68 years   
-
 
                   
Expired/Cancelled   
-
    
-
  
-
   
 
 
                   
Exercised   
-
    
-
  
-
   
 
 
                   
Outstanding, January 31, 2024   874,835    3.23   2.31 years   
 
 
                   
Granted   390,000    2.49   2.80 years  $378,300 
                   
Expired/Cancelled   
-
    
-
  
-
   
 
 
                   
Exercised   
-
    
-
  
-
   
 
 
                   
Outstanding- April 30, 2024   1,264,835   $2.63   2.31 years  $910,285 
                   
Exercisable - April 30, 2024   1,264,835   $2.63   2.31 years  $910,285 

 

F-43

 

 

The following table summarizes additional information relating to the options outstanding as of April 30, 2024:

 

Range of Exercise
Prices		   Number
Outstanding		   Weighted
Average
Life(Years)		   Weighted
Average
Exercise Price
for Shares
Outstanding		   Number
Exercisable		   Weighted
Average
Exercise Price
for Shares
Exercisable		   Intrinsic
Value		 
                                 
$1.93    214,500    2.74   $1.93    214,500   $1.93   $328,185 
$2.12    140,000    2.74   $2.12    140,000   $2.12   $187,600 
$2.37    195,000    2.37   $2.37    195,000   $2.37   $212,550 
$2.61    195,000    2.61   $2.61    195,000   $2.61   $165,750 
$2.65    20,000    2.63   $2.65    20,000   $2.65   $16,200 
$3.59    35,000    3.67   $3.59    35,000   $3.59   $
-
 
$3.75    57,500    1.85   $3.75    57,500   $3.75   $
-
 
$3.98    30,000    2.01   $3.98    30,000   $3.98   $
-
 
$4.09    78,750    1.50   $4.09    78,750   $4.09   $
-
 
$4.12    50,000    1.85   $4.12    50,000   $4.12   $
-
 
$4.16    144,083    0.97   $4.16    144,083   $4.16   $
-
 
$4.50    58,334    1.50   $4.50    58,334   $4.50   $
-
 
$4.58    46,668    0.97   $4.58    46,668   $4.58   $
-
 

 

9.SEGMENT REPORTING

 

We organize and manage our business by the following two segments which meet the definition of reportable segments under ASC280-10, Segment Reporting: Sales of Goods and Services. These segments are based on the customer type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief officer decision maker, who is our chief executive officer, in making resource allocation decisions for our segments. Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit.

 

   Three Months Ended
April 30,		 
   2024   2023 
Net sales        
Pocono Pharmaceuticals  $408,532   $401,057 
4P Therapeutics   
-
    75,875 
    408,532    476,932 
Gross profit          
Pocono Pharmaceuticals   164,786    169,308 
4P Therapeutics   
-
    52,976 
    164,786    222,284 
Operating expenses          
Selling, general and administrative-Pocono Pharmaceuticals   154,394    136,863 
Selling, general and administrative-4P Therapeutics   24,354    16,921 
Selling, general and administrative-Corporate   900,980    685,948 
Research and development-4P Therapeutics   974,535    400,430 
    2,054,263    1,240,162 
Depreciation and Amortization          
Pocono Pharmaceuticals  $56,823   $55,208 
Corporate   3,011    3,497 
4P Therapeutics   9,267    16,496 
   $69,101   $75,201 

 

F-44

 

 

The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.

 

   Three Months Ended
April 30,		 
   2024   2023 
Net sales        
United States  $408,532   $401,057 
Outside the United States   
-
    75,875 
   $408,532   $476,932 

 

   April 30,   January 31, 
   2024   2024 
Property and equipment, net of accumulated depreciation        
United States  $740,305   $774,924 
Outside the United States   
-
    
-
 
   $740,305   $774,924 
Assets          
Corporate  $8,210,779   $344,192 
Pocono Pharmaceuticals   5,044,569    5,079,293 
4P Therapeutics   1,899,132    2,093,369 
   $15,154,480   $7,516,854 

 

10.COMMITMENTS AND CONTIGENCIES

 

Employment Agreements

 

The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as directors and officers of the Company for the respective terms thereof. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $250,000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance bonus of 3.5% of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $150,000.

 

The Company entered into a three-year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $210,000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $110,000.

 

Kindeva Drug Delivery Agreement

 

On January 4, 2022, the Company signed a feasibility agreement with Kindeva Drug Delivery, L.P. (“Kindeva”) to develop Nutriband’s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system). The feasibility agreement provides for adapting Kindeva’s commercial transdermal manufacturing process to incorporate AVERSA technology in the fentanyl transdermal system.

 

F-45

 

 

The agreement will remain in force until the earlier of: (1) the completion of the work and deliverables under the Workplan; or (2) two (2) years after the Effective Date, after which time the agreement will expire. The feasibility Workplan was completed in February 2024.

 

The estimated cost to complete the feasibility Workplan was approximately $2.5 million. Nutriband made an advance deposit of $250,000 in January 2022, to be applied against the final invoices. As of April 30, 2024, Nutriband has incurred expenses of $2,950,998 and the deposit of $250,000 has been applied to the final invoices.

 

On January 15, 2024, the Nutriband signed a commercial development and clinical supply agreement for their lead product with Kindeva. Kindeva will perform commercial manufacturing process development and manufacturing clinical supplies for the human abuse liability clinical study required by the FDA in support of a New Drug Application. The new agreement replaces the previous feasibility agreement between the two companies which was focused on adapting Kindeva’s commercial transdermal manufacturing process to incorporate AVERSA abuse deterrent transdermal technology. The estimated cost to complete is approximately $8.1 million and the expected timing of FDA submission is twelve to eighteen months.

 

Lease Agreement

 

On February 1, 2022, Pocono Pharmaceuticals entered into a lease agreement with Geometric Group, LLC for 12,000 square feet of warehouse space currently occupied by Active Intelligence. The monthly rental is $3,000 and the lease expires on January 31, 2025. The lease can be extended for an additional three years at the same monthly rental. The Company recorded a Right of Use asset in the amount of $94,134 in connection with the valuation.

 

Sorrento Therapeutics, Inc. Agreement

 

On July 25, 2023, 4P Therapeutics assigned its claim under the bankruptcy proceedings from Sorrento Therapeutics Inc. and received proceeds of $106,528. The amount due under the claim was $118,675 and 4P Therapeutics recorded a reserve for bad debts of $118,675 during the year ended January 31, 2024. Under the agreement with the buyer of the claim, 4P Therapeutics will make proportional restitution and/or repayment of the purchase amount to the extent the claim is disallowed, reduced or not paid at the same time or distribution rate as other general unsecured claims against the Debtor are paid. The Company has recorded the amount of the proceeds as a secured loan payable to the factor as of April 30, 2024.

 

Legal Proceedings

 

The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (“Gunnar”) and Lucosky Brookman LLP (“LB”) in the Supreme Court of the State of New York, New York County, under Index No.654633/2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company’s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $500,000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees.

 

In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $1,000,000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims.

 

Currently, there are no pending hearings or motions as both parties are engaged in discovery and are attempting to resolve the matter amicably.

 

11.SUBSEQUENT EVENTS

 

(a)

The Company agreed on May 14, 2024, to convert $300,000, which as of that date of all the outstanding principal on the Credit line Promissory Note of the Company held by TII Jet Services LDA, a related party, (the “Holder”). The conversion was made pursuant to the terms of a Conversion Agreement dated May 14, 2024, which provided that the conversion of $300,000 of principal and $4,922 of accrued interest would be made at a price of $4.00 per share, resulting in the Company issuing on May 14, 2024, a total of 76,230 shares of common stock at the conversion price of $4.00 per share. On May 22, 2024, the Conversion Agreement was amended allowing the lender to purchase an additional 152,460 shares of common stock at a rate of two warrants per converted share, with an exercise price of $6.43 per share and a term of five years from the conversion date (May 14, 2024).

 

F-46

 

 

PART II

 

INFORMATION NOT REQUIRED IN PROSPECTUS

 

ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.(1)

 

Nature of Expense:  Amount 
SEC Registration Fee   -  
NASDAQ initial listing fee   -  
FINRA filing fee   -  
Accounting fees and expenses   $3,500  
Legal fees and expenses   6,500  
      
Printing   -  
Transfer Agent and Warrant Agent expenses   -  
Miscellaneous     
Total  $10,000 

 

(1) All expenses are estimated.

 

ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS.

 

Nevada Revised Statutes 78.7502 and 78.751 provide broad authority for the indemnification of directors, officers and certain other persons.

 

Section 78.7502 of the Nevada Revised Statutes permits a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he:

 

  (a) is not liable pursuant to Nevada Revised Statute 78.138, or
     
  (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.

 

In addition, Section 78.7502 permits a corporation to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement and attorneys’ fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if he:

 

  (a) is not liability pursuant to Nevada Revised Statute 78.138; or
     
  (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation.

 

II-1

 

 

To the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to above, or in defense of any claim, issue or matter, the corporation is required to indemnify him against expenses, including attorneys’ fees, actually and reasonably incurred by him in connection with the defense.

   

Section 78.751 of the Nevada Revised Statutes provides that such indemnification may also include payment by the Company of expenses incurred in defending a civil or criminal action or proceeding in advance of the final disposition of such action or proceeding upon receipt of an undertaking by the person indemnified to repay such payment if he shall be ultimately found not to be entitled to indemnification under Section 78.751. Indemnification may be provided even though the person to be indemnified is no longer a director, officer, employee or agent of the Company or such other entities.

 

Section 78.752 of the Nevada Revised Statutes allows a corporation to purchase and maintain insurance or make other financial arrangements on behalf of any person who is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise for any liability asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee or agent, or arising out of his status as such, whether or not the corporation has the authority to indemnify him against such liability and expenses.

 

Other financial arrangements made by the corporation pursuant to Section 78.752 may include the following:

 

  (a) the creation of a trust fund;
     
  (b) the establishment of a program of self-insurance;
     
  (c) the securing of its obligations of indemnification by granting a security interest or other lien on any assets of the corporation; and
     
  (d) the establishment of a letter of credit, guaranty or surety.

 

No financial arrangement made pursuant to Section 78.752 may provide protection for a person adjudged by a court of competent jurisdiction, after exhaustion of all appeals, to be liable for intentional misconduct, fraud or a knowing violation of law, except with respect to the advancement of expenses of indemnification ordered by a court.

 

Any discretionary indemnification pursuant to Section 78.7502 of the Nevada Revised Statutes, unless ordered by a court or advanced pursuant to an undertaking to repay the amount if it is determined by a court that the indemnified party is not entitled to be indemnified by the corporation, may be made by the corporation only as authorized in the specific case upon a determination that indemnification of the director, officer, employee or agent is proper in the circumstances. The determination must be made:

 

  (a) by the stockholders;
     
  (b) by the board of directors by a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding;
     
  (c) if a majority vote of a quorum consisting of directors who were not parties to the action, suit or proceeding so orders, by independent legal counsel in a written opinion, or
     
  (d) if a quorum consisting of directors who were not parties to the action, suit or proceeding cannot be obtained, by independent legal counsel in a written opinion.

 

Subsection 7 of Section 78.138 of the Nevada Revised Statutes provides that, subject to certain very limited statutory exceptions, a director or officer is not individually liable to the corporation or its stockholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a director or officer, unless it is proven that the act or failure to act constituted a breach of his or her fiduciary duties as a director or officer and such breach of those duties involved intentional misconduct, fraud or a knowing violation of law. The statutory standard of liability established by Section 78.138 controls even if there is a provision in the corporation’s articles of incorporation unless a provision in the corporation’s articles of incorporation provides for greater individual liability.

  

II-2

 

 

Our bylaws provide that each person who was or is made a party or is threatened to be made a party to or is involved (including, without limitation, as a witness) in any threatened, pending, or completed action, suit or proceeding, whether formal or informal, civil, criminal, administrative or investigative (hereinafter a “proceeding”), by reason of the fact that he or she is or was a director of or who is or was serving at our request as a director, officer, employee or agent of this or another corporation or of a partnership, joint venture, trust, other enterprise, or employee benefit plan (a “covered person”), whether the basis of such proceeding is alleged action in an official capacity as a covered person shall be indemnified and held harmless by us to the fullest extent permitted by applicable law, as then in effect, against all expense, liability and loss (including attorneys’ fees, costs, judgments, fines, ERISA excise taxes or penalties and amounts to be paid in settlement) reasonably incurred or suffered by such person in connection therewith, and such indemnification shall continue as to a person who ceased to be a covered person and shall inure to the benefit of his or her heirs, executors and administrators.

  

However, no indemnification shall be provided hereunder to any covered person to the extent that such indemnification would be prohibited by Nevada state law or other applicable law as then in effect, nor, with respect to proceedings seeking to enforce rights to indemnification, shall we indemnify any covered person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person except where such proceeding (or part thereof) was authorized by our board of directors, nor shall we indemnify any covered person who shall be adjudged in any action, suit or proceeding for which indemnification is sought, to be liable for any negligence or intentional misconduct in the performance of a duty.

 

Our directors may cause us to purchase and maintain insurance for the benefit of a person who is or was serving as a director, officer, employee or agent of us or of a corporation of which we are or were a stockholder and his heirs or personal representatives against a liability incurred by him as a director, officer, employee or agent.

 

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

 

ITEM 15. RECENT SALES OF UNREGISTERED SECURITIES

 

1. On January 5, 2021, the Company issued the following numbers of shares common stock to Company officers and members of its Board of Directors. All stock issuances were valued by the Board at $12.86 per share.

 

Name   No. of
Shares		  
Gareth Sheridan, CEO and Director     11,667  
Sean Gallagher, Executive Chairman and Director     11,667  
Serguei Melnik, Director     11,667  
Michael Myer, President of Pocono Pharma and Director(1)     5,833  
Radu Bujoreanu, Director     14,583  
Steven P. Damon, Director     11,667  
Michael Doron, Director     5,833  
Mark Hamilton, Director     14,583  
Stefan Mancas, Director     14,583  
Vsevolod Grigore, Director     5,833  
Patrick Ryan, Chief Technical Officer     5,833  
Gerald Goodman, Chief Financial Officer     11,667  
Alan Smith, Chief Operating Officer and President of 4P Therapeutics     7,963  
Vitalie Botgros, Consultant     5,833  
Thomas Cooney, Director     7,000  
Jay Moore, Director     5,833  

 

(1) Mr. Myer owns 225,914 shares of common stock, of which 5,833 were issued on January 5, 2021, and 220,081 shares that he has the right to receive from the August 31, 2021 acquisition of Pocono Coated Products, LLC, as a distribution from escrow terminating September 30, 2021, of certain distributions under the acquisition agreement.

 

2. On February 6, 2021, the Company issued 94,962 shares of common stock to BPM Inno Ltd.

 

Date     Title and Amount (1)   Purchaser   Total Offering Price/
Underwriting
Discounts
February 26, 2021     94,962 shares of common stock   BPM Inno Ltd.   $7.37 per share/NA

 

II-3

 

 

3. On October 22, 2021, the Company issued common stock purchase warrants to designees of the underwriters and to other persons As compensation for services rendered:

 

    Title and Amount (1)   Purchaser   Principal
Underwriter		   Total Offering Price/
Underwriting
Discounts
October 22, 2021   Three-Year Common Stock Purchase Warrant to purchase 17,248 shares of common stock at an exercise price of $6.43 per share.   WestPark Capital, Inc.   NA   $0.01 per share/NA
October 22, 2021   Three-Year Common Stock Purchase Warrant to purchase 7,392 shares of common stock at an exercise price of $6.43.   Craig Kaufman   NA   $0.01 per share/NA
October 22, 2021   Three-Year Common Stock Purchase Warrant to purchase 34,496 shares of common stock at an exercise price of $6.43 per share.   Douglas Bantum   NA   $0.01 per share/NA
October 22, 2021   Three-Year Common Stock Purchase Warrant to purchase 7,392 shares of common stock at an exercise price of $6.43 per share.   Gene McNeil   NA   $0.01 per share/NA
October 22, 2021   Three-Year Common Stock Purchase Warrant to purchase 7,392 shares of common stock at an exercise price of $6.43 per share.   Kenneth Bantum   NA   $0.01 per share/NA
October 22, 2021   Three-Year Common Stock Purchase Warrant to purchase 24,640 shares of common stock at an exercise price of $6.43per share.   Michael Wallach   NA   $0.01 per share/NA
October 22, 2021   Three-Year Common Stock Purchase Warrant to purchase 24,640 shares of comon stock at an exercise price of $7.50 per share.    David Beth   NA   $0.01 per share/NA
October 22, 2021   Three-Year Common Stock Purchase Warrant to purchase 87,500 shares s of common stock at an exercise price of $4.20 per share.   Gerald Goodman, Chief Financial Officer   NA   $0.01 per share/NA
October 22, 2021   Three-Year Common Stock Purchase Warrant to purchase 58,333 shares s of common stock at an exercise price of $4.20 per share.   Counsel   NA    
October 22, 2021   16,722 shares of common stock.   Employee compensation.   NA   $84,000/NA
October 22, 2021   12,027 shares of common stock   Employee compensation   NA   $60,000/N/A
October 22, 2021   20,046 shares of common stock issued in conversion of $100,000 of debt.   TII Jet Services       $100,000/NA

 

4. As of the dates set forth below, the  Company  issued shares of common stock to the persons listed below for services rendered.

 

Date   Title and Amount of Stock Issuance (1)   Purchaser   Total Price  
May 10, 2022   1,167 shares of common stock   Radu Bujoreanu, Director   $ 3,800  
May 10, 2022   1,167 shares of common stock   Stefani Mancas, Director   $ 3,800  
May 10, 2022   5,833 shares of common stock   Consultant   $ 19,000  
May 10, 2022   1,167 shares of common stock   Irina Gram, Director   $ 3,800  
May 10, 2022   1,167 shares of common stock   Consultant   $ 3,800  
May 10, 2022   1,167 shares of common stock   Mark Hamilton, Director   $ 3,800  
May 10, 2022   1,167 shares of common stock   Michael Meyer   $ 3,800  
May 10, 2022   11,667 shares of common stock   Gareth Sheridan, CEO   $ 38,000  
May 10, 2022   583 shares of common stock   Employee   $ 1,900  
May 10, 2022   583 shares of common stock   Employee   $ 1,900  
May 10, 2022   583 shares of common stock   Employee   $ 1,900  
May 10, 2022   583 shares of common stock   Employee   $ 1,900  
May 10, 2022   583 shares of common stock   Employee   $ 1,900  
November 8, 2022   1,887 shares of common stock   Consultant   $ 7,756  
November 8, 2022   3,000 shares of common stock   Consultant   $ 12,230  
November 8, 2022   25,000 shares of common stock   Consultant   $ 102,750  

 

(1) The issuances to directors and management and consultants set forth above in this Item 15 are viewed by the Company as exempt from registration under the Securities Act, alternatively as transactions either not involving any public offering, or as exempt under the provisions of Regulation D, Regulation S or Rule 701 promulgated by the SEC under the Securities Act.

 

II-4

 

 

On December 27, 2023, the Company issued 1,026,720 shares of common stock in conversion of the outstanding $2,000,000 principal amount, plus accrued interest for the Credit Line Note of the Company held TII Jet Services LDA; and on May 14, 2024, TII Jet Services agreed to convert an additional $300,000 of principal of the Credit Line Note plus accrued interest at a conversion price of $4.00 per share, in exchange for the issuance of 76,230 shares of common stock.

 

On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors, of which $7.12 million is from related parties, (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, each Unit consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock, the Warrants having an initial exercise price of $6.43, are exercisable by payment of the exercise price in cash only and expire April 19, 2029, five years from the date of issuance (“Warrants”). The Offering was made solely to investors resident outside the United States and was not registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any jurisdiction, including any jurisdiction outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act.

 

The Company on May 14, 2024 issued 76,230 shares of common stock upon conversion of $300,000 of the outstanding principal amount of the convertible Note of the Company held by TII Jet Services LDA; as a part of the conversion in addition to the conversion shares, the Company issued to the noteholder five-year Warrants to purchase 152,460 shares of Common Stock, at an exercise price of $6.43 per share.

 

II-5

 

 

ITEM 16 Exhibits.

 

Exhibit
Number 		   Description
1.1   [Reserved]
3.1A   Articles of Incorporation.(1)
3.1B   Amendment to Articles of Incorporation, filed May 12, 2016.(1)
3.1   Certificate of Amendment filed January 21, 2020. (Filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed January 27, 2020).
3.1C   Certificate of Change, filed with the Nevada Secretary of State on August 4, 2022.(13)
3.2   By-laws(1)
3.2B   Amended and Restated By-Laws adopted January 21, 2022.(12)
4.3   Securities purchase agreement dated October 29, 2019 among the Company, Jefferson Street Capital LLC and Platinum Point Capital LLC(6)
4.4   Form of convertible 6% promissory note issued pursuant to Exhibit 4.3(6)
4.10   Form of Common Stock Purchase Warrant issued to Platinum Point Capital LLC and Jefferson Street Capital LLC(6)
4.14†   2021 Employee Stock Option Plan.(11)
4.15†   Form of Stock Option Grant Notice.(11)
4.16   Form of Common Stock Purchase Warrant issued in the Company’s initial public offering in 2021(9)
4.17   Form of Warrant issued to the Representative.(14)
4.18†   2024 Amended and Restated Stock Option Plan, adopted March 20, 2024.(15)
4.19   Form of Common Stock Purchase Warrant issued in 2024 Equity Financing (18)
5.1   [Reserved]
10.1   Share exchange agreement dated January 15, 2016 by and among the Company, Nutriband Limited, an Ireland corporation, and Gareth Sheridan and/or his nominee(1)
10.4   Acquisition agreement dated April 5, 2018 between the Company and 4P Therapeutics LLC.(3)
10.5†   Form of agreement with independent directors.(4)
10.6   Exclusive master distribution agreement dated April 13, 2018 between the Company and EMI-Korea (Best Choice), Inc.(4)
10.15†   Employment Agreement, dated April 23, 2019, between Gareth Sheridan and the Company.(5)
10.16†   Employment Agreement, dated April 23, 2019, between Serguei Melnik and the Company.(5)
10.17†   Employment Agreement, dated February 19, 2019, between Jeffrey Patrick and the Company.(5)
10.18†   Employment Agreement, dated January 1, 2018, between Sean Gallagher and the Company.(5)
10.19   Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC.(7)
10.20   Security Agreement, between the Company and Pocono Coated Products, LLC.(7)
10.21   Promissory Note Issued by the Company on August 31, 2020 to Pocono Coated Products, LLC.(7)
10.22   License Agreement, dated December 9, 2020, between the Company and Rambam Med-Tech Ltd.(8)
10.23   Distribution Agreement, dated March 26, 2021, between the Company and BPM Inno Ltd.(8)
10.24   Stock Purchase Agreement, dated December 7, 2020, between the Company and BPM Inno Ltd.(8)
10.25   Amendment No. 1 to Purchase Agreement, dated August 31, 2020, by and among the Company and Pocono Coated Products, LLC(8a)
10.26   Services Agreement dated October 4, 2021, between Active Intelligence, LLC and Diomics Corporation.(10)
10.27†   Employment Agreement effective February 1, 2022, between the Company and Gareth Sheridan.(12)
10.28†   Employment Agreement effective February 1, 2022, between the Company and Serguei Melnik.(12)
10.29†   Employment Agreement effective February 1, 2022, between the Company and Gerald Goodman.(12)
10.30   Creditline Promissory Note, dated July 13, 2023. (16)
10.31   Conversion Agreement, dated December 19, 2023.(17)
10.32   Form of Subscription Agreement for April 19, 2024 Equity Financing (19)
10.33   Form of Note Conversion Agreement dated May 13, 202420
10.34   Amendment to Note Conversion Agreement dated May 13, 202421
21.1   List of Subsidiaries of Nutriband Inc.(14)
23.1   Consent of Sadler Gibb & Associates, LLC*
101.INS   Inline XBRL Instance Document.
101.SCH   Inline XBRL Taxonomy Extension Schema Document.
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
107   Filing Fee Table

 

* Filed herewith.
   
† Executive compensation plan or arrangement.

 

(1) Filed as exhibit to the Company’s registration statement on Form 10, which was filed with the Commission on June 2, 2016, and incorporated herein by reference.

II-6

 

 

(2) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on January 27, 2020 and incorporated herein by reference.
   
(3) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on April 10, 2018 and incorporated herein by reference.

  

(4) Filed as an exhibit to the Company’s annual report on Form 10-K for the year ended January 3, 2019 which was filed with the Commission on April 19, 2019, and incorporated herein by reference.
   
(5) Filed as an exhibit to the Company’s Registration Statement on Form S-1/A, which was filed with the Commission on May 19, 2020, and incorporated herein by reference.
   
(6) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on November 4, 2019, and incorporated herein by reference.
   
(7) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on September 4, 2020, and incorporated herein by reference.
   
(8) Filed as exhibits to the Company’s report on Form 8-K, which was filed with the Commission on March 11, 2021, and incorporated herein by reference.

 

(8a) Filed as an exhibit to the Company’s report on Form 8-K, which was filed with the Commission on September 1, 2021, and incorporated herein by reference.
   
(9) Filed as an exhibit to Amendment 2 to the Company’s Registration Statement on Form S-1, which was filed with the Commission on October 1, 2022.
   
(10) Filed as an exhibit to the Company’s Current Report on Form 8-K, which was filed with the Securities and Exchange Commission on October 12, 2021, and incorporated herein by reference.

 

(11) Filed as an exhibit to the Company’s Registration Statement on Form S-8, which was filed with the Commission on November 5, 2021, and incorporated herein by reference.
   
(12) Filed as an exhibit to the Company’s Current Report on Form 8-K, which was filed with the Commission on January 27, 2022, and incorporated herein by reference.
   
(13) Filed as Exhibit 3.1C to the Company’s Current Report on Form 8-K, which was filed with the Commission on August 10, 2022, and incorporated herein by reference.
   
(14) Filed as an exhibit to the Company’s Registration Statement on Form S-1, which was filed with the Commission on June 26, 2023, and incorporated herein by reference
   
(15) Filed as Exhibit 4.16 to the Company’s Amendment No. to its Current Report on Form 8-K, which was filed with the Commission on March 28, 2024 and incorporated herein by reference.
   
(16) Filed as Exhibit 10.30 to the Company’s Current Report on Form 8-K, which was filed with the Commission on July 14, 2023.
   
(17) Filed as Exhibit No. 10.31 to the Company’s Current Report on Form 8-K, which was filed with the Commission on December 29, 2023.

 

(18) Filed as Exhibit No.  4.19 to the Company’s Current Report on Form 8-K, which was filed with the Commission on April 23, 2024.
   
(19) Filed as Exhibit No. 10.32 to the Company’s Current Report on Form 8-K, which was filed with the Commission on April 23, 2024.

 

(20) Filed as Exhibit No. 10.33 to the Company’s Current Report on Form 8-K, which was filed with the Commission on May 21, 2024.

 

(21) Filed as Exhibit No. 10.34 to the Company’s Current Report on Form 8-K, which was filed with the Commission on June 3, 2024.

 

(b) Financial Statement Schedules

 

All schedules have been omitted because either they are not required, are not applicable or the information is otherwise set forth in the financial statements and related notes thereto.

 

II-7

 

 

Item 17. Undertakings.

 

The undersigned registrant hereby undertakes:

 

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (1)(i), (ii), and (iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in the registration statement,

 

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser: each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

 

(5) That, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

 

II-8

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Orlando, State of Florida on July 3, 2024.

 

  NUTRIBAND INC.
   
  By: /s/ Gareth Sheridan
    Gareth Sheridan
    Chief Executive Officer
   

July 3, 2024

     
  By: /s/ Gerald Goodman
    Gerald Goodman
    Chief Financial Officer (Principal Financial and Accounting Officer)
   

July 3, 2024

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Gareth Sheridan   Chief Executive Officer and Director   July 3, 2024
Gareth Sheridan        
         
/s/ Serguei Melnik   Director   July 3, 2024
Serguei Melnik        
         
     Director    
Sergei Glinka        
         
/s/ Radu Bujoreanu   Director   July 3, 2024
Radu Bujoreanu        
         
/s/ Mark Hamilton    Director   July 3, 2024
Mark Hamilton        
         
/s/ Stefani Mancas   Director   July 3, 2024
Stefani Mancas        
         
/s/ Irina Gram   Director   July 3, 2024
Irina Gram        

 

 

II-9

 

POS AM 0.53 0.69 7954105 8459547 0.13 0.21 7833150 9159869 true 0001676047 0001676047 2024-02-01 2024-04-30 0001676047 2024-01-31 0001676047 2023-01-31 0001676047 us-gaap:RelatedPartyMember 2024-01-31 0001676047 us-gaap:RelatedPartyMember 2023-01-31 0001676047 2024-04-30 0001676047 us-gaap:RelatedPartyMember 2024-04-30 0001676047 2023-02-01 2024-01-31 0001676047 2022-02-01 2023-01-31 0001676047 2023-02-01 2023-04-30 0001676047 us-gaap:CommonStockMember 2023-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2023-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-31 0001676047 us-gaap:RetainedEarningsMember 2023-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2023-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2023-02-01 2024-01-31 0001676047 us-gaap:CommonStockMember 2023-02-01 2024-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-02-01 2024-01-31 0001676047 us-gaap:RetainedEarningsMember 2023-02-01 2024-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2023-02-01 2024-01-31 0001676047 us-gaap:CommonStockMember 2024-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-31 0001676047 us-gaap:RetainedEarningsMember 2024-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2024-01-31 0001676047 2022-01-31 0001676047 us-gaap:CommonStockMember 2022-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-31 0001676047 us-gaap:RetainedEarningsMember 2022-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2022-01-31 0001676047 us-gaap:CommonStockMember 2022-02-01 2023-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2023-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2022-02-01 2023-01-31 0001676047 us-gaap:RetainedEarningsMember 2022-02-01 2023-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-02-01 2024-04-30 0001676047 us-gaap:CommonStockMember 2024-02-01 2024-04-30 0001676047 us-gaap:RetainedEarningsMember 2024-02-01 2024-04-30 0001676047 us-gaap:CommonStockMember 2024-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-30 0001676047 us-gaap:RetainedEarningsMember 2024-04-30 0001676047 us-gaap:TreasuryStockCommonMember 2024-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2023-02-01 2023-04-30 0001676047 us-gaap:RetainedEarningsMember 2023-02-01 2023-04-30 0001676047 2023-04-30 0001676047 us-gaap:CommonStockMember 2023-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2023-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-30 0001676047 us-gaap:RetainedEarningsMember 2023-04-30 0001676047 us-gaap:TreasuryStockCommonMember 2023-04-30 0001676047 2018-08-01 0001676047 srt:MinimumMember 2018-08-01 0001676047 srt:MaximumMember 2018-08-01 0001676047 ntrb:PoconoPharmaceuticalsMember 2020-08-31 0001676047 srt:MinimumMember 2022-07-26 0001676047 srt:MaximumMember 2022-07-26 0001676047 2021-10-01 2021-10-31 0001676047 2023-03-31 0001676047 2023-07-13 2023-07-13 0001676047 2024-04-19 2024-04-19 0001676047 us-gaap:AccountsReceivableMember 2023-02-01 2024-01-31 0001676047 us-gaap:AccountsReceivableMember 2022-02-01 2023-01-31 0001676047 us-gaap:InventoriesMember 2024-01-31 0001676047 srt:MinimumMember 2023-02-01 2024-01-31 0001676047 srt:MaximumMember 2023-02-01 2024-01-31 0001676047 2020-08-31 0001676047 ntrb:IntelligenceLLCMember 2023-02-01 2024-01-31 0001676047 ntrb:IntelligenceLLCMember 2022-02-01 2023-01-31 0001676047 country:US 2023-02-01 2024-01-31 0001676047 country:US 2022-02-01 2023-01-31 0001676047 us-gaap:NonUsMember 2023-02-01 2024-01-31 0001676047 us-gaap:NonUsMember 2022-02-01 2023-01-31 0001676047 srt:MinimumMember ntrb:LabEquipmentMember 2024-01-31 0001676047 srt:MaximumMember ntrb:LabEquipmentMember 2024-01-31 0001676047 us-gaap:FurnitureAndFixturesMember 2024-01-31 0001676047 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-01-31 0001676047 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-01-31 0001676047 ntrb:LabEquipmentMember 2024-01-31 0001676047 ntrb:LabEquipmentMember 2023-01-31 0001676047 us-gaap:MachineryAndEquipmentMember 2024-01-31 0001676047 us-gaap:MachineryAndEquipmentMember 2023-01-31 0001676047 us-gaap:FurnitureAndFixturesMember 2023-01-31 0001676047 us-gaap:LineOfCreditMember 2023-02-01 2024-01-31 0001676047 us-gaap:LineOfCreditMember 2024-01-31 0001676047 2022-04-03 0001676047 2022-04-03 2022-04-03 0001676047 us-gaap:NotesPayableToBanksMember 2022-02-01 2023-01-31 0001676047 2023-07-17 0001676047 2023-03-17 0001676047 srt:ScenarioPreviouslyReportedMember 2023-02-01 2024-01-31 0001676047 ntrb:SecuredBorrowingLiabilityMember 2023-02-01 2024-01-31 0001676047 ntrb:SecuredBorrowingLiabilityMember 2022-02-01 2023-01-31 0001676047 ntrb:RambamMedTechLtdMember 2021-02-28 2021-02-28 0001676047 ntrb:TerminationExpenseMember 2022-02-01 2023-01-31 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember 2024-01-31 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember 2023-01-31 0001676047 ntrb:newFiniteLivedIntangibleAssetsTwoMember 2024-01-31 0001676047 ntrb:newFiniteLivedIntangibleAssetsTwoMember 2023-01-31 0001676047 us-gaap:StockOptionMember 2023-02-01 2023-02-01 0001676047 us-gaap:StockOptionMember 2023-02-01 0001676047 us-gaap:StockOptionMember 2023-02-01 2024-01-31 0001676047 2023-09-01 2023-09-30 0001676047 2023-02-01 2023-10-31 0001676047 srt:ExecutiveOfficerMember 2023-09-30 0001676047 srt:ExecutiveOfficerMember 2023-10-31 0001676047 2023-09-30 0001676047 2023-10-31 0001676047 srt:DirectorMember 2023-09-30 0001676047 srt:DirectorMember 2023-10-31 0001676047 srt:ChiefFinancialOfficerMember us-gaap:WarrantMember 2023-02-01 2023-10-26 0001676047 us-gaap:WarrantMember 2023-10-26 0001676047 us-gaap:WarrantMember 2023-02-01 2023-10-31 0001676047 us-gaap:WarrantMember 2023-02-01 2024-01-31 0001676047 2023-07-01 2023-07-17 0001676047 2023-03-01 2023-03-17 0001676047 2023-12-31 2023-12-31 0001676047 srt:ChiefExecutiveOfficerMember 2022-05-01 2022-05-31 0001676047 2022-05-01 2022-05-31 0001676047 2022-08-01 2022-08-02 0001676047 srt:MinimumMember 2022-08-02 0001676047 srt:MaximumMember 2022-08-02 0001676047 2022-09-01 2022-09-30 0001676047 ntrb:IndependentDirectorsMember 2022-09-30 0001676047 2022-12-01 2022-12-07 0001676047 srt:MinimumMember 2022-12-07 0001676047 srt:MaximumMember 2022-12-07 0001676047 us-gaap:PreferredStockMember 2016-01-15 0001676047 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-05-24 2019-05-24 0001676047 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-06-20 2019-06-20 0001676047 us-gaap:CommonStockMember 2019-06-25 0001676047 srt:MinimumMember us-gaap:CommonStockMember 2019-06-25 0001676047 srt:MaximumMember us-gaap:CommonStockMember 2019-06-25 0001676047 srt:MinimumMember us-gaap:CommonStockMember 2020-01-27 0001676047 srt:MaximumMember us-gaap:CommonStockMember 2020-01-27 0001676047 srt:MinimumMember 2022-08-04 0001676047 srt:MaximumMember 2022-08-04 0001676047 srt:ScenarioForecastMember us-gaap:CommonStockMember 2024-12-31 2024-12-31 0001676047 srt:ScenarioForecastMember 2024-12-31 2024-12-31 0001676047 srt:ScenarioForecastMember us-gaap:CommonStockMember 2024-12-31 0001676047 srt:ScenarioForecastMember 2024-12-31 0001676047 us-gaap:CommonStockMember 2022-03-31 2022-03-31 0001676047 us-gaap:CommonStockMember 2022-05-31 2022-05-31 0001676047 2022-03-31 2022-03-31 0001676047 2022-05-31 2022-05-31 0001676047 2022-12-31 2022-12-31 0001676047 us-gaap:TreasuryStockCommonMember 2022-12-31 2022-12-31 0001676047 2022-07-01 2022-07-29 0001676047 2022-07-01 2022-07-31 0001676047 2023-03-07 0001676047 us-gaap:WarrantMember 2023-03-07 2023-03-07 0001676047 2023-10-27 0001676047 srt:ChiefExecutiveOfficerMember 2023-10-27 0001676047 ntrb:BlackScholesMember 2023-02-01 2024-01-31 0001676047 srt:MinimumMember ntrb:BlackScholesMember 2023-02-01 2024-01-31 0001676047 srt:MaximumMember ntrb:BlackScholesMember 2023-02-01 2024-01-31 0001676047 2021-11-01 0001676047 2022-02-01 2022-02-01 0001676047 2023-02-01 2023-02-01 0001676047 2021-11-03 2021-11-03 0001676047 ntrb:BlackScholesMember 2024-01-31 0001676047 srt:MinimumMember 2024-01-31 0001676047 srt:MaximumMember 2024-01-31 0001676047 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2023-01-31 0001676047 srt:MaximumMember srt:DirectorMember 2023-01-31 0001676047 us-gaap:WarrantMember 2022-02-01 2023-01-31 0001676047 srt:MinimumMember us-gaap:WarrantMember 2022-02-01 2023-01-31 0001676047 srt:MaximumMember us-gaap:WarrantMember 2022-02-01 2023-01-31 0001676047 us-gaap:WarrantMember 2022-01-30 0001676047 us-gaap:WarrantMember 2022-01-31 2022-01-31 0001676047 us-gaap:WarrantMember 2023-01-31 0001676047 srt:ScenarioPreviouslyReportedMember us-gaap:WarrantMember 2024-01-31 0001676047 srt:ScenarioPreviouslyReportedMember us-gaap:WarrantMember 2023-02-01 2024-01-31 0001676047 us-gaap:WarrantMember 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesOneMember 2023-02-01 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesOneMember 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesTwoMember 2023-02-01 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesTwoMember 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreeMember 2023-02-01 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreeMember 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesFourMember 2023-02-01 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesFourMember 2024-01-31 0001676047 us-gaap:StockOptionMember 2022-01-31 0001676047 us-gaap:StockOptionMember 2022-02-01 2023-01-31 0001676047 us-gaap:StockOptionMember 2023-01-31 0001676047 us-gaap:StockOptionMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSevenMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSevenMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2024-01-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2023-02-01 2024-01-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2022-02-01 2023-01-31 0001676047 ntrb:FourPTherapeuticsMember 2023-02-01 2024-01-31 0001676047 ntrb:FourPTherapeuticsMember 2022-02-01 2023-01-31 0001676047 us-gaap:CorporateAndOtherMember 2023-02-01 2024-01-31 0001676047 us-gaap:CorporateAndOtherMember 2022-02-01 2023-01-31 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2023-02-01 2024-01-31 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2022-02-01 2023-01-31 0001676047 ntrb:GoodwillImpairmentPoconoPharmacueticalsMember 2023-02-01 2024-01-31 0001676047 ntrb:GoodwillImpairmentPoconoPharmacueticalsMember 2022-02-01 2023-01-31 0001676047 ntrb:OutsideTheUnitedStatesMember 2023-02-01 2024-01-31 0001676047 ntrb:OutsideTheUnitedStatesMember 2022-02-01 2023-01-31 0001676047 country:US 2024-01-31 0001676047 country:US 2023-01-31 0001676047 ntrb:OutsideTheUnitedStatesMember 2024-01-31 0001676047 ntrb:OutsideTheUnitedStatesMember 2023-01-31 0001676047 us-gaap:CorporateAndOtherMember 2024-01-31 0001676047 us-gaap:CorporateAndOtherMember 2023-01-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-01-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2023-01-31 0001676047 ntrb:FourPTherapeuticsMember 2024-01-31 0001676047 ntrb:FourPTherapeuticsMember 2023-01-31 0001676047 ntrb:AgreementMember 2023-02-01 2024-01-31 0001676047 srt:ChiefExecutiveOfficerMember 2023-02-01 2024-01-31 0001676047 2022-07-31 2022-07-31 0001676047 srt:ChiefFinancialOfficerMember 2023-02-01 2024-01-31 0001676047 ntrb:MrGoodmanMember 2022-07-31 2022-07-31 0001676047 2022-01-01 0001676047 2022-02-01 0001676047 ntrb:AgreementMember 2022-02-01 2022-02-01 0001676047 ntrb:MDMWorldwideMember 2024-01-31 0001676047 2023-03-13 0001676047 ntrb:MoneyChannelMember 2023-03-13 2023-03-13 0001676047 ntrb:MoneyChannelMember 2024-01-31 0001676047 2023-07-01 2023-07-25 0001676047 2023-07-25 0001676047 ntrb:SorrentoTherapeuticsIncAgreementMember 2023-07-25 0001676047 us-gaap:SubsequentEventMember 2024-02-01 2024-04-30 0001676047 us-gaap:SubsequentEventMember 2024-03-20 2024-03-20 0001676047 srt:MinimumMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-20 0001676047 srt:MaximumMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-20 0001676047 us-gaap:SubsequentEventMember 2024-03-20 0001676047 ntrb:BoardOfDirectorsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-20 0001676047 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-20 0001676047 us-gaap:SubsequentEventMember 2024-04-19 2024-04-19 0001676047 us-gaap:SubsequentEventMember 2024-04-19 0001676047 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2024-04-19 0001676047 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2024-04-19 2024-04-19 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-04-30 0001676047 2023-07-13 0001676047 us-gaap:RelatedPartyMember 2024-04-19 2024-04-19 0001676047 srt:MinimumMember 2024-02-01 2024-04-30 0001676047 srt:MaximumMember 2024-02-01 2024-04-30 0001676047 ntrb:FourPTherapeuticsLLCMember 2024-04-30 0001676047 ntrb:PoconoCoatedProductsLLCAndActiveIntelligenceLLCMember 2020-08-31 0001676047 ntrb:SaleOfGoodsMember 2024-02-01 2024-04-30 0001676047 ntrb:SaleOfGoodsMember 2023-02-01 2023-04-30 0001676047 us-gaap:ServiceMember 2024-02-01 2024-04-30 0001676047 us-gaap:ServiceMember 2023-02-01 2023-04-30 0001676047 country:US 2024-02-01 2024-04-30 0001676047 country:US 2023-02-01 2023-04-30 0001676047 us-gaap:NonUsMember 2024-02-01 2024-04-30 0001676047 us-gaap:NonUsMember 2023-02-01 2023-04-30 0001676047 srt:MinimumMember us-gaap:EquipmentMember 2024-04-30 0001676047 srt:MaximumMember us-gaap:EquipmentMember 2024-04-30 0001676047 us-gaap:FurnitureAndFixturesMember 2024-04-30 0001676047 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-04-30 0001676047 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-04-30 0001676047 ntrb:LabEquipmentMember 2024-04-30 0001676047 us-gaap:MachineryAndEquipmentMember 2024-04-30 0001676047 us-gaap:LineOfCreditMember 2024-04-30 0001676047 us-gaap:LineOfCreditMember 2024-02-01 2024-04-30 0001676047 ntrb:CarolinaSmallBusinessDevelopmentFundMember 2024-04-30 2024-04-30 0001676047 us-gaap:NotesPayableToBanksMember 2024-01-31 0001676047 us-gaap:NotesPayableToBanksMember 2024-02-01 2024-04-30 0001676047 us-gaap:RelatedPartyMember 2024-02-01 2024-04-30 0001676047 ntrb:SecuredBorrowingLiabilityMember 2024-02-01 2024-04-30 0001676047 2023-08-01 2023-10-31 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember 2024-04-30 0001676047 ntrb:newFiniteLivedIntangibleAssetsTwoMember 2024-04-30 0001676047 srt:ExecutiveOfficerMember 2024-04-30 0001676047 ntrb:EmployeesMember 2024-04-30 0001676047 ntrb:EuropeanInvestorsMember 2024-04-19 2024-04-19 0001676047 srt:DirectorMember 2024-04-19 2024-04-19 0001676047 ntrb:SonMember 2024-04-19 2024-04-19 0001676047 ntrb:OtherRelatedPartyMember 2024-04-19 2024-04-19 0001676047 ntrb:TIIJetServicesLDAMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember 2023-02-01 2023-04-30 0001676047 us-gaap:SeriesAPreferredStockMember 2019-05-24 0001676047 us-gaap:SeriesAPreferredStockMember 2019-06-20 0001676047 srt:MinimumMember us-gaap:CommonStockMember 2020-01-27 0001676047 srt:MaximumMember us-gaap:CommonStockMember 2020-01-27 0001676047 us-gaap:CommonStockMember 2024-02-01 2024-04-30 0001676047 us-gaap:IPOMember 2024-04-19 2024-04-19 0001676047 us-gaap:CommonStockMember 2024-04-19 0001676047 2024-04-19 0001676047 us-gaap:CommonStockMember 2024-04-19 2024-04-19 0001676047 ntrb:Warrants1Member 2024-04-19 2024-04-19 0001676047 2023-03-07 2023-03-07 0001676047 us-gaap:WarrantMember 2024-02-01 2024-04-30 0001676047 ntrb:BlackScholesMember 2024-02-01 2024-04-30 0001676047 srt:MinimumMember ntrb:BlackScholesMember 2024-02-01 2024-04-30 0001676047 srt:MaximumMember ntrb:BlackScholesMember 2024-02-01 2024-04-30 0001676047 2024-03-20 0001676047 srt:ChiefExecutiveOfficerMember 2024-02-01 2024-04-30 0001676047 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2024-04-30 0001676047 srt:MaximumMember srt:ChiefExecutiveOfficerMember 2024-04-30 0001676047 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2024-01-31 0001676047 srt:MaximumMember srt:ChiefExecutiveOfficerMember 2024-01-31 0001676047 us-gaap:WarrantMember 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesOneMember 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesOneMember 2024-02-01 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesTwoMember 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesTwoMember 2024-02-01 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreeMember 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreeMember 2024-02-01 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesFourMember 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesFourMember 2024-02-01 2024-04-30 0001676047 us-gaap:EmployeeStockOptionMember us-gaap:StockOptionMember 2023-01-31 0001676047 us-gaap:EmployeeStockOptionMember us-gaap:StockOptionMember 2023-02-01 2024-01-31 0001676047 us-gaap:EmployeeStockOptionMember us-gaap:StockOptionMember 2024-01-31 0001676047 us-gaap:EmployeeStockOptionMember us-gaap:StockOptionMember 2024-02-01 2024-04-30 0001676047 us-gaap:EmployeeStockOptionMember us-gaap:StockOptionMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSevenMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSevenMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwelveMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwelveMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThirteenMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThirteenMember 2024-02-01 2024-04-30 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-02-01 2024-04-30 0001676047 ntrb:PoconoPharmaceuticalsMember 2023-02-01 2023-04-30 0001676047 ntrb:FourPTherapeuticsMember 2024-02-01 2024-04-30 0001676047 ntrb:FourPTherapeuticsMember 2023-02-01 2023-04-30 0001676047 us-gaap:CorporateAndOtherMember 2024-02-01 2024-04-30 0001676047 us-gaap:CorporateAndOtherMember 2023-02-01 2023-04-30 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2024-02-01 2024-04-30 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2023-02-01 2023-04-30 0001676047 ntrb:OutsideTheUnitedStatesMember 2024-02-01 2024-04-30 0001676047 ntrb:OutsideTheUnitedStatesMember 2023-02-01 2023-04-30 0001676047 country:US 2024-04-30 0001676047 ntrb:OutsideTheUnitedStatesMember 2024-04-30 0001676047 us-gaap:CorporateAndOtherMember 2024-04-30 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-04-30 0001676047 ntrb:FourPTherapeuticsMember 2024-04-30 0001676047 ntrb:AgreementMember 2024-02-01 2024-04-30 0001676047 2024-01-15 2024-01-15 0001676047 2023-07-25 2023-07-25 0001676047 ntrb:SorrentoTherapeuticsIncAgreementMember 2024-01-31 0001676047 ntrb:TIIJetServicesLDAMember us-gaap:SubsequentEventMember 2024-05-14 0001676047 ntrb:TIIJetServicesLDAMember us-gaap:SubsequentEventMember 2024-05-14 2024-05-14 0001676047 ntrb:TIIJetServicesLDAMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-05-14 2024-05-14 0001676047 ntrb:TIIJetServicesLDAMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-05-14 0001676047 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-05-22 0001676047 us-gaap:SubsequentEventMember 2024-05-22 2024-05-22 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure
EX-23.1 2 ea020597001ex23-1_nutri.htm CONSENT OF SADLER GIBB & ASSOCIATES, LLC

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

As independent registered public accountants, we hereby consent to the incorporation by reference in this Registration Statement on Form S-1 of Nutriband Inc. of our report dated April 30, 2024, relating to the consolidated financial statements of Nutriband Inc., appearing in the Annual Report on Form 10-K for the years ended January 31, 2024, and 2023. We also consent to the reference of our firm under the caption “Experts” in this Registration Statement.

 

/s/ Sadler, Gibb & Associates, LLC

 

Draper, UT

July 2, 2024

 EX-101.SCH 3 ntrb-20240430.xsd XBRL SCHEMA FILE 001 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Unaudited Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Unaudited Consolidated Statements of Operations (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Unaudited Consolidated Statements of Stockholders’ Equity link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Unaudited Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization and Description of Business link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Notes Payable link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Intangible Assets link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Options and Warrants link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Segment Reporting link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Commitments and Contigencies link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 996000 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 996001 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 996002 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 996003 - Disclosure - Income Taxes (Tables) link:presentationLink link:definitionLink link:calculationLink 996004 - Disclosure - Intangible Assets (Tables) link:presentationLink link:definitionLink link:calculationLink 996005 - Disclosure - Options and Warrants (Tables) link:presentationLink link:definitionLink link:calculationLink 996006 - Disclosure - Segment Reporting (Tables) link:presentationLink link:definitionLink link:calculationLink 996007 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:definitionLink link:calculationLink 996008 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 996009 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Disaggregates its Revenue from Contracts link:presentationLink link:definitionLink link:calculationLink 996010 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographic Location link:presentationLink link:definitionLink link:calculationLink 996011 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets link:presentationLink link:definitionLink link:calculationLink 996012 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 996013 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment link:presentationLink link:definitionLink link:calculationLink 996014 - Disclosure - Income Taxes (Details) link:presentationLink link:definitionLink link:calculationLink 996015 - Disclosure - Income Taxes (Details) - Schedule of Provision for Income Taxes link:presentationLink link:definitionLink link:calculationLink 996016 - Disclosure - Income Taxes (Details) - Schedule of Reconciliation of Taxes on Income link:presentationLink link:definitionLink link:calculationLink 996017 - Disclosure - Income Taxes (Details) - Schedule of Deferred Tax Liability and Deferred Tax Asset link:presentationLink link:definitionLink link:calculationLink 996018 - Disclosure - Notes Payable (Details) link:presentationLink link:definitionLink link:calculationLink 996019 - Disclosure - Intangible Assets (Details) link:presentationLink link:definitionLink link:calculationLink 996020 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets link:presentationLink link:definitionLink link:calculationLink 996021 - Disclosure - Intangible Assets (Details) - Schedule of Amortization Expenses link:presentationLink link:definitionLink link:calculationLink 996022 - Disclosure - Related Party Transactions (Details) link:presentationLink link:definitionLink link:calculationLink 996023 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 996024 - Disclosure - Options and Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 996025 - Disclosure - Options and Warrants (Details) - Schedule of Changes in Warrants Outstanding link:presentationLink link:definitionLink link:calculationLink 996026 - Disclosure - Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Warrants Outstanding link:presentationLink link:definitionLink link:calculationLink 996027 - Disclosure - Options and Warrants (Details) - Schedule of Changes in Options Outstanding link:presentationLink link:definitionLink link:calculationLink 996028 - Disclosure - Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Options Outstanding link:presentationLink link:definitionLink link:calculationLink 996029 - Disclosure - Segment Reporting (Details) link:presentationLink link:definitionLink link:calculationLink 996030 - Disclosure - Segment Reporting (Details) - Schedule of Segment Performance to the GAAP Measure of Gross Profit link:presentationLink link:definitionLink link:calculationLink 996031 - Disclosure - Segment Reporting (Details) - Schedule of Net Sales and Property and Equipment link:presentationLink link:definitionLink link:calculationLink 996032 - Disclosure - Commitments and Contigencies (Details) link:presentationLink link:definitionLink link:calculationLink 996033 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 996034 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Disaggregates its Revenue from Contracts link:presentationLink link:definitionLink link:calculationLink 996035 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographic Location link:presentationLink link:definitionLink link:calculationLink 996036 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on Straight-Line Basis Over Estimated Useful Life of Assets link:presentationLink link:definitionLink link:calculationLink 996037 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment link:presentationLink link:definitionLink link:calculationLink 996038 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets link:presentationLink link:definitionLink link:calculationLink 996039 - Disclosure - Intangible Assets (Details) - Schedule of Amortization Expenses link:presentationLink link:definitionLink link:calculationLink 996040 - Disclosure - Options and Warrants (Details) - Schedule of Warrants Exercisable link:presentationLink link:definitionLink link:calculationLink 996041 - Disclosure - Options and Warrants (Details) - Schedule of Additional Information Relating to the Warrants Outstanding link:presentationLink link:definitionLink link:calculationLink 996042 - Disclosure - Options and Warrants (Details) - Schedule of Changes in Options Outstanding link:presentationLink link:definitionLink link:calculationLink 996043 - Disclosure - Options and Warrants (Details) - Schedule of Additional Information Relating to the Options Outstanding link:presentationLink link:definitionLink link:calculationLink 996044 - Disclosure - Segment Reporting (Details) - Schedule of Segment Performance to the GAAP Measure of Gross Profit link:presentationLink link:definitionLink link:calculationLink 996045 - Disclosure - Segment Reporting (Details) - Schedule of Net Sales and Property and Equipment link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 4 ntrb-20240430_cal.xml XBRL CALCULATION FILE EX-101.DEF 5 ntrb-20240430_def.xml XBRL DEFINITION FILE EX-101.LAB 6 ntrb-20240430_lab.xml XBRL LABEL FILE EX-101.PRE 7 ntrb-20240430_pre.xml XBRL PRESENTATION FILE EXCEL 74 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 76 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 82 0001213900-24-059190-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-059190-xbrl.zip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�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ea0205970-posama4_nutri_htm.xml IDEA: XBRL DOCUMENT 0001676047 2024-02-01 2024-04-30 0001676047 2024-01-31 0001676047 2023-01-31 0001676047 us-gaap:RelatedPartyMember 2024-01-31 0001676047 us-gaap:RelatedPartyMember 2023-01-31 0001676047 2024-04-30 0001676047 us-gaap:RelatedPartyMember 2024-04-30 0001676047 2023-02-01 2024-01-31 0001676047 2022-02-01 2023-01-31 0001676047 2023-02-01 2023-04-30 0001676047 us-gaap:CommonStockMember 2023-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2023-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-31 0001676047 us-gaap:RetainedEarningsMember 2023-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2023-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2023-02-01 2024-01-31 0001676047 us-gaap:CommonStockMember 2023-02-01 2024-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-02-01 2024-01-31 0001676047 us-gaap:RetainedEarningsMember 2023-02-01 2024-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2023-02-01 2024-01-31 0001676047 us-gaap:CommonStockMember 2024-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-31 0001676047 us-gaap:RetainedEarningsMember 2024-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2024-01-31 0001676047 2022-01-31 0001676047 us-gaap:CommonStockMember 2022-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-31 0001676047 us-gaap:RetainedEarningsMember 2022-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2022-01-31 0001676047 us-gaap:CommonStockMember 2022-02-01 2023-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2023-01-31 0001676047 us-gaap:TreasuryStockCommonMember 2022-02-01 2023-01-31 0001676047 us-gaap:RetainedEarningsMember 2022-02-01 2023-01-31 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-02-01 2024-04-30 0001676047 us-gaap:CommonStockMember 2024-02-01 2024-04-30 0001676047 us-gaap:RetainedEarningsMember 2024-02-01 2024-04-30 0001676047 us-gaap:CommonStockMember 2024-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2024-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-30 0001676047 us-gaap:RetainedEarningsMember 2024-04-30 0001676047 us-gaap:TreasuryStockCommonMember 2024-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2023-02-01 2023-04-30 0001676047 us-gaap:RetainedEarningsMember 2023-02-01 2023-04-30 0001676047 2023-04-30 0001676047 us-gaap:CommonStockMember 2023-04-30 0001676047 us-gaap:AdditionalPaidInCapitalMember 2023-04-30 0001676047 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-30 0001676047 us-gaap:RetainedEarningsMember 2023-04-30 0001676047 us-gaap:TreasuryStockCommonMember 2023-04-30 0001676047 2018-08-01 0001676047 srt:MinimumMember 2018-08-01 0001676047 srt:MaximumMember 2018-08-01 0001676047 ntrb:PoconoPharmaceuticalsMember 2020-08-31 0001676047 srt:MinimumMember 2022-07-26 0001676047 srt:MaximumMember 2022-07-26 0001676047 2021-10-01 2021-10-31 0001676047 2023-03-31 0001676047 2023-07-13 2023-07-13 0001676047 2024-04-19 2024-04-19 0001676047 us-gaap:AccountsReceivableMember 2023-02-01 2024-01-31 0001676047 us-gaap:AccountsReceivableMember 2022-02-01 2023-01-31 0001676047 us-gaap:InventoriesMember 2024-01-31 0001676047 srt:MinimumMember 2023-02-01 2024-01-31 0001676047 srt:MaximumMember 2023-02-01 2024-01-31 0001676047 2020-08-31 0001676047 ntrb:IntelligenceLLCMember 2023-02-01 2024-01-31 0001676047 ntrb:IntelligenceLLCMember 2022-02-01 2023-01-31 0001676047 country:US 2023-02-01 2024-01-31 0001676047 country:US 2022-02-01 2023-01-31 0001676047 us-gaap:NonUsMember 2023-02-01 2024-01-31 0001676047 us-gaap:NonUsMember 2022-02-01 2023-01-31 0001676047 srt:MinimumMember ntrb:LabEquipmentMember 2024-01-31 0001676047 srt:MaximumMember ntrb:LabEquipmentMember 2024-01-31 0001676047 us-gaap:FurnitureAndFixturesMember 2024-01-31 0001676047 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-01-31 0001676047 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-01-31 0001676047 ntrb:LabEquipmentMember 2024-01-31 0001676047 ntrb:LabEquipmentMember 2023-01-31 0001676047 us-gaap:MachineryAndEquipmentMember 2024-01-31 0001676047 us-gaap:MachineryAndEquipmentMember 2023-01-31 0001676047 us-gaap:FurnitureAndFixturesMember 2023-01-31 0001676047 us-gaap:LineOfCreditMember 2023-02-01 2024-01-31 0001676047 us-gaap:LineOfCreditMember 2024-01-31 0001676047 2022-04-03 0001676047 2022-04-03 2022-04-03 0001676047 us-gaap:NotesPayableToBanksMember 2022-02-01 2023-01-31 0001676047 2023-07-17 0001676047 2023-03-17 0001676047 srt:ScenarioPreviouslyReportedMember 2023-02-01 2024-01-31 0001676047 ntrb:SecuredBorrowingLiabilityMember 2023-02-01 2024-01-31 0001676047 ntrb:SecuredBorrowingLiabilityMember 2022-02-01 2023-01-31 0001676047 ntrb:RambamMedTechLtdMember 2021-02-28 2021-02-28 0001676047 ntrb:TerminationExpenseMember 2022-02-01 2023-01-31 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember 2024-01-31 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember 2023-01-31 0001676047 ntrb:newFiniteLivedIntangibleAssetsTwoMember 2024-01-31 0001676047 ntrb:newFiniteLivedIntangibleAssetsTwoMember 2023-01-31 0001676047 us-gaap:StockOptionMember 2023-02-01 2023-02-01 0001676047 us-gaap:StockOptionMember 2023-02-01 0001676047 us-gaap:StockOptionMember 2023-02-01 2024-01-31 0001676047 2023-09-01 2023-09-30 0001676047 2023-02-01 2023-10-31 0001676047 srt:ExecutiveOfficerMember 2023-09-30 0001676047 srt:ExecutiveOfficerMember 2023-10-31 0001676047 2023-09-30 0001676047 2023-10-31 0001676047 srt:DirectorMember 2023-09-30 0001676047 srt:DirectorMember 2023-10-31 0001676047 srt:ChiefFinancialOfficerMember us-gaap:WarrantMember 2023-02-01 2023-10-26 0001676047 us-gaap:WarrantMember 2023-10-26 0001676047 us-gaap:WarrantMember 2023-02-01 2023-10-31 0001676047 us-gaap:WarrantMember 2023-02-01 2024-01-31 0001676047 2023-07-01 2023-07-17 0001676047 2023-03-01 2023-03-17 0001676047 2023-12-31 2023-12-31 0001676047 srt:ChiefExecutiveOfficerMember 2022-05-01 2022-05-31 0001676047 2022-05-01 2022-05-31 0001676047 2022-08-01 2022-08-02 0001676047 srt:MinimumMember 2022-08-02 0001676047 srt:MaximumMember 2022-08-02 0001676047 2022-09-01 2022-09-30 0001676047 ntrb:IndependentDirectorsMember 2022-09-30 0001676047 2022-12-01 2022-12-07 0001676047 srt:MinimumMember 2022-12-07 0001676047 srt:MaximumMember 2022-12-07 0001676047 us-gaap:PreferredStockMember 2016-01-15 0001676047 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-05-24 2019-05-24 0001676047 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-06-20 2019-06-20 0001676047 us-gaap:CommonStockMember 2019-06-25 0001676047 srt:MinimumMember us-gaap:CommonStockMember 2019-06-25 0001676047 srt:MaximumMember us-gaap:CommonStockMember 2019-06-25 0001676047 srt:MinimumMember us-gaap:CommonStockMember 2020-01-27 0001676047 srt:MaximumMember us-gaap:CommonStockMember 2020-01-27 0001676047 srt:MinimumMember 2022-08-04 0001676047 srt:MaximumMember 2022-08-04 0001676047 srt:ScenarioForecastMember us-gaap:CommonStockMember 2024-12-31 2024-12-31 0001676047 srt:ScenarioForecastMember 2024-12-31 2024-12-31 0001676047 srt:ScenarioForecastMember us-gaap:CommonStockMember 2024-12-31 0001676047 srt:ScenarioForecastMember 2024-12-31 0001676047 us-gaap:CommonStockMember 2022-03-31 2022-03-31 0001676047 us-gaap:CommonStockMember 2022-05-31 2022-05-31 0001676047 2022-03-31 2022-03-31 0001676047 2022-05-31 2022-05-31 0001676047 2022-12-31 2022-12-31 0001676047 us-gaap:TreasuryStockCommonMember 2022-12-31 2022-12-31 0001676047 2022-07-01 2022-07-29 0001676047 2022-07-01 2022-07-31 0001676047 2023-03-07 0001676047 us-gaap:WarrantMember 2023-03-07 2023-03-07 0001676047 2023-10-27 0001676047 srt:ChiefExecutiveOfficerMember 2023-10-27 0001676047 ntrb:BlackScholesMember 2023-02-01 2024-01-31 0001676047 srt:MinimumMember ntrb:BlackScholesMember 2023-02-01 2024-01-31 0001676047 srt:MaximumMember ntrb:BlackScholesMember 2023-02-01 2024-01-31 0001676047 2021-11-01 0001676047 2022-02-01 2022-02-01 0001676047 2023-02-01 2023-02-01 0001676047 2021-11-03 2021-11-03 0001676047 ntrb:BlackScholesMember 2024-01-31 0001676047 srt:MinimumMember 2024-01-31 0001676047 srt:MaximumMember 2024-01-31 0001676047 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2023-01-31 0001676047 srt:MaximumMember srt:DirectorMember 2023-01-31 0001676047 us-gaap:WarrantMember 2022-02-01 2023-01-31 0001676047 srt:MinimumMember us-gaap:WarrantMember 2022-02-01 2023-01-31 0001676047 srt:MaximumMember us-gaap:WarrantMember 2022-02-01 2023-01-31 0001676047 us-gaap:WarrantMember 2022-01-30 0001676047 us-gaap:WarrantMember 2022-01-31 2022-01-31 0001676047 us-gaap:WarrantMember 2023-01-31 0001676047 srt:ScenarioPreviouslyReportedMember us-gaap:WarrantMember 2024-01-31 0001676047 srt:ScenarioPreviouslyReportedMember us-gaap:WarrantMember 2023-02-01 2024-01-31 0001676047 us-gaap:WarrantMember 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesOneMember 2023-02-01 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesOneMember 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesTwoMember 2023-02-01 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesTwoMember 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreeMember 2023-02-01 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreeMember 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesFourMember 2023-02-01 2024-01-31 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesFourMember 2024-01-31 0001676047 us-gaap:StockOptionMember 2022-01-31 0001676047 us-gaap:StockOptionMember 2022-02-01 2023-01-31 0001676047 us-gaap:StockOptionMember 2023-01-31 0001676047 us-gaap:StockOptionMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSevenMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSevenMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2023-02-01 2024-01-31 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2024-01-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2023-02-01 2024-01-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2022-02-01 2023-01-31 0001676047 ntrb:FourPTherapeuticsMember 2023-02-01 2024-01-31 0001676047 ntrb:FourPTherapeuticsMember 2022-02-01 2023-01-31 0001676047 us-gaap:CorporateAndOtherMember 2023-02-01 2024-01-31 0001676047 us-gaap:CorporateAndOtherMember 2022-02-01 2023-01-31 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2023-02-01 2024-01-31 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2022-02-01 2023-01-31 0001676047 ntrb:GoodwillImpairmentPoconoPharmacueticalsMember 2023-02-01 2024-01-31 0001676047 ntrb:GoodwillImpairmentPoconoPharmacueticalsMember 2022-02-01 2023-01-31 0001676047 ntrb:OutsideTheUnitedStatesMember 2023-02-01 2024-01-31 0001676047 ntrb:OutsideTheUnitedStatesMember 2022-02-01 2023-01-31 0001676047 country:US 2024-01-31 0001676047 country:US 2023-01-31 0001676047 ntrb:OutsideTheUnitedStatesMember 2024-01-31 0001676047 ntrb:OutsideTheUnitedStatesMember 2023-01-31 0001676047 us-gaap:CorporateAndOtherMember 2024-01-31 0001676047 us-gaap:CorporateAndOtherMember 2023-01-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-01-31 0001676047 ntrb:PoconoPharmaceuticalsMember 2023-01-31 0001676047 ntrb:FourPTherapeuticsMember 2024-01-31 0001676047 ntrb:FourPTherapeuticsMember 2023-01-31 0001676047 ntrb:AgreementMember 2023-02-01 2024-01-31 0001676047 srt:ChiefExecutiveOfficerMember 2023-02-01 2024-01-31 0001676047 2022-07-31 2022-07-31 0001676047 srt:ChiefFinancialOfficerMember 2023-02-01 2024-01-31 0001676047 ntrb:MrGoodmanMember 2022-07-31 2022-07-31 0001676047 2022-01-01 0001676047 2022-02-01 0001676047 ntrb:AgreementMember 2022-02-01 2022-02-01 0001676047 ntrb:MDMWorldwideMember 2024-01-31 0001676047 2023-03-13 0001676047 ntrb:MoneyChannelMember 2023-03-13 2023-03-13 0001676047 ntrb:MoneyChannelMember 2024-01-31 0001676047 2023-07-01 2023-07-25 0001676047 2023-07-25 0001676047 ntrb:SorrentoTherapeuticsIncAgreementMember 2023-07-25 0001676047 us-gaap:SubsequentEventMember 2024-02-01 2024-04-30 0001676047 us-gaap:SubsequentEventMember 2024-03-20 2024-03-20 0001676047 srt:MinimumMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-20 0001676047 srt:MaximumMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-20 0001676047 us-gaap:SubsequentEventMember 2024-03-20 0001676047 ntrb:BoardOfDirectorsMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-20 0001676047 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-03-20 0001676047 us-gaap:SubsequentEventMember 2024-04-19 2024-04-19 0001676047 us-gaap:SubsequentEventMember 2024-04-19 0001676047 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2024-04-19 0001676047 us-gaap:WarrantMember us-gaap:SubsequentEventMember 2024-04-19 2024-04-19 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-04-30 0001676047 2023-07-13 0001676047 us-gaap:RelatedPartyMember 2024-04-19 2024-04-19 0001676047 srt:MinimumMember 2024-02-01 2024-04-30 0001676047 srt:MaximumMember 2024-02-01 2024-04-30 0001676047 ntrb:FourPTherapeuticsLLCMember 2024-04-30 0001676047 ntrb:PoconoCoatedProductsLLCAndActiveIntelligenceLLCMember 2020-08-31 0001676047 ntrb:SaleOfGoodsMember 2024-02-01 2024-04-30 0001676047 ntrb:SaleOfGoodsMember 2023-02-01 2023-04-30 0001676047 us-gaap:ServiceMember 2024-02-01 2024-04-30 0001676047 us-gaap:ServiceMember 2023-02-01 2023-04-30 0001676047 country:US 2024-02-01 2024-04-30 0001676047 country:US 2023-02-01 2023-04-30 0001676047 us-gaap:NonUsMember 2024-02-01 2024-04-30 0001676047 us-gaap:NonUsMember 2023-02-01 2023-04-30 0001676047 srt:MinimumMember us-gaap:EquipmentMember 2024-04-30 0001676047 srt:MaximumMember us-gaap:EquipmentMember 2024-04-30 0001676047 us-gaap:FurnitureAndFixturesMember 2024-04-30 0001676047 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2024-04-30 0001676047 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-04-30 0001676047 ntrb:LabEquipmentMember 2024-04-30 0001676047 us-gaap:MachineryAndEquipmentMember 2024-04-30 0001676047 us-gaap:LineOfCreditMember 2024-04-30 0001676047 us-gaap:LineOfCreditMember 2024-02-01 2024-04-30 0001676047 ntrb:CarolinaSmallBusinessDevelopmentFundMember 2024-04-30 2024-04-30 0001676047 us-gaap:NotesPayableToBanksMember 2024-01-31 0001676047 us-gaap:NotesPayableToBanksMember 2024-02-01 2024-04-30 0001676047 us-gaap:RelatedPartyMember 2024-02-01 2024-04-30 0001676047 ntrb:SecuredBorrowingLiabilityMember 2024-02-01 2024-04-30 0001676047 2023-08-01 2023-10-31 0001676047 us-gaap:FiniteLivedIntangibleAssetsMember 2024-04-30 0001676047 ntrb:newFiniteLivedIntangibleAssetsTwoMember 2024-04-30 0001676047 srt:ExecutiveOfficerMember 2024-04-30 0001676047 ntrb:EmployeesMember 2024-04-30 0001676047 ntrb:EuropeanInvestorsMember 2024-04-19 2024-04-19 0001676047 srt:DirectorMember 2024-04-19 2024-04-19 0001676047 ntrb:SonMember 2024-04-19 2024-04-19 0001676047 ntrb:OtherRelatedPartyMember 2024-04-19 2024-04-19 0001676047 ntrb:TIIJetServicesLDAMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember 2023-02-01 2023-04-30 0001676047 us-gaap:SeriesAPreferredStockMember 2019-05-24 0001676047 us-gaap:SeriesAPreferredStockMember 2019-06-20 0001676047 srt:MinimumMember us-gaap:CommonStockMember 2020-01-27 0001676047 srt:MaximumMember us-gaap:CommonStockMember 2020-01-27 0001676047 us-gaap:CommonStockMember 2024-02-01 2024-04-30 0001676047 us-gaap:IPOMember 2024-04-19 2024-04-19 0001676047 us-gaap:CommonStockMember 2024-04-19 0001676047 2024-04-19 0001676047 us-gaap:CommonStockMember 2024-04-19 2024-04-19 0001676047 ntrb:Warrants1Member 2024-04-19 2024-04-19 0001676047 2023-03-07 2023-03-07 0001676047 us-gaap:WarrantMember 2024-02-01 2024-04-30 0001676047 ntrb:BlackScholesMember 2024-02-01 2024-04-30 0001676047 srt:MinimumMember ntrb:BlackScholesMember 2024-02-01 2024-04-30 0001676047 srt:MaximumMember ntrb:BlackScholesMember 2024-02-01 2024-04-30 0001676047 2024-03-20 0001676047 srt:ChiefExecutiveOfficerMember 2024-02-01 2024-04-30 0001676047 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2024-04-30 0001676047 srt:MaximumMember srt:ChiefExecutiveOfficerMember 2024-04-30 0001676047 srt:MinimumMember srt:ChiefExecutiveOfficerMember 2024-01-31 0001676047 srt:MaximumMember srt:ChiefExecutiveOfficerMember 2024-01-31 0001676047 us-gaap:WarrantMember 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesOneMember 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesOneMember 2024-02-01 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesTwoMember 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesTwoMember 2024-02-01 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreeMember 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesThreeMember 2024-02-01 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesFourMember 2024-04-30 0001676047 us-gaap:WarrantMember ntrb:ExercisePricesFourMember 2024-02-01 2024-04-30 0001676047 us-gaap:EmployeeStockOptionMember us-gaap:StockOptionMember 2023-01-31 0001676047 us-gaap:EmployeeStockOptionMember us-gaap:StockOptionMember 2023-02-01 2024-01-31 0001676047 us-gaap:EmployeeStockOptionMember us-gaap:StockOptionMember 2024-01-31 0001676047 us-gaap:EmployeeStockOptionMember us-gaap:StockOptionMember 2024-02-01 2024-04-30 0001676047 us-gaap:EmployeeStockOptionMember us-gaap:StockOptionMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesOneMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwoMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThreeMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFourMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesFiveMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSixMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSevenMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesSevenMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesEightMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesNineMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTenMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesElevenMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwelveMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesTwelveMember 2024-02-01 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThirteenMember 2024-04-30 0001676047 us-gaap:StockOptionMember ntrb:ExercisePricesThirteenMember 2024-02-01 2024-04-30 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-02-01 2024-04-30 0001676047 ntrb:PoconoPharmaceuticalsMember 2023-02-01 2023-04-30 0001676047 ntrb:FourPTherapeuticsMember 2024-02-01 2024-04-30 0001676047 ntrb:FourPTherapeuticsMember 2023-02-01 2023-04-30 0001676047 us-gaap:CorporateAndOtherMember 2024-02-01 2024-04-30 0001676047 us-gaap:CorporateAndOtherMember 2023-02-01 2023-04-30 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2024-02-01 2024-04-30 0001676047 ntrb:ResearchAndDevelopment4PTherapeuticsMember 2023-02-01 2023-04-30 0001676047 ntrb:OutsideTheUnitedStatesMember 2024-02-01 2024-04-30 0001676047 ntrb:OutsideTheUnitedStatesMember 2023-02-01 2023-04-30 0001676047 country:US 2024-04-30 0001676047 ntrb:OutsideTheUnitedStatesMember 2024-04-30 0001676047 us-gaap:CorporateAndOtherMember 2024-04-30 0001676047 ntrb:PoconoPharmaceuticalsMember 2024-04-30 0001676047 ntrb:FourPTherapeuticsMember 2024-04-30 0001676047 ntrb:AgreementMember 2024-02-01 2024-04-30 0001676047 2024-01-15 2024-01-15 0001676047 2023-07-25 2023-07-25 0001676047 ntrb:SorrentoTherapeuticsIncAgreementMember 2024-01-31 0001676047 ntrb:TIIJetServicesLDAMember us-gaap:SubsequentEventMember 2024-05-14 0001676047 ntrb:TIIJetServicesLDAMember us-gaap:SubsequentEventMember 2024-05-14 2024-05-14 0001676047 ntrb:TIIJetServicesLDAMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-05-14 2024-05-14 0001676047 ntrb:TIIJetServicesLDAMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-05-14 0001676047 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2024-05-22 0001676047 us-gaap:SubsequentEventMember 2024-05-22 2024-05-22 iso4217:USD iso4217:USD shares shares pure AMENDMENT NO. 4 Nutriband Inc. NV Non-accelerated Filer true true true 492942 1985440 148649 113045 168605 229335 211667 365925 1021863 2693745 774924 897735 5021713 5021713 31374 62754 667280 780430 7517154 9456377 680132 534679 157502 162903 34276 31291 127183 19740 999093 748613 79826 100497 34277 1078919 883387 0.001 0.001 10000000 10000000 0 0 0.001 0.001 291666666 291666666 8869870 7843150 8859870 7833150 8860 7833 34442339 31092807 -304 -304 10000 10000 32641 32641 -27980019 -22494705 6438235 8572990 7517154 9456377 2085314 2079609 1223209 1329200 1960425 982227 327326 3773606 3916041 6957240 6554794 -4871926 -4475185 16850 -554423 75815 8289 -613388 -8289 -5485314 -4483474 -5485314 -4483474 -0.69 -0.53 7954105 8459547 8572990 7833150 7833 31092807 -304 -22494705 -32641 242840 242840 499856 499856 2607863 1026720 1027 2606836 -5485314 -5485314 6438235 8859870 8860 34442339 -304 -27980019 -32641 11859285 9154846 9155 29966132 -304 -18011231 -104467 296875 55417 56 296819 -1400000 -1400 1400 113155 33471 32 3746 109377 174025 25000 25 92545 81455 -119006 -35584 -35 35 -119006 732130 732130 -4483474 -4483474 8572990 7833150 7833 31092807 -304 -22494705 -32641 -5485314 -4483474 287722 330143 31380 38813 -554423 118365 113155 174025 327326 242840 499856 732130 153969 41665 -154258 -4547 -60730 97687 -5401 56636 -31292 -36287 198893 -104860 -3527509 -2987198 51761 79304 -51761 -79304 2000000 106528 296875 19756 17795 -119006 2086772 160074 -1492498 -2906428 1985440 4891868 492942 1985440 7352 4266 94134 22794 1400 2607863 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Organization</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Nutriband Inc. (the “Company”) is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was formed by the Company’s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">On August 1, 2018, the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics. The former owner resigned as a director in January 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics is engaged in the development of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics, the Company’s business was the development and marketing of a range of transdermal consumer patches. Most of these products are considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration (the “FDA”). The Company entered a feasibility agreement as an initial step to seek FDA approval of its consumer transdermal products and its consumer products which are not being marketed in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">With the acquisition of 4P Therapeutics, 4P Therapeutics’ drug development business became the Company’s principal business. The Company’s approach is to use generic drugs that are off patent and incorporate them into the Company’s transdermal drug delivery system. Although these medications have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc. (“Pocono Pharmaceuticals”), a wholly owned subsidiary of the Company. On August 31, 2020, the Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono Coated Products LLC (“PCP”). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction, Pocono Pharmaceuticals also acquired 100% of the membership interests of Active Intelligence LLC (“Active Intelligence”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals is a contract development and manufacturing organization with unique process capabilities and experience focused on coated product manufacturing. Pocono helps their customers with product design and development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical’s competitive edge is a low-cost manufacturing base: a result of its unique processes and state-of-the-art material technology. Active Intelligence manufactures activated kinesiology tape for transdermal or topical use.</span></p> 2250000 250000 1850000 400000 0.06 1 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0%"></td><td style="width: 0.5in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">2.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Forward Stock Split</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the “Stock Split”) of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250,000,000 authorized shares to 291,666,666 authorized shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">All share and per share information in these financial statements retroactively reflect the forward stock split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Going Concern Assessment </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look-forward period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">As of January 31, 2024, the Company had cash and cash equivalents of $492,942 and working capital of $22,770. For the year ended January 31, 2024, the Company incurred a loss from operations of $4,871,926 and used cash flow from operations of $3,527,509. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third-party and related-party debt to support cash flow from operations. In October 2021, the Company consummated a public offering and received net proceeds of $5,836,230. The Company has also received to date $3,239,845 in proceeds from the exercise of warrants. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 13, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. The Company was advanced $2,000,000, all of which was settled by the issuance of common stock during the year ended January 31, 2024. The $2,000,000 debt and accrued interest was converted into 1,026,720 shares of the Company’s common stock. On April 19, 2024, the Company received proceeds of $8,400,000 from a private placement of its common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Principles of Consolidation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020 under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Nutriband Ltd.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics LLC</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white; text-indent: 1.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Use of Estimates </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Revenue Recognition </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Revenue Types</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a description of the Company’s revenue types, which include professional services and sale of goods:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods </span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Product revenues derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in; background-color: white"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract research and development services for pharmaceuticals and medical devices for life sciences customers with revenues listed under services </span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Contracts with Customers</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Contract Liabilities</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 2.25pt"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Performance Obligations</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">All revenue recognized in the income statement is considered to be revenue from contracts with customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Disaggregation of Revenues</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Years Ended</b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Revenue by type</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Sale of goods</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,920,280</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,785,507</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Services</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">165,034</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">294,102</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,609</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Years Ended</b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Revenue by geographic location:</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,609</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,609</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Cash and cash equivalents.</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true">Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short-term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of January 31, 2024, the Company has no balances that exceed federally insured limits.</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Accounts receivable </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both the specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the years ended January 31, 2024, and 2023, the Company recorded bad debt expenses of $118,364 and $-0-, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $106,528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of January 31, 2024, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10%. The Company adopted ASU 2016-13 during 2023 and implemented the guidance on expected credit losses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Inventories</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of January 31, 2024, total inventory was $168,605, consisting of work-in-process of $7,466, finished goods of $8,707 and raw materials of $134,691. As of January 31, 2023, total inventory was $229,335, consisting of work-in-process of $11,021 and raw materials of $218,334.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Property, Plant and Equipment</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Property and equipment represent an important component of the Company’s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Lab Equipment</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">5-10 years</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Furniture and fixtures</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">3 years</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">10-20 years</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Intangible Assets</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisitions have also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Goodwill</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. During the years ended January 31, 2024, and 2023, the Company recorded an impairment charge of $-0- and $327,326, respectively, reducing the Active Intelligence LLC Goodwill to $3,302,478. As of January 31, 2024, and 2023, Goodwill amounted to $5,021,713 and $5,021,713, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Long-lived Assets</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Earnings per Share</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period.  Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of January 31, 2024, and 2023, there were 2,157,873 and 1,778,006 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Stock-Based Compensation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Business Combinations</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The Company recognizes the assets acquired, the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Leases</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;background-color: #FDFDFD">In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;background-color: #FDFDFD">The Company applies guidance for right-of-use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Research and Development Expenses</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Research and development costs are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Income Taxes</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The Company records net deferred tax assets to the extent they believe these assets will more-likely-than-not be realized.  In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.  In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in; background-color: #FDFDFD"><span style="-sec-ix-redline:true;background-color: #FDFDFD"><i><span style="text-decoration:underline">Fair Value Measurements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true">FASB ASC 820, “Fair Value Measurements and Disclosure” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true">The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 0.45in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-Observable inputs such as quoted market prices in active markets.</span></td></tr> <tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-Inputs other than quoted prices in active markets that are either directly or indirectly observable.</span></td></tr> <tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.75in; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true">The carrying value of the Company’s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Recent Accounting Standards</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (“CECL”), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016-13 during the year ended January 31, 2024. The adoption of ASU 2016-13 did not have a material impact on the Company’s balance sheet or statement of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true">The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Forward Stock Split</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the “Stock Split”) of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250,000,000 authorized shares to 291,666,666 authorized shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">All share and per share information in these financial statements retroactively reflect the forward stock split.</span></p> The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. 250000000 291666666 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Going Concern Assessment </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look-forward period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">As of January 31, 2024, the Company had cash and cash equivalents of $492,942 and working capital of $22,770. For the year ended January 31, 2024, the Company incurred a loss from operations of $4,871,926 and used cash flow from operations of $3,527,509. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third-party and related-party debt to support cash flow from operations. In October 2021, the Company consummated a public offering and received net proceeds of $5,836,230. The Company has also received to date $3,239,845 in proceeds from the exercise of warrants. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 13, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. The Company was advanced $2,000,000, all of which was settled by the issuance of common stock during the year ended January 31, 2024. The $2,000,000 debt and accrued interest was converted into 1,026,720 shares of the Company’s common stock. On April 19, 2024, the Company received proceeds of $8,400,000 from a private placement of its common stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> 492942 22770 -4871926 -3527509 5836230 3239845 2000000 5000000 2000000 2000000 1026720 8400000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Principles of Consolidation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020 under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Nutriband Ltd.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics LLC</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Use of Estimates </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Revenue Recognition </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Revenue Types</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a description of the Company’s revenue types, which include professional services and sale of goods:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods </span></td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Product revenues derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods</span></td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract research and development services for pharmaceuticals and medical devices for life sciences customers with revenues listed under services </span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Contracts with Customers</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Contract Liabilities</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Performance Obligations</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">All revenue recognized in the income statement is considered to be revenue from contracts with customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Disaggregation of Revenues</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Years Ended</b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Revenue by type</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Sale of goods</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,920,280</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,785,507</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Services</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">165,034</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">294,102</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,609</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Years Ended</b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Revenue by geographic location:</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,609</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,609</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <span style="-sec-ix-redline:true;-keep: true">The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Years Ended</b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Revenue by type</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Sale of goods</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,920,280</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,785,507</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Services</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">165,034</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">294,102</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,609</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 1920280 1785507 165034 294102 2085314 2079609 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Years Ended</b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Revenue by geographic location:</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,609</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,609</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 2085314 2079609 2085314 2079609 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Cash and cash equivalents.</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true">Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short-term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of January 31, 2024, the Company has no balances that exceed federally insured limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Accounts receivable </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both the specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the years ended January 31, 2024, and 2023, the Company recorded bad debt expenses of $118,364 and $-0-, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $106,528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of January 31, 2024, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10%. The Company adopted ASU 2016-13 during 2023 and implemented the guidance on expected credit losses.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> 118364 0 106528 0.10 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Inventories</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of January 31, 2024, total inventory was $168,605, consisting of work-in-process of $7,466, finished goods of $8,707 and raw materials of $134,691. As of January 31, 2023, total inventory was $229,335, consisting of work-in-process of $11,021 and raw materials of $218,334.</span></p> 168605 7466 8707 134691 229335 11021 218334 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Property, Plant and Equipment</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Property and equipment represent an important component of the Company’s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Lab Equipment</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">5-10 years</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Furniture and fixtures</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">3 years</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">10-20 years</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Lab Equipment</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">5-10 years</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Furniture and fixtures</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">3 years</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">10-20 years</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> P3Y P20Y P5Y P10Y P3Y P10Y P20Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Intangible Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisitions have also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.</span></p> P10Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Goodwill</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. During the years ended January 31, 2024, and 2023, the Company recorded an impairment charge of $-0- and $327,326, respectively, reducing the Active Intelligence LLC Goodwill to $3,302,478. As of January 31, 2024, and 2023, Goodwill amounted to $5,021,713 and $5,021,713, respectively.</span></p> 1719235 5810640 0 327326 3302478 5021713 5021713 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Long-lived Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Earnings per Share</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period.  Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of January 31, 2024, and 2023, there were 2,157,873 and 1,778,006 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.</span></p> 2157873 1778006 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Stock-Based Compensation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Business Combinations</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The Company recognizes the assets acquired, the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Leases</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;background-color: #FDFDFD">In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;background-color: #FDFDFD">The Company applies guidance for right-of-use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Research and Development Expenses</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Research and development costs are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Income Taxes</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The Company records net deferred tax assets to the extent they believe these assets will more-likely-than-not be realized.  In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.  In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in; background-color: #FDFDFD"><span style="-sec-ix-redline:true;background-color: #FDFDFD"><i><span style="text-decoration:underline">Fair Value Measurements</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true">FASB ASC 820, “Fair Value Measurements and Disclosure” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true">The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 0.45in"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-Observable inputs such as quoted market prices in active markets.</span></td></tr> <tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-Inputs other than quoted prices in active markets that are either directly or indirectly observable.</span></td></tr> <tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td> <td><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">-Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true">The carrying value of the Company’s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Recent Accounting Standards</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (“CECL”), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016-13 during the year ended January 31, 2024. The adoption of ASU 2016-13 did not have a material impact on the Company’s balance sheet or statement of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true">The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">3.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">PROPERTY AND EQUIPMENT</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Lab equipment</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,585</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,585</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,292,389</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,240,628</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Furniture and fixtures</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,643</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,643</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,456,617</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,404,856</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: Accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(681,693</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(507,121</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Net Property and Equipment</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">774,924</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">897,735</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Depreciation expenses amounted to $174,572 and $183,660 for the years ended January 31, 2024, and 2023, respectively. During the years ended January 31, 2024, and 2023, depreciation expenses of $131,360 and $139,689, respectively, have been allocated to cost of goods sold.</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Lab equipment</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,585</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,585</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,292,389</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,240,628</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Furniture and fixtures</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,643</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,643</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,456,617</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,404,856</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Less: Accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(681,693</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(507,121</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Net Property and Equipment</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">774,924</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">897,735</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 144585 144585 1292389 1240628 19643 19643 1456617 1404856 681693 507121 774924 897735 174572 183660 131360 139689 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">4.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">INCOME TAXES</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company adopted the provisions of ASC 740, “Income Taxes, (“ASC 740”). As a result of the implementation of ASC 740, the Company recognized no adjustment in the net liability for unrecognized income tax benefits. The Company believes there are no potential uncertain tax positions, and all tax returns are correct as filed. Should the Company recognize a liability for uncertain tax positions, the Company will separately recognize the liability for uncertain tax positions on its balance sheet. Included in any liability or uncertain tax positions, the Company will also set up a liability for interest and penalties. The Company’s policy is to recognize interest and penalties related to uncertain tax positions as a component of the current</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true">provision for income taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">There is no U.S. tax provision due to losses from U.S. operations for the years ended January 31, 2024 and 2023. Deferred income taxes are provided for the temporary differences between the financial reporting and tax basis of the Company’s assets and liabilities. The principal item giving rise to deferred taxes is the net operating loss carryforward in the U.S. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has set up a valuation allowance for losses for certain carryforwards that it believes may not be realized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true">The provision for income taxes consists of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="padding-bottom: 1.5pt; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ended <br/> January 31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Current</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%"><span style="-sec-ix-redline:true;-keep: true">Federal</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52"><span style="-sec-ix-redline:true;-keep: true">          -</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53"><span style="-sec-ix-redline:true;-keep: true">           -</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Deferred</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Federal</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true">A reconciliation of taxes on income computed at the federal statutory rate to amounts provided is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ended</b></span><b style="-sec-ix-redline:true;-keep: true"> <br/> January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Book Income (loss from operations)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,151,916</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(941,530</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Common stock issued for services</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">155,966</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">168,768</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Impairment expense</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">68,738</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Unused operating losses</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">995,950</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">704,024</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Income tax expense</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of January 31, 2024, the Company recorded a deferred tax asset associated with a net operating loss (“NOL”) carryforward of approximately $15,800,000 that was fully offset by a valuation allowance due to the determination that it was more likely than not that the Company would be unable to utilize those benefits in the foreseeable future. The Company’s NOL expires in 2041. The tax effect of the valuation allowance increased by approximately $1,151,916 during the year ended January 31, 2024. On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) significantly revised U.S. corporate income tax law by, among other things, reducing the corporate rate from 34% to 21%. Because the Company recognizes a valuation allowance for the entire balance, there is no net impact on the Company’s balance sheet or results of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The types of temporary differences between tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax asset and their approximate tax effects are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net operating loss carryforward (expire through 2040)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,312,698</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,316,748</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock issued for services</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,455,848</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,299,882</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Intangible impairment expense</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,051,714</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,051,714</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,820,260</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,668,344</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Net deferred taxes</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <span style="-sec-ix-redline:true;-keep: true">The provision for income taxes consists of the following:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="padding-bottom: 1.5pt; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ended <br/> January 31,</b></span></td><td style="padding-bottom: 1.5pt; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Current</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%"><span style="-sec-ix-redline:true;-keep: true">Federal</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52"><span style="-sec-ix-redline:true;-keep: true">          -</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53"><span style="-sec-ix-redline:true;-keep: true">           -</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Deferred</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Federal</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <span style="-sec-ix-redline:true;-keep: true">A reconciliation of taxes on income computed at the federal statutory rate to amounts provided is as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years Ended</b></span><b style="-sec-ix-redline:true;-keep: true"> <br/> January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Book Income (loss from operations)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,151,916</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(941,530</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Common stock issued for services</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">155,966</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">168,768</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Impairment expense</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">68,738</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Unused operating losses</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">995,950</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">704,024</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Income tax expense</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> -1151916 -941530 155966 168768 68738 995950 704024 15800000 1151916 0.34 0.21 <span style="-sec-ix-redline:true;-keep: true">The types of temporary differences between tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax asset and their approximate tax effects are as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Net operating loss carryforward (expire through 2040)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(3,312,698</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(2,316,748</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock issued for services</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,455,848</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,299,882</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Intangible impairment expense</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,051,714</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(1,051,714</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,820,260</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,668,344</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Net deferred taxes</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 3312698 2316748 -1455848 -1299882 -1051714 -1051714 5820260 4668344 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.5in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">5.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">NOTES PAYABLE</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-indent: 1in"><span style="-sec-ix-redline:true;text-decoration:underline">Notes Payable</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Active Intelligence, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due October 16, 2028, with interest of 5% per year. The amount assumed was $139,184. The loan requires monthly payments of principal and interest of $1,697. During the year ended January 31, 2024, the Company made $15,378 of principal payments. As of January 31, 2024, the amount due was $85,249, of which $16,129 is current. As of January 31, 2023, the amount due was $100,627.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">On April 3, 2022, the Company entered into a retail installment agreement for the purchase of an automobile. The contract price was $32,274, of which $22,795 was financed. The agreement is for five years bearing interest at 2.95% per annum with payments of $410 per month. The loan is secured by automobile. As of January 31, 2024, the amount due was $15,232 of which $4,456 is current. As of January 31, 2023, the amount due was $19,610.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;text-decoration:underline">Note payable-related party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">On July 17, 2023, the Company entered an amended Credit Line Note agreement, for an increased $5,000,000 credit line facility Note, with TII Jet Services LDA, a shareholder of the Company (replacing the $2,000,000 facility with the same lender that the Company entered on March 17, 2023). Outstanding advances under the Note bears interest at 7% per annum. The promissory note is due and payable in full on March 19, 2026. Interest is payable annually on December 31 of each year during the term of the note. During the year ended January 31, 2024, the Company received $2,000,000 on the Note. In December 2023, the Company converted the balance of the credit facility of $2,000,000 and $53,476 of accrued interest into 1,026,520 shares of common stock. The fair value of the common stock was $2,554,423 resulting in a $554,423 loss on extinguishment. As of January 31, 2024, the balance due was $-0-. The Company recorded interest expense of $60,453 for the year ended January 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;text-decoration:underline">Secured borrowing liability. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The Company entered into an accounts receivable sale agreement for one of its subsidiaries in connection with a bankruptcy claim. The Company received $106,528 and recorded the transaction as a secured loan payable against the account receivable. The sale of the account receivable balance was to an outside third party, whereby if the bankruptcy court does not pay the balance in full, the Company will owe back the unpaid portion. The loan is classified as a current liability as the Company expects the bankruptcy will be resolved in the next twelve months. The loan bears interest at 10%. For the year ended January 31, 2024, the Company recorded interest expense of $5,470.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white; text-indent: 0.25in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">Interest expenses for the year ended January 31, 2024, and 2023, were $75,815 and $6,289, respectively.</span></p> 160000 2028-10-16 0.05 139184 1697 15378 85249 16129 100627 32274 22795 0.0295 410 15232 4456 19610 5000000 2000000 0.07 2000000 2000000 53476 1026520 2554423 554423 0 60453 106528 0.10 5470 75815 6289 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.5in"><span style="-sec-ix-redline:true;-keep: true">6.</span></td><td><span style="-sec-ix-redline:true;-keep: true">INTANGIBLE ASSETS</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"><span style="-sec-ix-redline:true;-keep: true">As of January 31, 2024, and 2023, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Customer base</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">314,100</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">314,100</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Intellectual property and trademarks</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">817,400</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">817,400</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,131,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,131,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Less: Accumulated amortization</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(464,220</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(351,070</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Net Intangible Assets</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">667,280</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">780,430</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">In February 2021, the Company acquired an IP license from Rambam Med-Tech Ltd. for $50,000. The value of the intangible assets, consisting of intellectual property, license agreement and customer base has been recorded at their fair value by the Company and are being amortized over a period of three to ten years. The Company terminated the license agreement in October 2022. The Company issued 25,000 shares of its common stock from its treasury shares held by the Company and warrants to purchase 25,000 shares at an exercise price of $7.50 per share as part of the termination agreement. The Company recorded a termination expense of $174,025 during the year ended January 31, 2023. Which is included in selling, general and administrative expenses. The Company expensed the balance of the agreement of $33,334 during the year ended January 31, 2023, which is included in selling, general and administrative expenses. Amortization expenses for the years ended January 31, 2024, and 2023 amounted to $113,150 and $146,483, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Year Ended January 31,</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,109</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2026</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,109</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2027</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,109</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2028</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,109</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2029</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,109</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">2030 and thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">101,735</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">667,280</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <span style="-sec-ix-redline:true;-keep: true">As of January 31, 2024, and 2023, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">January 31,</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Customer base</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">314,100</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">314,100</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Intellectual property and trademarks</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">817,400</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">817,400</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,131,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,131,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Less: Accumulated amortization</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(464,220</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(351,070</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Net Intangible Assets</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">667,280</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">780,430</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 314100 314100 817400 817400 1131500 1131500 464220 351070 667280 780430 50000 P3Y P10Y 25000 25000 7.5 174025 33334 Amortization expenses for the years ended January 31, 2024, and 2023 amounted to $113,150 and $146,483, respectively.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Year Ended January 31,</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,109</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2026</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,109</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2027</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,109</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2028</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,109</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2029</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,109</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">2030 and thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">101,735</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">667,280</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 113150 146483 113109 113109 113109 113109 113109 101735 667280 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.5in"><span style="-sec-ix-redline:true;-keep: true">7.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">RELATED PARTY TRANSACTIONS</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true">Activity during the year ended January 31, 2024</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">a)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 1, 2023, options to purchase 30,000 shares of the Company’s common stock were issued to an executive of the Company at a price of $3.975 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $75,030 and was expensed during the year ended January 31, 2024.</span></td></tr></table><p style="margin-top: 0; margin-bottom: 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">b)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In September and October 2023, options to purchase 374,500 shares of common stock to executives and directors of the Company at a price of $1.93, $2.12 and $2.65 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $424,826 and was expensed during the year ended January 31, 2024.</span></td></tr><tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">c)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On October 26, 2023, warrants to purchase 87,500 shares of the Company’s common stock were issued to the Chief Financial Officer at a price of $1.93 per share. The warrant expires in three years. The fair value of the warrants issued amounted to $93,450 and was expensed during the year ended January 31, 2024.</span></td></tr><tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">d)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 17, 2023, the Company entered an amended Credit Line Note facility with TII Jet Services LDA, a shareholder of the Company, for a credit facility of $5 million (replacing the $2,000,000 facility with the same lender that the Company entered on March 17, 2023). See Note 5 for further information. TII Jet Services LDA is owned 100% by a shareholder of the Company. During the year ended January 31, 2024, the Company received $2,000,000 from the credit facility. In December 2023, TII Jet Services LDA converted the balance of the credit facility of $2,000,000 and $53,436 of accrued interest into 1,026,520 shares of the Company’s common stock.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.75in"><span style="-sec-ix-redline:true;-keep: true">Activity during the year ended January 31, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">a)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In May 2022, the Company issued stock awards to the Company’s CEO and the independent members of the Board of Directors. The CEO received 11,667 shares and the four directors received 1,167 shares each. The Company recorded a compensation expense of $53,200 in connection with the issuance of the shares.</span></td></tr><tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">b)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On August 2, 2022, 137,084 options to purchase shares of the Company’s common stock were issued to executives of the Company at prices of $4.09 and $4.50 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $399,075 and was expensed during the year ended January 31, 2023.</span></td></tr><tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">c)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On September 30, 2022, 35,000 options to purchase shares of the Company’s common stock were issued to the independent directors of the Company at a price of $3.59 per share. The options vest immediately and expire in five years. The fair value of the options issued for services amounted to $85,995 and was expensed during the year ended January 31, 2023</span></td></tr><tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">d)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On December 7, 2022, options to purchase 107,500 shares of the Company’s common stock were issued to executives of the Company at prices of $3.53 and $3.88 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $245,170 and was expensed during the year ended January 31, 2023.</span></td></tr></table> 30000 3.975 P3Y 75030 374500 374500 1.93 1.93 2.12 2.12 2.65 2.65 P3Y 424826 87500 1.93 P3Y 93450 5000000 2000000 1 2000000 2000000 53436 1026520 11667 1167 53200 137084 4.09 4.5 P3Y 399075 35000 3.59 P5Y 85995 107500 3.53 3.88 P3Y 245170 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.5in"><span style="-sec-ix-redline:true;-keep: true">8.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">STOCKHOLDERS’ EQUITY</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;text-decoration:underline">Preferred Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 15, 2016, the board of directors of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 24, 2019, the board of directors created a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock (“Series A Preferred Stock”). On June 20, 2019, the Series A preferred Stock was terminated, and the 2,500,000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the board of directors.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Common Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 25, 2019, the Company effected a one-for-four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0.25 shares of common stock, and the Company decreased its authorized common stock in the same ratio from 100,000,000 to 25,000,000 shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 27, 2020, the Company amended its Articles of Incorporation to increase its authorized common shares from 25,000,000 authorized shares to 250,000,000 authorized shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 26, 2022, the Board of Directors of the Company approved a 7-for-6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. Pursuant to the operation of the amendment providing for the forward stock split filed with the Secretary of State of Nevada on August 4, 2022, the authorized common stock of the Company was increased from 250,000,000 shares to 291,666,666 shares in connection with the forward split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="-sec-ix-redline:true;text-decoration:underline">Activity during the Year Ended January 31, 2024</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="text-align: justify; width: 38.4pt"></td><td style="text-align: justify; width: 18pt"><span style="-sec-ix-redline:true;-keep: true">(a)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of January 31, 2024, the Company holds 10,000 of its shares comprising $32,641 of treasury stock. There was no activity during the year ended January 31, 2024.</span></td></tr><tr style="vertical-align: top"> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="text-align: justify; width: 38.4pt"></td><td style="text-align: justify; width: 18pt"><span style="-sec-ix-redline:true;-keep: true">(b)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In December 2024, TII Jet Services LDA converted $2,000,000 of its outstanding credit facility and $53,436 of accrued interest into 1,026,720 shares of the Company’s common stock. The fair value of the common stock at the date of issuance was $2,554,423, resulting in a $554,423 loss on extinguishment.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Activity during the Year Ended January 31, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 37.8pt"></td><td style="width: 18pt"><span style="-sec-ix-redline:true;-keep: true">(a)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In March and May 2022, the Company purchased 35,584 shares of its common stock for $119,006 and recorded the purchase as Treasury Stock. In May and December 2022, the Company issued 33,397 shares of stock awards to management, directors and employees from the treasury shares and recorded compensation expense of $113,155 In December 2022, the Company issued 25,000 shares from the treasury shares to non-employees in connection of the termination of the Rambam license agreement. As of January 31, 2023, the Company held 10,000 of its shares comprising $32,641 of treasury stock.</span></td></tr><tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 37.8pt"></td><td style="width: 18pt"><span style="-sec-ix-redline:true;-keep: true">(b)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 29, 2022, the Company received proceeds of $296,875 from the exercise of warrants and issued 55,417 shares of common stock.</span></td></tr><tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 37.8pt"></td><td style="width: 18pt"><span style="-sec-ix-redline:true;-keep: true">(c)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In July 2022, the Company cancelled 1,400,000 shares received in connection with the settlement of a lawsuit. See Note 11 for further information.</span></td></tr></table> 10000000 0.001 2500000 2500000 0.25 100000000 25000000 25000000 250000000 the Company approved a 7-for-6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. 250000000 291666666 10000 32641 2000000 53436 1026720 2554423 554423 35584 35584 119006 119006 33397 33397 113155 25000 10000 32641 296875 55417 1400000 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.5in"><span style="-sec-ix-redline:true;-keep: true">9.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">OPTIONS and WARRANTS</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="-sec-ix-redline:true;text-decoration:underline">Warrants</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company’s common stock issued to non-employees of the Company during the year ended January 31, 2024. On March 7, 2023, the Company issued 30,000 warrants to purchase the Company’s common shares to Barandnic Holdings Ltd. for services provided. The warrants are exercisable at a price of $4.00 per share and expire five years from the date of issuance. On October 27, 2023, the Company issued 145,833 warrants to purchase the Company’s common shares to management (87,500 warrants were issued to the Chief Financial Officer) and non-employees of the Company. The warrants are exercisable at a price of $1.93 per share and expire in three years from the date of issuance. These warrants replace previously issued warrants that have now been cancelled. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 152.10-174.45%; and a risk-free rate of 4.31%-4.84%. Non-cash compensation for the year ended January 31, 2024, amounted to $242,840.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Exercise</b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Remaining</b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Intrinsic</b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Shares</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Price</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Life</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Value</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2022</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,435,622</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.91</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 3.93 years </span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">25,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 5.00 years </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(97,534</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.36</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(55,417</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.36</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2023</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,307,671</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">3.34 years</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">175,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.28</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.97 years</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(200,466</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.33</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding - January 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,283,038</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.88</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2.97 years </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">99,166</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Exercisable - January 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,283,038</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.88</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2.97 years </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">99,166</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes additional information relating to the warrants outstanding as of January 31, 2024: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Range of Exercise<br/> Prices</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Number<br/> Outstanding</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Weighted Average<br/> Remaining<br/> Contractual<br/> Life(Years)</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Weighted Average<br/> Exercise Price for <br/> Shares<br/> Outstanding</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Number<br/> Exercisable</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Weighted Average<br/> Exercise Price for<br/> Shares<br/> Exercisable</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Intrinsic<br/> Value</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.10</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,082,205</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.68</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,082,205</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">145,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.74</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">145,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">99,166</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">25,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.77</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">25,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><b style="-sec-ix-redline:true;-keep: true"> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Option</span>s</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the changes in options outstanding and the related price of the shares of the Company’s common stock issued to employees of the Company. See Note 7 for the issuance of related party options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 1, 2021, the Board of Directors adopted the 2021 Employee Stock Option Plan (the “Plan”). The Company has reserved 408,333 shares for issuance and sale upon the exercise of stock options. In accordance with the Plan, on February 1, 2022, the Company reserved an additional 233,333 shares and on February 1, 2023, the Company reserved an additional 233,333 shares. The options vest immediately and expire in three years. Under the Plan, options may be granted which are intended to qualify as Incentive Stock Options (“ISO’s”) under Section 422 of the Internal Revenue Code of 1986 (the “Code”) or which are not (“non-ISO’s”) intended to qualify as Incentive Stock Options thereunder. The Plan also provides for restricted stock awards representing shares of common stock that are issued subject to such restrictions on transfer and other incidents of ownership and such forfeiture conditions as the Board of Directors, or the committee administering the Plan composed of directors who qualify as “independent” under Nasdaq rules, may determine. On November 3, 2021, the Company filed a Registration Statement on Form S-8, to register under the Securities Act of 1933, as amended the 408,333 shares of common stock reserved for issuance under the Plan. As of January 31, 2024, 166 shares remain available and issuance under the Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the year ended January 31, 2024, 404,500 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $1.93-$3.975 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $499,856 and was recorded during the year ended January 31, 2024. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 121.52-143.54%; and a risk-free rate of 3.00-4.5%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the year ended January 31, 2023, 279,584 options to purchase shares of the Company’s common stock were issued to executive officers and directors of the Company at prices of $3.59 to $4.50 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $732,130 and was recorded during the year ended January 31, 2023. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rate of 152.10-174.45%; and a risk-free rate of 3%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes additional information relating to the options outstanding as of January 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Shares</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Exercise <br/> Price</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Remaining<br/> Life</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Intrinsic<br/> Value</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2022</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">190,751</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.26</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2.97 years </span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">279,584</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 3.00 years </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2023</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">470,335</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.13</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2.53 years </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">404,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.18</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2.68 years </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding- January 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">874,835</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.23</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.31 years </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,460</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Exercisable - January 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">874,835</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.23</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.31 years </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,460</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes additional information relating to the options outstanding as of January 31, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Prices</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Outstanding</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Life(Years)</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Shares Outstanding</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Exercisable</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Shares Exercisable</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Value</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,500</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.74</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,500</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">145,860</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.74</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">68,600</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.63</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.59</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">35,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.67</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.59</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">35,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.59</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.75</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">57,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.85</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.75</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">57,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.75</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.01</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.09</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">78,750</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.09</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">78,750</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.09</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.85</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,083</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.97</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,083</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">58,334</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">58,334</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.58</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,668</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.97</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.58</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,668</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.58</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">874,835</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.06</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.23</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">874,835</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.23</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,460</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 30000 4 P5Y 145833 87500 1.93 P3Y The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 152.10-174.45%; and a risk-free rate of 4.31%-4.84%. Non-cash compensation for the year ended January 31, 2024, amounted to $242,840.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Exercise</b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Remaining</b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="text-align: center"><b style="-sec-ix-redline:true;-keep: true">Intrinsic</b></td><td><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Shares</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Price</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Life</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Value</b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2022</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,435,622</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.91</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 3.93 years </span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-65"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">25,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 5.00 years </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(97,534</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.36</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(55,417</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.36</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-70"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2023</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,307,671</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">3.34 years</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">175,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.28</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.97 years</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-72"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(200,466</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.33</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-74"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-75"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-76"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-77"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-78"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding - January 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,283,038</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.88</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2.97 years </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">99,166</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Exercisable - January 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,283,038</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.88</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2.97 years </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">99,166</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 0 P1Y6M 1.521 1.7445 0.0431 0.0484 242840 1435622 6.91 P3Y11M4D 25000 7.5 P5Y 97534 5.36 -55417 5.36 1307671 6.43 P3Y4M2D 175833 2.28 P2Y11M19D 200466 6.33 1283038 5.88 P2Y11M19D 99166 1283038 5.88 P2Y11M19D 99166 The following table summarizes additional information relating to the warrants outstanding as of January 31, 2024:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Range of Exercise<br/> Prices</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Number<br/> Outstanding</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Weighted Average<br/> Remaining<br/> Contractual<br/> Life(Years)</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Weighted Average<br/> Exercise Price for <br/> Shares<br/> Outstanding</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Number<br/> Exercisable</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Weighted Average<br/> Exercise Price for<br/> Shares<br/> Exercisable</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Intrinsic<br/> Value</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.10</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-79"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,082,205</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.68</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,082,205</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-80"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">145,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.74</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">145,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">99,166</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">25,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.77</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">25,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-81"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white"><b style="-sec-ix-redline:true;-keep: true"> </b></p> 4 30000 P4Y1M6D 4 30000 4 6.43 1082205 P2Y8M4D 6.43 1082205 6.43 1.93 145833 P2Y8M26D 1.93 145833 1.93 99166 7.5 25000 P3Y9M7D 7.5 25000 7.5 408333 233333 233333 408333 166 404500 1.93 3.975 P3Y 499856 0 P1Y6M 1.2152 1.4354 0.03 0.045 279584 3.59 4.5 732130 0 P1Y6M 1.521 1.7445 0.03 <span style="-sec-ix-redline:true;-keep: true">The following table summarizes additional information relating to the options outstanding as of January 31, 2024.</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Shares</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Exercise <br/> Price</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Remaining<br/> Life</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Intrinsic<br/> Value</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2022</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">190,751</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.26</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2.97 years </span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">279,584</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 3.00 years </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-83"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-84"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-85"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-86"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-87"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2023</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">470,335</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.13</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2.53 years </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-92"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">404,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.18</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2.68 years </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-93"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-94"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-95"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-98"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-99"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-100"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-101"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding- January 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">874,835</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.23</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.31 years </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,460</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Exercisable - January 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">874,835</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.23</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">2.31 years </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,460</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p> 190751 4.26 P2Y11M19D 279584 3.93 P3Y 470335 4.13 P2Y6M10D 404500 2.18 P2Y8M4D 874835 3.23 P2Y3M21D 214460 874835 3.23 P2Y3M21D 214460 <span style="-sec-ix-redline:true;-keep: true">The following table summarizes additional information relating to the options outstanding as of January 31, 2024:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Prices</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Outstanding</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Life(Years)</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Shares Outstanding</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Exercisable</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Shares Exercisable</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Value</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,500</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.74</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,500</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">145,860</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.74</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">68,600</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.63</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.59</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">35,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.67</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.59</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">35,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.59</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.75</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">57,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.85</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.75</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">57,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.75</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.01</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.09</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">78,750</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.09</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">78,750</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.09</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.85</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,083</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.97</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,083</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">58,334</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">58,334</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.58</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,668</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.97</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.58</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,668</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.58</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">874,835</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.06</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.23</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">874,835</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.23</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,460</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 1.93 214500 P2Y8M26D 1.93 214500 1.93 145860 2.12 140000 P2Y8M26D 2.12 140000 2.12 68600 2.65 20000 P2Y7M17D 2.65 20000 2.65 3.59 35000 P3Y8M1D 3.59 35000 3.59 3.75 57500 P1Y10M6D 3.75 57500 3.75 3.98 30000 P2Y3D 3.98 30000 3.98 4.09 78750 P1Y6M 4.09 78750 4.09 4.12 50000 P1Y10M6D 4.12 50000 4.12 4.16 144083 P0Y11M19D 4.16 144083 4.16 4.5 58334 P1Y6M 4.5 58334 4.5 4.58 46668 P0Y11M19D 4.58 46668 4.58 874835 P2Y21D 3.23 874835 3.23 214460 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.5in"><span style="-sec-ix-redline:true;-keep: true">10.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">SEGMENT REPORTING</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">We organize and manage our business by the following two segments which meet the definition of reportable segments under ASC280-10, Segment Reporting: Sales of Goods and Services. These segments are based on the type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief officer decision maker, in making resource allocation decisions for our segments. Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Years Ended January 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Net sales</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,920,280</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,785,597</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">165,034</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">294,102</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,699</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Gross profit</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">744,391</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">726,702</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">117,714</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">23,702</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">862,105</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">750,404</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative-Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">606,275</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">577,930</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative-4P Therapeutics</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">236,953</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">103,181</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative-Corporate</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,930,378</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,234,930</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Research and development-4P Therapeutics</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,960,425</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">982,227</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Goodwill impairment-Pocono Pharmacueticals</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">327,326</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,734,031</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,225,594</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Depreciation and Amortization</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">222,159</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">264,156</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Corporate</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">13,986</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51,577</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">65,987</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">287,722</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">330,143</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Years Ended<br/> January 31,</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Net sales</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,699</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Outside the United States</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,699</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="margin: 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 76%"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="width: 1%"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="text-align: left; width: 1%"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; width: 9%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January 31,</b></span></td><td style="text-align: left; width: 1%"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="width: 1%"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="text-align: left; width: 1%"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; width: 9%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January 31,</b></span></td><td style="text-align: left; width: 1%"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net of accumulated depreciation</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">774,924</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">897,735</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Outside the United States</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">774,924</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">897,735</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Assets</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Corporate</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">344,192</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,745,731</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,079,293</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,400,814</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,093,369</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,309,832</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,516,854</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,456,377</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit.<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Years Ended January 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Net sales</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,920,280</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,785,597</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">165,034</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">294,102</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,699</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Gross profit</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">744,391</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">726,702</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">117,714</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">23,702</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">862,105</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">750,404</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative-Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">606,275</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">577,930</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative-4P Therapeutics</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">236,953</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">103,181</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative-Corporate</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,930,378</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,234,930</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Research and development-4P Therapeutics</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,960,425</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">982,227</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Goodwill impairment-Pocono Pharmacueticals</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-111"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">327,326</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,734,031</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,225,594</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Depreciation and Amortization</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">222,159</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">264,156</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">Corporate</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">13,986</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 9pt"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51,577</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">65,987</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">287,722</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">330,143</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> 1920280 1785597 165034 294102 2085314 2079699 744391 726702 117714 23702 862105 750404 606275 577930 236953 103181 2930378 3234930 1960425 982227 327326 5734031 5225594 222159 264156 13986 51577 65987 287722 330143 <span style="-sec-ix-redline:true;-keep: true">The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Years Ended<br/> January 31,</b></td><td style="padding-bottom: 1.5pt; text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="text-align: center; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Net sales</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,699</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Outside the United States</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-113"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-114"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,085,314</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,079,699</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 76%"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="width: 1%"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="text-align: left; width: 1%"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; width: 9%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January 31,</b></span></td><td style="text-align: left; width: 1%"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="width: 1%"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="text-align: left; width: 1%"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="text-align: center; width: 9%"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>January 31,</b></span></td><td style="text-align: left; width: 1%"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2024</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="border-bottom: Black 1.5pt solid; text-align: center"><b style="-sec-ix-redline:true;-keep: true">2023</b></td><td style="padding-bottom: 1.5pt; text-align: left"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net of accumulated depreciation</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">774,924</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">897,735</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Outside the United States</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-115"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-116"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">774,924</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">897,735</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Assets</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Corporate</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">344,192</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,745,731</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,079,293</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,400,814</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,093,369</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,309,832</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,516,854</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,456,377</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 2085314 2079699 2085314 2079699 774924 897735 774924 897735 344192 1745731 5079293 5400814 2093369 2309832 7516854 9456377 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.5in"><span style="-sec-ix-redline:true;-keep: true">11.</span></td><td><span style="-sec-ix-redline:true;-keep: true">COMMITMENTS AND CONTIGENCIES</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><i style="-sec-ix-redline:true;-keep: true">Employment Agreements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as directors and officers of the Company for the respective terms thereof. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $250,000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance bonus of 3.5% of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $150,000.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company entered into a three-year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $210,000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $110,000.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47.4pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true">Kindeva Drug Delivery Agreement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.75in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 4, 2022, the Company signed a feasibility agreement with Kindeva Drug Delivery, L.P. (“Kindeva”) to develop Nutriband’s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system). The feasibility agreement provides for adapting Kindeva’s commercial transdermal manufacturing process to incorporate AVERSA technology in the fentanyl transdermal system.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The agreement will remain in force until the earlier of: (1) the completion of the work and deliverables under the Workplan; or (2) two (2) years after the Effective Date, after which time the agreement will expire. The feasibility Workplan was completed in February 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The estimated cost to complete the feasibility Workplan was approximately $2.5 million. Nutriband made an advance deposit of $250,000 in January 2022, to be applied against the final invoices. As of January 31, 2024, Nutriband has incurred expenses of $2,369,508 and the net deposit of $138,250 after application to final invoices is included in prepaid expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In January 2024, Nutriband signed a commercial development and clinical supply agreement with Kindeva Drug Delivery for development of AVERSA Fentanyl using Kindeva’s FDA-approved fentanyl patch. Kindeva will perform commercial manufacturing process development and clinical supplies manufacturing for the human abuse potential clinical study required by the FDA in support of a New Drug Application. The agreement replaces the previous feasibility agreement between the two companies which was focused on adapting Kindeva’s commercial transdermal manufacturing process to incorporate AVERSA abuse deterrent transdermal technology. The estimated cost to complete the commercial process development and clinical supplies manufacturing is approximately $8.1 million and the expected timing of FDA submission is twelve to eighteen months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Lease Agreement</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 1, 2022, Pocono Pharmaceuticals entered into a lease agreement with Geometric Group, LLC for 12,000 square feet of warehouse space currently occupied by Active Intelligence. The monthly rental is $3,000 and the lease expires on January 31, 2025. The lease can be extended for an additional three years at the same monthly rental. The Company recorded a Right of Use asset in the amount of $94,134 in connection with the valuation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">MDM Worldwide Agreement</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In September 2022, the Company entered into a public relations agreement with MDM Worldwide. In connection with the agreement, the Company agreed to issue 20,000 options to MDM Worldwide. In October 2023, the contract was mutually terminated, and no options were issued. For the year ended January 31, 2024, the Company paid MDM Worldwide $190,000.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Money Channel Agreement </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On March 13, 2023, the Company entered into a media advertising agreement with Money Channel Inc. The Company will pay a monthly fee and after ninety days can cancel the agreement. The Company, after 90 days, will also issue options to purchase 50,000 shares of common stock to Money Channel Inc. at an exercise price of $4.00 per share. In June 2023, the parties agreed to terminate the agreement by mutual consent. No options were issued. For the year ended January 31, 2024, the Company paid the Money Channel $100,000.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Sorrento Therapeutics, Inc. Agreement</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics had unpaid account receivables related to a contract clinical research services agreement in place with Sorrento Therapeutics. On February 13, 2023, Sorrento declared Chapter 11 bankruptcy. On July 25, 2023, 4P Therapeutics assigned its claim under the bankruptcy proceedings from Sorrento Therapeutics Inc. and received proceeds of $106,528. The amount due under the claim was $118,675 and 4P Therapeutics recorded a reserve for bad debts of $118,675 during the year ended January 31, 2024. Under the agreement with the buyer of the claim, 4P Therapeutics will make proportional restitution and/or repayment of the purchase amount to the extent the claim is disallowed, reduced or not paid at the same time or distribution rate as other general unsecured claims against the Debtor are paid. The Company has recorded the amount of the proceeds as a secured loan payable to the factor as of January 31, 2024.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Upstream Termination</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 24, 2023, the Company sent notice of the termination of the Securities Facility Services Agreement, dated January 3, 2023, by and between MERJ DEP Ltd. And the Company (“Agreement”), which provided for the dual listing of the Company’s common stock on the MERJ Upstream exchange (“Upstream”), which is operated as a fully registered and licensed integrated securities exchange, clearing system and depository for digital and non-digital securities under the Seychelles security laws. The termination was effective May 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Legal Proceedings</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (“Gunnar”) and Lucosky Brookman LLP (“LB”) in the Supreme Court of the State of New York, New York County, under Index No.654633/2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company’s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $500,000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar &amp; Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $1,000,000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 34.8pt; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Currently, there are no pending hearings or motions as both parties are engaged in discovery and are attempting to resolve the matter amicably.</span></p> The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022 2025-01-31 250000 0.035 150000 210000 110000 the Company signed a feasibility agreement with Kindeva Drug Delivery, L.P. (“Kindeva”) to develop Nutriband’s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system). 2500000 250000 2369508 138250 8100000 12000 3000 2025-01-31 P3Y 94134 20000 190000 50000 4 100000 106528 118675 118675 500000 1000000 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top"> <td style="width: 0.5in"><span style="-sec-ix-redline:true;-keep: true">12.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">SUBSEQUENT EVENTS</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">(a)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In February and April 2024, the Company received proceeds of $300,000 from its Credit Line Facility.</span></td></tr><tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">(b)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On March 20, 2024, 390,000 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $2.37-$2.61 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued amounted to $450,000.</span></td></tr><tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">(c)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On March 20, 2024, our Board of Directors adopted an amendment to the Company’s Employee Stock Option Plan (the “Plan”) increasing the number of shares of common stock subject to the Plan (as of March 20, 2024, 875,000 shares) to 1,400,000 shares (the “Amendment”). The Company will submit the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting. If the Amendment is not approved by stockholders within one year of adoption, the increase in shares subject to the Plan will be void, together with any options issued following March 20,2024, in the period pending approval of the Plan by our stockholders.</span></td></tr><tr style="vertical-align: top"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">(d)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, each Unit consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock, the Warrants having an initial exercise price of $6.43, are exercisable by payment of the exercise price in cash only and expire April 19,2029, five years from the date of issuance (“Warrants”). The Offering was made solely to investors residing outside the United States and was not registered under the Security Act of 1933, as amended, (the “Security Act”), or the securities law of any jurisdiction, including outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act.</span></td></tr></table> 300000 390000 2.37 2.61 P3Y 450000 875000 1400000 P1Y 8400000 2100000 4 1 2 6.43 2029-04-19 P5Y 8347740 492942 85144 148649 168505 168605 128551 211667 8729940 1021863 740305 774924 5021713 5021713 23529 31374 638993 667280 15154480 7517154 994106 680132 269345 157502 25988 34276 127419 127183 1416858 999093 74509 79826 300000 1791367 1078919 0.001 0.001 10000000 10000000 0 0 0.001 0.001 291666666 291666666 10969870 8869870 10959870 8859870 10960 8860 43263194 34442339 -304 -304 10000 10000 32641 32641 -29878096 -27980019 13363113 6438235 15154480 7517154 408532 476932 243746 254648 974535 400430 1079728 839732 2298009 1494810 -1889477 -1017878 18 5815 8618 3166 -8600 2649 -1898077 -1015229 -1898077 -1015229 -0.21 -0.13 9159869 7833150 6438235 8859870 8860 34442339 -304 -27980019 -32641 422955 422955 8400000 2100000 2100 8397900 -1898077 -1898077 13363113 10959870 10960 43263194 -304 -29878096 -32641 8572990 7833150 7833 31092807 -304 -22494705 -32641 87090 87090 75030 75030 -1015229 -1015229 7719881 7833150 7833 31254927 -304 -23509934 -32641 -1898077 -1015229 69101 75201 7845 7845 87090 422955 75030 -63505 51596 -84631 3354 1415 -47838 111843 25794 -8288 -7557 313974 9074 -833926 -749864 6195 2624 -6195 -2624 300000 50000 8400000 5081 4877 8694919 45123 7854798 -707365 492942 1985440 8347740 1278075 611 1725 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; background-color: white; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Organization</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Nutriband Inc. (the “Company”) is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was formed by the Company’s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On August 1, 2018, the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics. The former owner resigned as a director in January 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics is engaged in the development of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics, the Company’s business was the development and marketing of a range of transdermal consumer patches. Most of these products are considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration (the “FDA”). The Company entered a feasibility agreement as an initial step to seek FDA approval of its consumer transdermal products and its consumer products which are not being marketed in the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">With the acquisition of 4P Therapeutics, 4P Therapeutics’ drug development business became the Company’s principal business. The Company’s approach is to use generic drugs that are off patent and incorporate them into the Company’s transdermal drug delivery system. Although these medications have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc. (“Pocono Pharmaceuticals”), a wholly owned subsidiary of the Company. On August 31, 2020, the Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono Coated Products LLC (“PCP”). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction, Pocono Pharmaceuticals also acquired 100% of the membership interests of Active Intelligence LLC (“Active Intelligence”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals is a coated products manufacturing entity organized to take advantage of its unique process capabilities and experience. Pocono helps their customers with product design and development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical’s competitive edge is a low-cost manufacturing base: a result of its unique processes and state-of-the-art material technology. Active Intelligence manufactures activated kinesiology tape. The tape has transdermal and topical properties. This tape is used the same as traditional kinesiology tape.</span></p> 2250000 250000 1850000 400000 0.06 1 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">2.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Unaudited Financial Statements</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The consolidated balance sheet as of April 30, 2024, and the consolidated statements of operations, stockholders’ equity, and cash flows for the periods presented have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to prepare fairly the financial position, results of operations, changes in stockholders’ equity and cash flows for all periods presented have been made. The results for the three months ended April 30, 2024, are not necessarily indicative of the results to be expected for the full year. The consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in Nutriband’s Annual Report on Form 10-K for the year ended January 31, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Certain information and footnote disclosures required under generally accepted accounting principles in the United States of America (U.S. GAAP”) have been condensed or omitted from these consolidated financial statements pursuant to the rules and regulations, including interim reporting requirements of the U.S. Securities and Exchange Commission (“SEC”). The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosures of contingent amounts in our consolidated financial statements and accompanying footnotes. Actual results could differ from estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company’s significant accounting policies in Note 2 in the Company’s Annual Report on Form 10-K for the year ended January 31, 2024. There were no significant changes to these accounting policies during the three months ended April 30, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Forward Stock Split</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the “Stock Split”) of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250,000,000 authorized shares to 291,666,666 authorized shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">All share and per share information in these financial statements retroactively reflect the forward stock split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Going Concern Assessment </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look-forward period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of April 30, 2024, the Company had cash and cash equivalents of $8,347,740 and working capital of $7,313,082. For the three months ended April 30, 2024, the Company incurred a net loss from operations of $1,898,077 and used cash flow from operations of $833,926. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third-party and related-party debt to support cash flow from operations. The Company has used these proceeds from the sales of securities and issuance of third-party and related party debt to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 13, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. On April 19, 2024, the Company received proceeds of $8,400,000 from equity financing with European investors, of which $7.12 million is from related parties.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Principles of Consolidation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020 under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 1in"><span style="-sec-ix-redline:true;-keep: true">Nutriband Ltd.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 1in"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics LLC</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 1in"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Use of Estimates </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Revenue Recognition </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; background-color: white; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Revenue Types</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following is a description of the Company’s revenue types, which include professional services and sale of goods:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">Product revenues derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">Contract research and development services for pharmaceutical and medical devices for life sciences customers with revenues listed under services.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Contracts with Customers</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Contract Liabilities</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Performance Obligations</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">All revenue recognized in the income statement is considered to be revenue from contracts with customers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Disaggregation of Revenues</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">April 30,</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Revenue by type</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Sale of goods</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">401,057</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Services</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">75,875</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">476,932</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">April 30,</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Revenue by geographic location:</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">476,932</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">476,932</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Cash and cash equivalents.</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short-term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of April 30, 2024, the Company had $7,879,000 that exceeded federally insured limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Accounts receivable </span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both the specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the three months ended April 30, 2024, and 2023, the Company recorded bad debt expenses of $1,200 and $-0-, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $106,528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of April 30, 2024, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10%. The Company adopted ASU 2016-13 during 2013 and implemented the guidance on expected credit losses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Inventories</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of April 30, 2024, total inventory was $168,505, consisting of work-in-process of $27,447, finished goods of $26,751 and raw materials of $114,307. As of January 31, 2024, total inventory was $168,605, consisting of work-in-process of $7,466, finished goods of $8,707 and raw materials of $134,691.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Property, Plant and Equipment</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Property and equipment represent an important component of the Company’s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Lab Equipment</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 11%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">5-10 years</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Furniture and fixtures</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">3 years</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">10-20 years</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Intangible Assets</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisitions have also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Goodwill</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. During the years ended January 31, 2024, and 2023, the Company recorded an impairment charge of $-0- and $327,326, respectively, reducing the Active Intelligence LLC Goodwill to $3,302,478. As of April 30, 2024, and January 31, 2024, Goodwill amounted to $5,021,713 and $5,021,713, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Long-lived Assets</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Earnings per Share</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period.  Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of April 30, 2024, and 2023, there were 6,747,873 and 1,783,373 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Stock-Based Compensation</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Business Combinations</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company recognizes the assets acquired, the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Leases</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;background-color: #FDFDFD">In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;background-color: #FDFDFD">The Company applies the guidance for right-of-use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Research and Development Expenses</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Research and development costs are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Income Taxes</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company records net deferred tax assets to the extent they believe these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.  In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;background-color: #FDFDFD"><i><span style="text-decoration:underline">Fair Value Measurements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">FASB ASC 820, “Fair Value Measurements and Disclosure” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 0.5in; text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td> <td style="width: 0.15in"><span style="-sec-ix-redline:true;-keep: true">-</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable inputs such as quoted market prices in active markets.</span></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td> <td><span style="-sec-ix-redline:true;-keep: true">-</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted prices in active markets that are either directly or indirectly observable.</span></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td> <td><span style="-sec-ix-redline:true;-keep: true">-</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The carrying value of the Company’s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Recent Accounting Standards</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (“CECL”), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016-13 during the year ended January 31, 2024. The adoption of ASU 2016-13 did not have a material impact on the Company’s balance sheet or statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Unaudited Financial Statements</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The consolidated balance sheet as of April 30, 2024, and the consolidated statements of operations, stockholders’ equity, and cash flows for the periods presented have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to prepare fairly the financial position, results of operations, changes in stockholders’ equity and cash flows for all periods presented have been made. The results for the three months ended April 30, 2024, are not necessarily indicative of the results to be expected for the full year. The consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in Nutriband’s Annual Report on Form 10-K for the year ended January 31, 2024.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Certain information and footnote disclosures required under generally accepted accounting principles in the United States of America (U.S. GAAP”) have been condensed or omitted from these consolidated financial statements pursuant to the rules and regulations, including interim reporting requirements of the U.S. Securities and Exchange Commission (“SEC”). The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosures of contingent amounts in our consolidated financial statements and accompanying footnotes. Actual results could differ from estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company’s significant accounting policies in Note 2 in the Company’s Annual Report on Form 10-K for the year ended January 31, 2024. There were no significant changes to these accounting policies during the three months ended April 30, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Forward Stock Split</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the “Stock Split”) of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250,000,000 authorized shares to 291,666,666 authorized shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">All share and per share information in these financial statements retroactively reflect the forward stock split.</span></p> The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. 250000000 291666666 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Going Concern Assessment </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look-forward period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of April 30, 2024, the Company had cash and cash equivalents of $8,347,740 and working capital of $7,313,082. For the three months ended April 30, 2024, the Company incurred a net loss from operations of $1,898,077 and used cash flow from operations of $833,926. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third-party and related-party debt to support cash flow from operations. The Company has used these proceeds from the sales of securities and issuance of third-party and related party debt to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 13, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. On April 19, 2024, the Company received proceeds of $8,400,000 from equity financing with European investors, of which $7.12 million is from related parties.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.</span></p> 8347740 7313082 -1898077 -833926 2000000 5000000 8400000 7120000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Principles of Consolidation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020 under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 1in"><span style="-sec-ix-redline:true;-keep: true">Nutriband Ltd.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 1in"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics LLC</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white; text-indent: 1in"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals Inc.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Use of Estimates </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Revenue Recognition </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; background-color: white; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Revenue Types</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following is a description of the Company’s revenue types, which include professional services and sale of goods:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">Product revenues derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods.</span></td> </tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">●</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif">Contract research and development services for pharmaceutical and medical devices for life sciences customers with revenues listed under services.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Contracts with Customers</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Contract Liabilities</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Performance Obligations</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">All revenue recognized in the income statement is considered to be revenue from contracts with customers.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Disaggregation of Revenues</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">April 30,</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Revenue by type</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Sale of goods</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">401,057</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Services</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">75,875</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">476,932</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">April 30,</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Revenue by geographic location:</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">476,932</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">476,932</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <span style="-sec-ix-redline:true;-keep: true">The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">April 30,</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Revenue by type</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="-sec-ix-redline:true;-keep: true">Sale of goods</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">401,057</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Services</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-117"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">75,875</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">476,932</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 408532 401057 75875 408532 476932 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">April 30,</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Revenue by geographic location:</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">476,932</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-118"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-119"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">476,932</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 408532 476932 408532 476932 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Cash and cash equivalents.</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short-term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of April 30, 2024, the Company had $7,879,000 that exceeded federally insured limits.</span></p> 7879000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Accounts receivable </span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both the specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the three months ended April 30, 2024, and 2023, the Company recorded bad debt expenses of $1,200 and $-0-, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $106,528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of April 30, 2024, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10%. The Company adopted ASU 2016-13 during 2013 and implemented the guidance on expected credit losses.</span></p> 1200 0 106528 0.10 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Inventories</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of April 30, 2024, total inventory was $168,505, consisting of work-in-process of $27,447, finished goods of $26,751 and raw materials of $114,307. As of January 31, 2024, total inventory was $168,605, consisting of work-in-process of $7,466, finished goods of $8,707 and raw materials of $134,691.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> 168505 27447 26751 114307 168605 7466 8707 134691 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Property, Plant and Equipment</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Property and equipment represent an important component of the Company’s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Lab Equipment</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 11%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">5-10 years</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Furniture and fixtures</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">3 years</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">10-20 years</span></td></tr> </table> The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Lab Equipment</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 11%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">5-10 years</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Furniture and fixtures</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">3 years</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">10-20 years</span></td></tr> </table> P3Y P20Y P5Y P10Y P3Y P10Y P20Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Intangible Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisitions have also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.</span></p> P10Y <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Goodwill</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. During the years ended January 31, 2024, and 2023, the Company recorded an impairment charge of $-0- and $327,326, respectively, reducing the Active Intelligence LLC Goodwill to $3,302,478. As of April 30, 2024, and January 31, 2024, Goodwill amounted to $5,021,713 and $5,021,713, respectively.</span></p> 1719235 5810640 0 327326 3302478 5021713 5021713 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Long-lived Assets</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Earnings per Share</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period.  Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of April 30, 2024, and 2023, there were 6,747,873 and 1,783,373 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> 6747873 1783373 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Stock-Based Compensation</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Business Combinations</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company recognizes the assets acquired, the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Leases</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;background-color: #FDFDFD">In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: #FDFDFD"><span style="-sec-ix-redline:true;background-color: #FDFDFD">The Company applies the guidance for right-of-use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Research and Development Expenses</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Research and development costs are expensed as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Income Taxes</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company records net deferred tax assets to the extent they believe these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.  In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;background-color: #FDFDFD"><i><span style="text-decoration:underline">Fair Value Measurements</span></i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">FASB ASC 820, “Fair Value Measurements and Disclosure” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.25in; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 0.5in; text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1</span></td> <td style="width: 0.15in"><span style="-sec-ix-redline:true;-keep: true">-</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Observable inputs such as quoted market prices in active markets.</span></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2</span></td> <td><span style="-sec-ix-redline:true;-keep: true">-</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Inputs other than quoted prices in active markets that are either directly or indirectly observable.</span></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3</span></td> <td><span style="-sec-ix-redline:true;-keep: true">-</span></td> <td style="text-align: justify; font-size: 10pt"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The carrying value of the Company’s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Recent Accounting Standards</span></i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (“CECL”), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016-13 during the year ended January 31, 2024. The adoption of ASU 2016-13 did not have a material impact on the Company’s balance sheet or statement of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">3.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">PROPERTY AND EQUIPMENT</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">April 30,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">January 31,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Lab equipment</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,585</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,585</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,298,584</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,292,389</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Furniture and fixtures</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,643</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,643</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,462,812</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,456,617</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Less: Accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(722,507</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(681,693</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Net Property and Equipment</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">740,305</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">774,924</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Depreciation expenses amounted to $40,814 and $46,914 for the three months ended April 30, 2024, and 2023, respectively. During the three months ended April 30, 2024, and 2023, depreciation expenses of $30,242 and $36,179, respectively, have been allocated to cost of goods sold.</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">April 30,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">January 31,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Lab equipment</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,585</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,585</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Machinery and equipment</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,298,584</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,292,389</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Furniture and fixtures</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,643</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">19,643</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,462,812</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,456,617</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Less: Accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(722,507</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(681,693</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Net Property and Equipment</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">740,305</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">774,924</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 144585 144585 1298584 1292389 19643 19643 1462812 1456617 722507 681693 740305 774924 40814 46914 30242 36179 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">4.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">NOTES PAYABLE</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.75in; text-align: justify; text-indent: 1in"><span style="-sec-ix-redline:true;text-decoration:underline">Notes Payable</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Active Intelligence, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due October 16, 2028, with interest of 5% per year. The amount assumed was $139,184. The loan requires monthly payments of principal and interest of $1,697. During the three months ended April 30, 2024, the Company made $3,959 of principal payments. As of April 30, 2024, the amount due was $81,290, of which $16,331 is current. As of January 31, 2024, the amount due was $85,249.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On April 3, 2022, the Company entered into a retail installment agreement for the purchase of an automobile. The contract price was $32,274, of which $22,795 was financed. The agreement is for five years bearing interest at 2.95% per annum with payments of $410 per month. The loan is secured by automobile. As of April 30, 2024, the amount due was $14,860 of which $4,560 is current. As of January 31, 2024, the amount due was $15,232.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Note payable-related party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 17, 2023, the Company entered an amended Credit Line Note agreement, for an increased $5,000,000 credit line facility t the Company entered on March 17, 2023). Outstanding advances under the Note bears interest at 7% per annum. The promissory note is due and payable in full on March 19, 2026. Interest is payable annually on December 31 of each year during the term of the note. During the year ended January 31, 2024, the Company received $2,000,000 on the Note. In December 2023, the Company converted the balance of the credit facility of $2,000,000 and $53,476 of accrued interest into 1,026,520 shares of common stock. The fair value of the common stock was $2,554,423 resulting in a $554,423 loss on extinguishment. The Company received advances of $300,000 during the three months ended April 30, 2024. As of April 30, 2024, the balance due was $300,000. The Company recorded interest expense of $4,163 for the three months ended April 30, 2024.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Secured borrowing liability. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company entered into an accounts receivable sale agreement for one of its subsidiaries in connection with a bankruptcy claim. The Company received $106,528 and recorded the transaction as a secured loan payable against the account receivable. The sale of the account receivable balance was to an outside third party, whereby if the bankruptcy court does not pay the balance in full, the Company will owe back the unpaid portion. The loan is classified as a current liability as the Company expects the bankruptcy will be resolved in the next twelve months. The loan bears interest at 10%. For the three months ended April 30, 2024, the Company recorded interest expense of $2,578.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white; text-indent: 0.25in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Interest expenses for the three months ended April 30, 2024, and 2023, were $8,618 and $3,166, respectively.</span></p> 160000 2028-10-16 0.05 139184 1697 3959 81290 16331 85249 32274 22795 0.0295 410 14860 4560 15232 5000000 0.07 2000000 2000000 53476 1026520 2554423 554423 300000 300000 4163 106528 0.10 2578 8618 3166 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">5.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">INTANGIBLE ASSETS</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of April 30, 2024, and January 31, 2024, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">April 30,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">January 31,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Customer base</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">314,100</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">314,100</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Intellectual property and trademarks</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">817,400</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">817,400</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,131,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,131,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Less: Accumulated amortization</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(492,507</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(464,220</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Net Intangible Assets</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">638,993</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">667,280</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Amortization expenses for the three months ended April 30, 2024, and 2023 amounted to $28,287 and $28,287, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Year Ended January 31,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">84,863</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2026</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,148</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2027</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,148</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2028</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,148</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2029</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">94,226</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">2030 and thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">120,460</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">638,993</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <span style="-sec-ix-redline:true;-keep: true">As of April 30, 2024, and January 31, 2024, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">April 30,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">January 31,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Customer base</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">314,100</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">314,100</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Intellectual property and trademarks</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">817,400</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">817,400</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,131,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,131,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Less: Accumulated amortization</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(492,507</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(464,220</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Net Intangible Assets</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">638,993</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">667,280</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 314100 314100 817400 817400 1131500 1131500 492507 464220 638993 667280 <span style="-sec-ix-redline:true;-keep: true">Amortization expenses for the three months ended April 30, 2024, and 2023 amounted to $28,287 and $28,287, respectively.</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Year Ended January 31,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">84,863</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2026</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,148</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2027</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,148</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2028</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">113,148</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">2029</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">94,226</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">2030 and thereafter</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">120,460</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">638,993</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 28287 28287 84863 113148 113148 113148 94226 120460 638993 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">6.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">RELATED PARTY TRANSACTIONS</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Activity during the year ended April 30, 2024</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">a)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In March 2024, options to purchase 390,000 shares of common stock to executives and employees of the Company at a price of $2.37 and $2.61 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $422,955 and was expensed during the three months ended April 30, 2024.</span></td> </tr></table><p style="margin: 0"><span style="-sec-ix-redline:true;-keep: true"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">b)</span></td><td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors which included related parties. The related parties invested a total of $7,120,000 and received 1,780,000 shares of common stock and warrants to purchase 3,560,000 shares of common stock @ $6.43 per share. One related party, a director of the Company, invested $4.5 million which included $500,000 from his son and $700,000 from an entity he controls. The other related party invested $2.62 million from entities controlled by the investor.</span></p></td> </tr><tr style="vertical-align: top; text-align: justify"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">c)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the three months ended April 30, 2024, the Company received $300,000 from the credit line facility with TII Jet Services LDA. See Note 4 for further information.</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.75in"><span style="-sec-ix-redline:true;-keep: true">Activity during the three months ended April 30, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">a)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 1, 2023, options to purchase 30,000 shares of the Company’s common stock were issued to an executive of the Company at a price of $3.975 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $75,030 and was expensed during the three months ended April 30, 2023.</span></td> </tr></table> 390000 2.37 2.61 P3Y 422955 8400000 7120000 1780000 3560000 6.43 4500000 500000 700000 2620000 300000 30000 3.975 P3Y 75030 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">7.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">STOCKHOLDERS’ EQUITY</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Preferred Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 15, 2016, the board of directors of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On May 24, 2019, the board of directors created a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock (“Series A Preferred Stock”). On June 20, 2019, the Series A preferred Stock was terminated, and the 2,500,000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the board of directors.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Common Stock</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 25, 2019, the Company effected a one-for-four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0.25 shares of common stock, and the Company decreased its authorized common stock in the same ratio from 100,000,000 to 25,000,000 shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 27, 2020, the Company amended its Articles of Incorporation to increase its authorized common shares from 25,000,000 authorized shares to 250,000,000 authorized shares.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 26, 2022, the Board of Directors of the Company approved a 7-for-6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. Pursuant to the operation of the amendment providing for the forward stock split filed with the Secretary of State of Nevada on August 4, 2022, the authorized common stock of the Company was increased from 250,000,000 shares to 291,666,666 shares in connection with the forward split.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.25in"><span style="-sec-ix-redline:true;text-decoration:underline">Activity during the Three Months Ended April 30, 2024</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">(a)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of April 30, 2024, the Company holds 10,000 of its shares comprising $32,641 of treasury stock. There was no activity during the three months ended April 30, 2024.</span></td> </tr><tr style="vertical-align: top; text-align: justify"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">(b)</span></td><td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors, of which $7.12 million is from related parties, (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock, the Warrant having an exercise price of $6.43, are exercisable by payment of the exercise price in cash only and expire April 19, 2029, five years from the date of issuance (“Warrants”). The offering was made solely to investors residing outside the United States and was not registered under the Security Act of 1933, as amended, (the “Security Act”), or the security law of any jurisdiction, including outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act. See Note 6 for further information.</span></p></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.4pt; text-align: justify; text-indent: -0.25in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;text-decoration:underline">Activity during the Three Months Ended January 31, 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">(a)</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of April 30, 2023, the Company held 10,000 of its shares comprising $32,641 of treasury stock. There was no activity during the three months ended April 30, 2023.</span></td> </tr></table> 10000000 0.001 2500000 2500000 0.25 100000000 25000000 25000000 250000000 7-for-6 forward stock split 250000000 291666666 10000 32641 8400000 7120000 2100000 4 2 6.43 P5Y 10000 32641 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">8.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">OPTIONS and WARRANTS</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="-sec-ix-redline:true;text-decoration:underline">Warrants</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company’s common stock issued to non-employees of the Company during the year ended January 31, 2024. On March 7, 2023, the Company issued 30,000 warrants to purchase the Company’s common shares to Barandnic Holdings Ltd. for services provided. The warrants are exercisable at a price of $4.00 per share and expire five years from the date of issuance. On October 27, 2023, the Company issued 145,833 warrants to purchase the Company’s common shares to management (87,500 warrants were issued to the Chief Financial Officer) and non-employees of the Company. The warrants are exercisable at a price of $1.93 per share and expire in three years from the date of issuance. These warrants replace previously issued warrants that have now been cancelled. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 152.10-174.45%; and a risk-free rate of 4.31%-4.84%. Non-cash compensation for the year ended January 31, 2024, amounted to $242,840.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On April 19, 2024, in connection with a private placement of the Company’s common stock, the Company issued 4,200,000 warrants. The warrants are exercisable at a price of $6.43 per share and expire five years from the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-style: normal; font-weight: normal">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-style: normal; font-weight: normal">Exercise <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-style: normal; font-weight: normal">Remaining <br/> Life</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">Intrinsic <br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2023</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,307,671</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 11%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">3.34 years</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">175,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.28</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.97 years</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(200,466</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.33</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-122"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><div style="-sec-ix-hidden: hidden-fact-126"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2024</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,283,038</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.88</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.97 years</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,200,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">5.00 years</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-132"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><div style="-sec-ix-hidden: hidden-fact-136"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding- April 30, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,483,038</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.30</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: center"><span style="-sec-ix-redline:true;-keep: true">4.25 years</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">233,125</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Exercisable - April 30, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,483,038</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.30</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: center"><span style="-sec-ix-redline:true;-keep: true">4.25 years</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">233,125</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes additional information relating to the warrants outstanding as of April 30, 2024: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Range of Exercise<br/> Prices</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number<br/> Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life(Years)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> Average<br/> Exercise Price<br/> for Shares<br/> Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number<br/> Exercisable</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> Average<br/> Exercise Price<br/> for Shares<br/> Exercisable</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Intrinsic Value</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.10</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,282,205</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.68</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,282,205</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">145,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.74</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">145,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">233,125</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">25,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.77</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">25,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,483,038</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,483,038</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">233,125</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><span style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Option</span>s</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes the changes in options outstanding and the related price of the shares of the Company’s common stock issued to employees of the Company. See Note 7 for the issuance of related party options.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 1, 2021, the Board of Directors adopted the 2021 Employee Stock Option Plan (the “Plan”). The Company has reserved 408,333 shares for issuance and sale upon the exercise of stock options. In accordance with the Plan, on February 1, 2022, the Company reserved an additional 233,333 shares and on February 1, 2023, the Company reserved an additional 233,333 shares. The options vest immediately and expire in three years. Under the Plan, options may be granted which are intended to qualify as Incentive Stock Options (“ISO’s”) under Section 422 of the Internal Revenue Code of 1986 (the “Code”) or which are not (“non-ISO’s”) intended to qualify as Incentive Stock Options thereunder. The Plan also provides for restricted stock awards representing shares of common stock that are issued subject to such restrictions on transfer and other incidents of ownership and such forfeiture conditions as the Board of Directors, or the committee administering the Plan composed of directors who qualify as “independent” under Nasdaq rules, may determine. On November 3, 2021, the Company filed a Registration Statement on Form S-8, to register under the Securities Act of 1933, as amended the 408,333 shares of common stock reserved for issuance under the Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On March 20, 2024, our Board of Directors adopted an amendment to the Company’s Employee Stock Option Plan (the “Plan”) increasing the number of shares of common stock subject to the Plan (as of March 20, 2024, 875,000 shares) to 1,400,000 shares (the “Amendment”). The Company will submit the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting. If the Amendment is not approved by stockholders within one year of adoption, the increase in shares subject to the Plan will be void, together with any options issued following March 20, 2024, in the period pending approval of the Plan by our stockholders. As of April 30, 2024, 135,165 shares remain available for issuance of options under the Plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the three months ended April 30, 2024, 390,000 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $2.37- $2.61 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $422,955 and was recorded during the three months ended April 30, 2024. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rate of 97.83%; and a risk-free rate of 4.87%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the year ended January 31, 2024, 404,500 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $1.93-$3.975 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $499,856 and was recorded during the year ended January 31, 2024. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 121.52-143.54%; and a risk-free rate of 3.00-4.5%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Exercise <br/> Price</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Remaining <br/> Life</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Intrinsic <br/> Value</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2023</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">470,335</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.13</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 11%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.53 years</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">404,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.18</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.68 years</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-145"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><div style="-sec-ix-hidden: hidden-fact-149"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2024</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">874,835</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.23</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.31 years</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">390,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.49</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.80 years</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">378,300</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-154"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><div style="-sec-ix-hidden: hidden-fact-158"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding- April 30, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,264,835</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.63</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.31 years</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">910,285</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Exercisable - April 30, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,264,835</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.63</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.31 years</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">910,285</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table summarizes additional information relating to the options outstanding as of April 30, 2024:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Range of Exercise<br/> Prices</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number<br/> Outstanding</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> Average<br/> Life(Years)</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> Average<br/> Exercise Price<br/> for Shares<br/> Outstanding</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number<br/> Exercisable</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> Average<br/> Exercise Price<br/> for Shares<br/> Exercisable</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Intrinsic <br/> Value</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,500</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.74</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,500</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">328,185</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.74</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">187,600</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.37</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">195,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.37</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.37</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">195,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.37</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">212,550</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.61</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">195,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.61</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.61</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">195,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.61</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">165,750</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.63</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">16,200</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.59</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">35,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.67</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.59</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">35,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.59</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.75</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">57,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.85</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.75</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">57,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.75</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.01</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.09</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">78,750</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.09</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">78,750</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.09</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.85</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,083</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.97</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,083</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">58,334</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">58,334</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.58</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,668</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.97</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.58</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,668</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.58</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 30000 4 P5Y 145833 87500 1.93 P3Y 0 P1Y6M 1.521 1.7445 0.0431 0.0484 242840 4200000 6.43 P5Y <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-style: normal; font-weight: normal">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-style: normal; font-weight: normal">Exercise <br/> Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b style="-sec-ix-redline:true;-keep: true"> </b></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;font-style: normal; font-weight: normal">Remaining <br/> Life</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><b style="-sec-ix-redline:true;-keep: true"> </b></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal">Intrinsic <br/> Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><b style="-sec-ix-redline:true;-keep: true"> </b></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2023</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,307,671</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 11%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">3.34 years</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-120"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">175,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.28</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.97 years</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(200,466</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.33</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-122"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-124"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-125"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><div style="-sec-ix-hidden: hidden-fact-126"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-127"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2024</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,283,038</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.88</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.97 years</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,200,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">5.00 years</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-132"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-133"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><div style="-sec-ix-hidden: hidden-fact-136"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding- April 30, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,483,038</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.30</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: center"><span style="-sec-ix-redline:true;-keep: true">4.25 years</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">233,125</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Exercisable - April 30, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,483,038</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.30</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: center"><span style="-sec-ix-redline:true;-keep: true">4.25 years</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">233,125</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 1307671 6.43 P3Y4M2D 175833 2.28 P2Y11M19D 200466 6.33 1283038 5.88 P2Y11M19D 4200000 6.43 P5Y 5483038 6.3 P4Y3M 233125 5483038 6.3 P4Y3M 233125 The following table summarizes additional information relating to the warrants outstanding as of April 30, 2024:<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Range of Exercise<br/> Prices</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number<br/> Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Life(Years)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> Average<br/> Exercise Price<br/> for Shares<br/> Outstanding</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number<br/> Exercisable</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> Average<br/> Exercise Price<br/> for Shares<br/> Exercisable</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Intrinsic Value</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.10</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.00</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,282,205</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.68</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,282,205</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.43</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-139"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">145,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.74</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">145,833</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">233,125</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">25,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.77</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">25,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7.50</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,483,038</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,483,038</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">233,125</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> 30000 P4Y1M6D 4 30000 4 5282205 P2Y8M4D 6.43 5282205 6.43 145833 P2Y8M26D 1.93 145833 1.93 233125 25000 P3Y9M7D 7.5 25000 7.5 5483038 5483038 233125 408333 233333 233333 408333 875000 1400000 135165 390000 2.37 2.61 P3Y 422955 0 P1Y6M 0.9783 0.0487 404500 1.93 3.975 P3Y 499856 0 P1Y6M 1.2152 1.4354 0.03 0.045 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Exercise <br/> Price</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Remaining <br/> Life</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Intrinsic <br/> Value</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2023</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">470,335</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.13</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 11%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.53 years</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">404,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.18</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.68 years</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-142"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-143"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-144"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-145"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-147"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-148"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><div style="-sec-ix-hidden: hidden-fact-149"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-150"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Outstanding, January 31, 2024</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">874,835</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.23</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.31 years</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">390,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.49</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.80 years</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">378,300</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Expired/Cancelled</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: center"><div style="-sec-ix-hidden: hidden-fact-154"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><div style="-sec-ix-hidden: hidden-fact-158"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159"><span style="-sec-ix-redline:true;-keep: true"> </span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding- April 30, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,264,835</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.63</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.31 years</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">910,285</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Exercisable - April 30, 2024</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,264,835</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.63</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2.31 years</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">910,285</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> 470335 4.13 P2Y6M10D 404500 2.18 P2Y8M4D 874835 3.23 P2Y3M21D 390000 2.49 P2Y9M18D 378300 1264835 2.63 P2Y3M21D 910285 1264835 2.63 P2Y3M21D 910285 <span style="-sec-ix-redline:true;-keep: true">The following table summarizes additional information relating to the options outstanding as of April 30, 2024:</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Range of Exercise<br/> Prices</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number<br/> Outstanding</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> Average<br/> Life(Years)</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> Average<br/> Exercise Price<br/> for Shares<br/> Outstanding</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number<br/> Exercisable</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted<br/> Average<br/> Exercise Price<br/> for Shares<br/> Exercisable</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Intrinsic <br/> Value</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,500</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 12%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.74</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">214,500</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.93</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 11%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">328,185</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.74</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">140,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">187,600</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.37</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">195,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.37</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.37</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">195,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.37</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">212,550</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.61</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">195,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.61</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.61</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">195,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.61</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">165,750</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.63</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.65</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">16,200</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.59</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">35,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.67</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.59</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">35,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.59</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.75</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">57,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.85</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.75</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">57,500</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.75</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.01</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">30,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3.98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.09</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">78,750</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.09</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">78,750</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.09</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.85</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">50,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.12</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,083</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.97</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">144,083</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.16</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">58,334</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">58,334</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.50</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.58</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,668</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.97</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.58</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">46,668</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.58</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 214500 P2Y8M26D P1Y11M4D 214500 1.93 328185 140000 P2Y8M26D P2Y1M13D 140000 2.12 187600 195000 P2Y4M13D P2Y4M13D 195000 2.37 212550 195000 P2Y7M9D P2Y7M9D 195000 2.61 165750 20000 P2Y7M17D P2Y7M24D 20000 2.65 16200 35000 P3Y8M1D P3Y7M2D 35000 3.59 57500 P1Y10M6D P3Y9M 57500 3.75 30000 P2Y3D P3Y11M23D 30000 3.98 78750 P1Y6M P4Y1M2D 78750 4.09 50000 P1Y10M6D P4Y1M13D 50000 4.12 144083 P0Y11M19D P4Y1M28D 144083 4.16 58334 P1Y6M P4Y6M 58334 4.5 46668 P0Y11M19D P4Y6M29D 46668 4.58 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">9.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">SEGMENT REPORTING</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">We organize and manage our business by the following two segments which meet the definition of reportable segments under ASC280-10, Segment Reporting: Sales of Goods and Services. These segments are based on the customer type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief officer decision maker, who is our chief executive officer, in making resource allocation decisions for our segments. Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended <br/> April 30,</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Net sales</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">401,057</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">75,875</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">476,932</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Gross profit</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">164,786</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">169,308</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">52,976</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">164,786</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">222,284</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative-Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">154,394</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">136,863</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative-4P Therapeutics</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">24,354</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">16,921</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative-Corporate</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">900,980</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">685,948</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Research and development-4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">974,535</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">400,430</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,054,263</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,240,162</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Depreciation and Amortization</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">56,823</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">55,208</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Corporate</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,011</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,497</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,267</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">16,496</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">69,101</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">75,201</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended <br/> April 30,</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Net sales</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">401,057</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Outside the United States</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">75,875</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">476,932</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">April 30,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">January 31,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net of accumulated depreciation</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">740,305</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">774,924</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Outside the United States</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">740,305</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">774,924</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Assets</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Corporate</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,210,779</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">344,192</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,044,569</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,079,293</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,899,132</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,093,369</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">15,154,480</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,516,854</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 2 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended <br/> April 30,</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Net sales</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">401,057</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">75,875</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">476,932</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Gross profit</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">164,786</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">169,308</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">52,976</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">164,786</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">222,284</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Operating expenses</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative-Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">154,394</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">136,863</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative-4P Therapeutics</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">24,354</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">16,921</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Selling, general and administrative-Corporate</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">900,980</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">685,948</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Research and development-4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">974,535</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">400,430</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,054,263</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,240,162</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Depreciation and Amortization</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">56,823</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">55,208</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Corporate</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,011</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,497</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">9,267</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">16,496</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">69,101</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">75,201</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> 408532 401057 75875 408532 476932 164786 169308 52976 164786 222284 154394 136863 24354 16921 900980 685948 974535 400430 2054263 1240162 56823 55208 3011 3497 9267 16496 69101 75201 <span style="-sec-ix-redline:true;-keep: true">The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.</span><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended <br/> April 30,</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2023</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Net sales</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">401,057</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Outside the United States</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">75,875</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">408,532</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">476,932</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">April 30,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">January 31,</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">Property and equipment, net of accumulated depreciation</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td colspan="2"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">United States</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">740,305</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">774,924</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Outside the United States</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">740,305</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">774,924</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Assets</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in"><span style="-sec-ix-redline:true;-keep: true">Corporate</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,210,779</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">344,192</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0.125in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Pocono Pharmaceuticals</span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,044,569</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">5,079,293</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">4P Therapeutics</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,899,132</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,093,369</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">15,154,480</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,516,854</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true"> </span></td></tr> </table> 408532 401057 75875 408532 476932 740305 774924 740305 774924 8210779 344192 5044569 5079293 1899132 2093369 15154480 7516854 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top"> <td style="width: 0in"></td><td style="width: 0.25in"><span style="-sec-ix-redline:true;-keep: true">10.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">COMMITMENTS AND CONTIGENCIES</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0pt"><i style="-sec-ix-redline:true;-keep: true">Employment Agreements</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as directors and officers of the Company for the respective terms thereof. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $250,000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance bonus of 3.5% of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $150,000.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company entered into a three-year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $210,000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $110,000.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: justify; text-indent: 0.5in"><i style="-sec-ix-redline:true;-keep: true">Kindeva Drug Delivery Agreement</i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.5in; text-align: justify; text-indent: 0.75in"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 4, 2022, the Company signed a feasibility agreement with Kindeva Drug Delivery, L.P. (“Kindeva”) to develop Nutriband’s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system). The feasibility agreement provides for adapting Kindeva’s commercial transdermal manufacturing process to incorporate AVERSA technology in the fentanyl transdermal system.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The agreement will remain in force until the earlier of: (1) the completion of the work and deliverables under the Workplan; or (2) two (2) years after the Effective Date, after which time the agreement will expire. The feasibility Workplan was completed in February 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The estimated cost to complete the feasibility Workplan was approximately $2.5 million. Nutriband made an advance deposit of $250,000 in January 2022, to be applied against the final invoices. As of April 30, 2024, Nutriband has incurred expenses of $2,950,998 and the deposit of $250,000 has been applied to the final invoices.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 15, 2024, the Nutriband signed a commercial development and clinical supply agreement for their lead product with Kindeva. Kindeva will perform commercial manufacturing process development and manufacturing clinical supplies for the human abuse liability clinical study required by the FDA in support of a New Drug Application. The new agreement replaces the previous feasibility agreement between the two companies which was focused on adapting Kindeva’s commercial transdermal manufacturing process to incorporate AVERSA abuse deterrent transdermal technology. The estimated cost to complete is approximately $8.1 million and the expected timing of FDA submission is twelve to eighteen months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Lease Agreement</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 1, 2022, Pocono Pharmaceuticals entered into a lease agreement with Geometric Group, LLC for 12,000 square feet of warehouse space currently occupied by Active Intelligence. The monthly rental is $3,000 and the lease expires on January 31, 2025. The lease can be extended for an additional three years at the same monthly rental. The Company recorded a Right of Use asset in the amount of $94,134 in connection with the valuation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Sorrento Therapeutics, Inc. Agreement</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On July 25, 2023, 4P Therapeutics assigned its claim under the bankruptcy proceedings from Sorrento Therapeutics Inc. and received proceeds of $106,528. The amount due under the claim was $118,675 and 4P Therapeutics recorded a reserve for bad debts of $118,675 during the year ended January 31, 2024. Under the agreement with the buyer of the claim, 4P Therapeutics will make proportional restitution and/or repayment of the purchase amount to the extent the claim is disallowed, reduced or not paid at the same time or distribution rate as other general unsecured claims against the Debtor are paid. The Company has recorded the amount of the proceeds as a secured loan payable to the factor as of April 30, 2024.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Legal Proceedings</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (“Gunnar”) and Lucosky Brookman LLP (“LB”) in the Supreme Court of the State of New York, New York County, under Index No.654633/2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company’s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $500,000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar &amp; Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $1,000,000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Currently, there are no pending hearings or motions as both parties are engaged in discovery and are attempting to resolve the matter amicably.</span></p> The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022 2025-01-31 250000 0.035 150000 210000 110000 the Company signed a feasibility agreement with Kindeva Drug Delivery, L.P. (“Kindeva”) to develop Nutriband’s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system). 2500000 250000 2950998 250000 8100000 12000 3000 2025-01-31 P3Y 94134 106528 118675 118675 500000 1000000 <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">11.</span></td><td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">SUBSEQUENT EVENTS</span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="-sec-ix-redline:true;-keep: true">(a)</span></td><td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="-sec-ix-redline:true;-keep: true">The Company agreed on May 14, 2024, to convert $300,000, which as of that date of all the outstanding principal on the Credit line Promissory Note of the Company held by TII Jet Services LDA, a related party, (the “Holder”). The conversion was made pursuant to the terms of a Conversion Agreement dated May 14, 2024, which provided that the conversion of $300,000 of principal and $4,922 of accrued interest would be made at a price of $4.00 per share, resulting in the Company issuing on May 14, 2024, a total of 76,230 shares of common stock at the conversion price of $4.00 per share. On May 22, 2024, the Conversion Agreement was amended allowing the lender to purchase an additional 152,460 shares of common stock at a rate of two warrants per converted share, with an exercise price of $6.43 per share and a term of five years from the conversion date (May 14, 2024).</span></p></td> </tr></table> 300000 300000 4922 4 76230 4 152460 6.43 POS AM -0.53 -0.69 7954105 8459547 -0.13 -0.21 7833150 9159869 true 0001676047 XML 86 R1.htm IDEA: XBRL DOCUMENT v3.24.2
    Document And Entity Information
    		 3 Months Ended
    Apr. 30, 2024
    Document Information Line Items  
    Entity Registrant Name Nutriband Inc.
    Document Type POS AM
    Amendment Flag true
    Amendment Description AMENDMENT NO. 4
    Entity Central Index Key 0001676047
    Entity Filer Category Non-accelerated Filer
    Entity Small Business true
    Entity Emerging Growth Company true
    Entity Ex Transition Period true
    Entity Incorporation, State or Country Code NV

    XML 87 R2.htm IDEA: XBRL DOCUMENT v3.24.2
    Condensed Consolidated Balance Sheets - USD ($)
    Apr. 30, 2024
    Jan. 31, 2024
    Jan. 31, 2023
    CURRENT ASSETS:      
    Cash and cash equivalents $ 8,347,740 $ 492,942 $ 1,985,440
    Accounts receivable 85,144 148,649 113,045
    Inventory 168,505 168,605 229,335
    Prepaid expenses 128,551 211,667 365,925
    Total Current Assets 8,729,940 1,021,863 2,693,745
    PROPERTY & EQUIPMENT-net 740,305 774,924 897,735
    OTHER ASSETS:      
    Goodwill 5,021,713 5,021,713 5,021,713
    Operating lease right of use asset 23,529 31,374 62,754
    Intangible assets-net 638,993 667,280 780,430
    TOTAL ASSETS 15,154,480 7,517,154 9,456,377
    CURRENT LIABILITIES:      
    Accounts payable and accrued expenses 994,106 680,132 534,679
    Deferred revenue 269,345 157,502 162,903
    Operating lease liability-current portion 25,988 34,276 31,291
    Notes payable-current portion 127,419 127,183 19,740
    Total Current Liabilities 1,416,858 999,093 748,613
    LONG-TERM LIABILITIES:      
    Note payable-net of current portion 74,509 79,826 100,497
    Operating lease liability-net of current portion   34,277
    Total Liabilities 1,791,367 1,078,919 883,387
    Commitments and Contingencies
    STOCKHOLDERS’ EQUITY:      
    Preferred stock, value
    Common stock, value 10,960 8,860 7,833
    Additional paid-in-capital 43,263,194 34,442,339 31,092,807
    Accumulated other comprehensive loss (304) (304) (304)
    Treasury stock, value (32,641) (32,641) (32,641)
    Accumulated deficit (29,878,096) (27,980,019) (22,494,705)
    Total Stockholders’ Equity 13,363,113 6,438,235 8,572,990
    TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY 15,154,480 7,517,154 9,456,377
    Related Party      
    LONG-TERM LIABILITIES:      
    Note payable-related party $ 300,000
    XML 88 R3.htm IDEA: XBRL DOCUMENT v3.24.2
    Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares
    Apr. 30, 2024
    Jan. 31, 2024
    Jan. 31, 2023
    Statement of Financial Position [Abstract]      
    Preferred stock par value (in Dollars per share) $ 0.001 $ 0.001 $ 0.001
    Preferred stock, shares authorized 10,000,000 10,000,000 10,000,000
    Preferred stock, shares outstanding 0 0 0
    Common stock, par value (in Dollars per share) $ 0.001 $ 0.001 $ 0.001
    Common stock, shares authorized 291,666,666 291,666,666 291,666,666
    Common stock, shares issued 10,969,870 8,869,870 7,843,150
    Common stock, shares outstanding 10,959,870 8,859,870 7,833,150
    Treasury stock, shares 10,000 10,000 10,000
    XML 89 R4.htm IDEA: XBRL DOCUMENT v3.24.2
    Unaudited Consolidated Statements of Operations - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Income Statement [Abstract]        
    Revenue $ 408,532 $ 476,932 $ 2,085,314 $ 2,079,609
    Costs and expenses:        
    Cost of revenues 243,746 254,648 1,223,209 1,329,200
    Research and development 974,535 400,430 1,960,425 982,227
    Goodwill impairment     327,326
    Selling, general and administrative 1,079,728 839,732 3,773,606 3,916,041
    Total Costs and Expenses 2,298,009 1,494,810 6,957,240 6,554,794
    Loss from operations (1,889,477) (1,017,878) (4,871,926) (4,475,185)
    Other income (expense):        
    Interest income 18 5,815 16,850
    Loss on extinguishment of debt     (554,423)
    Interest expense (8,618) (3,166) (75,815) (8,289)
    Total other income (expense) (8,600) 2,649 (613,388) (8,289)
    Loss before provision for income taxes (1,898,077) (1,015,229) (5,485,314) (4,483,474)
    Provision for income taxes    
    Net loss $ (1,898,077) $ (1,015,229) $ (5,485,314) $ (4,483,474)
    Net loss per share of common stock-basic (in Dollars per share) $ (0.21) $ (0.13) $ (0.69) $ (0.53)
    Weighted average shares of common stock outstanding        
    Weighted average shares of common stock outstanding - basic (in Shares) 9,159,869 7,833,150 7,954,105 8,459,547
    XML 90 R5.htm IDEA: XBRL DOCUMENT v3.24.2
    Unaudited Consolidated Statements of Operations (Parentheticals) - $ / shares
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Income Statement [Abstract]        
    Net loss per share of common stock- diluted $ (0.21) $ (0.13) $ (0.69) $ (0.53)
    Weighted average shares of common stock outstanding - diluted 9,159,869 7,833,150 7,954,105 8,459,547
    XML 91 R6.htm IDEA: XBRL DOCUMENT v3.24.2
    Unaudited Consolidated Statements of Stockholders’ Equity - USD ($)
    Common Stock
    Additional Paid In Capital
    Accumulated Other Comprehensive Income(Loss)
    Accumulated Deficit
    Treasury Stock
    Total
    Balance at Jan. 31, 2022 $ 9,155 $ 29,966,132 $ (304) $ (18,011,231) $ (104,467) $ 11,859,285
    Balance (in Shares) at Jan. 31, 2022 9,154,846          
    Exercise of warrants $ 56 296,819       296,875
    Exercise of warrants (in Shares) 55,417          
    Common stock returned in settlement $ (1,400) 1,400        
    Common stock returned in settlement (in Shares) (1,400,000)          
    Treasury stock issued for services $ 32 3,746     109,377 113,155
    Treasury stock issued for services (in Shares) 33,471          
    Treasury stock and warrants issued for termination agreement $ 25 92,545     81,455 174,025
    Treasury stock and warrants issued for termination agreement (in Shares) 25,000          
    Treasury stock repurchased $ (35) 35     (119,006) (119,006)
    Treasury stock repurchased (in Shares) (35,584)          
    Options issued for services   732,130       732,130
    Net loss       (4,483,474)   (4,483,474)
    Balance at Jan. 31, 2023 $ 7,833 31,092,807 (304) (22,494,705) (32,641) 8,572,990
    Balance (in Shares) at Jan. 31, 2023 7,833,150          
    Warrants issued for services   87,090       87,090
    Options issued for services   75,030       75,030
    Net loss       (1,015,229)   (1,015,229)
    Balance at Apr. 30, 2023 $ 7,833 31,254,927 (304) (23,509,934) (32,641) 7,719,881
    Balance (in Shares) at Apr. 30, 2023 7,833,150          
    Balance at Jan. 31, 2023 $ 7,833 31,092,807 (304) (22,494,705) (32,641) 8,572,990
    Balance (in Shares) at Jan. 31, 2023 7,833,150          
    Warrants issued for services   242,840       242,840
    Options issued for services 499,856 499,856
    Issuance of common stock for note payable and interest $ 1,027 2,606,836       2,607,863
    Issuance of common stock for note payable and interest (in Shares) 1,026,720          
    Net loss (5,485,314) (5,485,314)
    Balance at Jan. 31, 2024 $ 8,860 34,442,339 (304) (27,980,019) (32,641) 6,438,235
    Balance (in Shares) at Jan. 31, 2024 8,859,870          
    Options issued for services   422,955       422,955
    Proceeds from sale of common stock and warrants $ 2,100 8,397,900       8,400,000
    Proceeds from sale of common stock and warrants (in Shares) 2,100,000          
    Net loss       (1,898,077)   (1,898,077)
    Balance at Apr. 30, 2024 $ 10,960 $ 43,263,194 $ (304) $ (29,878,096) $ (32,641) $ 13,363,113
    Balance (in Shares) at Apr. 30, 2024 10,959,870          
    XML 92 R7.htm IDEA: XBRL DOCUMENT v3.24.2
    Unaudited Consolidated Statements of Cash Flows - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Statement of Cash Flows [Abstract]        
    Net loss $ (1,898,077) $ (1,015,229) $ (5,485,314) $ (4,483,474)
    Adjustments to reconcile net loss to net cash used in operating activities:        
    Depreciation and amortization 69,101 75,201 287,722 330,143
    Operating lease expense 7,845 7,845 31,380 38,813
    Loss on extinguishment of debt     554,423
    Reserve for doubtful accounts     118,365
    Treasury stock issued for services     113,155
    Treasury stock and warrants issued for termination agreement     174,025
    Goodwill impairment     327,326
    Stock-based compensation-warrants   87,090 242,840
    Stock-based compensation-options 422,955 75,030 499,856 732,130
    Changes in operating assets and liabilities:        
    Accounts receivable 63,505 (51,596) (153,969) (41,665)
    Prepaid expenses 84,631 (3,354) 154,258 4,547
    Inventories (1,415) 47,838 60,730 (97,687)
    Deferred revenue 111,843 25,794 (5,401) 56,636
    Operating lease liability (8,288) (7,557) (31,292) (36,287)
    Accounts payable and accrued expenses 313,974 9,074 198,893 (104,860)
    Net Cash Used In Operating Activities (833,926) (749,864) (3,527,509) (2,987,198)
    Cash flows from investing activities:        
    Purchase of equipment (6,195) (2,624) (51,761) (79,304)
    Net Cash Used in Investing Activities (6,195) (2,624) (51,761) (79,304)
    Cash flows from financing activities:        
    Proceeds from note payable-related party 300,000 50,000 2,000,000
    Proceeds from sale of common stock and warrants 8,400,000      
    Proceeds from secured borrowing liability     106,528
    Proceeds from exercise of warrants     296,875
    Payment on note payable (5,081) (4,877) (19,756) (17,795)
    Purchase of treasury stock     (119,006)
    Net Cash Provided by Financing Activities 8,694,919 45,123 2,086,772 160,074
    Net change in cash 7,854,798 (707,365) (1,492,498) (2,906,428)
    Cash and cash equivalents - Beginning of period 492,942 1,985,440 1,985,440 4,891,868
    Cash and cash equivalents - End of period 8,347,740 1,278,075 492,942 1,985,440
    Cash paid for:        
    Interest $ 611 $ 1,725 7,352 4,266
    Income taxes    
    Supplemental disclosure of non-cash investing and financing activities:        
    Adoption of ASC 842 Operating lease asset and liability     94,134
    Promissory note on equipment purchase     22,794
    Common stock returned in settlement     1,400
    Issuance of common stock for extinguishment of debt     $ 2,607,863
    XML 93 R8.htm IDEA: XBRL DOCUMENT v3.24.2
    Organization and Description of Business
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Organization and Description of Business [Abstract]    
    ORGANIZATION AND DESCRIPTION OF BUSINESS
    1.ORGANIZATION AND DESCRIPTION OF BUSINESS

     

    Organization

     

    Nutriband Inc. (the “Company”) is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was formed by the Company’s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.

     

    On August 1, 2018, the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics. The former owner resigned as a director in January 2022.

     

    4P Therapeutics is engaged in the development of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics, the Company’s business was the development and marketing of a range of transdermal consumer patches. Most of these products are considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration (the “FDA”). The Company entered a feasibility agreement as an initial step to seek FDA approval of its consumer transdermal products and its consumer products which are not being marketed in the United States.

     

    With the acquisition of 4P Therapeutics, 4P Therapeutics’ drug development business became the Company’s principal business. The Company’s approach is to use generic drugs that are off patent and incorporate them into the Company’s transdermal drug delivery system. Although these medications have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products.

     

    On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc. (“Pocono Pharmaceuticals”), a wholly owned subsidiary of the Company. On August 31, 2020, the Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono Coated Products LLC (“PCP”). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction, Pocono Pharmaceuticals also acquired 100% of the membership interests of Active Intelligence LLC (“Active Intelligence”).

     

    Pocono Pharmaceuticals is a coated products manufacturing entity organized to take advantage of its unique process capabilities and experience. Pocono helps their customers with product design and development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical’s competitive edge is a low-cost manufacturing base: a result of its unique processes and state-of-the-art material technology. Active Intelligence manufactures activated kinesiology tape. The tape has transdermal and topical properties. This tape is used the same as traditional kinesiology tape.
    1.ORGANIZATION AND DESCRIPTION OF BUSINESS

     

    Organization

     

    Nutriband Inc. (the “Company”) is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd, an Irish company which was formed by the Company’s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise.

     

    On August 1, 2018, the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of 250,000 shares of common stock, valued at $1,850,000, and $400,000, and a royalty of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics payable to the former owner of 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics. The former owner resigned as a director in January 2022.

     

    4P Therapeutics is engaged in the development of a series of transdermal pharmaceutical products, that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics, the Company’s business was the development and marketing of a range of transdermal consumer patches. Most of these products are considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration (the “FDA”). The Company entered a feasibility agreement as an initial step to seek FDA approval of its consumer transdermal products and its consumer products which are not being marketed in the United States.

     

    With the acquisition of 4P Therapeutics, 4P Therapeutics’ drug development business became the Company’s principal business. The Company’s approach is to use generic drugs that are off patent and incorporate them into the Company’s transdermal drug delivery system. Although these medications have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before we can market any of our pharmaceutical products.

     

    On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc. (“Pocono Pharmaceuticals”), a wholly owned subsidiary of the Company. On August 31, 2020, the Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono Coated Products LLC (“PCP”). The net assets were contributed to Pocono Pharmaceuticals. Included in the transaction, Pocono Pharmaceuticals also acquired 100% of the membership interests of Active Intelligence LLC (“Active Intelligence”).

     

    Pocono Pharmaceuticals is a contract development and manufacturing organization with unique process capabilities and experience focused on coated product manufacturing. Pocono helps their customers with product design and development along with manufacturing to bring new products to market with minimal capital investment. Pocono Pharmaceutical’s competitive edge is a low-cost manufacturing base: a result of its unique processes and state-of-the-art material technology. Active Intelligence manufactures activated kinesiology tape for transdermal or topical use.
    XML 94 R9.htm IDEA: XBRL DOCUMENT v3.24.2
    Summary of Significant Accounting Policies
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Summary of Significant Accounting Policies [Abstract]    
    SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
    2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     

    Unaudited Financial Statements

     

    The consolidated balance sheet as of April 30, 2024, and the consolidated statements of operations, stockholders’ equity, and cash flows for the periods presented have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to prepare fairly the financial position, results of operations, changes in stockholders’ equity and cash flows for all periods presented have been made. The results for the three months ended April 30, 2024, are not necessarily indicative of the results to be expected for the full year. The consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in Nutriband’s Annual Report on Form 10-K for the year ended January 31, 2024.

     

    Certain information and footnote disclosures required under generally accepted accounting principles in the United States of America (U.S. GAAP”) have been condensed or omitted from these consolidated financial statements pursuant to the rules and regulations, including interim reporting requirements of the U.S. Securities and Exchange Commission (“SEC”). The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosures of contingent amounts in our consolidated financial statements and accompanying footnotes. Actual results could differ from estimates.

     

    The Company’s significant accounting policies in Note 2 in the Company’s Annual Report on Form 10-K for the year ended January 31, 2024. There were no significant changes to these accounting policies during the three months ended April 30, 2024.

     

    Forward Stock Split

     

    On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the “Stock Split”) of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250,000,000 authorized shares to 291,666,666 authorized shares.

     

    All share and per share information in these financial statements retroactively reflect the forward stock split.

     

    Going Concern Assessment

     

    Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look-forward period.

     

    As of April 30, 2024, the Company had cash and cash equivalents of $8,347,740 and working capital of $7,313,082. For the three months ended April 30, 2024, the Company incurred a net loss from operations of $1,898,077 and used cash flow from operations of $833,926. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third-party and related-party debt to support cash flow from operations. The Company has used these proceeds from the sales of securities and issuance of third-party and related party debt to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 13, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. On April 19, 2024, the Company received proceeds of $8,400,000 from equity financing with European investors, of which $7.12 million is from related parties.

     

    Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern.

     

    Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.

     

    Principles of Consolidation

     

    The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020 under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows:

     

    Nutriband Ltd.

    4P Therapeutics LLC

    Pocono Pharmaceuticals Inc.

     

    Use of Estimates

     

    The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

     

    Revenue Recognition

     

    In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

     

    Revenue Types

     

    The following is a description of the Company’s revenue types, which include professional services and sale of goods:

     

    ●Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods.

     

    ●Product revenues derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods.

     

    ●Contract research and development services for pharmaceutical and medical devices for life sciences customers with revenues listed under services.

     

    Contracts with Customers

     

    A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

     

    Contract Liabilities

     

    Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

     

    Performance Obligations

     

    A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.

     

    All revenue recognized in the income statement is considered to be revenue from contracts with customers.

     

    Disaggregation of Revenues

     

    The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:

     

       Three Months Ended 
       April 30, 
       2024   2023 
    Revenue by type        
    Sale of goods  $408,532   $401,057 
    Services   
    -
    		    75,875 
    Total  $408,532   $476,932 

     

       Three Months Ended 
       April 30, 
       2024   2023 
    Revenue by geographic location:          
    United States  $408,532   $476,932 
    Foreign   
    -
    		    
    -
    		 
       $408,532   $476,932 

     

    Cash and cash equivalents.

     

    Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short-term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of April 30, 2024, the Company had $7,879,000 that exceeded federally insured limits.

     

    Accounts receivable

     

    Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both the specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the three months ended April 30, 2024, and 2023, the Company recorded bad debt expenses of $1,200 and $-0-, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $106,528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of April 30, 2024, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10%. The Company adopted ASU 2016-13 during 2013 and implemented the guidance on expected credit losses.

     

    Inventories

     

    Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of April 30, 2024, total inventory was $168,505, consisting of work-in-process of $27,447, finished goods of $26,751 and raw materials of $114,307. As of January 31, 2024, total inventory was $168,605, consisting of work-in-process of $7,466, finished goods of $8,707 and raw materials of $134,691.

     

    Property, Plant and Equipment

     

    Property and equipment represent an important component of the Company’s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:

     

    Lab Equipment  5-10 years
    Furniture and fixtures  3 years
    Machinery and equipment  10-20 years

     

    Intangible Assets

     

    Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisitions have also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.

     

    Goodwill

     

    Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. During the years ended January 31, 2024, and 2023, the Company recorded an impairment charge of $-0- and $327,326, respectively, reducing the Active Intelligence LLC Goodwill to $3,302,478. As of April 30, 2024, and January 31, 2024, Goodwill amounted to $5,021,713 and $5,021,713, respectively.

     

    Long-lived Assets

     

    Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value.

     

    Earnings per Share

     

    Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period.  Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of April 30, 2024, and 2023, there were 6,747,873 and 1,783,373 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.

     

    Stock-Based Compensation

     

    ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.

     

    Business Combinations

     

    The Company recognizes the assets acquired, the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value.

     

    Leases

     

    In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.

     

    The Company applies the guidance for right-of-use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.

     

    Research and Development Expenses

     

    Research and development costs are expensed as incurred.

     

    Income Taxes

     

    Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland.

     

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

     

    The Company records net deferred tax assets to the extent they believe these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.  In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.

     

    Fair Value Measurements

     

    FASB ASC 820, “Fair Value Measurements and Disclosure” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value.

     

    The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:

     

      Level 1 - Observable inputs such as quoted market prices in active markets.
           
      Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable.
           
      Level 3 - Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.

     

    The carrying value of the Company’s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments.

     

    Recent Accounting Standards

     

    In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (“CECL”), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016-13 during the year ended January 31, 2024. The adoption of ASU 2016-13 did not have a material impact on the Company’s balance sheet or statement of operations.

     

    The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.
    2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

     

    Forward Stock Split

     

    On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the “Stock Split”) of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250,000,000 authorized shares to 291,666,666 authorized shares.

     

    All share and per share information in these financial statements retroactively reflect the forward stock split.

     

    Going Concern Assessment

     

    Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look-forward period.

     

    As of January 31, 2024, the Company had cash and cash equivalents of $492,942 and working capital of $22,770. For the year ended January 31, 2024, the Company incurred a loss from operations of $4,871,926 and used cash flow from operations of $3,527,509. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third-party and related-party debt to support cash flow from operations. In October 2021, the Company consummated a public offering and received net proceeds of $5,836,230. The Company has also received to date $3,239,845 in proceeds from the exercise of warrants. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 13, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. The Company was advanced $2,000,000, all of which was settled by the issuance of common stock during the year ended January 31, 2024. The $2,000,000 debt and accrued interest was converted into 1,026,720 shares of the Company’s common stock. On April 19, 2024, the Company received proceeds of $8,400,000 from a private placement of its common stock.

     

    Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern.

     

    Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.

     

    Principles of Consolidation

     

    The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020 under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows:

     

    Nutriband Ltd.

    4P Therapeutics LLC

    Pocono Pharmaceuticals Inc.

     

    Use of Estimates

     

    The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

     

    Revenue Recognition

     

    In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

     

    Revenue Types

     

    The following is a description of the Company’s revenue types, which include professional services and sale of goods:

     

    ●Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods

     

    ●Product revenues derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods

     

    ●Contract research and development services for pharmaceuticals and medical devices for life sciences customers with revenues listed under services

     

    Contracts with Customers

     

    A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

     

    Contract Liabilities

     

    Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

     

    Performance Obligations

     

    A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.

     

    All revenue recognized in the income statement is considered to be revenue from contracts with customers.

     

    Disaggregation of Revenues

     

    The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:

     

       Years Ended 
       January 31, 
       2024   2023 
    Revenue by type        
    Sale of goods  $1,920,280   $1,785,507 
    Services   165,034    294,102 
    Total  $2,085,314   $2,079,609 

     

       Years Ended 
       January 31, 
       2024   2023 
    Revenue by geographic location:        
    United States  $2,085,314   $2,079,609 
    Foreign   
    -
    		    
    -
    		 
       $2,085,314   $2,079,609 

     

    Cash and cash equivalents.

     

    Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short-term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of January 31, 2024, the Company has no balances that exceed federally insured limits.

     

    Accounts receivable

     

    Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both the specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the years ended January 31, 2024, and 2023, the Company recorded bad debt expenses of $118,364 and $-0-, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $106,528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of January 31, 2024, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10%. The Company adopted ASU 2016-13 during 2023 and implemented the guidance on expected credit losses.

     

    Inventories

     

    Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of January 31, 2024, total inventory was $168,605, consisting of work-in-process of $7,466, finished goods of $8,707 and raw materials of $134,691. As of January 31, 2023, total inventory was $229,335, consisting of work-in-process of $11,021 and raw materials of $218,334.

     

    Property, Plant and Equipment

     

    Property and equipment represent an important component of the Company’s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:

     

    Lab Equipment   5-10 years 
    Furniture and fixtures   3 years 
    Machinery and equipment   10-20 years 

     

    Intangible Assets

     

    Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisitions have also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.

     

    Goodwill

     

    Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. During the years ended January 31, 2024, and 2023, the Company recorded an impairment charge of $-0- and $327,326, respectively, reducing the Active Intelligence LLC Goodwill to $3,302,478. As of January 31, 2024, and 2023, Goodwill amounted to $5,021,713 and $5,021,713, respectively.

     

    Long-lived Assets

     

    Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value.

     

    Earnings per Share

     

    Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period.  Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of January 31, 2024, and 2023, there were 2,157,873 and 1,778,006 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.

     

    Stock-Based Compensation

     

    ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.

     

    Business Combinations

     

    The Company recognizes the assets acquired, the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value.

     

    Leases

     

    In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.

     

    The Company applies guidance for right-of-use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.

     

    Research and Development Expenses

     

    Research and development costs are expensed as incurred.

     

    Income Taxes

     

    Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland.

     

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

     

    The Company records net deferred tax assets to the extent they believe these assets will more-likely-than-not be realized.  In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.  In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.

     

    Fair Value Measurements

     

    FASB ASC 820, “Fair Value Measurements and Disclosure” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value.

     

    The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:

     

      Level 1 -Observable inputs such as quoted market prices in active markets.
         
      Level 2 -Inputs other than quoted prices in active markets that are either directly or indirectly observable.
         
      Level 3 -Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.

     

    The carrying value of the Company’s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments.

     

    Recent Accounting Standards

     

    In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (“CECL”), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016-13 during the year ended January 31, 2024. The adoption of ASU 2016-13 did not have a material impact on the Company’s balance sheet or statement of operations.

     

    The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.
    XML 95 R10.htm IDEA: XBRL DOCUMENT v3.24.2
    Property and Equipment
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Property and Equipment [Abstract]    
    PROPERTY AND EQUIPMENT
    3.PROPERTY AND EQUIPMENT

     

       April 30,   January 31, 
       2024   2024 
    Lab equipment  $144,585   $144,585 
    Machinery and equipment   1,298,584    1,292,389 
    Furniture and fixtures   19,643    19,643 
        1,462,812    1,456,617 
    Less: Accumulated depreciation   (722,507)   (681,693)
    Net Property and Equipment  $740,305   $774,924 

     

    Depreciation expenses amounted to $40,814 and $46,914 for the three months ended April 30, 2024, and 2023, respectively. During the three months ended April 30, 2024, and 2023, depreciation expenses of $30,242 and $36,179, respectively, have been allocated to cost of goods sold.
    3.PROPERTY AND EQUIPMENT

     

       January 31, 
       2024   2023 
    Lab equipment  $144,585   $144,585 
    Machinery and equipment   1,292,389    1,240,628 
    Furniture and fixtures   19,643    19,643 
        1,456,617    1,404,856 
    Less: Accumulated depreciation   (681,693)   (507,121)
    Net Property and Equipment  $774,924   $897,735 

     

    Depreciation expenses amounted to $174,572 and $183,660 for the years ended January 31, 2024, and 2023, respectively. During the years ended January 31, 2024, and 2023, depreciation expenses of $131,360 and $139,689, respectively, have been allocated to cost of goods sold.
    XML 96 R11.htm IDEA: XBRL DOCUMENT v3.24.2
    Income Taxes
    		 12 Months Ended
    Jan. 31, 2024
    Income Taxes [Abstract]  
    INCOME TAXES
    4.INCOME TAXES

     

    The Company adopted the provisions of ASC 740, “Income Taxes, (“ASC 740”). As a result of the implementation of ASC 740, the Company recognized no adjustment in the net liability for unrecognized income tax benefits. The Company believes there are no potential uncertain tax positions, and all tax returns are correct as filed. Should the Company recognize a liability for uncertain tax positions, the Company will separately recognize the liability for uncertain tax positions on its balance sheet. Included in any liability or uncertain tax positions, the Company will also set up a liability for interest and penalties. The Company’s policy is to recognize interest and penalties related to uncertain tax positions as a component of the current

    provision for income taxes.

     

    There is no U.S. tax provision due to losses from U.S. operations for the years ended January 31, 2024 and 2023. Deferred income taxes are provided for the temporary differences between the financial reporting and tax basis of the Company’s assets and liabilities. The principal item giving rise to deferred taxes is the net operating loss carryforward in the U.S. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company has set up a valuation allowance for losses for certain carryforwards that it believes may not be realized.

     

    The provision for income taxes consists of the following:

     

        Years Ended
    January 31,    		 
        2024    2023 
    Current          
    Federal  $
              -
    		   $
               -
    		 
    Foreign   
    -
    		    
    -
    		 
               
    Deferred          
    Federal   
    -
    		    
    -
    		 
    Foreign   
    -
    		    
    -
    		 

     

    A reconciliation of taxes on income computed at the federal statutory rate to amounts provided is as follows:

     

       Years Ended
    January 31,    		 
       2024   2023 
    Book Income (loss from operations)  $(1,151,916)  $(941,530)
    Common stock issued for services   155,966    168,768 
    Impairment expense   
    -
    		    68,738 
    Unused operating losses   995,950    704,024 
    Income tax expense  $
    -
    		   $
    -
    		 

     

    As of January 31, 2024, the Company recorded a deferred tax asset associated with a net operating loss (“NOL”) carryforward of approximately $15,800,000 that was fully offset by a valuation allowance due to the determination that it was more likely than not that the Company would be unable to utilize those benefits in the foreseeable future. The Company’s NOL expires in 2041. The tax effect of the valuation allowance increased by approximately $1,151,916 during the year ended January 31, 2024. On December 22, 2017, the Tax Cuts and Jobs Act (the “Tax Act”) significantly revised U.S. corporate income tax law by, among other things, reducing the corporate rate from 34% to 21%. Because the Company recognizes a valuation allowance for the entire balance, there is no net impact on the Company’s balance sheet or results of operations.

     

    The types of temporary differences between tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax asset and their approximate tax effects are as follows:

     

       January 31, 
       2024   2023 
    Net operating loss carryforward (expire through 2040)  $(3,312,698)  $(2,316,748)
    Stock issued for services  $(1,455,848)   (1,299,882)
    Intangible impairment expense  $(1,051,714)   (1,051,714)
    Valuation allowance  $5,820,260    4,668,344 
    Net deferred taxes  $
    -
    		   $
    -
    		 
    XML 97 R12.htm IDEA: XBRL DOCUMENT v3.24.2
    Notes Payable
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Notes Payable [Abstract]    
    NOTES PAYABLE
    4.NOTES PAYABLE

     

    Notes Payable

     

    Active Intelligence, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due October 16, 2028, with interest of 5% per year. The amount assumed was $139,184. The loan requires monthly payments of principal and interest of $1,697. During the three months ended April 30, 2024, the Company made $3,959 of principal payments. As of April 30, 2024, the amount due was $81,290, of which $16,331 is current. As of January 31, 2024, the amount due was $85,249.

     

    On April 3, 2022, the Company entered into a retail installment agreement for the purchase of an automobile. The contract price was $32,274, of which $22,795 was financed. The agreement is for five years bearing interest at 2.95% per annum with payments of $410 per month. The loan is secured by automobile. As of April 30, 2024, the amount due was $14,860 of which $4,560 is current. As of January 31, 2024, the amount due was $15,232.

     

    Note payable-related party.

     

    On July 17, 2023, the Company entered an amended Credit Line Note agreement, for an increased $5,000,000 credit line facility t the Company entered on March 17, 2023). Outstanding advances under the Note bears interest at 7% per annum. The promissory note is due and payable in full on March 19, 2026. Interest is payable annually on December 31 of each year during the term of the note. During the year ended January 31, 2024, the Company received $2,000,000 on the Note. In December 2023, the Company converted the balance of the credit facility of $2,000,000 and $53,476 of accrued interest into 1,026,520 shares of common stock. The fair value of the common stock was $2,554,423 resulting in a $554,423 loss on extinguishment. The Company received advances of $300,000 during the three months ended April 30, 2024. As of April 30, 2024, the balance due was $300,000. The Company recorded interest expense of $4,163 for the three months ended April 30, 2024.

     

    Secured borrowing liability.

     

    The Company entered into an accounts receivable sale agreement for one of its subsidiaries in connection with a bankruptcy claim. The Company received $106,528 and recorded the transaction as a secured loan payable against the account receivable. The sale of the account receivable balance was to an outside third party, whereby if the bankruptcy court does not pay the balance in full, the Company will owe back the unpaid portion. The loan is classified as a current liability as the Company expects the bankruptcy will be resolved in the next twelve months. The loan bears interest at 10%. For the three months ended April 30, 2024, the Company recorded interest expense of $2,578.

     

    Interest expenses for the three months ended April 30, 2024, and 2023, were $8,618 and $3,166, respectively.
    5.NOTES PAYABLE

     

    Notes Payable

     

    Active Intelligence, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due October 16, 2028, with interest of 5% per year. The amount assumed was $139,184. The loan requires monthly payments of principal and interest of $1,697. During the year ended January 31, 2024, the Company made $15,378 of principal payments. As of January 31, 2024, the amount due was $85,249, of which $16,129 is current. As of January 31, 2023, the amount due was $100,627.

     

    On April 3, 2022, the Company entered into a retail installment agreement for the purchase of an automobile. The contract price was $32,274, of which $22,795 was financed. The agreement is for five years bearing interest at 2.95% per annum with payments of $410 per month. The loan is secured by automobile. As of January 31, 2024, the amount due was $15,232 of which $4,456 is current. As of January 31, 2023, the amount due was $19,610.

     

    Note payable-related party.

     

    On July 17, 2023, the Company entered an amended Credit Line Note agreement, for an increased $5,000,000 credit line facility Note, with TII Jet Services LDA, a shareholder of the Company (replacing the $2,000,000 facility with the same lender that the Company entered on March 17, 2023). Outstanding advances under the Note bears interest at 7% per annum. The promissory note is due and payable in full on March 19, 2026. Interest is payable annually on December 31 of each year during the term of the note. During the year ended January 31, 2024, the Company received $2,000,000 on the Note. In December 2023, the Company converted the balance of the credit facility of $2,000,000 and $53,476 of accrued interest into 1,026,520 shares of common stock. The fair value of the common stock was $2,554,423 resulting in a $554,423 loss on extinguishment. As of January 31, 2024, the balance due was $-0-. The Company recorded interest expense of $60,453 for the year ended January 31, 2024.

     

    Secured borrowing liability.

     

    The Company entered into an accounts receivable sale agreement for one of its subsidiaries in connection with a bankruptcy claim. The Company received $106,528 and recorded the transaction as a secured loan payable against the account receivable. The sale of the account receivable balance was to an outside third party, whereby if the bankruptcy court does not pay the balance in full, the Company will owe back the unpaid portion. The loan is classified as a current liability as the Company expects the bankruptcy will be resolved in the next twelve months. The loan bears interest at 10%. For the year ended January 31, 2024, the Company recorded interest expense of $5,470.

     

    Interest expenses for the year ended January 31, 2024, and 2023, were $75,815 and $6,289, respectively.
    XML 98 R13.htm IDEA: XBRL DOCUMENT v3.24.2
    Intangible Assets
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Intangible Assets [Abstract]    
    INTANGIBLE ASSETS
    5.INTANGIBLE ASSETS

     

    As of April 30, 2024, and January 31, 2024, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:

     

       April 30,   January 31, 
       2024   2024 
    Customer base  $314,100   $314,100 
    Intellectual property and trademarks   817,400    817,400 
               
    Total   1,131,500    1,131,500 
               
    Less: Accumulated amortization   (492,507)   (464,220)
               
    Net Intangible Assets  $638,993   $667,280 

     

    Amortization expenses for the three months ended April 30, 2024, and 2023 amounted to $28,287 and $28,287, respectively.

     

    Year Ended January 31,    
    2025  $84,863 
    2026   113,148 
    2027   113,148 
    2028   113,148 
    2029   94,226 
    2030 and thereafter   120,460 
       $638,993 
    6.INTANGIBLE ASSETS

     

    As of January 31, 2024, and 2023, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:

     

       January 31, 
       2024   2023 
    Customer base  $314,100   $314,100 
    Intellectual property and trademarks   817,400    817,400 
               
    Total   1,131,500    1,131,500 
               
    Less: Accumulated amortization   (464,220)   (351,070)
               
    Net Intangible Assets  $667,280   $780,430 

     

    In February 2021, the Company acquired an IP license from Rambam Med-Tech Ltd. for $50,000. The value of the intangible assets, consisting of intellectual property, license agreement and customer base has been recorded at their fair value by the Company and are being amortized over a period of three to ten years. The Company terminated the license agreement in October 2022. The Company issued 25,000 shares of its common stock from its treasury shares held by the Company and warrants to purchase 25,000 shares at an exercise price of $7.50 per share as part of the termination agreement. The Company recorded a termination expense of $174,025 during the year ended January 31, 2023. Which is included in selling, general and administrative expenses. The Company expensed the balance of the agreement of $33,334 during the year ended January 31, 2023, which is included in selling, general and administrative expenses. Amortization expenses for the years ended January 31, 2024, and 2023 amounted to $113,150 and $146,483, respectively.

     

    Year Ended January 31,    
    2025  $113,109 
    2026   113,109 
    2027   113,109 
    2028   113,109 
    2029   113,109 
    2030 and thereafter   101,735 
       $667,280 
    XML 99 R14.htm IDEA: XBRL DOCUMENT v3.24.2
    Related Party Transactions
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Related Party Transactions [Abstract]    
    RELATED PARTY TRANSACTIONS
    6.RELATED PARTY TRANSACTIONS

     

    Activity during the year ended April 30, 2024

     

    a)In March 2024, options to purchase 390,000 shares of common stock to executives and employees of the Company at a price of $2.37 and $2.61 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $422,955 and was expensed during the three months ended April 30, 2024.

     

    b)

    On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors which included related parties. The related parties invested a total of $7,120,000 and received 1,780,000 shares of common stock and warrants to purchase 3,560,000 shares of common stock @ $6.43 per share. One related party, a director of the Company, invested $4.5 million which included $500,000 from his son and $700,000 from an entity he controls. The other related party invested $2.62 million from entities controlled by the investor.
       
    c)During the three months ended April 30, 2024, the Company received $300,000 from the credit line facility with TII Jet Services LDA. See Note 4 for further information.

     

    Activity during the three months ended April 30, 2023

     

    a)On February 1, 2023, options to purchase 30,000 shares of the Company’s common stock were issued to an executive of the Company at a price of $3.975 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $75,030 and was expensed during the three months ended April 30, 2023.
    7.RELATED PARTY TRANSACTIONS

     

    Activity during the year ended January 31, 2024

     

    a)On February 1, 2023, options to purchase 30,000 shares of the Company’s common stock were issued to an executive of the Company at a price of $3.975 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $75,030 and was expensed during the year ended January 31, 2024.

     

    b)In September and October 2023, options to purchase 374,500 shares of common stock to executives and directors of the Company at a price of $1.93, $2.12 and $2.65 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $424,826 and was expensed during the year ended January 31, 2024.
       
    c)On October 26, 2023, warrants to purchase 87,500 shares of the Company’s common stock were issued to the Chief Financial Officer at a price of $1.93 per share. The warrant expires in three years. The fair value of the warrants issued amounted to $93,450 and was expensed during the year ended January 31, 2024.
       
    d)On July 17, 2023, the Company entered an amended Credit Line Note facility with TII Jet Services LDA, a shareholder of the Company, for a credit facility of $5 million (replacing the $2,000,000 facility with the same lender that the Company entered on March 17, 2023). See Note 5 for further information. TII Jet Services LDA is owned 100% by a shareholder of the Company. During the year ended January 31, 2024, the Company received $2,000,000 from the credit facility. In December 2023, TII Jet Services LDA converted the balance of the credit facility of $2,000,000 and $53,436 of accrued interest into 1,026,520 shares of the Company’s common stock.

     

    Activity during the year ended January 31, 2023

     

    a)In May 2022, the Company issued stock awards to the Company’s CEO and the independent members of the Board of Directors. The CEO received 11,667 shares and the four directors received 1,167 shares each. The Company recorded a compensation expense of $53,200 in connection with the issuance of the shares.
       
    b)On August 2, 2022, 137,084 options to purchase shares of the Company’s common stock were issued to executives of the Company at prices of $4.09 and $4.50 per share. The options vest immediately and expire in three years. The fair value of the options issued for services amounted to $399,075 and was expensed during the year ended January 31, 2023.
       
    c)On September 30, 2022, 35,000 options to purchase shares of the Company’s common stock were issued to the independent directors of the Company at a price of $3.59 per share. The options vest immediately and expire in five years. The fair value of the options issued for services amounted to $85,995 and was expensed during the year ended January 31, 2023
       
    d)On December 7, 2022, options to purchase 107,500 shares of the Company’s common stock were issued to executives of the Company at prices of $3.53 and $3.88 per share. The options vest immediately and expire in three years. The fair value of the options issued amounted to $245,170 and was expensed during the year ended January 31, 2023.
    XML 100 R15.htm IDEA: XBRL DOCUMENT v3.24.2
    Stockholders' Equity
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Stockholders' Equity [Abstract]    
    STOCKHOLDERS’ EQUITY
    7.STOCKHOLDERS’ EQUITY

     

    Preferred Stock

     

    On January 15, 2016, the board of directors of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share.

     

    On May 24, 2019, the board of directors created a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock (“Series A Preferred Stock”). On June 20, 2019, the Series A preferred Stock was terminated, and the 2,500,000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the board of directors.

     

    Common Stock

     

    On June 25, 2019, the Company effected a one-for-four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0.25 shares of common stock, and the Company decreased its authorized common stock in the same ratio from 100,000,000 to 25,000,000 shares.

     

    On January 27, 2020, the Company amended its Articles of Incorporation to increase its authorized common shares from 25,000,000 authorized shares to 250,000,000 authorized shares.

     

    On July 26, 2022, the Board of Directors of the Company approved a 7-for-6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. Pursuant to the operation of the amendment providing for the forward stock split filed with the Secretary of State of Nevada on August 4, 2022, the authorized common stock of the Company was increased from 250,000,000 shares to 291,666,666 shares in connection with the forward split.

     

    Activity during the Three Months Ended April 30, 2024

     

    (a)As of April 30, 2024, the Company holds 10,000 of its shares comprising $32,641 of treasury stock. There was no activity during the three months ended April 30, 2024.
       
    (b)

    On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors, of which $7.12 million is from related parties, (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock, the Warrant having an exercise price of $6.43, are exercisable by payment of the exercise price in cash only and expire April 19, 2029, five years from the date of issuance (“Warrants”). The offering was made solely to investors residing outside the United States and was not registered under the Security Act of 1933, as amended, (the “Security Act”), or the security law of any jurisdiction, including outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act. See Note 6 for further information.

     

    Activity during the Three Months Ended January 31, 2023

     

    (a)As of April 30, 2023, the Company held 10,000 of its shares comprising $32,641 of treasury stock. There was no activity during the three months ended April 30, 2023.
    8.STOCKHOLDERS’ EQUITY

     

    Preferred Stock

     

    On January 15, 2016, the board of directors of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share.

     

    On May 24, 2019, the board of directors created a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock (“Series A Preferred Stock”). On June 20, 2019, the Series A preferred Stock was terminated, and the 2,500,000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the board of directors.

     

    Common Stock

     

    On June 25, 2019, the Company effected a one-for-four reverse stock split, pursuant to which each outstanding share of common stock was changed into 0.25 shares of common stock, and the Company decreased its authorized common stock in the same ratio from 100,000,000 to 25,000,000 shares.

     

    On January 27, 2020, the Company amended its Articles of Incorporation to increase its authorized common shares from 25,000,000 authorized shares to 250,000,000 authorized shares.

     

    On July 26, 2022, the Board of Directors of the Company approved a 7-for-6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. Pursuant to the operation of the amendment providing for the forward stock split filed with the Secretary of State of Nevada on August 4, 2022, the authorized common stock of the Company was increased from 250,000,000 shares to 291,666,666 shares in connection with the forward split.

     

    Activity during the Year Ended January 31, 2024

     

    (a)As of January 31, 2024, the Company holds 10,000 of its shares comprising $32,641 of treasury stock. There was no activity during the year ended January 31, 2024.
       
    (b)In December 2024, TII Jet Services LDA converted $2,000,000 of its outstanding credit facility and $53,436 of accrued interest into 1,026,720 shares of the Company’s common stock. The fair value of the common stock at the date of issuance was $2,554,423, resulting in a $554,423 loss on extinguishment.

     

    Activity during the Year Ended January 31, 2023

     

    (a)In March and May 2022, the Company purchased 35,584 shares of its common stock for $119,006 and recorded the purchase as Treasury Stock. In May and December 2022, the Company issued 33,397 shares of stock awards to management, directors and employees from the treasury shares and recorded compensation expense of $113,155 In December 2022, the Company issued 25,000 shares from the treasury shares to non-employees in connection of the termination of the Rambam license agreement. As of January 31, 2023, the Company held 10,000 of its shares comprising $32,641 of treasury stock.
       
    (b)On July 29, 2022, the Company received proceeds of $296,875 from the exercise of warrants and issued 55,417 shares of common stock.
       
    (c)In July 2022, the Company cancelled 1,400,000 shares received in connection with the settlement of a lawsuit. See Note 11 for further information.
    XML 101 R16.htm IDEA: XBRL DOCUMENT v3.24.2
    Options and Warrants
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Options and Warrants [Abstract]    
    OPTIONS and WARRANTS
    8.OPTIONS and WARRANTS

     

    Warrants

     

    The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company’s common stock issued to non-employees of the Company during the year ended January 31, 2024. On March 7, 2023, the Company issued 30,000 warrants to purchase the Company’s common shares to Barandnic Holdings Ltd. for services provided. The warrants are exercisable at a price of $4.00 per share and expire five years from the date of issuance. On October 27, 2023, the Company issued 145,833 warrants to purchase the Company’s common shares to management (87,500 warrants were issued to the Chief Financial Officer) and non-employees of the Company. The warrants are exercisable at a price of $1.93 per share and expire in three years from the date of issuance. These warrants replace previously issued warrants that have now been cancelled. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 152.10-174.45%; and a risk-free rate of 4.31%-4.84%. Non-cash compensation for the year ended January 31, 2024, amounted to $242,840.

     

    On April 19, 2024, in connection with a private placement of the Company’s common stock, the Company issued 4,200,000 warrants. The warrants are exercisable at a price of $6.43 per share and expire five years from the date of issuance.

     

       Shares   Exercise
    Price    		   Remaining
    Life    		  Intrinsic
    Value    		 
    Outstanding, January 31, 2023   1,307,671   $6.43   3.34 years  $
    -
    		 
                       
    Granted   175,833    2.28   2.97 years   
    -
    		 
                       
    Expired/Cancelled   (200,466)   6.33  
    -
    		   
    -
    		 
                       
    Exercised   
    -
    		    
    -
    		  
    -
    		   
    -
    		 
                       
    Outstanding, January 31, 2024   1,283,038    5.88   2.97 years   
    -
    		 
                       
    Granted   4,200,000    6.43   5.00 years   
    -
    		 
                       
    Expired/Cancelled   
    -
    		    
    -
    		  
    -
    		   
    -
    		 
                       
    Exercised   
    -
    		    
    -
    		  
    -
    		   
    -
    		 
                       
    Outstanding- April 30, 2024   5,483,038   $6.30   4.25 years  $233,125 
                       
    Exercisable - April 30, 2024   5,483,038   $6.30   4.25 years  $233,125 

     

    The following table summarizes additional information relating to the warrants outstanding as of April 30, 2024: 

     

    Range of Exercise
    Prices    		   Number
    Outstanding    		   Weighted
    Average
    Remaining
    Contractual
    Life(Years)    		   Weighted
    Average
    Exercise Price
    for Shares
    Outstanding    		   Number
    Exercisable    		   Weighted
    Average
    Exercise Price
    for Shares
    Exercisable    		   Intrinsic Value 
                              
    $4.00    30,000    4.10   $4.00    30,000   $4.00   $
    -
    		 
    $6.43    5,282,205    2.68   $6.43    5,282,205   $6.43   $
    -
    		 
    $1.93    145,833    2.74   $1.93    145,833   $1.93   $233,125 
    $7.50    25,000    3.77   $7.50    25,000   $7.50   $
    -
    		 
          5,483,038              5,483,038        $233,125 

     

    Options

     

    The following table summarizes the changes in options outstanding and the related price of the shares of the Company’s common stock issued to employees of the Company. See Note 7 for the issuance of related party options.

     

    On November 1, 2021, the Board of Directors adopted the 2021 Employee Stock Option Plan (the “Plan”). The Company has reserved 408,333 shares for issuance and sale upon the exercise of stock options. In accordance with the Plan, on February 1, 2022, the Company reserved an additional 233,333 shares and on February 1, 2023, the Company reserved an additional 233,333 shares. The options vest immediately and expire in three years. Under the Plan, options may be granted which are intended to qualify as Incentive Stock Options (“ISO’s”) under Section 422 of the Internal Revenue Code of 1986 (the “Code”) or which are not (“non-ISO’s”) intended to qualify as Incentive Stock Options thereunder. The Plan also provides for restricted stock awards representing shares of common stock that are issued subject to such restrictions on transfer and other incidents of ownership and such forfeiture conditions as the Board of Directors, or the committee administering the Plan composed of directors who qualify as “independent” under Nasdaq rules, may determine. On November 3, 2021, the Company filed a Registration Statement on Form S-8, to register under the Securities Act of 1933, as amended the 408,333 shares of common stock reserved for issuance under the Plan.

     

    On March 20, 2024, our Board of Directors adopted an amendment to the Company’s Employee Stock Option Plan (the “Plan”) increasing the number of shares of common stock subject to the Plan (as of March 20, 2024, 875,000 shares) to 1,400,000 shares (the “Amendment”). The Company will submit the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting. If the Amendment is not approved by stockholders within one year of adoption, the increase in shares subject to the Plan will be void, together with any options issued following March 20, 2024, in the period pending approval of the Plan by our stockholders. As of April 30, 2024, 135,165 shares remain available for issuance of options under the Plan.

     

    During the three months ended April 30, 2024, 390,000 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $2.37- $2.61 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $422,955 and was recorded during the three months ended April 30, 2024. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rate of 97.83%; and a risk-free rate of 4.87%.

     

    During the year ended January 31, 2024, 404,500 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $1.93-$3.975 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $499,856 and was recorded during the year ended January 31, 2024. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 121.52-143.54%; and a risk-free rate of 3.00-4.5%.

     

       Shares   Exercise
    Price    		   Remaining
    Life    		  Intrinsic
    Value    		 
    Outstanding, January 31, 2023   470,335   $4.13   2.53 years   
     
    		 
                       
    Granted   404,500    2.18   2.68 years   
    -
    		 
                       
    Expired/Cancelled   
    -
    		    
    -
    		  
    -
    		   
     
    		 
                       
    Exercised   
    -
    		    
    -
    		  
    -
    		   
     
    		 
                       
    Outstanding, January 31, 2024   874,835    3.23   2.31 years   
     
    		 
                       
    Granted   390,000    2.49   2.80 years  $378,300 
                       
    Expired/Cancelled   
    -
    		    
    -
    		  
    -
    		   
     
    		 
                       
    Exercised   
    -
    		    
    -
    		  
    -
    		   
     
    		 
                       
    Outstanding- April 30, 2024   1,264,835   $2.63   2.31 years  $910,285 
                       
    Exercisable - April 30, 2024   1,264,835   $2.63   2.31 years  $910,285 

     

    The following table summarizes additional information relating to the options outstanding as of April 30, 2024:

     

    Range of Exercise
    Prices    		   Number
    Outstanding    		   Weighted
    Average
    Life(Years)    		   Weighted
    Average
    Exercise Price
    for Shares
    Outstanding    		   Number
    Exercisable    		   Weighted
    Average
    Exercise Price
    for Shares
    Exercisable    		   Intrinsic
    Value    		 
                                     
    $1.93    214,500    2.74   $1.93    214,500   $1.93   $328,185 
    $2.12    140,000    2.74   $2.12    140,000   $2.12   $187,600 
    $2.37    195,000    2.37   $2.37    195,000   $2.37   $212,550 
    $2.61    195,000    2.61   $2.61    195,000   $2.61   $165,750 
    $2.65    20,000    2.63   $2.65    20,000   $2.65   $16,200 
    $3.59    35,000    3.67   $3.59    35,000   $3.59   $
    -
    		 
    $3.75    57,500    1.85   $3.75    57,500   $3.75   $
    -
    		 
    $3.98    30,000    2.01   $3.98    30,000   $3.98   $
    -
    		 
    $4.09    78,750    1.50   $4.09    78,750   $4.09   $
    -
    		 
    $4.12    50,000    1.85   $4.12    50,000   $4.12   $
    -
    		 
    $4.16    144,083    0.97   $4.16    144,083   $4.16   $
    -
    		 
    $4.50    58,334    1.50   $4.50    58,334   $4.50   $
    -
    		 
    $4.58    46,668    0.97   $4.58    46,668   $4.58   $
    -
    		 
    9.OPTIONS and WARRANTS

     

    Warrants

     

    The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company’s common stock issued to non-employees of the Company during the year ended January 31, 2024. On March 7, 2023, the Company issued 30,000 warrants to purchase the Company’s common shares to Barandnic Holdings Ltd. for services provided. The warrants are exercisable at a price of $4.00 per share and expire five years from the date of issuance. On October 27, 2023, the Company issued 145,833 warrants to purchase the Company’s common shares to management (87,500 warrants were issued to the Chief Financial Officer) and non-employees of the Company. The warrants are exercisable at a price of $1.93 per share and expire in three years from the date of issuance. These warrants replace previously issued warrants that have now been cancelled. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 152.10-174.45%; and a risk-free rate of 4.31%-4.84%. Non-cash compensation for the year ended January 31, 2024, amounted to $242,840.

     

           Exercise   Remaining   Intrinsic 
       Shares   Price   Life   Value 
    Outstanding, January 31, 2022   1,435,622   $6.91     3.93 years    $
    -
    		 
                         
    Granted   25,000    7.50     5.00 years     
    -
    		 
                         
    Expired/Cancelled   (97,534)   5.36    
    -
    		    
    -
    		 
                         
    Exercised   (55,417)   5.36    
    -
    		    
    -
    		 
                         
    Outstanding, January 31, 2023   1,307,671    6.43    3.34 years    
    -
    		 
                         
    Granted   175,833    2.28    2.97 years    
    -
    		 
                         
    Expired/Cancelled   (200,466)   6.33    
    -
    		    
    -
    		 
                         
    Exercised   
    -
    		    
    -
    		    
    -
    		    
    -
    		 
                         
    Outstanding - January 31, 2024   1,283,038   $5.88     2.97 years    $99,166 
                         
    Exercisable - January 31, 2024   1,283,038   $5.88     2.97 years    $99,166 

     

    The following table summarizes additional information relating to the warrants outstanding as of January 31, 2024: 

     

    Range of Exercise
    Prices    		   Number
    Outstanding    		   Weighted Average
    Remaining
    Contractual
    Life(Years)    		   Weighted Average
    Exercise Price for
    Shares
    Outstanding    		   Number
    Exercisable    		   Weighted Average
    Exercise Price for
    Shares
    Exercisable    		   Intrinsic
    Value    		 
    $4.00    30,000    4.10   $4.00    30,000   $4.00   $
    -
    		 
    $6.43    1,082,205    2.68   $6.43    1,082,205   $6.43   $
    -
    		 
    $1.93    145,833    2.74   $1.93    145,833   $1.93   $99,166 
    $7.50    25,000    3.77   $7.50    25,000   $7.50   $
    -
    		 

     

    Options

     

    The following table summarizes the changes in options outstanding and the related price of the shares of the Company’s common stock issued to employees of the Company. See Note 7 for the issuance of related party options.

     

    On November 1, 2021, the Board of Directors adopted the 2021 Employee Stock Option Plan (the “Plan”). The Company has reserved 408,333 shares for issuance and sale upon the exercise of stock options. In accordance with the Plan, on February 1, 2022, the Company reserved an additional 233,333 shares and on February 1, 2023, the Company reserved an additional 233,333 shares. The options vest immediately and expire in three years. Under the Plan, options may be granted which are intended to qualify as Incentive Stock Options (“ISO’s”) under Section 422 of the Internal Revenue Code of 1986 (the “Code”) or which are not (“non-ISO’s”) intended to qualify as Incentive Stock Options thereunder. The Plan also provides for restricted stock awards representing shares of common stock that are issued subject to such restrictions on transfer and other incidents of ownership and such forfeiture conditions as the Board of Directors, or the committee administering the Plan composed of directors who qualify as “independent” under Nasdaq rules, may determine. On November 3, 2021, the Company filed a Registration Statement on Form S-8, to register under the Securities Act of 1933, as amended the 408,333 shares of common stock reserved for issuance under the Plan. As of January 31, 2024, 166 shares remain available and issuance under the Plan.

     

    During the year ended January 31, 2024, 404,500 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $1.93-$3.975 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $499,856 and was recorded during the year ended January 31, 2024. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 121.52-143.54%; and a risk-free rate of 3.00-4.5%.

     

    During the year ended January 31, 2023, 279,584 options to purchase shares of the Company’s common stock were issued to executive officers and directors of the Company at prices of $3.59 to $4.50 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued for services amounted to $732,130 and was recorded during the year ended January 31, 2023. The Company used the Black-Scholes valuation model to record the fair value. The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rate of 152.10-174.45%; and a risk-free rate of 3%.

     

    The following table summarizes additional information relating to the options outstanding as of January 31, 2024.

     

       Shares   Exercise
    Price    		   Remaining
    Life    		   Intrinsic
    Value    		 
    Outstanding, January 31, 2022   190,751   $4.26     2.97 years     
     
    		 
                         
    Granted   279,584    3.93     3.00 years     
    -
    		 
                         
    Expired/Cancelled   
    -
    		    
    -
    		    
    -
    		    
     
    		 
                         
    Exercised   
    -
    		    
    -
    		    
    -
    		    
     
    		 
                         
    Outstanding, January 31, 2023   470,335    4.13     2.53 years     
     
    		 
                         
    Granted   404,500    2.18     2.68 years     
    -
    		 
                         
    Expired/Cancelled   
    -
    		    
    -
    		    
    -
    		    
     
    		 
                         
    Exercised   
    -
    		    
    -
    		    
    -
    		    
     
    		 
                         
    Outstanding- January 31, 2024   874,835   $3.23    2.31 years    $214,460 
                         
    Exercisable - January 31, 2024   874,835   $3.23    2.31 years    $214,460 

     

    The following table summarizes additional information relating to the options outstanding as of January 31, 2024:

     

    Prices   Outstanding   Life(Years)   Shares Outstanding   Exercisable   Shares Exercisable   Value 
                              
    $1.93    214,500    2.74   $1.93    214,500   $1.93   $145,860 
    $2.12    140,000    2.74   $2.12    140,000   $2.12   $68,600 
    $2.65    20,000    2.63   $2.65    20,000   $2.65   $
    -
    		 
    $3.59    35,000    3.67   $3.59    35,000   $3.59   $
    -
    		 
    $3.75    57,500    1.85   $3.75    57,500   $3.75   $
    -
    		 
    $3.98    30,000    2.01   $3.98    30,000   $3.98   $
    -
    		 
    $4.09    78,750    1.50   $4.09    78,750   $4.09   $
    -
    		 
    $4.12    50,000    1.85   $4.12    50,000   $4.12   $
    -
    		 
    $4.16    144,083    0.97   $4.16    144,083   $4.16   $
    -
    		 
    $4.50    58,334    1.50   $4.50    58,334   $4.50   $
    -
    		 
    $4.58    46,668    0.97   $4.58    46,668   $4.58   $
    -
    		 
                                     
          874,835    2.06   $3.23    874,835   $3.23   $214,460 
    XML 102 R17.htm IDEA: XBRL DOCUMENT v3.24.2
    Segment Reporting
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Segment Reporting [Abstract]    
    SEGMENT REPORTING
    9.SEGMENT REPORTING

     

    We organize and manage our business by the following two segments which meet the definition of reportable segments under ASC280-10, Segment Reporting: Sales of Goods and Services. These segments are based on the customer type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief officer decision maker, who is our chief executive officer, in making resource allocation decisions for our segments. Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit.

     

       Three Months Ended
    April 30,    		 
       2024   2023 
    Net sales        
    Pocono Pharmaceuticals  $408,532   $401,057 
    4P Therapeutics   
    -
    		    75,875 
        408,532    476,932 
    Gross profit          
    Pocono Pharmaceuticals   164,786    169,308 
    4P Therapeutics   
    -
    		    52,976 
        164,786    222,284 
    Operating expenses          
    Selling, general and administrative-Pocono Pharmaceuticals   154,394    136,863 
    Selling, general and administrative-4P Therapeutics   24,354    16,921 
    Selling, general and administrative-Corporate   900,980    685,948 
    Research and development-4P Therapeutics   974,535    400,430 
        2,054,263    1,240,162 
    Depreciation and Amortization          
    Pocono Pharmaceuticals  $56,823   $55,208 
    Corporate   3,011    3,497 
    4P Therapeutics   9,267    16,496 
       $69,101   $75,201 

     

    The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.

     

       Three Months Ended
    April 30,    		 
       2024   2023 
    Net sales        
    United States  $408,532   $401,057 
    Outside the United States   
    -
    		    75,875 
       $408,532   $476,932 

     

       April 30,   January 31, 
       2024   2024 
    Property and equipment, net of accumulated depreciation        
    United States  $740,305   $774,924 
    Outside the United States   
    -
    		    
    -
    		 
       $740,305   $774,924 
    Assets          
    Corporate  $8,210,779   $344,192 
    Pocono Pharmaceuticals   5,044,569    5,079,293 
    4P Therapeutics   1,899,132    2,093,369 
       $15,154,480   $7,516,854 
    10.SEGMENT REPORTING

     

    We organize and manage our business by the following two segments which meet the definition of reportable segments under ASC280-10, Segment Reporting: Sales of Goods and Services. These segments are based on the type of products or services provided and are the same as our business units. Separate financial information is available and regularly reviewed by our chief officer decision maker, in making resource allocation decisions for our segments. Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit.

     

       Years Ended January 31, 
       2024   2023 
    Net sales        
    Pocono Pharmaceuticals  $1,920,280   $1,785,597 
    4P Therapeutics   165,034    294,102 
        2,085,314    2,079,699 
    Gross profit          
    Pocono Pharmaceuticals   744,391    726,702 
    4P Therapeutics   117,714    23,702 
        862,105    750,404 
    Operating expenses          
    Selling, general and administrative-Pocono Pharmaceuticals   606,275    577,930 
    Selling, general and administrative-4P Therapeutics   236,953    103,181 
    Selling, general and administrative-Corporate   2,930,378    3,234,930 
    Research and development-4P Therapeutics   1,960,425    982,227 
    Goodwill impairment-Pocono Pharmacueticals   
    -
    		    327,326 
        5,734,031    5,225,594 
    Depreciation and Amortization          
    Pocono Pharmaceuticals  $222,159   $264,156 
    Corporate   13,986    
    -
    		 
    4P Therapeutics   51,577    65,987 
       $287,722   $330,143 

     

    The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.

     

       Years Ended
    January 31,    		 
       2024   2023 
    Net sales        
    United States  $2,085,314   $2,079,699 
    Outside the United States   
    -
    		    
    -
    		 
       $2,085,314   $2,079,699 

     

        January 31,    January 31, 
        2024    2023 
    Property and equipment, net of accumulated depreciation          
    United States  $774,924   $897,735 
    Outside the United States   
    -
    		    
    -
    		 
       $774,924   $897,735 
    Assets          
    Corporate  $344,192   $1,745,731 
    Pocono Pharmaceuticals   5,079,293    5,400,814 
    4P Therapeutics   2,093,369    2,309,832 
       $7,516,854   $9,456,377 
    XML 103 R18.htm IDEA: XBRL DOCUMENT v3.24.2
    Commitments and Contigencies
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Commitments and Contigencies [Abstract]    
    COMMITMENTS AND CONTIGENCIES
    10.COMMITMENTS AND CONTIGENCIES

     

    Employment Agreements

     

    The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as directors and officers of the Company for the respective terms thereof. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $250,000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance bonus of 3.5% of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $150,000.

     

    The Company entered into a three-year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $210,000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $110,000.

     

    Kindeva Drug Delivery Agreement

     

    On January 4, 2022, the Company signed a feasibility agreement with Kindeva Drug Delivery, L.P. (“Kindeva”) to develop Nutriband’s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system). The feasibility agreement provides for adapting Kindeva’s commercial transdermal manufacturing process to incorporate AVERSA technology in the fentanyl transdermal system.

     

    The agreement will remain in force until the earlier of: (1) the completion of the work and deliverables under the Workplan; or (2) two (2) years after the Effective Date, after which time the agreement will expire. The feasibility Workplan was completed in February 2024.

     

    The estimated cost to complete the feasibility Workplan was approximately $2.5 million. Nutriband made an advance deposit of $250,000 in January 2022, to be applied against the final invoices. As of April 30, 2024, Nutriband has incurred expenses of $2,950,998 and the deposit of $250,000 has been applied to the final invoices.

     

    On January 15, 2024, the Nutriband signed a commercial development and clinical supply agreement for their lead product with Kindeva. Kindeva will perform commercial manufacturing process development and manufacturing clinical supplies for the human abuse liability clinical study required by the FDA in support of a New Drug Application. The new agreement replaces the previous feasibility agreement between the two companies which was focused on adapting Kindeva’s commercial transdermal manufacturing process to incorporate AVERSA abuse deterrent transdermal technology. The estimated cost to complete is approximately $8.1 million and the expected timing of FDA submission is twelve to eighteen months.

     

    Lease Agreement

     

    On February 1, 2022, Pocono Pharmaceuticals entered into a lease agreement with Geometric Group, LLC for 12,000 square feet of warehouse space currently occupied by Active Intelligence. The monthly rental is $3,000 and the lease expires on January 31, 2025. The lease can be extended for an additional three years at the same monthly rental. The Company recorded a Right of Use asset in the amount of $94,134 in connection with the valuation.

     

    Sorrento Therapeutics, Inc. Agreement

     

    On July 25, 2023, 4P Therapeutics assigned its claim under the bankruptcy proceedings from Sorrento Therapeutics Inc. and received proceeds of $106,528. The amount due under the claim was $118,675 and 4P Therapeutics recorded a reserve for bad debts of $118,675 during the year ended January 31, 2024. Under the agreement with the buyer of the claim, 4P Therapeutics will make proportional restitution and/or repayment of the purchase amount to the extent the claim is disallowed, reduced or not paid at the same time or distribution rate as other general unsecured claims against the Debtor are paid. The Company has recorded the amount of the proceeds as a secured loan payable to the factor as of April 30, 2024.

     

    Legal Proceedings

     

    The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (“Gunnar”) and Lucosky Brookman LLP (“LB”) in the Supreme Court of the State of New York, New York County, under Index No.654633/2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company’s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $500,000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees.

     

    In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $1,000,000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims.

     

    Currently, there are no pending hearings or motions as both parties are engaged in discovery and are attempting to resolve the matter amicably.
    11.COMMITMENTS AND CONTIGENCIES

     

    Employment Agreements

     

    The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022. The agreement also provides that the executives will continue as directors and officers of the Company for the respective terms thereof. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For their services to the Company during the term of the agreement, Mr. Sheridan and Mr. Melnik will receive an annual salary of $250,000 per annum, commencing on the effective date of the agreement. Mr. Sheridan and Mr. Melnik will also receive a performance bonus of 3.5% of net income before income taxes. As of July 31, 2022, the Company and Mr. Sheridan and Mr. Melnik mutually agreed to reduce their annual salary to $150,000.

     

    The Company entered into a three-year employment agreement with Gerald Goodman, our CFO, effective February 1, 2022. The agreement provides for an initial term, commencing on the effective date of the agreement and ending on January 31, 2025, and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or any one-year extension. For his services to the Company during the term of the agreement, Mr. Goodman will receive an annual salary of $210,000 per annum, commencing on the effective date of the agreement. As of July 31, 2022, the Company and Mr. Goodman mutually agreed to reduce his annual salary to $110,000.

     

    Kindeva Drug Delivery Agreement

     

    On January 4, 2022, the Company signed a feasibility agreement with Kindeva Drug Delivery, L.P. (“Kindeva”) to develop Nutriband’s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system). The feasibility agreement provides for adapting Kindeva’s commercial transdermal manufacturing process to incorporate AVERSA technology in the fentanyl transdermal system.

     

    The agreement will remain in force until the earlier of: (1) the completion of the work and deliverables under the Workplan; or (2) two (2) years after the Effective Date, after which time the agreement will expire. The feasibility Workplan was completed in February 2024.

     

    The estimated cost to complete the feasibility Workplan was approximately $2.5 million. Nutriband made an advance deposit of $250,000 in January 2022, to be applied against the final invoices. As of January 31, 2024, Nutriband has incurred expenses of $2,369,508 and the net deposit of $138,250 after application to final invoices is included in prepaid expenses.

     

    In January 2024, Nutriband signed a commercial development and clinical supply agreement with Kindeva Drug Delivery for development of AVERSA Fentanyl using Kindeva’s FDA-approved fentanyl patch. Kindeva will perform commercial manufacturing process development and clinical supplies manufacturing for the human abuse potential clinical study required by the FDA in support of a New Drug Application. The agreement replaces the previous feasibility agreement between the two companies which was focused on adapting Kindeva’s commercial transdermal manufacturing process to incorporate AVERSA abuse deterrent transdermal technology. The estimated cost to complete the commercial process development and clinical supplies manufacturing is approximately $8.1 million and the expected timing of FDA submission is twelve to eighteen months.

     

    Lease Agreement

     

    On February 1, 2022, Pocono Pharmaceuticals entered into a lease agreement with Geometric Group, LLC for 12,000 square feet of warehouse space currently occupied by Active Intelligence. The monthly rental is $3,000 and the lease expires on January 31, 2025. The lease can be extended for an additional three years at the same monthly rental. The Company recorded a Right of Use asset in the amount of $94,134 in connection with the valuation.

     

    MDM Worldwide Agreement

     

    In September 2022, the Company entered into a public relations agreement with MDM Worldwide. In connection with the agreement, the Company agreed to issue 20,000 options to MDM Worldwide. In October 2023, the contract was mutually terminated, and no options were issued. For the year ended January 31, 2024, the Company paid MDM Worldwide $190,000.

     

    Money Channel Agreement

     

    On March 13, 2023, the Company entered into a media advertising agreement with Money Channel Inc. The Company will pay a monthly fee and after ninety days can cancel the agreement. The Company, after 90 days, will also issue options to purchase 50,000 shares of common stock to Money Channel Inc. at an exercise price of $4.00 per share. In June 2023, the parties agreed to terminate the agreement by mutual consent. No options were issued. For the year ended January 31, 2024, the Company paid the Money Channel $100,000.

     

    Sorrento Therapeutics, Inc. Agreement

     

    4P Therapeutics had unpaid account receivables related to a contract clinical research services agreement in place with Sorrento Therapeutics. On February 13, 2023, Sorrento declared Chapter 11 bankruptcy. On July 25, 2023, 4P Therapeutics assigned its claim under the bankruptcy proceedings from Sorrento Therapeutics Inc. and received proceeds of $106,528. The amount due under the claim was $118,675 and 4P Therapeutics recorded a reserve for bad debts of $118,675 during the year ended January 31, 2024. Under the agreement with the buyer of the claim, 4P Therapeutics will make proportional restitution and/or repayment of the purchase amount to the extent the claim is disallowed, reduced or not paid at the same time or distribution rate as other general unsecured claims against the Debtor are paid. The Company has recorded the amount of the proceeds as a secured loan payable to the factor as of January 31, 2024.

     

    Upstream Termination

     

    On May 24, 2023, the Company sent notice of the termination of the Securities Facility Services Agreement, dated January 3, 2023, by and between MERJ DEP Ltd. And the Company (“Agreement”), which provided for the dual listing of the Company’s common stock on the MERJ Upstream exchange (“Upstream”), which is operated as a fully registered and licensed integrated securities exchange, clearing system and depository for digital and non-digital securities under the Seychelles security laws. The termination was effective May 31, 2023.

     

    Legal Proceedings

     

    The Company is currently a defendant in a lawsuit initiated by Joseph Gunnar, LLC (“Gunnar”) and Lucosky Brookman LLP (“LB”) in the Supreme Court of the State of New York, New York County, under Index No.654633/2023. The lawsuit alleges multiple allegations such as breach of contract, fraudulent activities, and tortious interference and seeks damages following the Company’s termination of an engagement letter for assistance with a public stock offering. Gunnar is seeking over $500,000 in damages plus punitive damages, while LB is demanding reimbursement of legal fees.

     

    In response, the Company denies all allegations, alleging that the engagement letter was unenforceable, and its termination was legally justified. The Company has also initiated counterclaims against Joseph Gunnar & Co., accusing them of intentional interference and breach of fiduciary duty, and is seeking $1,000,000 for each claim along with a declaratory judgment affirming the legality and justification of the termination. The plaintiffs have denied these counterclaims.

     

    Currently, there are no pending hearings or motions as both parties are engaged in discovery and are attempting to resolve the matter amicably.
    XML 104 R19.htm IDEA: XBRL DOCUMENT v3.24.2
    Subsequent Events
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Subsequent Events [Abstract]    
    SUBSEQUENT EVENTS
    11.SUBSEQUENT EVENTS

     

    (a)

    The Company agreed on May 14, 2024, to convert $300,000, which as of that date of all the outstanding principal on the Credit line Promissory Note of the Company held by TII Jet Services LDA, a related party, (the “Holder”). The conversion was made pursuant to the terms of a Conversion Agreement dated May 14, 2024, which provided that the conversion of $300,000 of principal and $4,922 of accrued interest would be made at a price of $4.00 per share, resulting in the Company issuing on May 14, 2024, a total of 76,230 shares of common stock at the conversion price of $4.00 per share. On May 22, 2024, the Conversion Agreement was amended allowing the lender to purchase an additional 152,460 shares of common stock at a rate of two warrants per converted share, with an exercise price of $6.43 per share and a term of five years from the conversion date (May 14, 2024).
    12.SUBSEQUENT EVENTS

     

    (a)In February and April 2024, the Company received proceeds of $300,000 from its Credit Line Facility.
       
    (b)On March 20, 2024, 390,000 options to purchase shares of the Company’s common stock were issued to executive officers and employees at prices of $2.37-$2.61 per share. The options vest immediately and expire three years from the date of issuance. The fair value of the options issued amounted to $450,000.
       
    (c)On March 20, 2024, our Board of Directors adopted an amendment to the Company’s Employee Stock Option Plan (the “Plan”) increasing the number of shares of common stock subject to the Plan (as of March 20, 2024, 875,000 shares) to 1,400,000 shares (the “Amendment”). The Company will submit the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting. If the Amendment is not approved by stockholders within one year of adoption, the increase in shares subject to the Plan will be void, together with any options issued following March 20,2024, in the period pending approval of the Plan by our stockholders.
       
    (d)On April 19, 2024, the Company completed an $8,400,000 equity financing with European investors (the “Offering”) of 2,100,000 units (“Units”), at a price of $4.00 per Unit, each Unit consisting of one share of common stock (“Shares”) and a Warrant to purchase two Shares of common stock, the Warrants having an initial exercise price of $6.43, are exercisable by payment of the exercise price in cash only and expire April 19,2029, five years from the date of issuance (“Warrants”). The Offering was made solely to investors residing outside the United States and was not registered under the Security Act of 1933, as amended, (the “Security Act”), or the securities law of any jurisdiction, including outside the United States, but was made privately by the Company pursuant to the exemptions from registration provided in the SEC’s Regulation S and other exemptions under the Securities Act.
    XML 105 R20.htm IDEA: XBRL DOCUMENT v3.24.2
    Accounting Policies, by Policy (Policies)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Summary of Significant Accounting Policies [Abstract]    
    Forward Stock Split

    Forward Stock Split

    On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the “Stock Split”) of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250,000,000 authorized shares to 291,666,666 authorized shares.

    All share and per share information in these financial statements retroactively reflect the forward stock split.

    Forward Stock Split

    On July 26, 2022, our Board of Directors approved the amendment to our Articles of Incorporation to effect a 7- for- 6 forward stock split (the “Stock Split”) of our outstanding common stock. The Company filed the amendment set forth in a Certificate of Change with the Secretary of State of Nevada on August 4, 2022. The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022. Each shareholder of record as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date. No fractional shares of common stock were issued in connection with the Stock Split. Instead, all shares were rounded up to the next whole share. In connection with the Stock Split, which did not require shareholder approval under the Nevada corporation law, the number of shares of common stock of the Company was increased in the same ratio as the shares of outstanding common stock were increased in the Stock Split, from 250,000,000 authorized shares to 291,666,666 authorized shares.

    All share and per share information in these financial statements retroactively reflect the forward stock split.
    Going Concern Assessment

    Going Concern Assessment

    Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look-forward period.

     

    As of April 30, 2024, the Company had cash and cash equivalents of $8,347,740 and working capital of $7,313,082. For the three months ended April 30, 2024, the Company incurred a net loss from operations of $1,898,077 and used cash flow from operations of $833,926. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third-party and related-party debt to support cash flow from operations. The Company has used these proceeds from the sales of securities and issuance of third-party and related party debt to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 13, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. On April 19, 2024, the Company received proceeds of $8,400,000 from equity financing with European investors, of which $7.12 million is from related parties.

    Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern.

    Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.

    Going Concern Assessment

    Management assesses liquidity and going concern uncertainty in the Company’s condensed financial statements to determine whether there is sufficient cash on hand and working capital, including available borrowings on loans, to operate for a period of at least one year from the date the consolidated financial statements are issued or available to be issued, which is referred to as the “look-forward period”, as defined in GAAP. As part of this assessment, based on conditions that are known and reasonably knowable to management, management will consider various scenarios, forecasts, projections, estimates and will make certain key assumptions, including timing and nature of projected cash expenditures or programs, its ability to delay or curtail expenditures or programs and its ability to raise additional capital, if necessary, among other factors. Based on this assessment, as necessary or applicable, management makes certain assumptions around implementing curtailments or delays in the nature and timing of programs and expenditures to the extent it deems probable those implementations can be achieved and management has the proper authority to execute them within the look-forward period.

    As of January 31, 2024, the Company had cash and cash equivalents of $492,942 and working capital of $22,770. For the year ended January 31, 2024, the Company incurred a loss from operations of $4,871,926 and used cash flow from operations of $3,527,509. The Company has generated operating losses since its inception and has relied on sales of securities and issuance of third-party and related-party debt to support cash flow from operations. In October 2021, the Company consummated a public offering and received net proceeds of $5,836,230. The Company has also received to date $3,239,845 in proceeds from the exercise of warrants. The Company has used these proceeds to fund operations and will continue to use the funds as needed. In March 2023, the Company entered into a three-year $2,000,000 Credit Line Note facility with a related party, amended on July 13, 2023, to $5,000,000, which will permit the Company to draw down on the credit line to fund the Company’s research and development of its Aversa product. The Company was advanced $2,000,000, all of which was settled by the issuance of common stock during the year ended January 31, 2024. The $2,000,000 debt and accrued interest was converted into 1,026,720 shares of the Company’s common stock. On April 19, 2024, the Company received proceeds of $8,400,000 from a private placement of its common stock.

    Management has prepared estimates of operations for the next twelve months and believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Company’s ability to continue operations as a going concern.

    Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.

     
    Principles of Consolidation

    Principles of Consolidation

    The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020 under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows:

    Nutriband Ltd.

    4P Therapeutics LLC

    Pocono Pharmaceuticals Inc.

    Principles of Consolidation

    The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018, and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020 under Pocono Pharmaceuticals Inc. The wholly owned subsidiaries are as follows:

    Nutriband Ltd.

    4P Therapeutics LLC

    Pocono Pharmaceuticals Inc.
    Use of Estimates

    Use of Estimates

    The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.

    Use of Estimates

    The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, the Company evaluates its estimates including, but not limited to, those related to such items as income tax exposures, accruals, depreciable/useful lives, allowance for doubtful accounts and valuation allowances. The Company bases its estimates on historical experience and on other various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates.
    Revenue Recognition

    Revenue Recognition

    In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

     

    Revenue Recognition

    In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606) (“ASU 2014-09”), which amends the accounting standards for revenue recognition. ASU 2014-09 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.
    Revenue Types

    Revenue Types

    The following is a description of the Company’s revenue types, which include professional services and sale of goods:

    ●Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods.
    ●Product revenues derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods.
    ●Contract research and development services for pharmaceutical and medical devices for life sciences customers with revenues listed under services.

    Revenue Types

    The following is a description of the Company’s revenue types, which include professional services and sale of goods:

    ●Contract development and manufacturing services for consumer health transdermal, topical and tape products with revenues listed under sale of goods
    ●Product revenues derived from the sale of the Company’s consumer transdermal, topical and tape products with sales listed under sale of goods
    ●Contract research and development services for pharmaceuticals and medical devices for life sciences customers with revenues listed under services
    Contracts with Customers

    Contracts with Customers

    A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.

    Contracts with Customers

    A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration.
    Contract Liabilities

    Contract Liabilities

    Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

    Contract Liabilities

    Deferred revenue is a liability related to a revenue producing activity for which revenue has not been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

     
    Performance Obligations

    Performance Obligations

    A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.

    All revenue recognized in the income statement is considered to be revenue from contracts with customers.

     

    Performance Obligations

    A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue service types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When we perform professional service work, we recognize revenue when we have the right to invoice the customer for the work completed, which typically occurs over time on a monthly basis for the work performed during that month.

    All revenue recognized in the income statement is considered to be revenue from contracts with customers.
    Disaggregation of Revenues

    Disaggregation of Revenues

    The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:

       Three Months Ended 
       April 30, 
       2024   2023 
    Revenue by type        
    Sale of goods  $408,532   $401,057 
    Services   
    -
    		    75,875 
    Total  $408,532   $476,932 
       Three Months Ended 
       April 30, 
       2024   2023 
    Revenue by geographic location:          
    United States  $408,532   $476,932 
    Foreign   
    -
    		    
    -
    		 
       $408,532   $476,932 

    Disaggregation of Revenues

    The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:

       Years Ended 
       January 31, 
       2024   2023 
    Revenue by type        
    Sale of goods  $1,920,280   $1,785,507 
    Services   165,034    294,102 
    Total  $2,085,314   $2,079,609 
       Years Ended 
       January 31, 
       2024   2023 
    Revenue by geographic location:        
    United States  $2,085,314   $2,079,609 
    Foreign   
    -
    		    
    -
    		 
       $2,085,314   $2,079,609 
    Cash and cash equivalents

    Cash and cash equivalents.

    Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short-term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of April 30, 2024, the Company had $7,879,000 that exceeded federally insured limits.

    Cash and cash equivalents.

    Cash and cash equivalents include cash on hand, cash on deposit in money market accounts. The Company considers short-term highly liquid investments with an original maturity date of three months or less that are not part of an investment pool to be cash equivalents. As of January 31, 2024, the Company has no balances that exceed federally insured limits.
    Accounts receivable

    Accounts receivable

    Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both the specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the three months ended April 30, 2024, and 2023, the Company recorded bad debt expenses of $1,200 and $-0-, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $106,528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of April 30, 2024, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10%. The Company adopted ASU 2016-13 during 2013 and implemented the guidance on expected credit losses.

    Accounts receivable

    Trade accounts receivables are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make the required payments. The Company determines its allowances by both the specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the years ended January 31, 2024, and 2023, the Company recorded bad debt expenses of $118,364 and $-0-, respectively, for doubtful accounts related to accounts receivable. During the year ended January 31, 2024, the Company entered into an accounts receivable sale agreement for one of its subsidiaries. The Company received $106,528 in funds against an account receivable that is currently a claim in bankruptcy. The net accounts receivable remain on the books of the Company and a corresponding amount has been included as a secured borrowing liability under Notes payable. As of January 31, 2024, the receivable has been reserved in full. If the bankruptcy claim is not paid in full by the debtor, Company is obligated to pay any difference to the factor. The loan bears interest at 10%. The Company adopted ASU 2016-13 during 2023 and implemented the guidance on expected credit losses.

     
    Inventories

    Inventories

    Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of April 30, 2024, total inventory was $168,505, consisting of work-in-process of $27,447, finished goods of $26,751 and raw materials of $114,307. As of January 31, 2024, total inventory was $168,605, consisting of work-in-process of $7,466, finished goods of $8,707 and raw materials of $134,691.

     

    Inventories

    Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net realized value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). As of January 31, 2024, total inventory was $168,605, consisting of work-in-process of $7,466, finished goods of $8,707 and raw materials of $134,691. As of January 31, 2023, total inventory was $229,335, consisting of work-in-process of $11,021 and raw materials of $218,334.
    Property, Plant and Equipment

    Property, Plant and Equipment

    Property and equipment represent an important component of the Company’s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:

    Lab Equipment  5-10 years
    Furniture and fixtures  3 years
    Machinery and equipment  10-20 years

    Property, Plant and Equipment

    Property and equipment represent an important component of the Company’s assets. The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the assets. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. All major additions and improvements are capitalized. Depreciation is computed using the straight-line method. The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:

    Lab Equipment   5-10 years 
    Furniture and fixtures   3 years 
    Machinery and equipment   10-20 years 
    Intangible Assets

    Intangible Assets

    Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisitions have also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.

    Intangible Assets

    Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisitions have also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.
    Goodwill

    Goodwill

    Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. During the years ended January 31, 2024, and 2023, the Company recorded an impairment charge of $-0- and $327,326, respectively, reducing the Active Intelligence LLC Goodwill to $3,302,478. As of April 30, 2024, and January 31, 2024, Goodwill amounted to $5,021,713 and $5,021,713, respectively.

    Goodwill

    Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. In connection with the Company’s acquisition of 4P Therapeutics LLC in 2018, the Company recorded Goodwill of $1,719,235. On August 31, 2020, in connection with the Company’s acquisition of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $5,810,640. During the years ended January 31, 2024, and 2023, the Company recorded an impairment charge of $-0- and $327,326, respectively, reducing the Active Intelligence LLC Goodwill to $3,302,478. As of January 31, 2024, and 2023, Goodwill amounted to $5,021,713 and $5,021,713, respectively.
    Long-lived Assets

    Long-lived Assets

    Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value.

    Long-lived Assets

    Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value.

     
    Earnings per Share

    Earnings per Share

    Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period.  Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of April 30, 2024, and 2023, there were 6,747,873 and 1,783,373 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.

     

    Earnings per Share

    Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period.  Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of January 31, 2024, and 2023, there were 2,157,873 and 1,778,006 common stock equivalents outstanding, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.
    Stock-Based Compensation

    Stock-Based Compensation

    ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.

    Stock-Based Compensation

    ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.
    Business Combinations

    Business Combinations

    The Company recognizes the assets acquired, the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value.

    Business Combinations

    The Company recognizes the assets acquired, the liabilities assumed, and any non-controlling interest in the acquired entity at the acquisition date, measured at their fair values as of that date, with limited exceptions specified in the accounting literature. In accordance with this guidance, acquisition-related costs, including restructuring costs, must be recognized separately from the acquisition and will generally be expensed as incurred. That replaces the cost-allocation process detailed in previous accounting literature, which required the cost of an acquisition to be allocated to the individual assets acquired and liabilities assumed based on their estimated fair value.
    Leases

    Leases

    In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.

    The Company applies the guidance for right-of-use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.

    Leases

    In February 2016, the FASB issued ASU 2016-02, “Leases” (Topic 842), to provide a new comprehensive model for lease accounting under this guidance, lessees and lessors should apply a “right-of-use” model in accounting for all leases (including subleases) and eliminate the concept of operating leases and off-balance-sheet leases. Recognition, measurement and presentation of expenses will depend on classification as a finance or operating lease. Similar modifications have been made to lessor accounting in-line with revenue recognition guidance.

    The Company applies guidance for right-of-use accounting for all leases and records the operating lease liabilities on its balance sheet. The Company completed the necessary changes to its accounting policies, processes, disclosure and internal control over financial reporting.
    Research and Development Expenses

    Research and Development Expenses

    Research and development costs are expensed as incurred.

    Research and Development Expenses

    Research and development costs are expensed as incurred.
    Income Taxes

    Income Taxes

    Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland.

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company records net deferred tax assets to the extent they believe these assets will more likely than not be realized. In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.  In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.

     

    Income Taxes

    Taxes are calculated in accordance with taxation principles currently effective in the United States and Ireland.

     

    The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements.  Under this method, deferred tax assets and liabilities are determined based on the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.

    The Company records net deferred tax assets to the extent they believe these assets will more-likely-than-not be realized.  In making such determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations.  In the event the Company was to determine that it would be able to realize its deferred income tax assets in the future in excess of its net recorded amount, the Company would make an adjustment to the valuation allowance which would reduce the provision for income taxes.
    Fair Value Measurements

    Fair Value Measurements

    FASB ASC 820, “Fair Value Measurements and Disclosure” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value.

    The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:

      Level 1 - Observable inputs such as quoted market prices in active markets.
           
      Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable.
           
      Level 3 - Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.

    The carrying value of the Company’s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments.

    Fair Value Measurements

    FASB ASC 820, “Fair Value Measurements and Disclosure” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value.

    The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows:

      Level 1 -Observable inputs such as quoted market prices in active markets.
         
      Level 2 -Inputs other than quoted prices in active markets that are either directly or indirectly observable.
         
      Level 3 -Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions.

    The carrying value of the Company’s financial instruments, including accounts receivable, prepaid expenses, accounts payable and accrued expenses, and deferred revenue approximate their fair value due to the short maturities of these financial instruments.
    Recent Accounting Standards

    Recent Accounting Standards

    In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (“CECL”), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016-13 during the year ended January 31, 2024. The adoption of ASU 2016-13 did not have a material impact on the Company’s balance sheet or statement of operations.

    The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.

    Recent Accounting Standards

    In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), The ASU introduces a new credit loss methodology. Current Expected Credit Loss (“CECL”), which requires earlier recognition of credit losses, which also provides additional transparency about credit risk. Since its original issuance in 2016, the FASB has issued several updates to the original ASU. The Company adopted ASU 2016-13 during the year ended January 31, 2024. The adoption of ASU 2016-13 did not have a material impact on the Company’s balance sheet or statement of operations.

     

    The Company has reviewed all other FASB-issued ASU accounting pronouncements and interpretations thereof that have effective dates during the period reported and in future periods. The Company has carefully considered the new pronouncements that alter previous GAAP and does not believe that any new or modified principles will have a material impact on the Company’s reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company’s financial management and certain standards are under consideration.
    Unaudited Financial Statements

    Unaudited Financial Statements

    The consolidated balance sheet as of April 30, 2024, and the consolidated statements of operations, stockholders’ equity, and cash flows for the periods presented have been prepared by the Company and are unaudited. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to prepare fairly the financial position, results of operations, changes in stockholders’ equity and cash flows for all periods presented have been made. The results for the three months ended April 30, 2024, are not necessarily indicative of the results to be expected for the full year. The consolidated financial statements should be read in conjunction with the consolidated financial statements and footnotes thereto included in Nutriband’s Annual Report on Form 10-K for the year ended January 31, 2024.

    Certain information and footnote disclosures required under generally accepted accounting principles in the United States of America (U.S. GAAP”) have been condensed or omitted from these consolidated financial statements pursuant to the rules and regulations, including interim reporting requirements of the U.S. Securities and Exchange Commission (“SEC”). The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosures of contingent amounts in our consolidated financial statements and accompanying footnotes. Actual results could differ from estimates.

    The Company’s significant accounting policies in Note 2 in the Company’s Annual Report on Form 10-K for the year ended January 31, 2024. There were no significant changes to these accounting policies during the three months ended April 30, 2024.

    		  
    XML 106 R21.htm IDEA: XBRL DOCUMENT v3.24.2
    Summary of Significant Accounting Policies (Tables)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Summary of Significant Accounting Policies [Abstract]    
    Schedule of Disaggregates Its Revenue from Contracts The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:
       Three Months Ended 
       April 30, 
       2024   2023 
    Revenue by type        
    Sale of goods  $408,532   $401,057 
    Services   
    -
    		    75,875 
    Total  $408,532   $476,932 
    		 The Company disaggregates its revenue from contracts with customers by type and by geographical location. See the tables:
       Years Ended 
       January 31, 
       2024   2023 
    Revenue by type        
    Sale of goods  $1,920,280   $1,785,507 
    Services   165,034    294,102 
    Total  $2,085,314   $2,079,609 
    Schedule of Revenue by Geographic Location
       Three Months Ended 
       April 30, 
       2024   2023 
    Revenue by geographic location:          
    United States  $408,532   $476,932 
    Foreign   
    -
    		    
    -
    		 
       $408,532   $476,932 
       Years Ended 
       January 31, 
       2024   2023 
    Revenue by geographic location:        
    United States  $2,085,314   $2,079,609 
    Foreign   
    -
    		    
    -
    		 
       $2,085,314   $2,079,609 
    Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:
    Lab Equipment  5-10 years
    Furniture and fixtures  3 years
    Machinery and equipment  10-20 years
    		 The lives over which the fixed assets are depreciated range from 3 to 20 years as follows:
    Lab Equipment   5-10 years 
    Furniture and fixtures   3 years 
    Machinery and equipment   10-20 years 
    XML 107 R22.htm IDEA: XBRL DOCUMENT v3.24.2
    Property and Equipment (Tables)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Property and Equipment [Abstract]    
    Schedule of Property and Equipment
       April 30,   January 31, 
       2024   2024 
    Lab equipment  $144,585   $144,585 
    Machinery and equipment   1,298,584    1,292,389 
    Furniture and fixtures   19,643    19,643 
        1,462,812    1,456,617 
    Less: Accumulated depreciation   (722,507)   (681,693)
    Net Property and Equipment  $740,305   $774,924 
       January 31, 
       2024   2023 
    Lab equipment  $144,585   $144,585 
    Machinery and equipment   1,292,389    1,240,628 
    Furniture and fixtures   19,643    19,643 
        1,456,617    1,404,856 
    Less: Accumulated depreciation   (681,693)   (507,121)
    Net Property and Equipment  $774,924   $897,735 
    XML 108 R23.htm IDEA: XBRL DOCUMENT v3.24.2
    Income Taxes (Tables)
    		 12 Months Ended
    Jan. 31, 2024
    Income Taxes [Abstract]  
    Schedule of Provision for Income Taxes The provision for income taxes consists of the following:
        Years Ended
    January 31,    		 
        2024    2023 
    Current          
    Federal  $
              -
    		   $
               -
    		 
    Foreign   
    -
    		    
    -
    		 
               
    Deferred          
    Federal   
    -
    		    
    -
    		 
    Foreign   
    -
    		    
    -
    		 
    Schedule of Reconciliation of Taxes on Income A reconciliation of taxes on income computed at the federal statutory rate to amounts provided is as follows:
       Years Ended
    January 31,    		 
       2024   2023 
    Book Income (loss from operations)  $(1,151,916)  $(941,530)
    Common stock issued for services   155,966    168,768 
    Impairment expense   
    -
    		    68,738 
    Unused operating losses   995,950    704,024 
    Income tax expense  $
    -
    		   $
    -
    		 
    Schedule of Deferred Tax Liability and Deferred Tax Asset The types of temporary differences between tax basis of assets and liabilities and their financial reporting amounts that give rise to the deferred tax liability and deferred tax asset and their approximate tax effects are as follows:
       January 31, 
       2024   2023 
    Net operating loss carryforward (expire through 2040)  $(3,312,698)  $(2,316,748)
    Stock issued for services  $(1,455,848)   (1,299,882)
    Intangible impairment expense  $(1,051,714)   (1,051,714)
    Valuation allowance  $5,820,260    4,668,344 
    Net deferred taxes  $
    -
    		   $
    -
    		 
    XML 109 R24.htm IDEA: XBRL DOCUMENT v3.24.2
    Intangible Assets (Tables)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Intangible Assets [Abstract]    
    Schedule of Intangible Assets As of April 30, 2024, and January 31, 2024, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:
       April 30,   January 31, 
       2024   2024 
    Customer base  $314,100   $314,100 
    Intellectual property and trademarks   817,400    817,400 
               
    Total   1,131,500    1,131,500 
               
    Less: Accumulated amortization   (492,507)   (464,220)
               
    Net Intangible Assets  $638,993   $667,280 
    		 As of January 31, 2024, and 2023, intangible assets consisted of intellectual property and trademarks, customer base, and license agreement, net of amortization, as follows:
       January 31, 
       2024   2023 
    Customer base  $314,100   $314,100 
    Intellectual property and trademarks   817,400    817,400 
               
    Total   1,131,500    1,131,500 
               
    Less: Accumulated amortization   (464,220)   (351,070)
               
    Net Intangible Assets  $667,280   $780,430 
    Schedule of Amortization Expenses Amortization expenses for the three months ended April 30, 2024, and 2023 amounted to $28,287 and $28,287, respectively.
    Year Ended January 31,    
    2025  $84,863 
    2026   113,148 
    2027   113,148 
    2028   113,148 
    2029   94,226 
    2030 and thereafter   120,460 
       $638,993 
    		 Amortization expenses for the years ended January 31, 2024, and 2023 amounted to $113,150 and $146,483, respectively.
    Year Ended January 31,    
    2025  $113,109 
    2026   113,109 
    2027   113,109 
    2028   113,109 
    2029   113,109 
    2030 and thereafter   101,735 
       $667,280 
    XML 110 R25.htm IDEA: XBRL DOCUMENT v3.24.2
    Options and Warrants (Tables)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Options and Warrants [Line Items]    
    Schedule of Changes in Warrants Outstanding
       Shares   Exercise
    Price    		   Remaining
    Life    		  Intrinsic
    Value    		 
    Outstanding, January 31, 2023   1,307,671   $6.43   3.34 years  $
    -
    		 
                       
    Granted   175,833    2.28   2.97 years   
    -
    		 
                       
    Expired/Cancelled   (200,466)   6.33  
    -
    		   
    -
    		 
                       
    Exercised   
    -
    		    
    -
    		  
    -
    		   
    -
    		 
                       
    Outstanding, January 31, 2024   1,283,038    5.88   2.97 years   
    -
    		 
                       
    Granted   4,200,000    6.43   5.00 years   
    -
    		 
                       
    Expired/Cancelled   
    -
    		    
    -
    		  
    -
    		   
    -
    		 
                       
    Exercised   
    -
    		    
    -
    		  
    -
    		   
    -
    		 
                       
    Outstanding- April 30, 2024   5,483,038   $6.30   4.25 years  $233,125 
                       
    Exercisable - April 30, 2024   5,483,038   $6.30   4.25 years  $233,125 
    		 The valuation model used a dividend rate of 0%; expected term of 1.5 years; volatility rates of 152.10-174.45%; and a risk-free rate of 4.31%-4.84%. Non-cash compensation for the year ended January 31, 2024, amounted to $242,840.
           Exercise   Remaining   Intrinsic 
       Shares   Price   Life   Value 
    Outstanding, January 31, 2022   1,435,622   $6.91     3.93 years    $
    -
    		 
                         
    Granted   25,000    7.50     5.00 years     
    -
    		 
                         
    Expired/Cancelled   (97,534)   5.36    
    -
    		    
    -
    		 
                         
    Exercised   (55,417)   5.36    
    -
    		    
    -
    		 
                         
    Outstanding, January 31, 2023   1,307,671    6.43    3.34 years    
    -
    		 
                         
    Granted   175,833    2.28    2.97 years    
    -
    		 
                         
    Expired/Cancelled   (200,466)   6.33    
    -
    		    
    -
    		 
                         
    Exercised   
    -
    		    
    -
    		    
    -
    		    
    -
    		 
                         
    Outstanding - January 31, 2024   1,283,038   $5.88     2.97 years    $99,166 
                         
    Exercisable - January 31, 2024   1,283,038   $5.88     2.97 years    $99,166 
    Schedule of Summarizes Additional Information Relating to the Warrants Outstanding The following table summarizes additional information relating to the warrants outstanding as of April 30, 2024:
    Range of Exercise
    Prices    		   Number
    Outstanding    		   Weighted
    Average
    Remaining
    Contractual
    Life(Years)    		   Weighted
    Average
    Exercise Price
    for Shares
    Outstanding    		   Number
    Exercisable    		   Weighted
    Average
    Exercise Price
    for Shares
    Exercisable    		   Intrinsic Value 
                              
    $4.00    30,000    4.10   $4.00    30,000   $4.00   $
    -
    		 
    $6.43    5,282,205    2.68   $6.43    5,282,205   $6.43   $
    -
    		 
    $1.93    145,833    2.74   $1.93    145,833   $1.93   $233,125 
    $7.50    25,000    3.77   $7.50    25,000   $7.50   $
    -
    		 
          5,483,038              5,483,038        $233,125 

     

    		 The following table summarizes additional information relating to the warrants outstanding as of January 31, 2024:
    Range of Exercise
    Prices    		   Number
    Outstanding    		   Weighted Average
    Remaining
    Contractual
    Life(Years)    		   Weighted Average
    Exercise Price for
    Shares
    Outstanding    		   Number
    Exercisable    		   Weighted Average
    Exercise Price for
    Shares
    Exercisable    		   Intrinsic
    Value    		 
    $4.00    30,000    4.10   $4.00    30,000   $4.00   $
    -
    		 
    $6.43    1,082,205    2.68   $6.43    1,082,205   $6.43   $
    -
    		 
    $1.93    145,833    2.74   $1.93    145,833   $1.93   $99,166 
    $7.50    25,000    3.77   $7.50    25,000   $7.50   $
    -
    		 

     
    Schedule of Changes in Options Outstanding
       Shares   Exercise
    Price    		   Remaining
    Life    		  Intrinsic
    Value    		 
    Outstanding, January 31, 2023   470,335   $4.13   2.53 years   
     
    		 
                       
    Granted   404,500    2.18   2.68 years   
    -
    		 
                       
    Expired/Cancelled   
    -
    		    
    -
    		  
    -
    		   
     
    		 
                       
    Exercised   
    -
    		    
    -
    		  
    -
    		   
     
    		 
                       
    Outstanding, January 31, 2024   874,835    3.23   2.31 years   
     
    		 
                       
    Granted   390,000    2.49   2.80 years  $378,300 
                       
    Expired/Cancelled   
    -
    		    
    -
    		  
    -
    		   
     
    		 
                       
    Exercised   
    -
    		    
    -
    		  
    -
    		   
     
    		 
                       
    Outstanding- April 30, 2024   1,264,835   $2.63   2.31 years  $910,285 
                       
    Exercisable - April 30, 2024   1,264,835   $2.63   2.31 years  $910,285 

     

    		 The following table summarizes additional information relating to the options outstanding as of January 31, 2024.
       Shares   Exercise
    Price    		   Remaining
    Life    		   Intrinsic
    Value    		 
    Outstanding, January 31, 2022   190,751   $4.26     2.97 years     
     
    		 
                         
    Granted   279,584    3.93     3.00 years     
    -
    		 
                         
    Expired/Cancelled   
    -
    		    
    -
    		    
    -
    		    
     
    		 
                         
    Exercised   
    -
    		    
    -
    		    
    -
    		    
     
    		 
                         
    Outstanding, January 31, 2023   470,335    4.13     2.53 years     
     
    		 
                         
    Granted   404,500    2.18     2.68 years     
    -
    		 
                         
    Expired/Cancelled   
    -
    		    
    -
    		    
    -
    		    
     
    		 
                         
    Exercised   
    -
    		    
    -
    		    
    -
    		    
     
    		 
                         
    Outstanding- January 31, 2024   874,835   $3.23    2.31 years    $214,460 
                         
    Exercisable - January 31, 2024   874,835   $3.23    2.31 years    $214,460 

     
    Schedule of Summarizes Additional Information Relating to the Options Outstanding The following table summarizes additional information relating to the options outstanding as of April 30, 2024:
    Range of Exercise
    Prices    		   Number
    Outstanding    		   Weighted
    Average
    Life(Years)    		   Weighted
    Average
    Exercise Price
    for Shares
    Outstanding    		   Number
    Exercisable    		   Weighted
    Average
    Exercise Price
    for Shares
    Exercisable    		   Intrinsic
    Value    		 
                                     
    $1.93    214,500    2.74   $1.93    214,500   $1.93   $328,185 
    $2.12    140,000    2.74   $2.12    140,000   $2.12   $187,600 
    $2.37    195,000    2.37   $2.37    195,000   $2.37   $212,550 
    $2.61    195,000    2.61   $2.61    195,000   $2.61   $165,750 
    $2.65    20,000    2.63   $2.65    20,000   $2.65   $16,200 
    $3.59    35,000    3.67   $3.59    35,000   $3.59   $
    -
    		 
    $3.75    57,500    1.85   $3.75    57,500   $3.75   $
    -
    		 
    $3.98    30,000    2.01   $3.98    30,000   $3.98   $
    -
    		 
    $4.09    78,750    1.50   $4.09    78,750   $4.09   $
    -
    		 
    $4.12    50,000    1.85   $4.12    50,000   $4.12   $
    -
    		 
    $4.16    144,083    0.97   $4.16    144,083   $4.16   $
    -
    		 
    $4.50    58,334    1.50   $4.50    58,334   $4.50   $
    -
    		 
    $4.58    46,668    0.97   $4.58    46,668   $4.58   $
    -
    		 
    		 The following table summarizes additional information relating to the options outstanding as of January 31, 2024:
    Prices   Outstanding   Life(Years)   Shares Outstanding   Exercisable   Shares Exercisable   Value 
                              
    $1.93    214,500    2.74   $1.93    214,500   $1.93   $145,860 
    $2.12    140,000    2.74   $2.12    140,000   $2.12   $68,600 
    $2.65    20,000    2.63   $2.65    20,000   $2.65   $
    -
    		 
    $3.59    35,000    3.67   $3.59    35,000   $3.59   $
    -
    		 
    $3.75    57,500    1.85   $3.75    57,500   $3.75   $
    -
    		 
    $3.98    30,000    2.01   $3.98    30,000   $3.98   $
    -
    		 
    $4.09    78,750    1.50   $4.09    78,750   $4.09   $
    -
    		 
    $4.12    50,000    1.85   $4.12    50,000   $4.12   $
    -
    		 
    $4.16    144,083    0.97   $4.16    144,083   $4.16   $
    -
    		 
    $4.50    58,334    1.50   $4.50    58,334   $4.50   $
    -
    		 
    $4.58    46,668    0.97   $4.58    46,668   $4.58   $
    -
    		 
                                     
          874,835    2.06   $3.23    874,835   $3.23   $214,460 
    XML 111 R26.htm IDEA: XBRL DOCUMENT v3.24.2
    Segment Reporting (Tables)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Segment Reporting [Abstract]    
    Schedule of Segment Performance to the GAAP Measure of Gross Profit
       Three Months Ended
    April 30,    		 
       2024   2023 
    Net sales        
    Pocono Pharmaceuticals  $408,532   $401,057 
    4P Therapeutics   
    -
    		    75,875 
        408,532    476,932 
    Gross profit          
    Pocono Pharmaceuticals   164,786    169,308 
    4P Therapeutics   
    -
    		    52,976 
        164,786    222,284 
    Operating expenses          
    Selling, general and administrative-Pocono Pharmaceuticals   154,394    136,863 
    Selling, general and administrative-4P Therapeutics   24,354    16,921 
    Selling, general and administrative-Corporate   900,980    685,948 
    Research and development-4P Therapeutics   974,535    400,430 
        2,054,263    1,240,162 
    Depreciation and Amortization          
    Pocono Pharmaceuticals  $56,823   $55,208 
    Corporate   3,011    3,497 
    4P Therapeutics   9,267    16,496 
       $69,101   $75,201 

     

    		 Our chief officer decision maker evaluates segment performance to the GAAP measure of gross profit.
       Years Ended January 31, 
       2024   2023 
    Net sales        
    Pocono Pharmaceuticals  $1,920,280   $1,785,597 
    4P Therapeutics   165,034    294,102 
        2,085,314    2,079,699 
    Gross profit          
    Pocono Pharmaceuticals   744,391    726,702 
    4P Therapeutics   117,714    23,702 
        862,105    750,404 
    Operating expenses          
    Selling, general and administrative-Pocono Pharmaceuticals   606,275    577,930 
    Selling, general and administrative-4P Therapeutics   236,953    103,181 
    Selling, general and administrative-Corporate   2,930,378    3,234,930 
    Research and development-4P Therapeutics   1,960,425    982,227 
    Goodwill impairment-Pocono Pharmacueticals   
    -
    		    327,326 
        5,734,031    5,225,594 
    Depreciation and Amortization          
    Pocono Pharmaceuticals  $222,159   $264,156 
    Corporate   13,986    
    -
    		 
    4P Therapeutics   51,577    65,987 
       $287,722   $330,143 

     
    Schedule of Net Sales and Property and Equipment The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.
       Three Months Ended
    April 30,    		 
       2024   2023 
    Net sales        
    United States  $408,532   $401,057 
    Outside the United States   
    -
    		    75,875 
       $408,532   $476,932 
       April 30,   January 31, 
       2024   2024 
    Property and equipment, net of accumulated depreciation        
    United States  $740,305   $774,924 
    Outside the United States   
    -
    		    
    -
    		 
       $740,305   $774,924 
    Assets          
    Corporate  $8,210,779   $344,192 
    Pocono Pharmaceuticals   5,044,569    5,079,293 
    4P Therapeutics   1,899,132    2,093,369 
       $15,154,480   $7,516,854 
    		 The following table presents information about net sales and property and equipment, net of accumulated depreciation, in the United States and elsewhere.
       Years Ended
    January 31,    		 
       2024   2023 
    Net sales        
    United States  $2,085,314   $2,079,699 
    Outside the United States   
    -
    		    
    -
    		 
       $2,085,314   $2,079,699 
        January 31,    January 31, 
        2024    2023 
    Property and equipment, net of accumulated depreciation          
    United States  $774,924   $897,735 
    Outside the United States   
    -
    		    
    -
    		 
       $774,924   $897,735 
    Assets          
    Corporate  $344,192   $1,745,731 
    Pocono Pharmaceuticals   5,079,293    5,400,814 
    4P Therapeutics   2,093,369    2,309,832 
       $7,516,854   $9,456,377 
    XML 112 R27.htm IDEA: XBRL DOCUMENT v3.24.2
    Organization and Description of Business (Details) - USD ($)
    Apr. 30, 2024
    Jan. 31, 2024
    Jan. 31, 2023
    Aug. 31, 2020
    Aug. 01, 2018
    Organization and Description of Business [Line Items]          
    Acquired costs         $ 2,250,000
    Common stock share (in Shares) 10,969,870 8,869,870 7,843,150   250,000
    Common stock value $ 10,960 $ 8,860 $ 7,833    
    Royalty, percentage         6.00%
    Pocono Pharmaceuticals [Member]          
    Organization and Description of Business [Line Items]          
    Acquired percentage 100.00%     100.00%  
    Minimum [Member]          
    Organization and Description of Business [Line Items]          
    Common stock value         $ 1,850,000
    Maximum [Member]          
    Organization and Description of Business [Line Items]          
    Common stock value         $ 400,000
    XML 113 R28.htm IDEA: XBRL DOCUMENT v3.24.2
    Summary of Significant Accounting Policies (Details) - USD ($)
    		 1 Months Ended 3 Months Ended 12 Months Ended
    Apr. 19, 2024
    Jul. 13, 2023
    Oct. 31, 2021
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Mar. 31, 2023
    Jul. 26, 2022
    Apr. 03, 2022
    Aug. 31, 2020
    Summary of Significant Accounting Policies [Line Items]                      
    Forward stock split, description       The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022.   The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022.          
    Cash and cash equivalents           $ 492,942          
    Working capital       $ 7,313,082   22,770          
    Loss from operations       (1,889,477) $ (1,017,878) (4,871,926) $ (4,475,185)        
    Used cash flow from operations       (833,926) $ (749,864) (3,527,509) (2,987,198)        
    Net proceeds     $ 5,836,230                
    Exercise warrants     $ 3,239,845                
    Credit line note               $ 2,000,000      
    Research and development   $ 5,000,000                  
    Advance repaid           2,000,000          
    Debt amount           2,000,000          
    Accrued interest           1,026,720          
    Private placement $ 8,400,000                    
    Account receivable       $ 106,528   $ 106,528          
    Loan bears interest, percentage       10.00%   10.00%          
    Total inventory           $ 168,605 229,335        
    Work in process       $ 27,447     11,021        
    Finished goods       26,751   8,707          
    Raw materials       $ 114,307   $ 134,691 218,334        
    Estimated useful lives       10 years   10 years          
    Goodwill           $ 1,719,235         $ 5,810,640
    Impairment goodwill           3,302,478          
    Goodwill amounted           $ 5,021,713 $ 5,021,713        
    Common stock equivalents outstanding (in Shares)       6,747,873 1,783,373 2,157,873 1,778,006        
    Cash and cash equivalents       $ 8,347,740   $ 492,942 $ 1,985,440        
    Loss from operations       (1,898,077) $ (1,015,229) (5,485,314) (4,483,474)        
    Draw down on credit line   $ 5,000,000               $ 32,274  
    Proceeds from equity financing 8,400,000     8,400,000              
    Cash federally insured amount       7,879,000              
    Bad debt expenses       1,200 $ 0            
    Total inventory       168,505   168,605 229,335        
    Goodwill       5,021,713   5,021,713 5,021,713        
    4P Therapeutics LLC [Member]                      
    Summary of Significant Accounting Policies [Line Items]                      
    Goodwill       $ 1,719,235              
    Pocono Coated Products LLC and Active Intelligence LLC [Member]                      
    Summary of Significant Accounting Policies [Line Items]                      
    Goodwill                     $ 5,810,640
    Intelligence LLC [Member]                      
    Summary of Significant Accounting Policies [Line Items]                      
    Impairment charge           $ 0 327,326        
    Related Party [Member]                      
    Summary of Significant Accounting Policies [Line Items]                      
    Proceeds from equity financing $ 7,120,000                    
    Minimum [Member]                      
    Summary of Significant Accounting Policies [Line Items]                      
    Authorized shares (in Shares)                 250,000,000    
    Asset depreciated range       3 years   3 years          
    Maximum [Member]                      
    Summary of Significant Accounting Policies [Line Items]                      
    Authorized shares (in Shares)                 291,666,666    
    Asset depreciated range       20 years   20 years          
    Accounts Receivable [Member]                      
    Summary of Significant Accounting Policies [Line Items]                      
    Bad debt expense           $ 118,364 $ 0        
    Inventories [Member]                      
    Summary of Significant Accounting Policies [Line Items]                      
    Work in process           $ 7,466          
    XML 114 R29.htm IDEA: XBRL DOCUMENT v3.24.2
    Summary of Significant Accounting Policies (Details) - Schedule of Disaggregates its Revenue from Contracts - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Disaggregates its Revenue from Contracts [Abstract]        
    Sale of goods     $ 1,920,280 $ 1,785,507
    Services     165,034 294,102
    Total $ 408,532 $ 476,932 $ 2,085,314 $ 2,079,609
    XML 115 R30.htm IDEA: XBRL DOCUMENT v3.24.2
    Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographic Location - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Revenue by geographic location:        
    Total $ 408,532 $ 476,932 $ 2,085,314 $ 2,079,609
    United States [Member]        
    Revenue by geographic location:        
    Total 408,532 476,932 2,085,314 2,079,609
    Foreign [Member]        
    Revenue by geographic location:        
    Total
    XML 116 R31.htm IDEA: XBRL DOCUMENT v3.24.2
    Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets
    Apr. 30, 2024
    Jan. 31, 2024
    Furniture and fixtures [Member]    
    Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets [Line Items]    
    Property plant and equipment, useful life 3 years 3 years
    Minimum [Member] | Lab Equipment [Member]    
    Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets [Line Items]    
    Property plant and equipment, useful life   5 years
    Minimum [Member] | Machinery and equipment [Member]    
    Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets [Line Items]    
    Property plant and equipment, useful life 10 years 10 years
    Maximum [Member] | Lab Equipment [Member]    
    Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets [Line Items]    
    Property plant and equipment, useful life   10 years
    Maximum [Member] | Machinery and equipment [Member]    
    Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets [Line Items]    
    Property plant and equipment, useful life 20 years 20 years
    XML 117 R32.htm IDEA: XBRL DOCUMENT v3.24.2
    Property and Equipment (Details) - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Property and Equipment [Abstract]        
    Depreciation expense $ 40,814 $ 46,914 $ 174,572 $ 183,660
    Cost of goods sold $ 30,242 $ 36,179 $ 131,360 $ 139,689
    XML 118 R33.htm IDEA: XBRL DOCUMENT v3.24.2
    Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)
    Apr. 30, 2024
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Property and Equipment [Line Items]      
    Property and equipment, gross $ 1,462,812 $ 1,456,617 $ 1,404,856
    Less: Accumulated depreciation (722,507) (681,693) (507,121)
    Net Property and Equipment 740,305 774,924 897,735
    Lab equipment [Member]      
    Schedule of Property and Equipment [Line Items]      
    Property and equipment, gross 144,585 144,585 144,585
    Machinery and equipment [Member]      
    Schedule of Property and Equipment [Line Items]      
    Property and equipment, gross 1,298,584 1,292,389 1,240,628
    Furniture and fixtures [Member]      
    Schedule of Property and Equipment [Line Items]      
    Property and equipment, gross $ 19,643 $ 19,643 $ 19,643
    XML 119 R34.htm IDEA: XBRL DOCUMENT v3.24.2
    Income Taxes (Details)
    		 12 Months Ended
    Jan. 31, 2024
    USD ($)
    Income Taxes [Line Items]  
    Deferred tax asset $ 15,800,000
    Tax effect valuation allowance $ 1,151,916
    Minimum [Member]  
    Income Taxes [Line Items]  
    Percentage of corporate rate 34.00%
    Maximum [Member]  
    Income Taxes [Line Items]  
    Percentage of corporate rate 21.00%
    XML 120 R35.htm IDEA: XBRL DOCUMENT v3.24.2
    Income Taxes (Details) - Schedule of Provision for Income Taxes - USD ($)
    		 12 Months Ended
    Jan. 31, 2024
    Jan. 31, 2023
    Current    
    Federal
    Foreign
    Deferred    
    Federal
    Foreign
    XML 121 R36.htm IDEA: XBRL DOCUMENT v3.24.2
    Income Taxes (Details) - Schedule of Reconciliation of Taxes on Income - USD ($)
    		 12 Months Ended
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Reconciliation of Taxes on Income [Abstract]    
    Book Income (loss from operations) $ (1,151,916) $ (941,530)
    Common stock issued for services 155,966 168,768
    Impairment expense 68,738
    Unused operating losses 995,950 704,024
    Income tax expense
    XML 122 R37.htm IDEA: XBRL DOCUMENT v3.24.2
    Income Taxes (Details) - Schedule of Deferred Tax Liability and Deferred Tax Asset - USD ($)
    		 12 Months Ended
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Deferred Tax Liability and Deferred Tax Asset [Abstract]    
    Net operating loss carryforward $ (3,312,698) $ (2,316,748)
    Stock issued for services (1,455,848) (1,299,882)
    Intangible impairment expense (1,051,714) (1,051,714)
    Valuation allowance 5,820,260 4,668,344
    Net deferred taxes
    XML 123 R38.htm IDEA: XBRL DOCUMENT v3.24.2
    Notes Payable (Details) - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Apr. 03, 2022
    Apr. 30, 2024
    Oct. 31, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Jul. 17, 2023
    Jul. 13, 2023
    Mar. 17, 2023
    Notes Payable [Line Items]                  
    Line of credit facility           $ 53,476      
    Due date     Oct. 16, 2028   Oct. 16, 2028        
    Interest rate during period   2.95% 5.00%   5.00%        
    Balance due         $ 85,249        
    Convertible notes payable current         16,129        
    Amount due   $ 15,232 $ 300,000   15,232 100,627      
    Contract Price   32,274           $ 5,000,000  
    Financed amount   22,795              
    Payments made per month   410              
    Current outstanding   $ 4,456 4,560            
    Credit facility             $ 5,000,000   $ 2,000,000
    Bearing interest             7.00%    
    Line of credit facility converted           $ 2,000,000      
    Line of credit facility, common stock (in Shares)           1,026,520      
    Fair value of common stock     2,554,423     $ 2,554,423      
    Loss on extinguishment         (554,423)      
    Interest expense     2,578 $ 3,166 5,470        
    Secured loan payable         $ 106,528        
    Percentage of interest rate         10.00%        
    Note payable $ 81,290   81,290            
    Note payable current 16,331   16,331            
    Received advances 300,000   300,000            
    Related Party [Member]                  
    Notes Payable [Line Items]                  
    Interest expense     4,163            
    Carolina Small Business Development Fund [Member]                  
    Notes Payable [Line Items]                  
    Debt Instrument, Periodic Payment, Principal 3,959                
    Line of Credit [Member]                  
    Notes Payable [Line Items]                  
    Line of credit facility         $ 160,000        
    Assumed amount 139,184   139,184   139,184        
    Principal interest     1,697   1,697        
    Payments of principal interest         15,378        
    Advances amount         2,000,000        
    Interest expense         60,453        
    Line of credit $ 160,000   160,000            
    Notes Payable [Member]                  
    Notes Payable [Line Items]                  
    Amount due     14,860     19,610      
    Loss on extinguishment     554,423     554,423      
    Note payable         85,249        
    Secured Borrowing Liability                  
    Notes Payable [Line Items]                  
    Interest expense     $ 8,618   75,815 $ 6,289      
    Previously Reported [Member]                  
    Notes Payable [Line Items]                  
    Amount due         $ 0        
    XML 124 R39.htm IDEA: XBRL DOCUMENT v3.24.2
    Intangible Assets (Details) - USD ($)
    		 3 Months Ended 12 Months Ended
    Feb. 28, 2021
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Intangible Assets [Line Items]          
    Issued shares (in Shares)       25,000  
    Warrants purchase (in Shares)       25,000  
    Exercise price per share (in Dollars per share)       $ 7.5  
    Interest expense         $ 33,334
    Amortization expenses   $ 28,287 $ 28,287 $ 113,150 146,483
    Rambam Med-Tech Ltd [Member]          
    Intangible Assets [Line Items]          
    IP license fee $ 50,000        
    Minimum [Member]          
    Intangible Assets [Line Items]          
    Amortized period       3 years  
    Maximum [Member]          
    Intangible Assets [Line Items]          
    Amortized period       10 years  
    Termination expense [Member]          
    Intangible Assets [Line Items]          
    Termination expense         $ 174,025
    XML 125 R40.htm IDEA: XBRL DOCUMENT v3.24.2
    Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)
    Apr. 30, 2024
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Intangible Assets [Line items]      
    Total $ 1,131,500 $ 1,131,500 $ 1,131,500
    Less: Accumulated amortization (492,507) (464,220) (351,070)
    Net Intangible Assets 638,993 667,280 780,430
    Customer base [Member]      
    Schedule of Intangible Assets [Line items]      
    Total 314,100 314,100 314,100
    Intellectual property and trademarks [Member]      
    Schedule of Intangible Assets [Line items]      
    Total $ 817,400 $ 817,400 $ 817,400
    XML 126 R41.htm IDEA: XBRL DOCUMENT v3.24.2
    Intangible Assets (Details) - Schedule of Amortization Expenses - USD ($)
    Apr. 30, 2024
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Amortization Expenses [Abstract]      
    2025 $ 84,863 $ 113,109  
    2026 113,148 113,109  
    2027 113,148 113,109  
    2028 113,148 113,109  
    2029 94,226 113,109  
    2030 and thereafter 120,460 101,735  
    Total $ 638,993 $ 667,280 $ 780,430
    XML 127 R42.htm IDEA: XBRL DOCUMENT v3.24.2
    Related Party Transactions (Details) - USD ($)
    		 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
    Apr. 19, 2024
    Dec. 31, 2023
    Feb. 01, 2023
    Dec. 07, 2022
    Aug. 02, 2022
    Sep. 30, 2023
    Jul. 17, 2023
    Mar. 17, 2023
    Sep. 30, 2022
    May 31, 2022
    Apr. 30, 2024
    Apr. 30, 2023
    Oct. 31, 2023
    Oct. 26, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Jul. 26, 2022
    Related Party Transactions [Line Items]                                  
    Purchase shares (in Shares)       107,500 137,084 374,500     35,000   390,000   374,500        
    Share price (in Dollars per share)           $ 2.12         $ 6.43   $ 2.12        
    Expire year       3 years 3 years       5 years       3 years        
    Received amount       $ 245,170 $ 399,075   $ 5,000,000 $ 2,000,000 $ 85,995   $ 422,955       $ 424,826    
    Percentage of jet services LDA             100.00%                    
    Cash received                             $ 2,000,000    
    Line of credit facility   $ 2,000,000                              
    Accrued interest                               $ 53,476  
    Common stock (in Shares)                     291,666,666       291,666,666 291,666,666  
    Shares received (in Shares)                   1,167              
    Compensation expense                   $ 53,200              
    Options vest and expire term                     3 years 3 years          
    Equity financing $ 8,400,000                   $ 8,400,000            
    Invested amount                     7,120,000            
    Investment receivable                     $ 1,780,000            
    Number of common stock (in Shares)                     3,560,000            
    Warrant [Member]                                  
    Related Party Transactions [Line Items]                                  
    Share price (in Dollars per share)                           $ 1.93      
    Expire year                         3 years        
    Received amount                             $ 93,450    
    Minimum [Member]                                  
    Related Party Transactions [Line Items]                                  
    Share price (in Dollars per share)       $ 3.53 $ 4.09                        
    Common stock (in Shares)                                 250,000,000
    Maximum [Member]                                  
    Related Party Transactions [Line Items]                                  
    Share price (in Dollars per share)       $ 3.88 $ 4.5                        
    Common stock (in Shares)                                 291,666,666
    Options [Member]                                  
    Related Party Transactions [Line Items]                                  
    Purchase shares (in Shares)     30,000                            
    Share price (in Dollars per share)     $ 3.975                            
    Expire year     3 years                            
    Received amount                       $ 75,030     $ 75,030    
    Common Stock [Member]                                  
    Related Party Transactions [Line Items]                                  
    Accrued interest                               $ 53,436  
    Common stock (in Shares)                               1,026,520  
    TII Jet Services LDA [Member]                                  
    Related Party Transactions [Line Items]                                  
    Received amount                     $ 300,000            
    European Investors [Member]                                  
    Related Party Transactions [Line Items]                                  
    Equity financing 8,400,000                                
    Invested amount 700,000                                
    Other Related Party [Member]                                  
    Related Party Transactions [Line Items]                                  
    Invested amount 2,620,000                                
    Executives [Member]                                  
    Related Party Transactions [Line Items]                                  
    Share price (in Dollars per share)           1.93         $ 2.37   $ 1.93        
    Director [Member]                                  
    Related Party Transactions [Line Items]                                  
    Share price (in Dollars per share)           $ 2.65             $ 2.65        
    Invested amount 4,500,000                                
    Chief Financial Officer [Member] | Warrant [Member]                                  
    Related Party Transactions [Line Items]                                  
    Purchase shares (in Shares)                           87,500      
    CEO [Member]                                  
    Related Party Transactions [Line Items]                                  
    Shares received (in Shares)                   11,667              
    Independent Directors [Member]                                  
    Related Party Transactions [Line Items]                                  
    Share price (in Dollars per share)                 $ 3.59                
    Employees [Member]                                  
    Related Party Transactions [Line Items]                                  
    Share price (in Dollars per share)                     $ 2.61            
    Son [Member]                                  
    Related Party Transactions [Line Items]                                  
    Invested amount $ 500,000                                
    XML 128 R43.htm IDEA: XBRL DOCUMENT v3.24.2
    Stockholders' Equity (Details) - USD ($)
    		 1 Months Ended 3 Months Ended 12 Months Ended
    Dec. 31, 2024
    Apr. 19, 2024
    Dec. 31, 2022
    May 31, 2022
    Mar. 31, 2022
    Jun. 20, 2019
    May 24, 2019
    Jul. 31, 2022
    Jul. 29, 2022
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Aug. 04, 2022
    Jul. 26, 2022
    Jan. 27, 2020
    Jun. 25, 2019
    Jan. 15, 2016
    Stockholders' Equity [Line Items]                                    
    Preferred stock, shares authorized                   10,000,000   10,000,000 10,000,000          
    Preferred stock, par value (in Dollars per share)                   $ 0.001   $ 0.001 $ 0.001          
    Per shares of common stock (in Dollars per share)                   $ 0.001   $ 0.001 $ 0.001          
    Common shares authorized                   291,666,666   291,666,666 291,666,666          
    Forward stock split, description                       the Company approved a 7-for-6 forward stock split, effective for trading purposes as of August 12, 2022, pursuant to which each shareholder as of the August 15, 2022 record date received one (1) additional share for each six (6) shares held as of the record date.            
    Shares issued                   10,000 10,000 10,000 10,000          
    Treasury stock value (in Dollars)                   $ 32,641 $ 32,641 $ 32,641 $ 32,641          
    Share per unit                   10,959,870   8,859,870 7,833,150          
    Common stock share purchase                   3,560,000                
    Treasury stock share purchase (in Dollars)       $ 119,006 $ 119,006                          
    Issuance of common stock     33,397 33,397         55,417                  
    Treasury shares and recorded compensation expense (in Dollars)       $ 113,155                            
    Proceed from exercise of warrants (in Dollars)                 $ 296,875     $ 296,875          
    Cancelled shares               1,400,000                    
    Forward stock split                   The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022.   The 7:6 forward stock split was effective for trading purposes on the Nasdaq Capital Market on August 12, 2022.            
    Proceeds from equity financing (in Dollars)   $ 8,400,000               $ 8,400,000                
    Warrant to purchase shares   2                                
    Exercise price per share (in Dollars per share)                   $ 1.93   $ 1.93            
    Warrants [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Date of issuance   5 years                                
    Minimum [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Common shares authorized                             250,000,000      
    Increase decreased in authorized common stock                           250,000,000        
    Maximum [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Common shares authorized                             291,666,666      
    Increase decreased in authorized common stock                           291,666,666        
    Common Stock [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Common shares authorized                         1,026,520          
    Share per unit   4                                
    Exercise price per share (in Dollars per share)   $ 6.43                                
    Common Stock [Member] | Minimum [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Increase decreased in authorized common stock                               25,000,000    
    Common Stock [Member] | Maximum [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Increase decreased in authorized common stock                               250,000,000    
    Treasury Stock, Common [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Issuance of common stock     25,000                              
    Related Party [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Proceeds from equity financing (in Dollars)   $ 7,120,000                                
    Preferred Stock [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Preferred stock, shares authorized                                   10,000,000
    Preferred stock, par value (in Dollars per share)                                   $ 0.001
    Series A Preferred Stock [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Preferred stock consisting           2,500,000 2,500,000                      
    Series A Preferred Stock [Member] | Preferred Stock [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Preferred stock, shares designated           2,500,000 2,500,000                      
    Common Stock [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Per shares of common stock (in Dollars per share)                                 $ 0.25  
    Forward stock split                   7-for-6 forward stock split                
    Common Stock [Member] | Minimum [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Common shares authorized                               25,000,000 100,000,000  
    Common Stock [Member] | Maximum [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Common shares authorized                               250,000,000 25,000,000  
    Common Stock [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Common stock share purchase       35,584 35,584                          
    IPO [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Credit facility (in Dollars)   $ 2,100,000                                
    Forecast [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Credit facility (in Dollars) $ 53,436                                  
    Issuance (in Dollars) 2,554,423                                  
    Loss on extinguishment (in Dollars) $ 554,423                                  
    Forecast [Member] | Common Stock [Member]                                    
    Stockholders' Equity [Line Items]                                    
    Converted shares 2,000,000                                  
    Share per unit 1,026,720                                  
    XML 129 R44.htm IDEA: XBRL DOCUMENT v3.24.2
    Options and Warrants (Details) - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 19, 2024
    Mar. 07, 2023
    Feb. 01, 2023
    Feb. 01, 2022
    Nov. 03, 2021
    Apr. 30, 2024
    Jan. 31, 2024
    Jan. 31, 2023
    Mar. 20, 2024
    Oct. 27, 2023
    Nov. 01, 2021
    Options and Warrants [Line Items]                      
    Issued warrants (in Shares)   30,000                  
    Warrants exercisable price (in Dollars per share)           $ 1.93 $ 1.93        
    Expire years 5 years 5 years         5 years        
    Purchase warrant (in Shares)                   145,833  
    Expire year           3 years 3 years        
    Dividend rate           0.00% 0.00%        
    Expected term           1 year 6 months 1 year 6 months        
    Volatility rate           97.83%          
    Risk-free rate           4.87%   3.00%      
    Non cash compensation (in Dollars)             $ 242,840        
    Exercise price (in Shares)                     408,333
    Additional share (in Shares)     233,333 233,333              
    Common stock reserved (in Shares)         408,333            
    Remaining shares (in Shares)             166        
    Options issued for service (in Dollars)           $ 422,955 $ 499,856        
    Purchase shares (in Shares)               279,584      
    Options issued (in Dollars)               $ 732,130      
    Issued warrants (in Shares) 4,200,000                    
    Employee stock option plan shares (in Shares)                 875,000    
    Shares of common stock (in Shares)                 1,400,000    
    Shares remain for issuance of options (in Shares)           135,165          
    Black-Scholes [Member]                      
    Options and Warrants [Line Items]                      
    Expire year             3 years        
    Dividend rate           0.00% 0.00%        
    Expected term           1 year 6 months 1 year 6 months        
    Exercise price (in Shares)             404,500        
    Warrant [Member]                      
    Options and Warrants [Line Items]                      
    Warrants exercisable price (in Dollars per share)   $ 4                  
    Purchase warrant (in Shares)           5,483,038          
    Expire year           3 years 3 years        
    Dividend rate               0.00%      
    Expected term               1 year 6 months      
    Minimum [Member]                      
    Options and Warrants [Line Items]                      
    Volatility rate             121.52%        
    Risk-free rate             3.00%        
    Purchase shares (in Dollars per share)             $ 1.93        
    Minimum [Member] | Black-Scholes [Member]                      
    Options and Warrants [Line Items]                      
    Volatility rate           152.10% 152.10%        
    Risk-free rate           4.31% 4.31%        
    Minimum [Member] | Warrant [Member]                      
    Options and Warrants [Line Items]                      
    Volatility rate               152.10%      
    Maximum [Member]                      
    Options and Warrants [Line Items]                      
    Volatility rate             143.54%        
    Risk-free rate             4.50%        
    Purchase shares (in Dollars per share)             $ 3.975        
    Maximum [Member] | Black-Scholes [Member]                      
    Options and Warrants [Line Items]                      
    Volatility rate           174.45% 174.45%        
    Risk-free rate           4.84% 4.84%        
    Maximum [Member] | Warrant [Member]                      
    Options and Warrants [Line Items]                      
    Volatility rate               174.45%      
    Chief Executive Officer [Member]                      
    Options and Warrants [Line Items]                      
    Purchase warrant (in Shares)                   87,500  
    Purchase shares (in Shares)           390,000 404,500        
    Chief Executive Officer [Member] | Minimum [Member]                      
    Options and Warrants [Line Items]                      
    Purchase shares (in Dollars per share)           $ 2.37 $ 1.93 $ 3.59      
    Chief Executive Officer [Member] | Maximum [Member]                      
    Options and Warrants [Line Items]                      
    Purchase shares (in Dollars per share)           $ 2.61 $ 3.975        
    Director [Member] | Maximum [Member]                      
    Options and Warrants [Line Items]                      
    Purchase shares (in Dollars per share)               $ 4.5      
    Common Stock [Member]                      
    Options and Warrants [Line Items]                      
    Warrants exercisable price (in Dollars per share) $ 6.43                    
    XML 130 R45.htm IDEA: XBRL DOCUMENT v3.24.2
    Options and Warrants (Details) - Schedule of Changes in Warrants Outstanding - Warrant [Member] - USD ($)
    		 3 Months Ended 12 Months Ended
    Jan. 31, 2022
    Apr. 30, 2024
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Changes in Warrants Outstanding [Line Items]        
    Shares, Outstanding beginning balance 1,435,622   1,307,671  
    Exercise Price, Outstanding beginning balance $ 6.91 $ 5.88 $ 6.43  
    Remaining Life, Outstanding beginning balance 3 years 11 months 4 days      
    Intrinsic Value, Outstanding beginning balance  
    Shares, Granted   4,200,000 175,833 25,000
    Exercise Price, Granted   $ 6.43 $ 2.28 $ 7.5
    Remaining Life, Granted   5 years 2 years 11 months 19 days 5 years
    Intrinsic Value, Granted  
    Shares, Expired/Cancelled   (200,466) (97,534)
    Exercise Price, Expired/Cancelled   $ 6.33 $ 5.36
    Remaining Life, Expired/Cancelled  
    Intrinsic Value, Expired/Cancelled  
    Shares, Exercised     (55,417)
    Exercise Price, Exercised   $ 5.36
    Remaining Life, Exercised  
    Intrinsic Value, Exercised  
    Shares, Outstanding ending balance       1,307,671
    Exercise Price, Outstanding ending balance   $ 6.3 $ 5.88 $ 6.43
    Remaining Life, Outstanding ending balance   4 years 3 months 2 years 11 months 19 days 3 years 4 months 2 days
    Intrinsic Value, Outstanding ending balance   $ 233,125
    Shares, Exercisable   5,483,038 1,283,038  
    Exercise Price, Exercisable   $ 6.3 $ 5.88  
    Remaining Life, Exercisable   4 years 3 months 2 years 11 months 19 days  
    Intrinsic Value, Exercisable   $ 233,125 $ 99,166  
    Previously Reported [Member]        
    Schedule of Changes in Warrants Outstanding [Line Items]        
    Shares, Outstanding beginning balance   1,283,038    
    Exercise Price, Outstanding beginning balance   $ 5.88    
    Intrinsic Value, Outstanding beginning balance   $ 99,166    
    Shares, Outstanding ending balance     1,283,038  
    Exercise Price, Outstanding ending balance     $ 5.88  
    Remaining Life, Outstanding ending balance     2 years 11 months 19 days  
    Intrinsic Value, Outstanding ending balance     $ 99,166  
    XML 131 R46.htm IDEA: XBRL DOCUMENT v3.24.2
    Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Warrants Outstanding - Warrant [Member] - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Exercise Prices 4.00 [Member]    
    Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [Line Items]    
    Range of Exercise Prices   $ 4
    Number Outstanding (in Shares)   30,000
    Weighted Average Remaining Contractual Life (Years) 4 years 1 month 6 days 4 years 1 month 6 days
    Weighted Average Exercise Price for Shares Outstanding   $ 4
    Number Exercisable (in Shares)   30,000
    Weighted Average Exercise Price for Shares Exercisable $ 4 $ 4
    Intrinsic Value (in Dollars)  
    Exercise Prices 6.43 [Member]    
    Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [Line Items]    
    Range of Exercise Prices   $ 6.43
    Number Outstanding (in Shares)   1,082,205
    Weighted Average Remaining Contractual Life (Years) 2 years 8 months 4 days 2 years 8 months 4 days
    Weighted Average Exercise Price for Shares Outstanding   $ 6.43
    Number Exercisable (in Shares)   1,082,205
    Weighted Average Exercise Price for Shares Exercisable $ 6.43 $ 6.43
    Intrinsic Value (in Dollars)  
    Exercise Prices 1.93 [Member]    
    Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [Line Items]    
    Range of Exercise Prices   $ 1.93
    Number Outstanding (in Shares)   145,833
    Weighted Average Remaining Contractual Life (Years) 2 years 8 months 26 days 2 years 8 months 26 days
    Weighted Average Exercise Price for Shares Outstanding   $ 1.93
    Number Exercisable (in Shares)   145,833
    Weighted Average Exercise Price for Shares Exercisable $ 1.93 $ 1.93
    Intrinsic Value (in Dollars)   $ 99,166
    Exercise Prices 7.50 [Member]    
    Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [Line Items]    
    Range of Exercise Prices   $ 7.5
    Number Outstanding (in Shares)   25,000
    Weighted Average Remaining Contractual Life (Years) 3 years 9 months 7 days 3 years 9 months 7 days
    Weighted Average Exercise Price for Shares Outstanding   $ 7.5
    Number Exercisable (in Shares)   25,000
    Weighted Average Exercise Price for Shares Exercisable $ 7.5 $ 7.5
    Intrinsic Value (in Dollars)  
    XML 132 R47.htm IDEA: XBRL DOCUMENT v3.24.2
    Options and Warrants (Details) - Schedule of Changes in Options Outstanding - Options [Member] - USD ($)
    		 12 Months Ended
    Jan. 31, 2024
    Jan. 31, 2023
    Options and Warrants (Details) - Schedule of Changes in Options Outstanding [Line Items]    
    Shares, Outstanding, Beginning balance 470,335 190,751
    Exercise Price, Outstanding, Beginning balance $ 4.13 $ 4.26
    Remaining Life, Outstanding, Beginning balance   2 years 11 months 19 days
    Intrinsic Value, Outstanding, Beginning balance
    Shares, Granted 404,500 279,584
    Exercise Price, Granted $ 2.18 $ 3.93
    Remaining Life, Granted 2 years 8 months 4 days 3 years
    Intrinsic Value, Granted
    Shares, Expired/Cancelled
    Exercise Price, Expired/Cancelled
    Remaining Life, Expired/Cancelled
    Intrinsic Value, Expired/Cancelled
    Shares, Exercised
    Exercise Price, Exercised
    Remaining Life, Exercised
    Intrinsic Value, Exercised
    Shares, Outstanding, Ending balance 874,835 470,335
    Exercise Price, Outstanding, Ending balance $ 3.23 $ 4.13
    Remaining Life, Outstanding, Ending balance 2 years 3 months 21 days 2 years 6 months 10 days
    Intrinsic Value, Outstanding, Ending balance $ 214,460
    Shares, Exercisable 874,835  
    Exercise Price, Exercisable $ 3.23  
    Remaining Life, Exercisable 2 years 3 months 21 days  
    Intrinsic Value, Exercisable $ 214,460  
    XML 133 R48.htm IDEA: XBRL DOCUMENT v3.24.2
    Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Options Outstanding - Options Outstanding [Member] - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding (in Shares)   874,835
    Weighted Average Remaining Contractual Life(Years)   2 years 21 days
    Weighted Average Exercise Price for Shares Outstanding   $ 3.23
    Number Exercisable (in Shares)   874,835
    Weighted Average Exercise Price for Shares Exercisable   $ 3.23
    Intrinsic Value (in Dollars)   $ 214,460
    Exercise Prices 1.93 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Range of Exercise Prices   $ 1.93
    Number Outstanding (in Shares)   214,500
    Weighted Average Remaining Contractual Life(Years) 1 year 11 months 4 days 2 years 8 months 26 days
    Weighted Average Exercise Price for Shares Outstanding   $ 1.93
    Number Exercisable (in Shares) 1.93 214,500
    Weighted Average Exercise Price for Shares Exercisable   $ 1.93
    Intrinsic Value (in Dollars)   $ 145,860
    Exercise Prices 2.12 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Range of Exercise Prices   $ 2.12
    Number Outstanding (in Shares)   140,000
    Weighted Average Remaining Contractual Life(Years) 2 years 1 month 13 days 2 years 8 months 26 days
    Weighted Average Exercise Price for Shares Outstanding   $ 2.12
    Number Exercisable (in Shares) 2.12 140,000
    Weighted Average Exercise Price for Shares Exercisable   $ 2.12
    Intrinsic Value (in Dollars)   $ 68,600
    Exercise Prices 2.65 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Range of Exercise Prices   $ 2.65
    Number Outstanding (in Shares)   20,000
    Weighted Average Remaining Contractual Life(Years) 2 years 4 months 13 days 2 years 7 months 17 days
    Weighted Average Exercise Price for Shares Outstanding   $ 2.65
    Number Exercisable (in Shares) 2.37 20,000
    Weighted Average Exercise Price for Shares Exercisable   $ 2.65
    Intrinsic Value (in Dollars)  
    Exercise Prices 3.59 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Range of Exercise Prices   $ 3.59
    Number Outstanding (in Shares)   35,000
    Weighted Average Remaining Contractual Life(Years) 2 years 7 months 9 days 3 years 8 months 1 day
    Weighted Average Exercise Price for Shares Outstanding   $ 3.59
    Number Exercisable (in Shares) 2.61 35,000
    Weighted Average Exercise Price for Shares Exercisable   $ 3.59
    Intrinsic Value (in Dollars)  
    Exercise Prices 3.75 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Range of Exercise Prices   $ 3.75
    Number Outstanding (in Shares)   57,500
    Weighted Average Remaining Contractual Life(Years) 2 years 7 months 24 days 1 year 10 months 6 days
    Weighted Average Exercise Price for Shares Outstanding   $ 3.75
    Number Exercisable (in Shares) 2.65 57,500
    Weighted Average Exercise Price for Shares Exercisable   $ 3.75
    Intrinsic Value (in Dollars)  
    Exercise Prices 3.98 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Range of Exercise Prices   $ 3.98
    Number Outstanding (in Shares)   30,000
    Weighted Average Remaining Contractual Life(Years) 3 years 7 months 2 days 2 years 3 days
    Weighted Average Exercise Price for Shares Outstanding   $ 3.98
    Number Exercisable (in Shares) 3.59 30,000
    Weighted Average Exercise Price for Shares Exercisable   $ 3.98
    Intrinsic Value (in Dollars)  
    Exercise Prices 4.09 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Range of Exercise Prices   $ 4.09
    Number Outstanding (in Shares)   78,750
    Weighted Average Remaining Contractual Life(Years) 3 years 9 months 1 year 6 months
    Weighted Average Exercise Price for Shares Outstanding   $ 4.09
    Number Exercisable (in Shares) 3.75 78,750
    Weighted Average Exercise Price for Shares Exercisable   $ 4.09
    Intrinsic Value (in Dollars)  
    Exercise Prices 4.12 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Range of Exercise Prices   $ 4.12
    Number Outstanding (in Shares)   50,000
    Weighted Average Remaining Contractual Life(Years) 3 years 11 months 23 days 1 year 10 months 6 days
    Weighted Average Exercise Price for Shares Outstanding   $ 4.12
    Number Exercisable (in Shares) 3.98 50,000
    Weighted Average Exercise Price for Shares Exercisable   $ 4.12
    Intrinsic Value (in Dollars)  
    Exercise Prices 4.16 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Range of Exercise Prices   $ 4.16
    Number Outstanding (in Shares)   144,083
    Weighted Average Remaining Contractual Life(Years) 4 years 1 month 2 days 11 months 19 days
    Weighted Average Exercise Price for Shares Outstanding   $ 4.16
    Number Exercisable (in Shares) 4.09 144,083
    Weighted Average Exercise Price for Shares Exercisable   $ 4.16
    Intrinsic Value (in Dollars)  
    Exercise Prices 4.50 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Range of Exercise Prices   $ 4.5
    Number Outstanding (in Shares)   58,334
    Weighted Average Remaining Contractual Life(Years) 4 years 1 month 13 days 1 year 6 months
    Weighted Average Exercise Price for Shares Outstanding   $ 4.5
    Number Exercisable (in Shares) 4.12 58,334
    Weighted Average Exercise Price for Shares Exercisable   $ 4.5
    Intrinsic Value (in Dollars)  
    Exercise Prices 4.58 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Range of Exercise Prices   $ 4.58
    Number Outstanding (in Shares)   46,668
    Weighted Average Remaining Contractual Life(Years) 4 years 1 month 28 days 11 months 19 days
    Weighted Average Exercise Price for Shares Outstanding   $ 4.58
    Number Exercisable (in Shares) 4.16 46,668
    Weighted Average Exercise Price for Shares Exercisable   $ 4.58
    Intrinsic Value (in Dollars)  
    XML 134 R49.htm IDEA: XBRL DOCUMENT v3.24.2
    Segment Reporting (Details)
    		 3 Months Ended
    Apr. 30, 2024
    Segment Reporting [Abstract]  
    Number of segments 2
    XML 135 R50.htm IDEA: XBRL DOCUMENT v3.24.2
    Segment Reporting (Details) - Schedule of Segment Performance to the GAAP Measure of Gross Profit - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Segment Performance to the GAAP Measure of Gross Profit [Line Items]        
    Net sales $ 408,532 $ 476,932 $ 2,085,314 $ 2,079,699
    Gross profit 164,786 222,284 862,105 750,404
    Operating expenses 2,054,263 1,240,162 5,734,031 5,225,594
    Depreciation and Amortization 69,101 75,201 287,722 330,143
    Pocono Pharmaceuticals [Member]        
    Schedule of Segment Performance to the GAAP Measure of Gross Profit [Line Items]        
    Net sales 408,532 401,057 1,920,280 1,785,597
    Gross profit 164,786 169,308 744,391 726,702
    Operating expenses 154,394 136,863 606,275 577,930
    Depreciation and Amortization 56,823 55,208 222,159 264,156
    4P Therapeutics [Member]        
    Schedule of Segment Performance to the GAAP Measure of Gross Profit [Line Items]        
    Net sales 75,875 165,034 294,102
    Gross profit 52,976 117,714 23,702
    Operating expenses 24,354 16,921 236,953 103,181
    Depreciation and Amortization 9,267 16,496 51,577 65,987
    Corporate [Member]        
    Schedule of Segment Performance to the GAAP Measure of Gross Profit [Line Items]        
    Operating expenses 900,980 685,948 2,930,378 3,234,930
    Depreciation and Amortization 3,011 3,497 13,986
    Research and development-4P Therapeutics [Member]        
    Schedule of Segment Performance to the GAAP Measure of Gross Profit [Line Items]        
    Operating expenses $ 974,535 $ 400,430 1,960,425 982,227
    Goodwill impairment-Pocono Pharmacueticals [Member]        
    Schedule of Segment Performance to the GAAP Measure of Gross Profit [Line Items]        
    Operating expenses     $ 327,326
    XML 136 R51.htm IDEA: XBRL DOCUMENT v3.24.2
    Segment Reporting (Details) - Schedule of Net Sales and Property and Equipment - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Net Sales and Property and Equipment [Line Items]        
    Net sales $ 408,532 $ 476,932 $ 2,085,314 $ 2,079,699
    Property and equipment, net of accumulated depreciation 740,305   774,924 897,735
    Assets        
    Total assets 15,154,480   7,516,854 9,456,377
    United States [Member]        
    Schedule of Net Sales and Property and Equipment [Line Items]        
    Net sales 408,532 401,057 2,085,314 2,079,699
    Property and equipment, net of accumulated depreciation 740,305   774,924 897,735
    Outside of the United States [Member]        
    Schedule of Net Sales and Property and Equipment [Line Items]        
    Net sales $ 75,875
    Property and equipment, net of accumulated depreciation  
    Corporate [Member]        
    Assets        
    Total assets 8,210,779   344,192 1,745,731
    Pocono Pharmaceuticals [Member]        
    Assets        
    Total assets 5,044,569   5,079,293 5,400,814
    4P Therapeutics [Member]        
    Assets        
    Total assets $ 1,899,132   $ 2,093,369 $ 2,309,832
    XML 137 R52.htm IDEA: XBRL DOCUMENT v3.24.2
    Commitments and Contigencies (Details)
    		 1 Months Ended 3 Months Ended 12 Months Ended
    Jan. 15, 2024
    USD ($)
    Jul. 25, 2023
    USD ($)
    Mar. 13, 2023
    $ / shares
    shares
    Jul. 31, 2022
    USD ($)
    Feb. 01, 2022
    USD ($)
    Jul. 25, 2023
    USD ($)
    Sep. 30, 2022
    USD ($)
    Apr. 30, 2024
    USD ($)
    $ / shares
    Jan. 31, 2024
    USD ($)
    $ / shares
    Jan. 31, 2022
    USD ($)
    Jan. 01, 2022
    USD ($)
    Commitments and Contigencies [Line Items]                      
    Forward stock split, description               The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022 The Company entered into three-year employment agreements with Gareth Sheridan, our CEO, and Serguei Melnik, our President, effective February 1, 2022    
    Annual salary       $ 150,000       $ 250,000      
    Percentage of performance bonus               3.50% 3.50%    
    Agreed to annual salary       150,000              
    Other commitments term, description               the Company signed a feasibility agreement with Kindeva Drug Delivery, L.P. (“Kindeva”) to develop Nutriband’s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system). the Company signed a feasibility agreement with Kindeva Drug Delivery, L.P. (“Kindeva”) to develop Nutriband’s lead product, AVERSA Fentanyl, based on its proprietary AVERSA abuse deterrent transdermal technology and Kindeva’s FDA-approved transdermal fentanyl patch (fentanyl transdermal system).    
    Estimated cost                 $ 2,500,000    
    Advance deposit                   $ 250,000 $ 250,000
    Incurred expenses               $ 2,950,998 2,369,508    
    Prepaid expenses               250,000 138,250    
    Estimated cost $ 8,100,000             $ 2,500,000 $ 8,100,000    
    Warehouse space         12,000            
    Lease rental         $ 3,000            
    Lease can be extended for an additional         3 years            
    Right of use assets         $ 94,134            
    Agreed issued             $ 20,000        
    Purchase warrants (in Shares) | shares     50,000                
    Exercise of price (in Dollars per share) | $ / shares               $ 1.93 $ 1.93    
    Received amount   $ 106,528       $ 106,528          
    Due amount   118,675       118,675     $ 118,675    
    legal fees               $ 500,000 500,000    
    Cash               $ 1,000,000 1,000,000    
    MDM Worldwide [Member]                      
    Commitments and Contigencies [Line Items]                      
    Amount paid                 190,000    
    Money Channel [Member]                      
    Commitments and Contigencies [Line Items]                      
    Amount paid                 100,000    
    Exercise of price (in Dollars per share) | $ / shares     $ 4                
    Sorrento Therapeutics Inc Agreement [Member]                      
    Commitments and Contigencies [Line Items]                      
    Bad debt expense   $ 118,675       $ 118,675     $ 118,675    
    Agreement [Member]                      
    Commitments and Contigencies [Line Items]                      
    Maturity date         Jan. 31, 2025     Jan. 31, 2025 Jan. 31, 2025    
    Mr. Goodman [Member]                      
    Commitments and Contigencies [Line Items]                      
    Annual salary       110,000              
    Agreed to annual salary       $ 110,000              
    Chief Executive Officer [Member]                      
    Commitments and Contigencies [Line Items]                      
    Annual salary               $ 210,000 $ 250,000    
    Chief Financial Officer [Member]                      
    Commitments and Contigencies [Line Items]                      
    Annual salary                 $ 210,000    
    XML 138 R53.htm IDEA: XBRL DOCUMENT v3.24.2
    Subsequent Events (Details) - Subsequent Event [Member] - USD ($)
    		 3 Months Ended
    May 22, 2024
    May 14, 2024
    Apr. 19, 2024
    Mar. 20, 2024
    Apr. 30, 2024
    Subsequent Events [Line Items]          
    Received proceeds (in Dollars)         $ 300,000
    Purchase shares       390,000  
    Expire years     5 years 3 years  
    Shares issued       450,000  
    Date of adoption       1 year  
    Equity financing (in Dollars)     $ 8,400,000    
    Purchase an additional shares     2,100,000    
    Number of shares     1    
    Exercise price per share (in Dollars per share) $ 6.43        
    Warrant [Member]          
    Subsequent Events [Line Items]          
    Prices per share (in Dollars per share)     $ 4    
    Number of shares     2    
    Exercise price per shares (in Dollars per share)     $ 6.43    
    Expire date     Apr. 19, 2029    
    Common Stock [Member]          
    Subsequent Events [Line Items]          
    Shares issued       1,400,000  
    Purchase an additional shares 152,460        
    Common Stock [Member] | Minimum [Member]          
    Subsequent Events [Line Items]          
    Prices per share (in Dollars per share)       $ 2.37  
    Common Stock [Member] | Maximum [Member]          
    Subsequent Events [Line Items]          
    Prices per share (in Dollars per share)       $ 2.61  
    TII Jet Services LDA [Member]          
    Subsequent Events [Line Items]          
    Prices per share (in Dollars per share)   $ 4      
    Outstanding principal amount (in Dollars)   $ 300,000      
    Conversion of principal (in Dollars)   $ 300,000      
    TII Jet Services LDA [Member] | Common Stock [Member]          
    Subsequent Events [Line Items]          
    Prices per share (in Dollars per share)   $ 4      
    Accrued interest (in Dollars)   $ 4,922      
    Common stock shares   76,230      
    Board of Directors [Member] | Common Stock [Member]          
    Subsequent Events [Line Items]          
    Shares issued       875,000  
    XML 139 R54.htm IDEA: XBRL DOCUMENT v3.24.2
    Summary of Significant Accounting Policies (Details) - Schedule of Disaggregates its Revenue from Contracts - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Revenue by type        
    Revenue $ 408,532 $ 476,932 $ 2,085,314 $ 2,079,699
    Total 408,532 476,932 $ 2,085,314 $ 2,079,609
    Sale of goods ]Member[        
    Revenue by type        
    Revenue 408,532 401,057    
    Services [Member]        
    Revenue by type        
    Revenue $ 75,875    
    XML 140 R55.htm IDEA: XBRL DOCUMENT v3.24.2
    Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographic Location - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Revenue by geographic location:        
    Total $ 408,532 $ 476,932 $ 2,085,314 $ 2,079,609
    United States [Member]        
    Revenue by geographic location:        
    Total 408,532 476,932 2,085,314 2,079,609
    Foreign [Member]        
    Revenue by geographic location:        
    Total
    XML 141 R56.htm IDEA: XBRL DOCUMENT v3.24.2
    Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on Straight-Line Basis Over Estimated Useful Life of Assets
    Apr. 30, 2024
    Jan. 31, 2024
    Furniture and fixtures [Member]    
    Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets [Line Items]    
    Property plant and equipment, useful life 3 years 3 years
    Minimum [Member] | Lab Equipment [Member]    
    Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets [Line Items]    
    Property plant and equipment, useful life 5 years  
    Minimum [Member] | Machinery and equipment [Member]    
    Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets [Line Items]    
    Property plant and equipment, useful life 10 years 10 years
    Maximum [Member] | Lab Equipment [Member]    
    Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets [Line Items]    
    Property plant and equipment, useful life 10 years  
    Maximum [Member] | Machinery and equipment [Member]    
    Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets [Line Items]    
    Property plant and equipment, useful life 20 years 20 years
    XML 142 R57.htm IDEA: XBRL DOCUMENT v3.24.2
    Property and Equipment (Details) - Schedule of Property and Equipment - USD ($)
    Apr. 30, 2024
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Property and Equipment [Line Items]      
    Property and equipment, gross $ 1,462,812 $ 1,456,617 $ 1,404,856
    Less: Accumulated depreciation (722,507) (681,693) (507,121)
    Net Property and Equipment 740,305 774,924 897,735
    Lab equipment [Member]      
    Schedule of Property and Equipment [Line Items]      
    Property and equipment, gross 144,585 144,585 144,585
    Machinery and equipment [Member]      
    Schedule of Property and Equipment [Line Items]      
    Property and equipment, gross 1,298,584 1,292,389 1,240,628
    Furniture and fixtures [Member]      
    Schedule of Property and Equipment [Line Items]      
    Property and equipment, gross $ 19,643 $ 19,643 $ 19,643
    XML 143 R58.htm IDEA: XBRL DOCUMENT v3.24.2
    Intangible Assets (Details) - Schedule of Intangible Assets - USD ($)
    Apr. 30, 2024
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Intangible Assets [Line items]      
    Total $ 1,131,500 $ 1,131,500 $ 1,131,500
    Less: Accumulated amortization (492,507) (464,220) (351,070)
    Net Intangible Assets 638,993 667,280 780,430
    Customer base [Member]      
    Schedule of Intangible Assets [Line items]      
    Total 314,100 314,100 314,100
    Intellectual property and trademarks [Member]      
    Schedule of Intangible Assets [Line items]      
    Total $ 817,400 $ 817,400 $ 817,400
    XML 144 R59.htm IDEA: XBRL DOCUMENT v3.24.2
    Intangible Assets (Details) - Schedule of Amortization Expenses - USD ($)
    Apr. 30, 2024
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Amortization Expenses [Abstract]      
    2025 $ 84,863 $ 113,109  
    2026 113,148 113,109  
    2027 113,148 113,109  
    2028 113,148 113,109  
    2029 94,226 113,109  
    2030 and thereafter 120,460 101,735  
    Total $ 638,993 $ 667,280 $ 780,430
    XML 145 R60.htm IDEA: XBRL DOCUMENT v3.24.2
    Options and Warrants (Details) - Schedule of Warrants Exercisable - Warrants [Member] - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Changes in Warrants Outstanding [Line Items]      
    Shares, Outstanding beginning balance 1,283,038 1,307,671  
    Exercise Price, Outstanding beginning balance $ 5.88 $ 6.43  
    Remaining Life, Outstanding beginning balance   3 years 4 months 2 days  
    Intrinsic Value, Outstanding beginning balance  
    Shares, Granted 4,200,000 175,833 25,000
    Exercise Price, Granted $ 6.43 $ 2.28 $ 7.5
    Remaining Life, Granted 5 years 2 years 11 months 19 days 5 years
    Intrinsic Value, Granted
    Shares, Expired/Cancelled (200,466) (97,534)
    Exercise Price, Expired/Cancelled $ 6.33 $ 5.36
    Remaining Life, Expired/Cancelled
    Intrinsic Value, Expired/Cancelled
    Shares, Exercised  
    Exercise Price, Exercised $ 5.36
    Remaining Life, Exercised
    Intrinsic Value, Exercised
    Shares, Outstanding ending balance 5,483,038 1,283,038 1,307,671
    Exercise Price, Outstanding ending balance $ 6.3 $ 5.88 $ 6.43
    Remaining Life, Outstanding ending balance 4 years 3 months 2 years 11 months 19 days 3 years 4 months 2 days
    Intrinsic Value, Outstanding ending balance $ 233,125
    Shares, Exercisable 5,483,038 1,283,038  
    Exercise Price, Exercisable $ 6.3 $ 5.88  
    Remaining Life, Exercisable 4 years 3 months 2 years 11 months 19 days  
    Intrinsic Value, Exercisable $ 233,125 $ 99,166  
    XML 146 R61.htm IDEA: XBRL DOCUMENT v3.24.2
    Options and Warrants (Details) - Schedule of Additional Information Relating to the Warrants Outstanding - Warrant [Member] - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [Line Items]    
    Number Outstanding 5,483,038  
    Number Exercisable 5,483,038  
    Intrinsic Value (in Dollars) $ 233,125 $ 99,166
    Exercise Prices 4.00 [Member]    
    Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [Line Items]    
    Number Outstanding 30,000  
    Weighted Average Remaining Contractual Life (Years) 4 years 1 month 6 days 4 years 1 month 6 days
    Weighted Average Exercise Price for Shares Outstanding (in Dollars per share) $ 4  
    Number Exercisable 30,000  
    Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) $ 4 $ 4
    Intrinsic Value (in Dollars)  
    Exercise Prices 6.43 [Member]    
    Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [Line Items]    
    Number Outstanding 5,282,205  
    Weighted Average Remaining Contractual Life (Years) 2 years 8 months 4 days 2 years 8 months 4 days
    Weighted Average Exercise Price for Shares Outstanding (in Dollars per share) $ 6.43  
    Number Exercisable 5,282,205  
    Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) $ 6.43 $ 6.43
    Intrinsic Value (in Dollars)  
    Exercise Prices 1.93 [Member]    
    Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [Line Items]    
    Number Outstanding 145,833  
    Weighted Average Remaining Contractual Life (Years) 2 years 8 months 26 days 2 years 8 months 26 days
    Weighted Average Exercise Price for Shares Outstanding (in Dollars per share) $ 1.93  
    Number Exercisable 145,833  
    Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) $ 1.93 $ 1.93
    Intrinsic Value (in Dollars) $ 233,125  
    Exercise Prices 7.50 [Member]    
    Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [Line Items]    
    Number Outstanding 25,000  
    Weighted Average Remaining Contractual Life (Years) 3 years 9 months 7 days 3 years 9 months 7 days
    Weighted Average Exercise Price for Shares Outstanding (in Dollars per share) $ 7.5  
    Number Exercisable 25,000  
    Weighted Average Exercise Price for Shares Exercisable (in Dollars per share) $ 7.5 $ 7.5
    Intrinsic Value (in Dollars)  
    XML 147 R62.htm IDEA: XBRL DOCUMENT v3.24.2
    Options and Warrants (Details) - Schedule of Changes in Options Outstanding - Options [Member] - Options [Member] - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Schedule of Changes in Options Outstanding [Line Items]    
    Shares, Outstanding, Beginning balance 874,835 470,335
    Exercise Price, Outstanding, Beginning balance $ 3.23 $ 4.13
    Remaining Life, Outstanding, Beginning balance   2 years 6 months 10 days
    Intrinsic Value, Outstanding, Beginning balance
    Shares, Granted 390,000 404,500
    Exercise Price, Granted $ 2.49 $ 2.18
    Remaining Life, Granted 2 years 9 months 18 days 2 years 8 months 4 days
    Intrinsic Value, Granted $ 378,300
    Shares, Expired/Cancelled
    Exercise Price, Expired/Cancelled
    Remaining Life, Expired/Cancelled
    Intrinsic Value, Expired/Cancelled
    Shares, Exercised
    Exercise Price, Exercised
    Remaining Life, Exercised
    Intrinsic Value, Exercised
    Shares, Outstanding, Ending balance 1,264,835 874,835
    Exercise Price, Outstanding, Ending balance $ 2.63 $ 3.23
    Remaining Life, Outstanding, Ending balance 2 years 3 months 21 days 2 years 3 months 21 days
    Intrinsic Value, Outstanding, Ending balance $ 910,285
    Shares, Exercisable 1,264,835  
    Exercise Price, Exercisable $ 2.63  
    Remaining Life, Exercisable 2 years 3 months 21 days  
    Intrinsic Value, Exercisable $ 910,285  
    XML 148 R63.htm IDEA: XBRL DOCUMENT v3.24.2
    Options and Warrants (Details) - Schedule of Additional Information Relating to the Options Outstanding - Options Outstanding [Member] - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Jan. 31, 2024
    Exercise Prices 1.93 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding 214,500  
    Weighted Average Life(Years) 2 years 8 months 26 days  
    Weighted Average Exercise Price for Shares Outstanding 1 year 11 months 4 days 2 years 8 months 26 days
    Number Exercisable 214,500  
    Weighted Average Exercise Price for Shares Exercisable 1.93 214,500
    Intrinsic Value (in Dollars) $ 328,185  
    Exercise Prices 2.12 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding 140,000  
    Weighted Average Life(Years) 2 years 8 months 26 days  
    Weighted Average Exercise Price for Shares Outstanding 2 years 1 month 13 days 2 years 8 months 26 days
    Number Exercisable 140,000  
    Weighted Average Exercise Price for Shares Exercisable 2.12 140,000
    Intrinsic Value (in Dollars) $ 187,600  
    Exercise Prices 2.37 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding 195,000  
    Weighted Average Life(Years) 2 years 4 months 13 days  
    Weighted Average Exercise Price for Shares Outstanding 2 years 4 months 13 days 2 years 7 months 17 days
    Number Exercisable 195,000  
    Weighted Average Exercise Price for Shares Exercisable 2.37 20,000
    Intrinsic Value (in Dollars) $ 212,550  
    Exercise Prices 2.61 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding 195,000  
    Weighted Average Life(Years) 2 years 7 months 9 days  
    Weighted Average Exercise Price for Shares Outstanding 2 years 7 months 9 days 3 years 8 months 1 day
    Number Exercisable 195,000  
    Weighted Average Exercise Price for Shares Exercisable 2.61 35,000
    Intrinsic Value (in Dollars) $ 165,750  
    Exercise Prices 2.65 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding 20,000  
    Weighted Average Life(Years) 2 years 7 months 17 days  
    Weighted Average Exercise Price for Shares Outstanding 2 years 7 months 24 days 1 year 10 months 6 days
    Number Exercisable 20,000  
    Weighted Average Exercise Price for Shares Exercisable 2.65 57,500
    Intrinsic Value (in Dollars) $ 16,200  
    Exercise Prices 3.59 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding 35,000  
    Weighted Average Life(Years) 3 years 8 months 1 day  
    Weighted Average Exercise Price for Shares Outstanding 3 years 7 months 2 days 2 years 3 days
    Number Exercisable 35,000  
    Weighted Average Exercise Price for Shares Exercisable 3.59 30,000
    Intrinsic Value (in Dollars)  
    Exercise Prices 3.75 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding 57,500  
    Weighted Average Life(Years) 1 year 10 months 6 days  
    Weighted Average Exercise Price for Shares Outstanding 3 years 9 months 1 year 6 months
    Number Exercisable 57,500  
    Weighted Average Exercise Price for Shares Exercisable 3.75 78,750
    Intrinsic Value (in Dollars)  
    Exercise Prices 3.98 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding 30,000  
    Weighted Average Life(Years) 2 years 3 days  
    Weighted Average Exercise Price for Shares Outstanding 3 years 11 months 23 days 1 year 10 months 6 days
    Number Exercisable 30,000  
    Weighted Average Exercise Price for Shares Exercisable 3.98 50,000
    Intrinsic Value (in Dollars)  
    Exercise Prices 4.09 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding 78,750  
    Weighted Average Life(Years) 1 year 6 months  
    Weighted Average Exercise Price for Shares Outstanding 4 years 1 month 2 days 11 months 19 days
    Number Exercisable 78,750  
    Weighted Average Exercise Price for Shares Exercisable 4.09 144,083
    Intrinsic Value (in Dollars)  
    Exercise Prices 4.12 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding 50,000  
    Weighted Average Life(Years) 1 year 10 months 6 days  
    Weighted Average Exercise Price for Shares Outstanding 4 years 1 month 13 days 1 year 6 months
    Number Exercisable 50,000  
    Weighted Average Exercise Price for Shares Exercisable 4.12 58,334
    Intrinsic Value (in Dollars)  
    Exercise Prices 4.16 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding 144,083  
    Weighted Average Life(Years) 11 months 19 days  
    Weighted Average Exercise Price for Shares Outstanding 4 years 1 month 28 days 11 months 19 days
    Number Exercisable 144,083  
    Weighted Average Exercise Price for Shares Exercisable 4.16 46,668
    Intrinsic Value (in Dollars)  
    Exercise Prices 4.50 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding 58,334  
    Weighted Average Life(Years) 1 year 6 months  
    Weighted Average Exercise Price for Shares Outstanding 4 years 6 months  
    Number Exercisable 58,334  
    Weighted Average Exercise Price for Shares Exercisable 4.5  
    Intrinsic Value (in Dollars)  
    Exercise Prices 4.58 [Member]    
    Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]    
    Number Outstanding 46,668  
    Weighted Average Life(Years) 11 months 19 days  
    Weighted Average Exercise Price for Shares Outstanding 4 years 6 months 29 days  
    Number Exercisable 46,668  
    Weighted Average Exercise Price for Shares Exercisable 4.58  
    Intrinsic Value (in Dollars)  
    XML 149 R64.htm IDEA: XBRL DOCUMENT v3.24.2
    Segment Reporting (Details) - Schedule of Segment Performance to the GAAP Measure of Gross Profit - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Net sales        
    Net sales $ 408,532 $ 476,932 $ 2,085,314 $ 2,079,699
    Gross profit        
    Gross profit 164,786 222,284 862,105 750,404
    Operating expenses        
    Operating expenses 2,054,263 1,240,162 5,734,031 5,225,594
    Depreciation and Amortization        
    Depreciation and Amortization 69,101 75,201 287,722 330,143
    Pocono Pharmaceuticals [Member]        
    Net sales        
    Net sales 408,532 401,057 1,920,280 1,785,597
    Gross profit        
    Gross profit 164,786 169,308 744,391 726,702
    Operating expenses        
    Operating expenses 154,394 136,863 606,275 577,930
    Depreciation and Amortization        
    Depreciation and Amortization 56,823 55,208 222,159 264,156
    4P Therapeutics [Member]        
    Net sales        
    Net sales 75,875 165,034 294,102
    Gross profit        
    Gross profit 52,976 117,714 23,702
    Operating expenses        
    Operating expenses 24,354 16,921 236,953 103,181
    Depreciation and Amortization        
    Depreciation and Amortization 9,267 16,496 51,577 65,987
    Corporate [Member]        
    Operating expenses        
    Operating expenses 900,980 685,948 2,930,378 3,234,930
    Depreciation and Amortization        
    Depreciation and Amortization 3,011 3,497 13,986
    Research and development-4P Therapeutics [Member]        
    Operating expenses        
    Operating expenses $ 974,535 $ 400,430 $ 1,960,425 $ 982,227
    XML 150 R65.htm IDEA: XBRL DOCUMENT v3.24.2
    Segment Reporting (Details) - Schedule of Net Sales and Property and Equipment - USD ($)
    		 3 Months Ended 12 Months Ended
    Apr. 30, 2024
    Apr. 30, 2023
    Jan. 31, 2024
    Jan. 31, 2023
    Schedule of Net Sales and Property and Equipment [Line Items]        
    Net sales $ 408,532 $ 476,932 $ 2,085,314 $ 2,079,699
    Property and equipment, net of accumulated depreciation 740,305   774,924 897,735
    Assets        
    Total assets 15,154,480   7,516,854 9,456,377
    United States [Member]        
    Schedule of Net Sales and Property and Equipment [Line Items]        
    Net sales 408,532 401,057 2,085,314 2,079,699
    Property and equipment, net of accumulated depreciation 740,305   774,924 897,735
    Outside of the United States [Member]        
    Schedule of Net Sales and Property and Equipment [Line Items]        
    Net sales $ 75,875
    Property and equipment, net of accumulated depreciation  
    Corporate [Member]        
    Assets        
    Total assets 8,210,779   344,192 1,745,731
    Pocono Pharmaceuticals [Member]        
    Assets        
    Total assets 5,044,569   5,079,293 5,400,814
    4P Therapeutics [Member]        
    Assets        
    Total assets $ 1,899,132   $ 2,093,369 $ 2,309,832
    XML 151 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2 html 382 408 1 false 81 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://nutriband.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets Sheet http://nutriband.com/role/ConsolidatedBalanceSheet Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Unaudited Consolidated Statements of Operations Sheet http://nutriband.com/role/ConsolidatedIncomeStatement Unaudited Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Unaudited Consolidated Statements of Operations (Parentheticals) Sheet http://nutriband.com/role/ConsolidatedIncomeStatement_Parentheticals Unaudited Consolidated Statements of Operations (Parentheticals) Statements 5 false false R6.htm 005 - Statement - Unaudited Consolidated Statements of Stockholders??? Equity Sheet http://nutriband.com/role/ShareholdersEquityType2or3 Unaudited Consolidated Statements of Stockholders??? Equity Statements 6 false false R7.htm 006 - Statement - Unaudited Consolidated Statements of Cash Flows Sheet http://nutriband.com/role/ConsolidatedCashFlow Unaudited Consolidated Statements of Cash Flows Statements 7 false false R8.htm 007 - Disclosure - Organization and Description of Business Sheet http://nutriband.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 8 false false R9.htm 008 - Disclosure - Summary of Significant Accounting Policies Sheet http://nutriband.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 009 - Disclosure - Property and Equipment Sheet http://nutriband.com/role/PropertyandEquipment Property and Equipment Notes 10 false false R11.htm 010 - Disclosure - Income Taxes Sheet http://nutriband.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 011 - Disclosure - Notes Payable Notes http://nutriband.com/role/NotesPayable Notes Payable Notes 12 false false R13.htm 012 - Disclosure - Intangible Assets Sheet http://nutriband.com/role/IntangibleAssets Intangible Assets Notes 13 false false R14.htm 013 - Disclosure - Related Party Transactions Sheet http://nutriband.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 014 - Disclosure - Stockholders' Equity Sheet http://nutriband.com/role/StockholdersEquity Stockholders' Equity Notes 15 false false R16.htm 015 - Disclosure - Options and Warrants Sheet http://nutriband.com/role/OptionsandWarrants Options and Warrants Notes 16 false false R17.htm 016 - Disclosure - Segment Reporting Sheet http://nutriband.com/role/SegmentReporting Segment Reporting Notes 17 false false R18.htm 017 - Disclosure - Commitments and Contigencies Sheet http://nutriband.com/role/CommitmentsandContigencies Commitments and Contigencies Notes 18 false false R19.htm 018 - Disclosure - Subsequent Events Sheet http://nutriband.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 996000 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://nutriband.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://nutriband.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 996001 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://nutriband.com/role/SummaryofSignificantAccountingPolicies 21 false false R22.htm 996002 - Disclosure - Property and Equipment (Tables) Sheet http://nutriband.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://nutriband.com/role/PropertyandEquipment 22 false false R23.htm 996003 - Disclosure - Income Taxes (Tables) Sheet http://nutriband.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://nutriband.com/role/IncomeTaxes 23 false false R24.htm 996004 - Disclosure - Intangible Assets (Tables) Sheet http://nutriband.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://nutriband.com/role/IntangibleAssets 24 false false R25.htm 996005 - Disclosure - Options and Warrants (Tables) Sheet http://nutriband.com/role/OptionsandWarrantsTables Options and Warrants (Tables) Tables http://nutriband.com/role/OptionsandWarrants 25 false false R26.htm 996006 - Disclosure - Segment Reporting (Tables) Sheet http://nutriband.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://nutriband.com/role/SegmentReporting 26 false false R27.htm 996007 - Disclosure - Organization and Description of Business (Details) Sheet http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails Organization and Description of Business (Details) Details http://nutriband.com/role/OrganizationandDescriptionofBusiness 27 false false R28.htm 996008 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables 28 false false R29.htm 996009 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Disaggregates its Revenue from Contracts Sheet http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable Summary of Significant Accounting Policies (Details) - Schedule of Disaggregates its Revenue from Contracts Details http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables 29 false false R30.htm 996010 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographic Location Sheet http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographic Location Details http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables 30 false false R31.htm 996011 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets Sheet http://nutriband.com/role/ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets Details http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables 31 false false R32.htm 996012 - Disclosure - Property and Equipment (Details) Sheet http://nutriband.com/role/PropertyandEquipmentDetails Property and Equipment (Details) Details http://nutriband.com/role/PropertyandEquipmentTables 32 false false R33.htm 996013 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment Sheet http://nutriband.com/role/ScheduleofPropertyandEquipmentTable Property and Equipment (Details) - Schedule of Property and Equipment Details http://nutriband.com/role/PropertyandEquipmentTables 33 false false R34.htm 996014 - Disclosure - Income Taxes (Details) Sheet http://nutriband.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://nutriband.com/role/IncomeTaxesTables 34 false false R35.htm 996015 - Disclosure - Income Taxes (Details) - Schedule of Provision for Income Taxes Sheet http://nutriband.com/role/ScheduleofProvisionforIncomeTaxesTable Income Taxes (Details) - Schedule of Provision for Income Taxes Details http://nutriband.com/role/IncomeTaxesTables 35 false false R36.htm 996016 - Disclosure - Income Taxes (Details) - Schedule of Reconciliation of Taxes on Income Sheet http://nutriband.com/role/ScheduleofReconciliationofTaxesonIncomeTable Income Taxes (Details) - Schedule of Reconciliation of Taxes on Income Details http://nutriband.com/role/IncomeTaxesTables 36 false false R37.htm 996017 - Disclosure - Income Taxes (Details) - Schedule of Deferred Tax Liability and Deferred Tax Asset Sheet http://nutriband.com/role/ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable Income Taxes (Details) - Schedule of Deferred Tax Liability and Deferred Tax Asset Details http://nutriband.com/role/IncomeTaxesTables 37 false false R38.htm 996018 - Disclosure - Notes Payable (Details) Notes http://nutriband.com/role/NotesPayableDetails Notes Payable (Details) Details http://nutriband.com/role/NotesPayable 38 false false R39.htm 996019 - Disclosure - Intangible Assets (Details) Sheet http://nutriband.com/role/IntangibleAssetsDetails Intangible Assets (Details) Details http://nutriband.com/role/IntangibleAssetsTables 39 false false R40.htm 996020 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets Sheet http://nutriband.com/role/ScheduleofIntangibleAssetsTable Intangible Assets (Details) - Schedule of Intangible Assets Details http://nutriband.com/role/IntangibleAssetsTables 40 false false R41.htm 996021 - Disclosure - Intangible Assets (Details) - Schedule of Amortization Expenses Sheet http://nutriband.com/role/ScheduleofAmortizationExpensesTable Intangible Assets (Details) - Schedule of Amortization Expenses Details http://nutriband.com/role/IntangibleAssetsTables 41 false false R42.htm 996022 - Disclosure - Related Party Transactions (Details) Sheet http://nutriband.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://nutriband.com/role/RelatedPartyTransactions 42 false false R43.htm 996023 - Disclosure - Stockholders' Equity (Details) Sheet http://nutriband.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://nutriband.com/role/StockholdersEquity 43 false false R44.htm 996024 - Disclosure - Options and Warrants (Details) Sheet http://nutriband.com/role/OptionsandWarrantsDetails Options and Warrants (Details) Details http://nutriband.com/role/OptionsandWarrantsTables 44 false false R45.htm 996025 - Disclosure - Options and Warrants (Details) - Schedule of Changes in Warrants Outstanding Sheet http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable Options and Warrants (Details) - Schedule of Changes in Warrants Outstanding Details http://nutriband.com/role/OptionsandWarrantsTables 45 false false R46.htm 996026 - Disclosure - Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Warrants Outstanding Sheet http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Warrants Outstanding Details http://nutriband.com/role/OptionsandWarrantsTables 46 false false R47.htm 996027 - Disclosure - Options and Warrants (Details) - Schedule of Changes in Options Outstanding Sheet http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable Options and Warrants (Details) - Schedule of Changes in Options Outstanding Details http://nutriband.com/role/OptionsandWarrantsTables 47 false false R48.htm 996028 - Disclosure - Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Options Outstanding Sheet http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Options Outstanding Details http://nutriband.com/role/OptionsandWarrantsTables 48 false false R49.htm 996029 - Disclosure - Segment Reporting (Details) Sheet http://nutriband.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://nutriband.com/role/SegmentReportingTables 49 false false R50.htm 996030 - Disclosure - Segment Reporting (Details) - Schedule of Segment Performance to the GAAP Measure of Gross Profit Sheet http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable Segment Reporting (Details) - Schedule of Segment Performance to the GAAP Measure of Gross Profit Details http://nutriband.com/role/SegmentReportingTables 50 false false R51.htm 996031 - Disclosure - Segment Reporting (Details) - Schedule of Net Sales and Property and Equipment Sheet http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable Segment Reporting (Details) - Schedule of Net Sales and Property and Equipment Details http://nutriband.com/role/SegmentReportingTables 51 false false R52.htm 996032 - Disclosure - Commitments and Contigencies (Details) Sheet http://nutriband.com/role/CommitmentsandContigenciesDetails Commitments and Contigencies (Details) Details http://nutriband.com/role/CommitmentsandContigencies 52 false false R53.htm 996033 - Disclosure - Subsequent Events (Details) Sheet http://nutriband.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://nutriband.com/role/SubsequentEvents 53 false false R54.htm 996034 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Disaggregates its Revenue from Contracts Sheet http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable0 Summary of Significant Accounting Policies (Details) - Schedule of Disaggregates its Revenue from Contracts Details http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables 54 false false R55.htm 996035 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographic Location Sheet http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable0 Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographic Location Details http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables 55 false false R56.htm 996036 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on Straight-Line Basis Over Estimated Useful Life of Assets Sheet http://nutriband.com/role/ScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on Straight-Line Basis Over Estimated Useful Life of Assets Details http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables 56 false false R57.htm 996037 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment Sheet http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0 Property and Equipment (Details) - Schedule of Property and Equipment Details http://nutriband.com/role/PropertyandEquipmentTables 57 false false R58.htm 996038 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets Sheet http://nutriband.com/role/ScheduleofIntangibleAssetsTable0 Intangible Assets (Details) - Schedule of Intangible Assets Details http://nutriband.com/role/IntangibleAssetsTables 58 false false R59.htm 996039 - Disclosure - Intangible Assets (Details) - Schedule of Amortization Expenses Sheet http://nutriband.com/role/ScheduleofAmortizationExpensesTable0 Intangible Assets (Details) - Schedule of Amortization Expenses Details http://nutriband.com/role/IntangibleAssetsTables 59 false false R60.htm 996040 - Disclosure - Options and Warrants (Details) - Schedule of Warrants Exercisable Sheet http://nutriband.com/role/ScheduleofWarrantsExercisableTable Options and Warrants (Details) - Schedule of Warrants Exercisable Details http://nutriband.com/role/OptionsandWarrantsTables 60 false false R61.htm 996041 - Disclosure - Options and Warrants (Details) - Schedule of Additional Information Relating to the Warrants Outstanding Sheet http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable Options and Warrants (Details) - Schedule of Additional Information Relating to the Warrants Outstanding Details http://nutriband.com/role/OptionsandWarrantsTables 61 false false R62.htm 996042 - Disclosure - Options and Warrants (Details) - Schedule of Changes in Options Outstanding Sheet http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0 Options and Warrants (Details) - Schedule of Changes in Options Outstanding Details http://nutriband.com/role/OptionsandWarrantsTables 62 false false R63.htm 996043 - Disclosure - Options and Warrants (Details) - Schedule of Additional Information Relating to the Options Outstanding Sheet http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable Options and Warrants (Details) - Schedule of Additional Information Relating to the Options Outstanding Details http://nutriband.com/role/OptionsandWarrantsTables 63 false false R64.htm 996044 - Disclosure - Segment Reporting (Details) - Schedule of Segment Performance to the GAAP Measure of Gross Profit Sheet http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0 Segment Reporting (Details) - Schedule of Segment Performance to the GAAP Measure of Gross Profit Details http://nutriband.com/role/SegmentReportingTables 64 false false R65.htm 996045 - Disclosure - Segment Reporting (Details) - Schedule of Net Sales and Property and Equipment Sheet http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0 Segment Reporting (Details) - Schedule of Net Sales and Property and Equipment Details http://nutriband.com/role/SegmentReportingTables 65 false false All Reports Book All Reports ea0205970-posama4_nutri.htm ntrb-20240430.xsd ntrb-20240430_cal.xml ntrb-20240430_def.xml ntrb-20240430_lab.xml ntrb-20240430_pre.xml http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 153 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0205970-posama4_nutri.htm": { "nsprefix": "ntrb", "nsuri": "http://nutriband.com/20240430", "dts": { "inline": { "local": [ "ea0205970-posama4_nutri.htm" ] }, "schema": { "local": [ "ntrb-20240430.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "ntrb-20240430_cal.xml" ] }, "definitionLink": { "local": [ "ntrb-20240430_def.xml" ] }, "labelLink": { "local": [ "ntrb-20240430_lab.xml" ] }, "presentationLink": { "local": [ "ntrb-20240430_pre.xml" ] } }, "keyStandard": 305, "keyCustom": 103, "axisStandard": 24, "axisCustom": 0, "memberStandard": 33, "memberCustom": 42, "hidden": { "total": 175, "http://fasb.org/us-gaap/2024": 119, "http://nutriband.com/20240430": 53, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 382, "entityCount": 1, "segmentCount": 81, "elementCount": 647, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1247, "http://xbrl.sec.gov/dei/2024": 10, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://nutriband.com/role/DocumentAndEntityInformation", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R2": { "role": "http://nutriband.com/role/ConsolidatedBalanceSheet", "longName": "001 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c5", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R3": { "role": "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)", "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c5", "name": "us-gaap:PreferredStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R4": { "role": "http://nutriband.com/role/ConsolidatedIncomeStatement", "longName": "003 - Statement - Unaudited Consolidated Statements of Operations", "shortName": "Unaudited Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CostOfRevenue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R5": { "role": "http://nutriband.com/role/ConsolidatedIncomeStatement_Parentheticals", "longName": "004 - Statement - Unaudited Consolidated Statements of Operations (Parentheticals)", "shortName": "Unaudited Consolidated Statements of Operations (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": null, "uniqueAnchor": null }, "R6": { "role": "http://nutriband.com/role/ShareholdersEquityType2or3", "longName": "005 - Statement - Unaudited Consolidated Statements of Stockholders\u2019 Equity", "shortName": "Unaudited Consolidated Statements of Stockholders\u2019 Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c26", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c26", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R7": { "role": "http://nutriband.com/role/ConsolidatedCashFlow", "longName": "006 - Statement - Unaudited Consolidated Statements of Cash Flows", "shortName": "Unaudited Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R8": { "role": "http://nutriband.com/role/OrganizationandDescriptionofBusiness", "longName": "007 - Disclosure - Organization and Description of Business", "shortName": "Organization and Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R9": { "role": "http://nutriband.com/role/SummaryofSignificantAccountingPolicies", "longName": "008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R10": { "role": "http://nutriband.com/role/PropertyandEquipment", "longName": "009 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R11": { "role": "http://nutriband.com/role/IncomeTaxes", "longName": "010 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c7", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c7", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R12": { "role": "http://nutriband.com/role/NotesPayable", "longName": "011 - Disclosure - Notes Payable", "shortName": "Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R13": { "role": "http://nutriband.com/role/IntangibleAssets", "longName": "012 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R14": { "role": "http://nutriband.com/role/RelatedPartyTransactions", "longName": "013 - Disclosure - Related Party Transactions", "shortName": "Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R15": { "role": "http://nutriband.com/role/StockholdersEquity", "longName": "014 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R16": { "role": "http://nutriband.com/role/OptionsandWarrants", "longName": "015 - Disclosure - Options and Warrants", "shortName": "Options and Warrants", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "ntrb:OptionsAndWarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ntrb:OptionsAndWarrantsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R17": { "role": "http://nutriband.com/role/SegmentReporting", "longName": "016 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R18": { "role": "http://nutriband.com/role/CommitmentsandContigencies", "longName": "017 - Disclosure - Commitments and Contigencies", "shortName": "Commitments and Contigencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R19": { "role": "http://nutriband.com/role/SubsequentEvents", "longName": "018 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R20": { "role": "http://nutriband.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "ntrb:ForwardStockSplitPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "ntrb:ForwardStockSplitPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R21": { "role": "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R22": { "role": "http://nutriband.com/role/PropertyandEquipmentTables", "longName": "996002 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R23": { "role": "http://nutriband.com/role/IncomeTaxesTables", "longName": "996003 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c7", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c7", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R24": { "role": "http://nutriband.com/role/IntangibleAssetsTables", "longName": "996004 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R25": { "role": "http://nutriband.com/role/OptionsandWarrantsTables", "longName": "996005 - Disclosure - Options and Warrants (Tables)", "shortName": "Options and Warrants (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ntrb:OptionsAndWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ntrb:OptionsAndWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R26": { "role": "http://nutriband.com/role/SegmentReportingTables", "longName": "996006 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R27": { "role": "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails", "longName": "996007 - Disclosure - Organization and Description of Business (Details)", "shortName": "Organization and Description of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "c51", "name": "us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c51", "name": "us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R28": { "role": "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "996008 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:OtherCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ix:continuation", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R29": { "role": "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable", "longName": "996009 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Disaggregates its Revenue from Contracts", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Disaggregates its Revenue from Contracts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "c7", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c7", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R30": { "role": "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable", "longName": "996010 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographic Location", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographic Location", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": null }, "R31": { "role": "http://nutriband.com/role/ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable", "longName": "996011 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c273", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c73", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R32": { "role": "http://nutriband.com/role/PropertyandEquipmentDetails", "longName": "996012 - Disclosure - Property and Equipment (Details)", "shortName": "Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R33": { "role": "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable", "longName": "996013 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment", "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": null }, "R34": { "role": "http://nutriband.com/role/IncomeTaxesDetails", "longName": "996014 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R35": { "role": "http://nutriband.com/role/ScheduleofProvisionforIncomeTaxesTable", "longName": "996015 - Disclosure - Income Taxes (Details) - Schedule of Provision for Income Taxes", "shortName": "Income Taxes (Details) - Schedule of Provision for Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": null, "uniqueAnchor": null }, "R36": { "role": "http://nutriband.com/role/ScheduleofReconciliationofTaxesonIncomeTable", "longName": "996016 - Disclosure - Income Taxes (Details) - Schedule of Reconciliation of Taxes on Income", "shortName": "Income Taxes (Details) - Schedule of Reconciliation of Taxes on Income", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c7", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c7", "name": "us-gaap:IncomeLossFromContinuingOperations", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R37": { "role": "http://nutriband.com/role/ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable", "longName": "996017 - Disclosure - Income Taxes (Details) - Schedule of Deferred Tax Liability and Deferred Tax Asset", "shortName": "Income Taxes (Details) - Schedule of Deferred Tax Liability and Deferred Tax Asset", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R38": { "role": "http://nutriband.com/role/NotesPayableDetails", "longName": "996018 - Disclosure - Notes Payable (Details)", "shortName": "Notes Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c8", "name": "us-gaap:LineOfCreditFacilityIncreaseAccruedInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LineOfCreditFacilityExpirationDate1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R39": { "role": "http://nutriband.com/role/IntangibleAssetsDetails", "longName": "996019 - Disclosure - Intangible Assets (Details)", "shortName": "Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:ExcessStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:ExcessStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R40": { "role": "http://nutriband.com/role/ScheduleofIntangibleAssetsTable", "longName": "996020 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets", "shortName": "Intangible Assets (Details) - Schedule of Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://nutriband.com/role/ScheduleofAmortizationExpensesTable", "longName": "996021 - Disclosure - Intangible Assets (Details) - Schedule of Amortization Expenses", "shortName": "Intangible Assets (Details) - Schedule of Amortization Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://nutriband.com/role/RelatedPartyTransactionsDetails", "longName": "996022 - Disclosure - Related Party Transactions (Details)", "shortName": "Related Party Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c124", "name": "us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c124", "name": "us-gaap:StockIssuedDuringPeriodSharesPurchaseOfAssets", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R43": { "role": "http://nutriband.com/role/StockholdersEquityDetails", "longName": "996023 - Disclosure - Stockholders' Equity (Details)", "shortName": "Stockholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c7", "name": "ntrb:StockholderEquityNoteStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R44": { "role": "http://nutriband.com/role/OptionsandWarrantsDetails", "longName": "996024 - Disclosure - Options and Warrants (Details)", "shortName": "Options and Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c149", "name": "us-gaap:TemporaryEquitySharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ntrb:OptionsAndWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c149", "name": "us-gaap:TemporaryEquitySharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ntrb:OptionsAndWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R45": { "role": "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "longName": "996025 - Disclosure - Options and Warrants (Details) - Schedule of Changes in Warrants Outstanding", "shortName": "Options and Warrants (Details) - Schedule of Changes in Warrants Outstanding", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c168", "name": "ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ntrb:OptionsAndWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c168", "name": "ntrb:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ntrb:OptionsAndWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R46": { "role": "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable", "longName": "996026 - Disclosure - Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Warrants Outstanding", "shortName": "Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Warrants Outstanding", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c174", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ntrb:OptionsAndWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c174", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ntrb:OptionsAndWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R47": { "role": "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "longName": "996027 - Disclosure - Options and Warrants (Details) - Schedule of Changes in Options Outstanding", "shortName": "Options and Warrants (Details) - Schedule of Changes in Options Outstanding", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c184", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c182", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R48": { "role": "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable", "longName": "996028 - Disclosure - Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Options Outstanding", "shortName": "Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Options Outstanding", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c185", "name": "ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c185", "name": "ntrb:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R49": { "role": "http://nutriband.com/role/SegmentReportingDetails", "longName": "996029 - Disclosure - Segment Reporting (Details)", "shortName": "Segment Reporting (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R50": { "role": "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable", "longName": "996030 - Disclosure - Segment Reporting (Details) - Schedule of Segment Performance to the GAAP Measure of Gross Profit", "shortName": "Segment Reporting (Details) - Schedule of Segment Performance to the GAAP Measure of Gross Profit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:GainLossOnSalesOfLoansNet", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c217", "name": "us-gaap:OtherCostAndExpenseOperating", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R51": { "role": "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "longName": "996031 - Disclosure - Segment Reporting (Details) - Schedule of Net Sales and Property and Equipment", "shortName": "Segment Reporting (Details) - Schedule of Net Sales and Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": null }, "R52": { "role": "http://nutriband.com/role/CommitmentsandContigenciesDetails", "longName": "996032 - Disclosure - Commitments and Contigencies (Details)", "shortName": "Commitments and Contigencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R53": { "role": "http://nutriband.com/role/SubsequentEventsDetails", "longName": "996033 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c245", "name": "us-gaap:ProceedsFromInterestReceived", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c245", "name": "us-gaap:ProceedsFromInterestReceived", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R54": { "role": "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable0", "longName": "996034 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Disaggregates its Revenue from Contracts", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Disaggregates its Revenue from Contracts", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c263", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R55": { "role": "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable0", "longName": "996035 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographic Location", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographic Location", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": null }, "R56": { "role": "http://nutriband.com/role/ScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable", "longName": "996036 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on Straight-Line Basis Over Estimated Useful Life of Assets", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on Straight-Line Basis Over Estimated Useful Life of Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c273", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c271", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R57": { "role": "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0", "longName": "996037 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment", "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": null }, "R58": { "role": "http://nutriband.com/role/ScheduleofIntangibleAssetsTable0", "longName": "996038 - Disclosure - Intangible Assets (Details) - Schedule of Intangible Assets", "shortName": "Intangible Assets (Details) - Schedule of Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": null }, "R59": { "role": "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0", "longName": "996039 - Disclosure - Intangible Assets (Details) - Schedule of Amortization Expenses", "shortName": "Intangible Assets (Details) - Schedule of Amortization Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IntangibleAssetsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://nutriband.com/role/ScheduleofWarrantsExercisableTable", "longName": "996040 - Disclosure - Options and Warrants (Details) - Schedule of Warrants Exercisable", "shortName": "Options and Warrants (Details) - Schedule of Warrants Exercisable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c173", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ntrb:OptionsAndWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c113", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ntrb:OptionsAndWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R61": { "role": "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable", "longName": "996041 - Disclosure - Options and Warrants (Details) - Schedule of Additional Information Relating to the Warrants Outstanding", "shortName": "Options and Warrants (Details) - Schedule of Additional Information Relating to the Warrants Outstanding", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c317", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ntrb:OptionsAndWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c317", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ntrb:OptionsAndWarrantsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R62": { "role": "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "longName": "996042 - Disclosure - Options and Warrants (Details) - Schedule of Changes in Options Outstanding", "shortName": "Options and Warrants (Details) - Schedule of Changes in Options Outstanding", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c328", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": { "contextRef": "c326", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "unique": true } }, "R63": { "role": "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "longName": "996043 - Disclosure - Options and Warrants (Details) - Schedule of Additional Information Relating to the Options Outstanding", "shortName": "Options and Warrants (Details) - Schedule of Additional Information Relating to the Options Outstanding", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c331", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c331", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true, "unique": true } }, "R64": { "role": "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0", "longName": "996044 - Disclosure - Segment Reporting (Details) - Schedule of Segment Performance to the GAAP Measure of Gross Profit", "shortName": "Segment Reporting (Details) - Schedule of Segment Performance to the GAAP Measure of Gross Profit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:GainLossOnSalesOfLoansNet", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": null }, "R65": { "role": "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0", "longName": "996045 - Disclosure - Segment Reporting (Details) - Schedule of Net Sales and Property and Equipment", "shortName": "Segment Reporting (Details) - Schedule of Net Sales and Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0205970-posama4_nutri.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": [ "r76", "r82" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r64", "r65" ] }, "us-gaap_AccountsReceivableFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableFairValueDisclosure", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Account receivable", "label": "Accounts Receivable, Fair Value Disclosure", "documentation": "Fair value portion of amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties." } } }, "auth_ref": [ "r521" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable [Member]", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r773" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r923" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r13", "r14", "r83", "r210", "r612", "r649", "r653" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income(Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r7", "r14", "r510", "r513", "r543", "r644", "r645", "r893", "r894", "r895", "r907", "r908", "r909", "r912" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in-capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r77", "r835", "r1027" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r669", "r907", "r908", "r909", "r912", "r960", "r1028" ] }, "ntrb_AdditionalSharesReserved": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "AdditionalSharesReserved", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional share (in Shares)", "documentation": "Number of additional shares reserved.", "label": "Additional Shares Reserved" } } }, "auth_ref": [] }, "us-gaap_AdjustmentOfWarrantsGrantedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentOfWarrantsGrantedForServices", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants issued for services", "label": "Adjustment of Warrants Granted for Services", "documentation": "Adjustment for noncash service expenses paid for by granting of warrants." } } }, "auth_ref": [ "r5" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Options issued for services", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration." } } }, "auth_ref": [ "r8", "r115" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ntrb_AdoptionofOperatingLeaseAssetandLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "AdoptionofOperatingLeaseAssetandLiability", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption of ASC 842 Operating lease asset and liability", "documentation": "Amount to adoption of operating lease asset and liability.", "label": "Adoptionof Operating Lease Assetand Liability" } } }, "auth_ref": [] }, "us-gaap_AdvanceRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdvanceRent", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Received advances", "label": "Advance Rent", "documentation": "Amount at the balance sheet date that has been received by the entity that represents rents paid in advance." } } }, "auth_ref": [] }, "ntrb_AdvancesAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "AdvancesAmount", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advances amount", "documentation": "Advances amount.", "label": "Advances Amount" } } }, "auth_ref": [] }, "ntrb_AgreedToAnnualSalary": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "AgreedToAnnualSalary", "crdr": "credit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreed to annual salary", "documentation": "The amount of agreed to annual salary.", "label": "Agreed To Annual Salary" } } }, "auth_ref": [] }, "ntrb_AgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "AgreementMember", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement [Member]", "label": "Agreement Member" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non cash compensation (in Dollars)", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r465", "r470" ] }, "us-gaap_AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables", "crdr": "credit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bad debt expenses", "label": "Allowance for Doubtful Accounts, Premiums and Other Receivables", "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet." } } }, "auth_ref": [ "r925" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://nutriband.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Description", "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://nutriband.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expenses", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r5", "r334", "r341", "r813" ] }, "ntrb_AssetDepreciatedRange": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "AssetDepreciatedRange", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset depreciated range", "documentation": "Asset depreciated range.", "label": "Asset Depreciated Range" } } }, "auth_ref": [] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible impairment expense", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r5", "r32" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r132", "r146", "r204", "r232", "r264", "r272", "r291", "r295", "r308", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r505", "r507", "r522", "r605", "r713", "r806", "r807", "r835", "r868", "r946", "r947", "r981" ] }, "ntrb_AssetsAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "AssetsAbstract0", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets Abstract0" } } }, "auth_ref": [] }, "ntrb_AssetsAbstract1": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "AssetsAbstract1", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets Abstract1" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r196", "r214", "r232", "r308", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r505", "r507", "r522", "r835", "r946", "r947", "r981" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT ASSETS:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r436", "r437", "r438", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r460", "r461", "r462", "r463", "r464" ] }, "ntrb_BadDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "BadDebt", "crdr": "credit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bad debt expense", "documentation": "Amount of bad debt.", "label": "Bad Debt" } } }, "auth_ref": [] }, "ntrb_BalanceSharesIssuanceOfOptions": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "BalanceSharesIssuanceOfOptions", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares remain for issuance of options (in Shares)", "documentation": "Represent the share value of balance shares issuance of options.", "label": "Balance Shares Issuance Of Options" } } }, "auth_ref": [] }, "ntrb_BlackScholesMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "BlackScholesMember", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Black-Scholes [Member]", "label": "Black Scholes Member" } } }, "auth_ref": [] }, "ntrb_BoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "BoardOfDirectorsMember", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board of Directors [Member]", "label": "Board Of Directors Member" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails", "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r335", "r336", "r337", "r338", "r339", "r502", "r823", "r824" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails", "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r49", "r51", "r335", "r336", "r337", "r338", "r339", "r502", "r823", "r824" ] }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "crdr": "debit", "presentation": [ "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired costs", "label": "Business Acquisition, Transaction Costs", "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired percentage", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r50" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r122", "r123", "r124", "r125" ] }, "ntrb_CancelledShares": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "CancelledShares", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cancelled shares", "documentation": "Number of share cancelled.", "label": "Cancelled Shares" } } }, "auth_ref": [] }, "ntrb_CarolinaSmallBusinessDevelopmentFundMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "CarolinaSmallBusinessDevelopmentFundMember", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Carolina Small Business Development Fund [Member]", "label": "Carolina Small Business Development Fund Member" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Cash", "crdr": "debit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r148", "r609", "r681", "r707", "r835", "r868", "r884" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r16", "r199", "r791" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r17" ] }, "us-gaap_CashAndDueFromBanks": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndDueFromBanks", "crdr": "debit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due amount", "label": "Cash and Due from Banks", "documentation": "For banks and other depository institutions: Includes cash on hand (currency and coin), cash items in process of collection, noninterest bearing deposits due from other financial institutions (including corporate credit unions), and noninterest bearing balances with the Federal Reserve Banks, Federal Home Loan Banks and central banks." } } }, "auth_ref": [ "r130" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents - Beginning of period", "periodEndLabel": "Cash and cash equivalents - End of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r16", "r98", "r228" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net change in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r98" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash federally insured amount", "label": "Cash, FDIC Insured Amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "ntrb_CashPaidForAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "CashPaidForAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for:", "label": "Cash Paid For Abstract" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails", "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CEO [Member]", "verboseLabel": "Executive Officers [Member]", "netLabel": "Chief Executive Officer [Member]", "label": "Chief Executive Officer [Member]", "documentation": "Person with designation of chief executive officer." } } }, "auth_ref": [ "r922" ] }, "srt_ChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefFinancialOfficerMember", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Chief Financial Officer [Member]", "label": "Chief Financial Officer [Member]", "documentation": "Person with designation of chief financial officer." } } }, "auth_ref": [ "r922" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r162", "r207", "r208", "r209", "r232", "r256", "r257", "r259", "r261", "r266", "r267", "r308", "r365", "r367", "r368", "r369", "r372", "r373", "r402", "r403", "r406", "r409", "r415", "r522", "r660", "r661", "r662", "r663", "r669", "r670", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r682", "r699", "r722", "r742", "r766", "r767", "r768", "r769", "r770", "r871", "r903", "r913" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price per share (in Dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r416" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Changes in Warrants Outstanding [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r42" ] }, "us-gaap_ClassOfWarrantOrRightUnissued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightUnissued", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant to purchase shares", "label": "Class of Warrant or Right, Unissued", "documentation": "The number of warrants or rights which entitle the entity to receive future services in exchange for the unvested, forfeitable warrants or rights." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r71", "r137", "r608", "r698" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contigencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://nutriband.com/role/CommitmentsandContigencies" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTIGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r110", "r357", "r358", "r774", "r938", "r943" ] }, "ntrb_CommitmentsandContigenciesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "CommitmentsandContigenciesDetailsLineItems", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "label": "Commitments and Contigencies [Line Items]" } } }, "auth_ref": [] }, "ntrb_CommitmentsandContigenciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "CommitmentsandContigenciesDetailsTable", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "label": "Commitments and Contigencies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_CommonStockConvertibleConversionPriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockConvertibleConversionPriceIncrease", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price per share (in Dollars per share)", "label": "Common Stock, Convertible, Conversion Price, Increase", "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r416" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/ShareholdersEquityType2or3", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r858", "r859", "r860", "r862", "r863", "r864", "r865", "r907", "r908", "r912", "r960", "r1025", "r1028" ] }, "us-gaap_CommonStockOtherSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockOtherSharesOutstanding", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock equivalents outstanding (in Shares)", "label": "Common Stock, Other Shares, Outstanding", "documentation": "Number of shares of other common stock instruments held by shareholder, including, but not limited to, exchangeable shares." } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "verboseLabel": "Per shares of common stock (in Dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r75" ] }, "ntrb_CommonStockReserved": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "CommonStockReserved", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock reserved (in Shares)", "documentation": "Common stock reserved.", "label": "Common Stock Reserved" } } }, "auth_ref": [] }, "ntrb_CommonStockReturnedInSettlementinShares": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "CommonStockReturnedInSettlementinShares", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock returned in settlement (in Shares)", "documentation": "Common stock returned in settlement.", "label": "Common Stock Returned In Settlementin Shares" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "verboseLabel": "Common stock (in Shares)", "netLabel": "Common shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r75", "r699" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock share (in Shares)", "netLabel": "Common stock shares", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r75" ] }, "ntrb_CommonStockSharesIssuedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "CommonStockSharesIssuedWarrants", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued warrants (in Shares)", "documentation": "Represent the share of common stock shares issued warrants.", "label": "Common Stock Shares Issued Warrants" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "verboseLabel": "Share per unit", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r8", "r75", "r699", "r719", "r1028", "r1029" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet", "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, value", "verboseLabel": "Common stock value", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r75", "r611", "r835" ] }, "us-gaap_CommonUnitIssuanceValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonUnitIssuanceValue", "crdr": "credit", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance (in Dollars)", "label": "Common Unit, Issuance Value", "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC)." } } }, "auth_ref": [] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r53", "r795" ] }, "ntrb_ContractLiabilitiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ContractLiabilitiesPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Liabilities", "documentation": "Accounting policy for contract liability.", "label": "Contract Liabilities Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r418", "r419", "r430" ] }, "us-gaap_ConversionOfStockAmountIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockAmountIssued1", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock returned in settlement", "label": "Conversion of Stock, Amount Issued", "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r19", "r20", "r21" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Converted shares", "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r19", "r20", "r21" ] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes payable current", "label": "Convertible Notes Payable, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r65" ] }, "us-gaap_CorporateAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateAndOtherMember", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative-Corporate [Member]", "verboseLabel": "Corporate [Member]", "label": "Corporate Segment and Other Operating Segment [Member]", "documentation": "Component of entity providing financial and operational oversight and administrative support considered to be operating segment and operating segment, classified as other. Excludes intersegment elimination and reconciling item." } } }, "auth_ref": [ "r915" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of goods", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r86", "r87", "r563" ] }, "us-gaap_CostOfGoodsAndServicesSoldDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSoldDepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and Amortization", "label": "Cost, Depreciation and Amortization", "documentation": "Amount of expense for allocation of cost of tangible and intangible assets over their useful lives directly used in production of good and rendering of service." } } }, "auth_ref": [ "r896" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenues", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r88", "r232", "r308", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r522", "r806", "r946" ] }, "us-gaap_CostOfServicesCatering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfServicesCatering", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Services", "label": "Cost of Services, Catering", "documentation": "Cost of food and beverage catering for passengers." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total Costs and Expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r95" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "ntrb_CurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "CurrentAbstract", "presentation": [ "http://nutriband.com/role/ScheduleofProvisionforIncomeTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current Abstract" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofProvisionforIncomeTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r879", "r906", "r959" ] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofProvisionforIncomeTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r879", "r906" ] }, "ntrb_DateDoAdoption": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "DateDoAdoption", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date of adoption", "documentation": "Date of adoption.", "label": "Date Do Adoption" } } }, "auth_ref": [] }, "ntrb_DateOfIssuance": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "DateOfIssuance", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expire years", "documentation": "Date of issuance.", "label": "Date Of Issuance" } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for extinguishment of debt", "label": "Debt Conversion, Converted Instrument, Amount", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r19", "r21" ] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtCurrent", "crdr": "credit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt amount", "label": "Debt, Current", "documentation": "Amount of debt and lease obligation, classified as current." } } }, "auth_ref": [ "r205" ] }, "us-gaap_DebtDefaultLongtermDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDefaultLongtermDebtAmount", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assumed amount", "label": "Debt Instrument, Debt Default, Amount", "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured." } } }, "auth_ref": [ "r230" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://nutriband.com/role/NotesPayable" ], "lang": { "en-us": { "role": { "terseLabel": "NOTES PAYABLE", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r111", "r230", "r350", "r351", "r352", "r353", "r354", "r363", "r364", "r374", "r380", "r381", "r382", "r383", "r384", "r385", "r390", "r397", "r398", "r399", "r531" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails", "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r12", "r64", "r65", "r133", "r136", "r236", "r375", "r376", "r377", "r378", "r379", "r381", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r814", "r815", "r816", "r817", "r818", "r833", "r904", "r939", "r940", "r941", "r974", "r975" ] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bad debt expense", "label": "Debt Instrument, Fee Amount", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": [ "r68" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity date", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r206", "r814", "r963", "r964" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails", "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r12", "r236", "r375", "r376", "r377", "r378", "r379", "r381", "r386", "r387", "r388", "r389", "r391", "r392", "r393", "r394", "r395", "r396", "r814", "r815", "r816", "r817", "r818", "r833", "r904", "r939", "r940", "r941", "r974", "r975" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal interest", "label": "Debt Instrument, Periodic Payment", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r12", "r59" ] }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentInterest", "crdr": "debit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments of principal interest", "label": "Debt Instrument, Periodic Payment, Interest", "documentation": "Amount of the required periodic payments applied to interest." } } }, "auth_ref": [ "r12" ] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Periodic Payment, Principal", "label": "Debt Instrument, Periodic Payment, Principal", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": [ "r12" ] }, "ntrb_DeferredAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "DeferredAbstract", "presentation": [ "http://nutriband.com/role/ScheduleofProvisionforIncomeTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred", "label": "Deferred Abstract" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense", "crdr": "debit", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation expense", "label": "Deferred Compensation Arrangement with Individual, Compensation Expense", "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement." } } }, "auth_ref": [ "r43", "r117" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofProvisionforIncomeTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r906", "r958", "r959" ] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofProvisionforIncomeTaxesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r906", "r958" ] }, "us-gaap_DeferredRevenueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Disaggregates its Revenue from Contracts [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net deferred taxes", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r953" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Net operating loss carryforward", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r956" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "crdr": "debit", "presentation": [ "http://nutriband.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax asset", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates." } } }, "auth_ref": [ "r956" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r486" ] }, "us-gaap_DepositAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositAssets", "crdr": "debit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advance deposit", "label": "Deposit Assets", "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement." } } }, "auth_ref": [ "r885" ] }, "us-gaap_DepositLiabilitiesAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepositLiabilitiesAccruedInterest", "crdr": "credit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Deposit Liabilities, Accrued Interest", "documentation": "Amount of accrued but unpaid interest on deposit liabilities." } } }, "auth_ref": [ "r134" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://nutriband.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r33" ] }, "ntrb_DepreciationAndAmortizationAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "DepreciationAndAmortizationAbstract0", "presentation": [ "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and Amortization", "label": "Depreciation And Amortization Abstract0" } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r5", "r264", "r277", "r295", "r806", "r807" ] }, "us-gaap_DerivativeCashReceivedOnHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeCashReceivedOnHedge", "crdr": "credit", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received", "label": "Derivative, Cash Received on Hedge", "documentation": "The amount of cash received during the period on settlement of a hedge." } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r687", "r690", "r704", "r705", "r706", "r708", "r709", "r710", "r711", "r714", "r715", "r716", "r717", "r730", "r731", "r732", "r733", "r736", "r737", "r738", "r739", "r759", "r760", "r761", "r762", "r858", "r860", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r54", "r55", "r56", "r127", "r687", "r690", "r704", "r705", "r706", "r708", "r709", "r710", "r711", "r714", "r715", "r716", "r717", "r730", "r731", "r732", "r733", "r736", "r737", "r738", "r739", "r759", "r760", "r761", "r762", "r794", "r858", "r860", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972" ] }, "ntrb_DesignatedSharesOfPreferredStocks": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "DesignatedSharesOfPreferredStocks", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares designated", "documentation": "Designated shares to be issued.", "label": "Designated Shares Of Preferred Stocks" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Director [Member]", "label": "Director [Member]", "documentation": "Person serving on board of directors." } } }, "auth_ref": [ "r882", "r922", "r1026" ] }, "ntrb_DisaggregationOfRevenuesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nutriband.com/20240430", "localname": "DisaggregationOfRevenuesPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenues", "documentation": "The entire disclosure of disaggregation of revenues.", "label": "Disaggregation Of Revenues Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Gross profit", "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r61", "r195" ] }, "ntrb_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "DocumentAndEntityInformationAbstract", "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://nutriband.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [ "http://nutriband.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://nutriband.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ntrb_DueBalanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "DueBalanceAmount", "crdr": "debit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance due", "documentation": "The amount of due balance.", "label": "Due Balance Amount" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share of common stock-basic (in Dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r222", "r242", "r243", "r245", "r246", "r247", "r249", "r254", "r256", "r259", "r260", "r261", "r263", "r500", "r504", "r518", "r519", "r599", "r621", "r799" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share of common stock- diluted", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r222", "r242", "r243", "r245", "r246", "r247", "r249", "r256", "r259", "r260", "r261", "r263", "r500", "r504", "r518", "r519", "r599", "r621", "r799" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per Share", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r22", "r23", "r262" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://nutriband.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of corporate rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r478", "r827" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Options [Member]", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "ntrb_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "EmployeesMember", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employees [Member]", "label": "Employees Member" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://nutriband.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r869" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://nutriband.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r869" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://nutriband.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r870" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://nutriband.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r869" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://nutriband.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://nutriband.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r869" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://nutriband.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r869" ] }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EntityWideRevenueMajorCustomerLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable0" ], "lang": { "en-us": { "role": { "label": "Revenue, Major Customer [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": [ "http://nutriband.com/role/ScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Lab Equipment [Member]", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/ShareholdersEquityType2or3", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r8", "r192", "r218", "r219", "r220", "r237", "r238", "r239", "r241", "r247", "r250", "r252", "r265", "r309", "r312", "r348", "r417", "r490", "r491", "r497", "r498", "r499", "r501", "r503", "r504", "r509", "r510", "r511", "r512", "r513", "r514", "r517", "r523", "r524", "r525", "r526", "r527", "r528", "r533", "r535", "r543", "r620", "r644", "r645", "r646", "r669", "r742" ] }, "us-gaap_EquityMethodInvestmentSoldCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentSoldCarryingAmount", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity financing (in Dollars)", "label": "Equity Method Investment, Amount Sold", "documentation": "Amount of the entity's equity method investment which has been sold." } } }, "auth_ref": [] }, "ntrb_EstimatedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "EstimatedCost", "crdr": "debit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated cost", "documentation": "Estimated cost is the projection of the amount of costs that will be incurred to build a product or construct something.", "label": "Estimated Cost" } } }, "auth_ref": [] }, "ntrb_EstimatedUsefulLive": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "EstimatedUsefulLive", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated useful lives", "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Estimated Useful Live" } } }, "auth_ref": [] }, "ntrb_EuropeanInvestorsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "EuropeanInvestorsMember", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "European Investors [Member]", "label": "European Investors Member" } } }, "auth_ref": [] }, "us-gaap_ExcessStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExcessStockSharesAuthorized", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized shares (in Shares)", "label": "Excess Stock, Shares Authorized", "documentation": "Maximum number of excess stock shares permitted to be issued." } } }, "auth_ref": [] }, "us-gaap_ExcessStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ExcessStockSharesIssued", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued shares (in Shares)", "verboseLabel": "Purchase an additional shares", "label": "Excess Stock, Shares Issued", "documentation": "Number of excess stock shares of an entity that have been sold or granted to shareholders." } } }, "auth_ref": [] }, "srt_ExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ExecutiveOfficerMember", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Executives [Member]", "verboseLabel": "Executive Officer [Member]", "label": "Executive Officer [Member]", "documentation": "Person with designation of executive officer." } } }, "auth_ref": [ "r922" ] }, "ntrb_ExercisePriceOutstanding": { "xbrltype": "perShareItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePriceOutstanding", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Exercise Price, Outstanding, Beginning balance", "periodEndLabel": "Exercise Price, Outstanding, Ending balance", "documentation": "Exercise Price, Outstanding.", "label": "Exercise Price Outstanding" } } }, "auth_ref": [] }, "ntrb_ExercisePricesEightMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePricesEightMember", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Prices 4.12 [Member]", "verboseLabel": "Exercise Prices 3.98 [Member]", "label": "Exercise Prices Eight Member" } } }, "auth_ref": [] }, "ntrb_ExercisePricesElevenMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePricesElevenMember", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Prices 4.58 [Member]", "verboseLabel": "Exercise Prices 4.16 [Member]", "label": "Exercise Prices Eleven Member" } } }, "auth_ref": [] }, "ntrb_ExercisePricesFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePricesFiveMember", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Prices 3.75 [Member]", "verboseLabel": "Exercise Prices 2.65 [Member]", "label": "Exercise Prices Five Member" } } }, "auth_ref": [] }, "ntrb_ExercisePricesFourMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePricesFourMember", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Prices 7.50 [Member]", "verboseLabel": "Exercise Prices 3.59 [Member]", "netLabel": "Exercise Prices 2.61 [Member]", "label": "Exercise Prices Four Member" } } }, "auth_ref": [] }, "ntrb_ExercisePricesNineMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePricesNineMember", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Prices 4.16 [Member]", "verboseLabel": "Exercise Prices 4.09 [Member]", "label": "Exercise Prices Nine Member" } } }, "auth_ref": [] }, "ntrb_ExercisePricesOneMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePricesOneMember", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Prices 4.00 [Member]", "verboseLabel": "Exercise Prices 1.93 [Member]", "label": "Exercise Prices One Member" } } }, "auth_ref": [] }, "ntrb_ExercisePricesSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePricesSevenMember", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Prices 4.09 [Member]", "verboseLabel": "Exercise Prices 3.75 [Member]", "label": "Exercise Prices Seven Member" } } }, "auth_ref": [] }, "ntrb_ExercisePricesSixMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePricesSixMember", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Prices 3.98 [Member]", "verboseLabel": "Exercise Prices 3.59 [Member]", "label": "Exercise Prices Six Member" } } }, "auth_ref": [] }, "ntrb_ExercisePricesTenMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePricesTenMember", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Prices 4.50 [Member]", "verboseLabel": "Exercise Prices 4.12 [Member]", "label": "Exercise Prices Ten Member" } } }, "auth_ref": [] }, "ntrb_ExercisePricesThirteenMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePricesThirteenMember", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Prices 4.58 [Member]", "label": "Exercise Prices Thirteen Member" } } }, "auth_ref": [] }, "ntrb_ExercisePricesThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePricesThreeMember", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Prices 1.93 [Member]", "verboseLabel": "Exercise Prices 2.65 [Member]", "netLabel": "Exercise Prices 2.37 [Member]", "label": "Exercise Prices Three Member" } } }, "auth_ref": [] }, "ntrb_ExercisePricesTwelveMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePricesTwelveMember", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Prices 4.50 [Member]", "label": "Exercise Prices Twelve Member" } } }, "auth_ref": [] }, "ntrb_ExercisePricesTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExercisePricesTwoMember", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Prices 6.43 [Member]", "verboseLabel": "Exercise Prices 2.12 [Member]", "label": "Exercise Prices Two Member" } } }, "auth_ref": [] }, "ntrb_ExpireYear": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ExpireYear", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expire year", "documentation": "The expire year of issuance of vest.", "label": "Expire Year" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "ntrb_FairValueOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "FairValueOfCommonStock", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of common stock", "label": "Fair Value Of Common Stock" } } }, "auth_ref": [] }, "us-gaap_FairValueOptionIneligibleItemsAggregateCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueOptionIneligibleItemsAggregateCarryingAmount", "crdr": "debit", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options issued for service (in Dollars)", "label": "Fair Value, Option, Ineligible Items, Carrying Amount", "documentation": "Carrying amount of items included in each line item in the statement of financial position that are not eligible for the fair value option." } } }, "auth_ref": [ "r57" ] }, "ntrb_FairValueOptionsServiceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "FairValueOptionsServiceAmount", "crdr": "debit", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options issued (in Dollars)", "documentation": "The amount of Fair value Options Service amount.", "label": "Fair Value Options Service Amount" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://nutriband.com/role/ScheduleofIntangibleAssetsTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 }, "http://nutriband.com/role/ScheduleofIntangibleAssetsTable0": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ScheduleofIntangibleAssetsTable", "http://nutriband.com/role/ScheduleofIntangibleAssetsTable0" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r202", "r319", "r340", "r813" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nutriband.com/role/ScheduleofAmortizationExpensesTable", "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0" ], "lang": { "en-us": { "role": { "terseLabel": "2030 and thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r934", "r1034" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ScheduleofAmortizationExpensesTable", "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r342", "r787", "r813" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nutriband.com/role/ScheduleofAmortizationExpensesTable", "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r342", "r787", "r813" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nutriband.com/role/ScheduleofAmortizationExpensesTable", "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r342", "r787", "r813" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nutriband.com/role/ScheduleofAmortizationExpensesTable", "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r342", "r787", "r813" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ScheduleofAmortizationExpensesTable", "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r342", "r787", "r813" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://nutriband.com/role/ScheduleofIntangibleAssetsTable", "http://nutriband.com/role/ScheduleofIntangibleAssetsTable0" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r333", "r335", "r336", "r337", "r339", "r340", "r343", "r344", "r564", "r565", "r787" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://nutriband.com/role/ScheduleofIntangibleAssetsTable": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 }, "http://nutriband.com/role/ScheduleofIntangibleAssetsTable0": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ScheduleofIntangibleAssetsTable", "http://nutriband.com/role/ScheduleofIntangibleAssetsTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r319", "r340", "r565", "r813" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://nutriband.com/role/ScheduleofIntangibleAssetsTable", "http://nutriband.com/role/ScheduleofIntangibleAssetsTable0" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r333", "r335", "r336", "r337", "r339", "r340", "r343", "r344", "r787" ] }, "us-gaap_FiniteLivedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMember", "presentation": [ "http://nutriband.com/role/ScheduleofIntangibleAssetsTable", "http://nutriband.com/role/ScheduleofIntangibleAssetsTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Customer base [Member]", "label": "Finite-Lived Intangible Assets [Member]", "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://nutriband.com/role/ScheduleofIntangibleAssetsTable": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://nutriband.com/role/ScheduleofIntangibleAssetsTable0": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nutriband.com/role/ScheduleofAmortizationExpensesTable", "http://nutriband.com/role/ScheduleofAmortizationExpensesTable0", "http://nutriband.com/role/ScheduleofIntangibleAssetsTable", "http://nutriband.com/role/ScheduleofIntangibleAssetsTable0" ], "lang": { "en-us": { "role": { "totalLabel": "Net Intangible Assets", "terseLabel": "Total", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r564", "r933" ] }, "ntrb_ForwardStockSplitPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ForwardStockSplitPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Forward Stock Split", "documentation": "The entire disclosure of forward stock split.", "label": "Forward Stock Split Policy Text Block" } } }, "auth_ref": [] }, "ntrb_FourPTherapeuticsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "FourPTherapeuticsLLCMember", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4P Therapeutics LLC [Member]", "label": "Four PTherapeutics LLCMember" } } }, "auth_ref": [] }, "ntrb_FourPTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "FourPTherapeuticsMember", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "terseLabel": "4P Therapeutics [Member]", "verboseLabel": "Selling, general and administrative-4P Therapeutics [Member]", "label": "Four PTherapeutics Member" } } }, "auth_ref": [] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://nutriband.com/role/ScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable", "http://nutriband.com/role/ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Furniture and fixtures [Member]", "label": "Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_GainLossOnSalesOfLoansNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSalesOfLoansNet", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Gain (Loss) on Sales of Loans, Net", "documentation": "The net gain (loss) resulting from a sale of loans, including adjustments to record loans classified as held-for-sale at the lower-of-cost-or-market and fair value adjustments to loan held for investment purposes." } } }, "auth_ref": [ "r5", "r139" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 }, "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow", "http://nutriband.com/role/ConsolidatedIncomeStatement", "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on extinguishment of debt", "negatedLabel": "Loss on extinguishment of debt", "verboseLabel": "Loss on extinguishment", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r5", "r36", "r37" ] }, "ntrb_GoingConcernPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nutriband.com/20240430", "localname": "GoingConcernPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Going Concern Assessment", "documentation": "The disclosure of accounting policy for Going Concern.", "label": "Going Concern Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r201", "r320", "r598", "r807", "r812", "r828", "r835", "r930", "r931" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r929", "r932" ] }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "crdr": "credit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment goodwill", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r323", "r330", "r812" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 }, "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow", "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill impairment", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r5", "r321", "r327", "r331", "r812", "r828" ] }, "ntrb_GoodwillImpairmentPoconoPharmacueticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "GoodwillImpairmentPoconoPharmacueticalsMember", "presentation": [ "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill impairment-Pocono Pharmacueticals [Member]", "label": "Goodwill Impairment Pocono Pharmacueticals Member" } } }, "auth_ref": [] }, "us-gaap_GoodwillOtherIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillOtherIncreaseDecrease", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill amounted", "label": "Goodwill, Other Increase (Decrease)", "documentation": "Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other." } } }, "auth_ref": [ "r329" ] }, "ntrb_GoodwillValue": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "GoodwillValue", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "documentation": "Goodwill value.", "label": "Goodwill Value" } } }, "auth_ref": [] }, "ntrb_GrossProfitAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "GrossProfitAbstract0", "presentation": [ "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Gross profit", "label": "Gross Profit Abstract0" } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IPO [Member]", "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Long-lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r109" ] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ScheduleofReconciliationofTaxesonIncomeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Book Income (loss from operations)", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r52", "r85", "r102", "r242", "r243", "r245", "r246", "r247", "r258", "r261", "r504" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r84", "r140", "r145", "r600", "r618", "r801", "r806", "r914", "r917", "r918", "r919", "r920" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://nutriband.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r233", "r474", "r478", "r481", "r482", "r483", "r484", "r488", "r492", "r494", "r495", "r496", "r665", "r827" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement", "http://nutriband.com/role/ScheduleofReconciliationofTaxesonIncomeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for income taxes", "verboseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r147", "r159", "r251", "r252", "r264", "r280", "r295", "r477", "r478", "r493", "r623", "r827" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r217", "r475", "r476", "r484", "r485", "r487", "r489", "r659" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "presentation": [ "http://nutriband.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax effect valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r480", "r827", "r951" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofReconciliationofTaxesonIncomeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment expense", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss." } } }, "auth_ref": [ "r827", "r951", "r952" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseOther", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofReconciliationofTaxesonIncomeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Unused operating losses", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses." } } }, "auth_ref": [ "r827", "r951", "r952" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofReconciliationofTaxesonIncomeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued for services", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount", "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": [ "r827", "r951", "r952" ] }, "ntrb_IncomeTaxesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "IncomeTaxesDetailsLineItems", "presentation": [ "http://nutriband.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Taxes [Line Items]" } } }, "auth_ref": [] }, "ntrb_IncomeTaxesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "IncomeTaxesDetailsTable", "presentation": [ "http://nutriband.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Income Taxes (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r18", "r101", "r902", "r954", "r955" ] }, "us-gaap_IncomeTaxesPaidNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNetAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r558", "r900" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r875", "r900" ] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "ntrb_IncreaseDecreasedInAuthorizedCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "IncreaseDecreasedInAuthorizedCommonStock", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase decreased in authorized common stock", "documentation": "Increase decreased in authorized common stock.", "label": "Increase Decreased In Authorized Common Stock" } } }, "auth_ref": [] }, "ntrb_IndependentDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "IndependentDirectorsMember", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Independent Directors [Member]", "label": "Independent Directors Member" } } }, "auth_ref": [] }, "ntrb_IntangibleAssetsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "IntangibleAssetsDetailsLineItems", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Assets [Line Items]" } } }, "auth_ref": [] }, "ntrb_IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "IntangibleAssetsDetailsScheduleofIntangibleAssetsLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofIntangibleAssetsTable", "http://nutriband.com/role/ScheduleofIntangibleAssetsTable0" ], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets [Line items]" } } }, "auth_ref": [] }, "ntrb_IntangibleAssetsDetailsScheduleofIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "IntangibleAssetsDetailsScheduleofIntangibleAssetsTable", "presentation": [ "http://nutriband.com/role/ScheduleofIntangibleAssetsTable", "http://nutriband.com/role/ScheduleofIntangibleAssetsTable0" ], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) - Schedule of Intangible Assets [Table]" } } }, "auth_ref": [] }, "ntrb_IntangibleAssetsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "IntangibleAssetsDetailsTable", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible Assets (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://nutriband.com/role/IntangibleAssets" ], "lang": { "en-us": { "role": { "terseLabel": "INTANGIBLE ASSETS", "label": "Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r332", "r345", "r347", "r786", "r787" ] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r560", "r561", "r562", "r564", "r796", "r932" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets-net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r333", "r933", "r935" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwillAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets [Abstract]" } } }, "auth_ref": [] }, "ntrb_IntelligenceLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "IntelligenceLLCMember", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intelligence LLC [Member]", "label": "Intelligence LLCMember" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r264", "r272", "r276", "r282", "r295", "r530", "r806", "r807" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r93", "r394", "r400", "r817", "r818" ] }, "us-gaap_InterestExpenseDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDeposits", "crdr": "debit", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Deposits", "documentation": "Aggregate amount of interest expense on all deposits." } } }, "auth_ref": [ "r142" ] }, "us-gaap_InterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeOther", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income, Other", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r224", "r226", "r227" ] }, "ntrb_IntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "IntrinsicValue", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic Value (in Dollars)", "documentation": "The amount of measures the value of an investment based on its cash flows.", "label": "Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_InventoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoriesMember", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories [Member]", "label": "Inventories [Member]", "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale." } } }, "auth_ref": [] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Gross", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r889" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "verboseLabel": "Total inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r212", "r792", "r835" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r149", "r198", "r211", "r314", "r315", "r316", "r559", "r797" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterials", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Gross", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r891" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work in process", "label": "Inventory, Work in Process, Gross", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r890" ] }, "us-gaap_InvestmentCompanyCommittedCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentCompanyCommittedCapital", "crdr": "credit", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "IP license fee", "label": "Investment Company, Committed Capital", "documentation": "Amount of funds committed to investment company from investors." } } }, "auth_ref": [ "r671" ] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentOwnedBalanceShares", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining shares (in Shares)", "label": "Investment Owned, Balance, Shares", "documentation": "Number of shares of investment owned." } } }, "auth_ref": [ "r683", "r688", "r751", "r757", "r764", "r860" ] }, "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Invested amount", "label": "Investments", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } }, "auth_ref": [ "r602", "r603", "r855", "r857" ] }, "ntrb_IssuanceOfCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "IssuanceOfCommonStock", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock", "documentation": "Number of shares issued issuance of common stock.", "label": "Issuance Of Common Stock" } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock issued for services", "label": "Issuance of Stock and Warrants for Services or Claims", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r5" ] }, "ntrb_LabEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "LabEquipmentMember", "presentation": [ "http://nutriband.com/role/ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Lab Equipment [Member]", "verboseLabel": "Lab equipment [Member]", "label": "Lab Equipment Member" } } }, "auth_ref": [] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalFees", "crdr": "debit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "legal fees", "label": "Legal Fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r880" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r538" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease rental", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r540" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r12", "r64", "r65", "r66", "r69", "r70", "r71", "r72", "r232", "r308", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r506", "r507", "r508", "r522", "r697", "r800", "r868", "r946", "r981", "r982" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r81", "r138", "r614", "r835", "r905", "r926", "r973" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r66", "r197", "r232", "r308", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r506", "r507", "r508", "r522", "r835", "r946", "r981", "r982" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT LIABILITIES:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "LONG-TERM LIABILITIES:", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1", "crdr": "debit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Incurred expenses", "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims", "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process." } } }, "auth_ref": [ "r849", "r995" ] }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Draw down on credit line", "verboseLabel": "Contract Price", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r12", "r136", "r992" ] }, "ntrb_LineOfCreditFacility": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "LineOfCreditFacility", "crdr": "debit", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility", "documentation": "Line of credit facility.", "label": "Line Of Credit Facility" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAverageOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityAverageOutstandingAmount", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount due", "label": "Line of Credit Facility, Average Outstanding Amount", "documentation": "Average amount borrowed under the credit facility during the period." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCapacityAvailableForTradePurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCapacityAvailableForTradePurchases", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility", "label": "Line of Credit Facility, Capacity Available for Trade Purchases", "documentation": "The maximum amount of borrowing capacity under a line of credit that is available as of the balance sheet date for financing purchases of goods acquired for inventory or imminent delivery to a customer." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeeAmount", "crdr": "debit", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility (in Dollars)", "label": "Line of Credit Facility, Commitment Fee Amount", "documentation": "Amount of the fee for available but unused credit capacity under the credit facility." } } }, "auth_ref": [ "r63", "r68", "r364" ] }, "ntrb_LineOfCreditFacilityCommonStock": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "LineOfCreditFacilityCommonStock", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, common stock (in Shares)", "label": "Line Of Credit Facility Common Stock" } } }, "auth_ref": [] }, "ntrb_LineOfCreditFacilityConverted": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "LineOfCreditFacilityConverted", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility converted", "label": "Line Of Credit Facility Converted" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityExpirationDate1", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due date", "label": "Line of Credit Facility, Expiration Date", "documentation": "Date the credit facility terminates, in YYYY-MM-DD format." } } }, "auth_ref": [ "r63", "r68" ] }, "us-gaap_LineOfCreditFacilityIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityIncreaseAccruedInterest", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility", "verboseLabel": "Accrued interest", "netLabel": "Accrued interest (in Dollars)", "label": "Line of Credit Facility, Increase, Accrued Interest", "documentation": "Increase for accrued, but unpaid interest on the credit facility for the period." } } }, "auth_ref": [ "r904" ] }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate during period", "label": "Line of Credit Facility, Interest Rate During Period", "documentation": "The effective interest rate during the reporting period." } } }, "auth_ref": [ "r63", "r68" ] }, "us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current outstanding", "label": "Line of Credit Facility, Maximum Amount Outstanding During Period", "documentation": "Maximum amount borrowed under the credit facility at any time during the period." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financed amount", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r63", "r68" ] }, "us-gaap_LineOfCreditFacilityPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityPeriodicPayment", "crdr": "debit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments made per month", "label": "Line of Credit Facility, Periodic Payment", "documentation": "Amount of the required periodic payments of both interest and principal." } } }, "auth_ref": [ "r63", "r68" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit [Member]", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit line note", "label": "Line of Credit, Current", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r64", "r133" ] }, "ntrb_LoanBearsInterestPercentage": { "xbrltype": "percentItemType", "nsuri": "http://nutriband.com/20240430", "localname": "LoanBearsInterestPercentage", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan bears interest, percentage", "documentation": "Loan bears interest, percentage.", "label": "Loan Bears Interest Percentage" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtPercentageBearingFixedInterestRate", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bearing interest", "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate", "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate." } } }, "auth_ref": [ "r67" ] }, "us-gaap_LongTermDebtPercentageBearingVariableInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtPercentageBearingVariableInterestRate", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of interest rate", "label": "Long-Term Debt, Percentage Bearing Variable Interest, Percentage Rate", "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time." } } }, "auth_ref": [ "r67" ] }, "us-gaap_LongTermInvestmentsAndReceivablesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermInvestmentsAndReceivablesNet", "crdr": "debit", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment receivable", "label": "Long-Term Investments and Receivables, Net", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle) and amount due to the Entity from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such investments and receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r886" ] }, "ntrb_LongTermLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "LongTermLiabilitiesAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "LONG-TERM LIABILITIES:", "label": "Long Term Liabilities Abstract" } } }, "auth_ref": [] }, "us-gaap_LongTermLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermLineOfCredit", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit", "label": "Long-Term Line of Credit, Noncurrent", "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r12", "r34", "r35" ] }, "us-gaap_LongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermNotesPayable", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Note payable-net of current portion", "label": "Notes Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": [ "r12" ] }, "ntrb_LossOnExtinguishment": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "LossOnExtinguishment", "crdr": "debit", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on extinguishment (in Dollars)", "documentation": "Loss on extinguishment.", "label": "Loss On Extinguishment" } } }, "auth_ref": [] }, "ntrb_MDMWorldwideMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "MDMWorldwideMember", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "MDM Worldwide [Member]", "label": "MDMWorldwide Member" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://nutriband.com/role/ScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable", "http://nutriband.com/role/ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment [Member]", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r302", "r822", "r847", "r853", "r950", "r994", "r996", "r997", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1023", "r1024" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://nutriband.com/role/IncomeTaxesDetails", "http://nutriband.com/role/IntangibleAssetsDetails", "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/ScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable", "http://nutriband.com/role/ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SubsequentEventsDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r163", "r165", "r167", "r168", "r170", "r190", "r191", "r359", "r360", "r361", "r362", "r433", "r471", "r520", "r557", "r642", "r643", "r654", "r689", "r690", "r750", "r753", "r755", "r756", "r763", "r784", "r785", "r811", "r819", "r825", "r829", "r830", "r831", "r832", "r848", "r948", "r983", "r984", "r985", "r986", "r987", "r988" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://nutriband.com/role/IncomeTaxesDetails", "http://nutriband.com/role/IntangibleAssetsDetails", "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/ScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable", "http://nutriband.com/role/ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SubsequentEventsDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "verboseLabel": "Maximum [Member]", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r163", "r165", "r167", "r168", "r170", "r190", "r191", "r359", "r360", "r361", "r362", "r433", "r471", "r520", "r557", "r642", "r643", "r654", "r689", "r690", "r750", "r753", "r755", "r756", "r763", "r784", "r785", "r811", "r819", "r825", "r829", "r830", "r831", "r848", "r948", "r983", "r984", "r985", "r986", "r987", "r988" ] }, "ntrb_MoneyChannelMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "MoneyChannelMember", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money Channel [Member]", "label": "Money Channel Member" } } }, "auth_ref": [] }, "ntrb_MrGoodmanMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "MrGoodmanMember", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Mr. Goodman [Member]", "label": "Mr Goodman Member" } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r302", "r822", "r847", "r853", "r950", "r994", "r996", "r997", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1023", "r1024" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r225" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Used in Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r225" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Used In Operating Activities", "terseLabel": "Used cash flow from operations", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r98", "r99", "r102" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow", "http://nutriband.com/role/ConsolidatedIncomeStatement", "http://nutriband.com/role/ShareholdersEquityType2or3", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Loss from operations", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r89", "r102", "r141", "r195", "r215", "r216", "r220", "r232", "r240", "r242", "r243", "r245", "r246", "r247", "r251", "r252", "r258", "r308", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r500", "r504", "r519", "r522", "r619", "r721", "r740", "r741", "r866", "r946" ] }, "ntrb_NetSalesAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "NetSalesAbstract0", "presentation": [ "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Net Sales Abstract0" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable", "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign [Member]", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1030", "r1031", "r1032", "r1033" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:", "label": "Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesAndLoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesAndLoansPayable", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured loan payable", "label": "Notes and Loans Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r12", "r136", "r992" ] }, "us-gaap_NotesIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesIssued1", "crdr": "credit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreed issued", "label": "Notes Issued", "documentation": "The fair value of notes issued in noncash investing and financing activities." } } }, "auth_ref": [ "r19", "r20", "r21" ] }, "us-gaap_NotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayable", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note payable", "label": "Notes Payable", "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r12", "r136", "r992", "r993" ] }, "us-gaap_NotesPayableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableAbstract", "lang": { "en-us": { "role": { "label": "Notes Payable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Notes payable-current portion", "label": "Notes Payable, Current", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r64", "r65" ] }, "ntrb_NotesPayableDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "NotesPayableDetailsLineItems", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payable [Line Items]" } } }, "auth_ref": [] }, "ntrb_NotesPayableDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "NotesPayableDetailsTable", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Notes Payable (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_NotesPayableToBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NotesPayableToBanksMember", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notes Payable to Banks [Member]", "verboseLabel": "Notes Payable [Member]", "label": "Notes Payable to Banks [Member]", "documentation": "A written promise to pay a note to a bank." } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://nutriband.com/role/SegmentReportingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r802", "r810", "r916" ] }, "ntrb_NumberOfShares": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "NumberOfShares", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares", "documentation": "Shares of number of shares issued.", "label": "Number Of Shares" } } }, "auth_ref": [] }, "ntrb_OperatingExpensesAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OperatingExpensesAbstract0", "presentation": [ "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses Abstract0" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r145", "r801", "r914", "r917", "r918", "r919", "r920" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r976" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability-current portion", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r537" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability-net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r537" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right of use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r536" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use assets", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r901" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease can be extended for an additional", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r539", "r834" ] }, "us-gaap_OptionIndexedToIssuersEquityShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OptionIndexedToIssuersEquityShares", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued", "label": "Option Indexed to Issuer's Equity, Shares", "documentation": "Maximum number of shares that could be issued to settle option contract indexed to equity." } } }, "auth_ref": [ "r128", "r129" ] }, "ntrb_OptionsAndWarrantsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsAndWarrantsAbstract", "lang": { "en-us": { "role": { "label": "Options and Warrants [Abstract]" } } }, "auth_ref": [] }, "ntrb_OptionsAndWarrantsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsAndWarrantsTextBlock", "presentation": [ "http://nutriband.com/role/OptionsandWarrants" ], "lang": { "en-us": { "role": { "terseLabel": "OPTIONS and WARRANTS", "documentation": "The entire disclosure of options and warrants.", "label": "Options And Warrants Text Block" } } }, "auth_ref": [] }, "ntrb_OptionsVestAndExpireTerm": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsVestAndExpireTerm", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vest and expire term", "documentation": "Options vest and expire term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Options Vest And Expire Term" } } }, "auth_ref": [] }, "ntrb_OptionsVestExpireYear": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsVestExpireYear", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expire years", "documentation": "Options Vest Expire Year.", "label": "Options Vest Expire Year" } } }, "auth_ref": [] }, "ntrb_OptionsandWarrantsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsandWarrantsDetailsLineItems", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options and Warrants [Line Items]", "label": "Optionsand Warrants Details Line Items" } } }, "auth_ref": [] }, "ntrb_OptionsandWarrantsDetailsScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsandWarrantsDetailsScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "label": "Options and Warrants (Details) - Schedule of Additional Information Relating to the Options Outstanding [Table]" } } }, "auth_ref": [] }, "ntrb_OptionsandWarrantsDetailsScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsandWarrantsDetailsScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "label": "Options and Warrants (Details) - Schedule of Additional Information Relating to the Warrants Outstanding [Table]" } } }, "auth_ref": [] }, "ntrb_OptionsandWarrantsDetailsScheduleofChangesinOptionsOutstandingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsandWarrantsDetailsScheduleofChangesinOptionsOutstandingLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "label": "Options and Warrants (Details) - Schedule of Changes in Options Outstanding [Line Items]" } } }, "auth_ref": [] }, "ntrb_OptionsandWarrantsDetailsScheduleofChangesinOptionsOutstandingTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsandWarrantsDetailsScheduleofChangesinOptionsOutstandingTable", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0" ], "lang": { "en-us": { "role": { "label": "Options and Warrants (Details) - Schedule of Changes in Options Outstanding [Table]" } } }, "auth_ref": [] }, "ntrb_OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]" } } }, "auth_ref": [] }, "ntrb_OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "label": "Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Options Outstanding [Table]" } } }, "auth_ref": [] }, "ntrb_OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [Line Items]" } } }, "auth_ref": [] }, "ntrb_OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsandWarrantsDetailsScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "label": "Options and Warrants (Details) - Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [Table]" } } }, "auth_ref": [] }, "ntrb_OptionsandWarrantsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsandWarrantsDetailsTable", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Options and Warrants (Details) [Table]" } } }, "auth_ref": [] }, "ntrb_OptionsandWarrantsTablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsandWarrantsTablesLineItems", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Options and Warrants [Line Items]" } } }, "auth_ref": [] }, "ntrb_OptionsandWarrantsTablesTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OptionsandWarrantsTablesTable", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsTables" ], "lang": { "en-us": { "role": { "label": "Options and Warrants (Tables) [Table]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Description of Business [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://nutriband.com/role/OrganizationandDescriptionofBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r60", "r126", "r655", "r656" ] }, "ntrb_OrganizationandDescriptionofBusinessDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OrganizationandDescriptionofBusinessDetailsLineItems", "presentation": [ "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Description of Business [Line Items]" } } }, "auth_ref": [] }, "ntrb_OrganizationandDescriptionofBusinessDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OrganizationandDescriptionofBusinessDetailsTable", "presentation": [ "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetImpairmentCharges", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment charge", "label": "Other Asset Impairment Charges", "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value." } } }, "auth_ref": [ "r901", "r937" ] }, "us-gaap_OtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssets", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Total assets", "label": "Other Assets", "documentation": "Amount of assets classified as other." } } }, "auth_ref": [ "r131", "r203", "r604", "r807", "r868" ] }, "us-gaap_OtherAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER ASSETS:", "label": "Other Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Other Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates, classified as other. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsDescription", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other commitments term, description", "label": "Other Commitments, Description", "documentation": "Description of the nature and terms of commitment." } } }, "auth_ref": [] }, "us-gaap_OtherCostAndExpenseOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCostAndExpenseOperating", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Other Cost and Expense, Operating", "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": [ "r90", "r622", "r806" ] }, "us-gaap_OtherDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherDepreciationAndAmortization", "crdr": "debit", "presentation": [ "http://nutriband.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of goods sold", "label": "Other Depreciation and Amortization", "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other." } } }, "auth_ref": [ "r5", "r33", "r90" ] }, "us-gaap_OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenses", "crdr": "debit", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination expense", "label": "Other Expenses", "documentation": "Amount of expense classified as other." } } }, "auth_ref": [ "r91", "r92" ] }, "us-gaap_OtherInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherInventory", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total inventory", "label": "Other Inventory, Gross", "documentation": "Amount before valuation and LIFO reserves of other inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r892" ] }, "us-gaap_OtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilities", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Note payable-related party", "label": "Other Liabilities", "documentation": "Amount of liabilities classified as other." } } }, "auth_ref": [ "r135", "r606", "r693", "r694", "r868", "r993", "r1026" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r94" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNotesPayableCurrent", "crdr": "credit", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Note payable current", "label": "Other Notes Payable, Current", "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r65" ] }, "ntrb_OtherRelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OtherRelatedPartyMember", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other Related Party [Member]", "label": "Other Related Party Member" } } }, "auth_ref": [] }, "ntrb_OutsideTheUnitedStatesMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "OutsideTheUnitedStatesMember", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Outside of the United States [Member]", "label": "Outside The United States Member" } } }, "auth_ref": [] }, "ntrb_PaymentsForRepurchaseOfWarrant": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "PaymentsForRepurchaseOfWarrant", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase warrants (in Shares)", "documentation": "Payments for repurchase of warrant.", "label": "Payments For Repurchase Of Warrant" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r96" ] }, "ntrb_PercentageOfNetIncome": { "xbrltype": "percentItemType", "nsuri": "http://nutriband.com/20240430", "localname": "PercentageOfNetIncome", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of performance bonus", "documentation": "Amount of describes the gain (or loss) in net income of a business over a given amount of time, thus allowing us to establish what the ROI (return rate) of a specific investment has been.", "label": "Percentage Of Net Income" } } }, "auth_ref": [] }, "ntrb_PerformanceObligationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nutriband.com/20240430", "localname": "PerformanceObligationsPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Obligations", "documentation": "The entire disclosure of performance obligations.", "label": "Performance Obligations Policy Text Block" } } }, "auth_ref": [] }, "ntrb_PoconoCoatedProductsLLCAndActiveIntelligenceLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "PoconoCoatedProductsLLCAndActiveIntelligenceLLCMember", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pocono Coated Products LLC and Active Intelligence LLC [Member]", "label": "Pocono Coated Products LLCAnd Active Intelligence LLCMember" } } }, "auth_ref": [] }, "ntrb_PoconoPharmaceuticalsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "PoconoPharmaceuticalsMember", "presentation": [ "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Pocono Pharmaceuticals [Member]", "verboseLabel": "Selling, general and administrative-Pocono Pharmaceuticals [Member]", "label": "Pocono Pharmaceuticals Member" } } }, "auth_ref": [] }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockConvertibleSharesIssuable", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock consisting", "label": "Preferred Stock, Convertible, Shares Issuable", "documentation": "Number of common shares issuable upon conversion of preferred stock." } } }, "auth_ref": [ "r404" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock [Member]", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r858", "r859", "r862", "r863", "r864", "r865", "r1025", "r1028" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock par value (in Dollars per share)", "verboseLabel": "Preferred stock, par value (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r74", "r402" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r74", "r699" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r74", "r699", "r719", "r1028", "r1029" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, value", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r74", "r610", "r835" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r213", "r317", "r318", "r793" ] }, "us-gaap_PrepaidExpenseCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrentAndNoncurrent", "crdr": "debit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense", "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs." } } }, "auth_ref": [ "r131", "r213", "r712", "r991" ] }, "srt_PreviouslyEstimatedDevelopmentCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "PreviouslyEstimatedDevelopmentCostsIncurred", "crdr": "debit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated cost", "label": "Oil and Gas, Standardized Measure, Discounted Future Net Cash Flow, Previously Estimated Development Cost Incurred", "documentation": "Amount of increase in standardized measure of discounted future net cash flow as a result of previously estimated development costs incurred." } } }, "auth_ref": [ "r155", "r156", "r161", "r583", "r584", "r840", "r845" ] }, "us-gaap_PrincipalAmountOutstandingOfLoansHeldInPortfolio": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrincipalAmountOutstandingOfLoansHeldInPortfolio", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding principal amount (in Dollars)", "label": "Loan, Held-in-Portfolio, Principal Outstanding", "documentation": "This is the result of the principal amount outstanding of total loans managed or securitized less securitized loans and loans that are in the process of being securitized." } } }, "auth_ref": [ "r11" ] }, "us-gaap_PrincipalTransactionsRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrincipalTransactionsRevenue", "crdr": "credit", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of principal (in Dollars)", "label": "Principal Transactions Revenue, Net", "documentation": "Amount of realized and unrealized gain (loss) resulting from the difference between acquisition price and selling price or fair value of trading assets and trading liabilities, and from the firm's direct investment activity, conducted separately from customer trading activities, including, but not limited to, investments in private equity, alternative investment products, real estate, and exchanges and memberships." } } }, "auth_ref": [ "r990" ] }, "us-gaap_ProceedsFromFeesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromFeesReceived", "crdr": "debit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Received amount", "label": "Proceeds from Fees Received", "documentation": "Cash received for fees during the current period. This element excludes cash proceeds from license fees." } } }, "auth_ref": [ "r100" ] }, "us-gaap_ProceedsFromInterestReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromInterestReceived", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Received proceeds (in Dollars)", "label": "Proceeds from Interest Received", "documentation": "Interest received on loans and other debt instruments during the current period." } } }, "auth_ref": [ "r899" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from secured borrowing liability", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r898" ] }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private placement", "label": "Proceeds from Issuance of Private Placement", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of common stock and warrants", "verboseLabel": "Proceeds from equity financing", "netLabel": "Equity financing", "label": "Proceeds from equity financing (in Dollars)", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r3", "r660" ] }, "ntrb_ProceedsFromIssuancesInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ProceedsFromIssuancesInitialPublicOffering", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds From Issuances Initial Public Offering" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRelatedPartyDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRelatedPartyDebt", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from note payable-related party", "label": "Proceeds from Related Party Debt", "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates." } } }, "auth_ref": [ "r15" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow", "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from exercise of warrants", "verboseLabel": "Proceed from exercise of warrants (in Dollars)", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r897" ] }, "ntrb_ProceedsFromWarrantsExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ProceedsFromWarrantsExercises", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise warrants", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds From Warrants Exercises" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable0" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r172", "r173", "r174", "r175", "r176", "r177", "r188", "r298", "r563", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r789", "r820", "r846", "r848", "r850", "r854", "r856", "r883", "r944", "r945", "r950", "r994", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1023", "r1024" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable0" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r172", "r173", "r174", "r175", "r176", "r177", "r188", "r298", "r563", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r789", "r820", "r846", "r848", "r850", "r854", "r856", "r883", "r944", "r945", "r950", "r994", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1023", "r1024" ] }, "ntrb_PromissoryNoteOnEquipmentPurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "PromissoryNoteOnEquipmentPurchase", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Promissory note on equipment purchase", "documentation": "Promissory note on equipment purchase.", "label": "Promissory Note On Equipment Purchase" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://nutriband.com/role/ScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable", "http://nutriband.com/role/ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6", "r541" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://nutriband.com/role/PropertyandEquipment" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r107", "r152", "r157", "r158" ] }, "ntrb_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nutriband.com/20240430", "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets", "verboseLabel": "Schedule of Plant and Equipment on Straight-Line Basis Over Estimated Useful Life of Assets", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense, and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment Estimated Useful Life Table Text Block" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 }, "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r108", "r200", "r617" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "label": "Schedule of Property and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r541" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "totalLabel": "Net Property and Equipment", "terseLabel": "PROPERTY & EQUIPMENT-net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r541", "r601", "r617", "r835" ] }, "us-gaap_PropertyPlantAndEquipmentOtherAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentOtherAccumulatedDepreciation", "crdr": "credit", "calculation": { "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 }, "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Accumulated depreciation", "label": "Property, Plant and Equipment, Other, Accumulated Depreciation", "documentation": "Amount of accumulated depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentOwnedAccumulatedDepreciation", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net of accumulated depreciation", "label": "Property, Plant, and Equipment, Owned, Accumulated Depreciation", "documentation": "Amount of accumulated depreciation from long-lived, depreciable flight asset owned. Excludes right-of-use asset from finance lease for flight asset." } } }, "auth_ref": [ "r936" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r152", "r157", "r616" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://nutriband.com/role/PropertyandEquipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r108", "r541" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://nutriband.com/role/ScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable", "http://nutriband.com/role/ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Property plant and equipment, useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Reserve for doubtful accounts", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r223", "r313" ] }, "us-gaap_PurchaseObligationDueInThirdYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligationDueInThirdYear", "crdr": "credit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amount paid", "label": "Purchase Obligation, to be Paid, Year Three", "documentation": "Amount of purchase arrangement to be paid in third fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "ntrb_PurchaseOfTreasuryStock": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "PurchaseOfTreasuryStock", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of treasury stock", "documentation": "Treasury stock, also known as treasury shares or reacquired stock, refers to previously outstanding stock that is bought back from stockholders by the issuing company.", "label": "Purchase Of Treasury Stock" } } }, "auth_ref": [] }, "ntrb_PurchaseShare": { "xbrltype": "percentItemType", "nsuri": "http://nutriband.com/20240430", "localname": "PurchaseShare", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of jet services LDA", "documentation": "Purchase share of percentage.", "label": "Purchase Share" } } }, "auth_ref": [] }, "ntrb_PurchaseShares": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "PurchaseShares", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase shares (in Shares)", "documentation": "The option purchase shares.", "label": "Purchase Shares" } } }, "auth_ref": [] }, "ntrb_RambamMedTechLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "RambamMedTechLtdMember", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rambam Med-Tech Ltd [Member]", "label": "Rambam Med Tech Ltd Member" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://nutriband.com/role/IncomeTaxesDetails", "http://nutriband.com/role/IntangibleAssetsDetails", "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/ScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable", "http://nutriband.com/role/ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SubsequentEventsDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r163", "r165", "r167", "r168", "r170", "r190", "r191", "r359", "r360", "r361", "r362", "r431", "r433", "r461", "r462", "r463", "r471", "r520", "r555", "r556", "r557", "r642", "r643", "r654", "r689", "r690", "r750", "r753", "r755", "r756", "r763", "r784", "r785", "r811", "r819", "r825", "r829", "r830", "r831", "r832", "r848", "r860", "r942", "r948", "r963", "r984", "r985", "r986", "r987", "r988" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://nutriband.com/role/IncomeTaxesDetails", "http://nutriband.com/role/IntangibleAssetsDetails", "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/ScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable", "http://nutriband.com/role/ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SubsequentEventsDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r163", "r165", "r167", "r168", "r170", "r190", "r191", "r359", "r360", "r361", "r362", "r431", "r433", "r461", "r462", "r463", "r471", "r520", "r555", "r556", "r557", "r642", "r643", "r654", "r689", "r690", "r750", "r753", "r755", "r756", "r763", "r784", "r785", "r811", "r819", "r825", "r829", "r830", "r831", "r832", "r848", "r860", "r942", "r948", "r963", "r984", "r985", "r986", "r987", "r988" ] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivableTypeDomain", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Receivable [Domain]", "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": [ "r76", "r82" ] }, "us-gaap_ReceivablesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable." } } }, "auth_ref": [ "r304", "r305", "r306", "r307", "r924" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r30", "r31" ] }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "presentation": [ "http://nutriband.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Sales and Property and Equipment", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues." } } }, "auth_ref": [ "r30", "r31" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityOtherCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RedeemableNoncontrollingInterestEquityOtherCarryingAmount", "crdr": "credit", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock value (in Dollars)", "label": "Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount", "documentation": "Amount of noncontrolling interests which are redeemable by the parent entity, classified as other equity." } } }, "auth_ref": [ "r38", "r39", "r112", "r113" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet", "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SubsequentEventsDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r303", "r432", "r547", "r548", "r607", "r615", "r692", "r693", "r694", "r695", "r696", "r718", "r720", "r749" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyMember", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet", "http://nutriband.com/role/NotesPayableDetails", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "verboseLabel": "Related Party [Member]", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r234", "r235", "r547", "r548", "r549", "r550", "r607", "r615", "r692", "r693", "r694", "r695", "r696", "r718", "r720", "r749" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Received amount", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r58", "r547" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails", "http://nutriband.com/role/NotesPayableDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r547", "r548", "r980" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails", "http://nutriband.com/role/NotesPayableDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "crdr": "debit", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Invested amount", "label": "Related Party Transaction, Purchases from Related Party", "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet", "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SubsequentEventsDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r303", "r432", "r547", "r548", "r607", "r615", "r692", "r693", "r694", "r695", "r696", "r718", "r720", "r749", "r980" ] }, "ntrb_RelatedPartyTransactionsDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "RelatedPartyTransactionsDetailsLineItems", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Line Items]" } } }, "auth_ref": [] }, "ntrb_RelatedPartyTransactionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "RelatedPartyTransactionsDetailsTable", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transactions (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r544", "r545", "r546", "r548", "r551", "r666", "r667", "r668", "r725", "r726", "r727", "r746", "r748" ] }, "us-gaap_RepaymentsOfAdvancesForConstruction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfAdvancesForConstruction", "crdr": "credit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Advance repaid", "label": "Payment for Advance for Construction, Investing Activity", "documentation": "Amount of cash outflow for repayment of advance for construction, classified as investing activity. Includes, but is not limited to, payment to developer, builder, government agency, and municipality for borrowing received in construction." } } }, "auth_ref": [ "r96" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Payment on note payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r97" ] }, "ntrb_ResearchAndDevelopment4PTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ResearchAndDevelopment4PTherapeuticsMember", "presentation": [ "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development-4P Therapeutics\t[Member]", "label": "Research And Development4 PTherapeutics Member" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r473", "r787", "r806", "r989" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expenses", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r472" ] }, "srt_RestatementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementAxis", "presentation": [ "http://nutriband.com/role/NotesPayableDetails", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Axis]", "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r189", "r193", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r249", "r250", "r251", "r252", "r253", "r263", "r310", "r311", "r498", "r499", "r500", "r501", "r503", "r504", "r516", "r517", "r518", "r519", "r532", "r534", "r542", "r543", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r657", "r921" ] }, "srt_RestatementDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RestatementDomain", "presentation": [ "http://nutriband.com/role/NotesPayableDetails", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "label": "Revision of Prior Period [Domain]", "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r189", "r193", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r248", "r249", "r250", "r251", "r252", "r253", "r263", "r310", "r311", "r498", "r499", "r500", "r501", "r503", "r504", "r516", "r517", "r518", "r519", "r532", "r534", "r542", "r543", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r657", "r921" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r78", "r115", "r613", "r648", "r653", "r664", "r700", "r835" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r192", "r237", "r238", "r239", "r241", "r247", "r250", "r252", "r309", "r312", "r348", "r490", "r491", "r497", "r498", "r499", "r501", "r503", "r504", "r509", "r511", "r512", "r514", "r517", "r533", "r535", "r644", "r646", "r669", "r1028" ] }, "ntrb_RevenueByGeographicLocationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "RevenueByGeographicLocationAbstract", "presentation": [ "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue by geographic location:", "label": "Revenue By Geographic Location Abstract" } } }, "auth_ref": [] }, "ntrb_RevenueByGeographicLocationAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "RevenueByGeographicLocationAbstract0", "presentation": [ "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue by geographic location:", "label": "Revenue By Geographic Location Abstract0" } } }, "auth_ref": [] }, "ntrb_RevenueByTypeAbstract0": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "RevenueByTypeAbstract0", "presentation": [ "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue by type", "label": "Revenue By Type Abstract0" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable0", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "verboseLabel": "Revenue", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r143", "r144", "r264", "r273", "r274", "r289", "r295", "r298", "r300", "r302", "r428", "r429", "r563" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Contracts with Customers", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r160", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r788" ] }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue by Geographic Location", "label": "Revenue from External Customers by Geographic Areas [Table Text Block]", "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue." } } }, "auth_ref": [ "r104" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r723", "r788", "r798" ] }, "ntrb_RevenueRemainingPerformanceObligationsOptionalExemptionRemainingDuration": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "RevenueRemainingPerformanceObligationsOptionalExemptionRemainingDuration", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Date of issuance", "documentation": "Remaining duration of performance obligations for which optional exemption was applied not to disclose amount of transaction price allocated to and timing of revenue recognition for remaining performance obligation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue Remaining Performance Obligations Optional Exemption Remaining Duration" } } }, "auth_ref": [] }, "ntrb_RevenueTypesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nutriband.com/20240430", "localname": "RevenueTypesPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Types", "documentation": "Disclosure of accounting policy for revenue types.", "label": "Revenue Types Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement", "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable", "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable0", "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable", "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "verboseLabel": "Total", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r143", "r144", "r221", "r232", "r264", "r273", "r274", "r289", "r295", "r298", "r300", "r302", "r308", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r522", "r600", "r806", "r946" ] }, "ntrb_RoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://nutriband.com/20240430", "localname": "RoyaltyPercentage", "presentation": [ "http://nutriband.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty, percentage", "documentation": "Royalty percentage.", "label": "Royalty Percentage" } } }, "auth_ref": [] }, "us-gaap_SalariesWagesAndOfficersCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SalariesWagesAndOfficersCompensation", "crdr": "debit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Annual salary", "label": "Salary and Wage, Excluding Cost of Good and Service Sold", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [] }, "ntrb_SaleOfGoodsMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SaleOfGoodsMember", "presentation": [ "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of goods ]Member[", "label": "Sale Of Goods Member" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of common stock (in Shares)", "verboseLabel": "Common stock share purchase", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in Dollars per share)", "verboseLabel": "Exercise price per shares (in Dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast [Member]", "label": "Forecast [Member]", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": [ "r434", "r881", "r911" ] }, "srt_ScenarioPreviouslyReportedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioPreviouslyReportedMember", "presentation": [ "http://nutriband.com/role/NotesPayableDetails", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Previously Reported [Member]", "label": "Previously Reported [Member]", "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision." } } }, "auth_ref": [ "r193", "r237", "r239", "r240", "r241", "r242", "r243", "r252", "r263", "r498", "r500", "r501", "r503", "r504", "r516", "r517", "r518", "r532", "r534", "r644", "r645", "r646", "r647", "r648", "r649", "r650", "r651", "r652", "r653", "r657", "r874", "r876", "r877", "r878", "r910", "r921", "r927", "r928", "r961", "r977", "r978" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r189", "r253", "r434", "r872", "r911" ] }, "ntrb_ScheduleOfAdditionalInformationRelatingToTheOptionsOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfAdditionalInformationRelatingToTheOptionsOutstandingAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Additional Information Relating To The Options Outstanding Abstract" } } }, "auth_ref": [] }, "ntrb_ScheduleOfAdditionalInformationRelatingToTheWarrantsOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfAdditionalInformationRelatingToTheWarrantsOutstandingAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Additional Information Relating To The Warrants Outstanding Abstract" } } }, "auth_ref": [] }, "ntrb_ScheduleOfAdditionalRelatingWarrantsOutstanding": { "xbrltype": "textBlockItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfAdditionalRelatingWarrantsOutstanding", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Summarizes Additional Information Relating to the Warrants Outstanding", "verboseLabel": "Schedule of Additional Information Relating to the Warrants Outstanding", "documentation": "The entire disclosure schedule of additional relating warrants outstanding.", "label": "Schedule Of Additional Relating Warrants Outstanding" } } }, "auth_ref": [] }, "ntrb_ScheduleOfAmortizationExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfAmortizationExpensesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Amortization Expenses [Abstract]" } } }, "auth_ref": [] }, "ntrb_ScheduleOfChangesInOptionsOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfChangesInOptionsOutstandingAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Changes in Options Outstanding [Abstract]" } } }, "auth_ref": [] }, "ntrb_ScheduleOfChangesInOptionsOutstandingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfChangesInOptionsOutstandingLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0" ], "lang": { "en-us": { "role": { "label": "Schedule of Changes in Options Outstanding [Line Items]" } } }, "auth_ref": [] }, "ntrb_ScheduleOfChangesInWarrantsOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfChangesInWarrantsOutstandingAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Changes In Warrants Outstanding Abstract" } } }, "auth_ref": [] }, "ntrb_ScheduleOfChangesInWarrantsOutstandingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfChangesInWarrantsOutstandingLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Warrants Outstanding [Line Items]", "label": "Schedule Of Changes In Warrants Outstanding Line Items" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://nutriband.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Provision for Income Taxes", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r957" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://nutriband.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Liability and Deferred Tax Asset", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r953" ] }, "ntrb_ScheduleOfDeferredTaxLiabilityAndDeferredTaxAssetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfDeferredTaxLiabilityAndDeferredTaxAssetAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Liability and Deferred Tax Asset [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://nutriband.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Taxes on Income", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r479", "r827", "r951" ] }, "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable", "presentation": [ "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable0" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]", "documentation": "Disclosure of information about the extent of the entity's reliance on its major customers." } } }, "auth_ref": [ "r105" ] }, "ntrb_ScheduleOfIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Intangible Assets Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://nutriband.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r929", "r932" ] }, "ntrb_ScheduleOfNetSalesAndPropertyAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfNetSalesAndPropertyAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Net Sales And Property And Equipment Abstract" } } }, "auth_ref": [] }, "ntrb_ScheduleOfPlantAndEquipmentOnAStraightLineBasisOverTheEstimatedUsefulLifeOfTheAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfPlantAndEquipmentOnAStraightLineBasisOverTheEstimatedUsefulLifeOfTheAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Plant And Equipment On AStraight Line Basis Over The Estimated Useful Life Of The Assets Abstract" } } }, "auth_ref": [] }, "ntrb_ScheduleOfPlantAndEquipmentOnAStraightLineBasisOverTheEstimatedUsefulLifeOfTheAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfPlantAndEquipmentOnAStraightLineBasisOverTheEstimatedUsefulLifeOfTheAssetsLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets [Line Items]", "label": "Schedule Of Plant And Equipment On AStraight Line Basis Over The Estimated Useful Life Of The Assets Line Items" } } }, "auth_ref": [] }, "ntrb_ScheduleOfPlantAndEquipmentOnStraightLineBasisOverEstimatedUsefulLifeOfAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfPlantAndEquipmentOnStraightLineBasisOverEstimatedUsefulLifeOfAssetsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Plant And Equipment On Straight Line Basis Over Estimated Useful Life Of Assets Abstract" } } }, "auth_ref": [] }, "ntrb_ScheduleOfPropertyAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfPropertyAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6", "r541" ] }, "ntrb_ScheduleOfProvisionForIncomeTaxesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfProvisionForIncomeTaxesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Provision for Income Taxes [Abstract]" } } }, "auth_ref": [] }, "ntrb_ScheduleOfReconciliationOfTaxesOnIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfReconciliationOfTaxesOnIncomeAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Reconciliation of Taxes on Income [Abstract]" } } }, "auth_ref": [] }, "ntrb_ScheduleOfRevenueByGeographicLocationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfRevenueByGeographicLocationAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Revenue By Geographic Location Abstract" } } }, "auth_ref": [] }, "ntrb_ScheduleOfRevenueByGeographicLocationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfRevenueByGeographicLocationLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable0" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenue by Geographic Location [Line Items]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregates Its Revenue from Contracts", "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]", "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer." } } }, "auth_ref": [] }, "ntrb_ScheduleOfSegmentPerformanceToTheGaapMeasureOfGrossProfitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfSegmentPerformanceToTheGaapMeasureOfGrossProfitAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Segment Performance To The Gaap Measure Of Gross Profit Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r27", "r28", "r29" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://nutriband.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Performance to the GAAP Measure of Gross Profit", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r27", "r28", "r29" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Options Outstanding", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r9", "r10", "r118" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Warrants Outstanding", "verboseLabel": "Schedule of Warrants Exercisable", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r42" ] }, "ntrb_ScheduleOfSummarizesAdditionalInformationRelatingToTheOptionsOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfSummarizesAdditionalInformationRelatingToTheOptionsOutstandingAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Summarizes Additional Information Relating To The Options Outstanding Abstract" } } }, "auth_ref": [] }, "ntrb_ScheduleOfSummarizesAdditionalInformationRelatingToTheOptionsOutstandingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfSummarizesAdditionalInformationRelatingToTheOptionsOutstandingLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Summarizes Additional Information Relating to the Options Outstanding [Line Items]", "label": "Schedule Of Summarizes Additional Information Relating To The Options Outstanding Line Items" } } }, "auth_ref": [] }, "ntrb_ScheduleOfSummarizesAdditionalInformationRelatingToTheOptionsOutstandingTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfSummarizesAdditionalInformationRelatingToTheOptionsOutstandingTableTextBlock", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Summarizes Additional Information Relating to the Options Outstanding", "verboseLabel": "Schedule of Additional Information Relating to the Options Outstanding", "documentation": "Tabular disclosure of option outstanding.", "label": "Schedule Of Summarizes Additional Information Relating To The Options Outstanding Table Text Block" } } }, "auth_ref": [] }, "ntrb_ScheduleOfSummarizesAdditionalInformationRelatingToTheWarrantsOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfSummarizesAdditionalInformationRelatingToTheWarrantsOutstandingAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Summarizes Additional Information Relating To The Warrants Outstanding Abstract" } } }, "auth_ref": [] }, "ntrb_ScheduleOfSummarizesAdditionalInformationRelatingToTheWarrantsOutstandingLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfSummarizesAdditionalInformationRelatingToTheWarrantsOutstandingLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Summarizes Additional Information Relating to the Warrants Outstanding [Line Items]", "label": "Schedule Of Summarizes Additional Information Relating To The Warrants Outstanding Line Items" } } }, "auth_ref": [] }, "ntrb_ScheduleOfWarrantsExercisableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ScheduleOfWarrantsExercisableAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Warrants Exercisable Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://nutriband.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amortization Expenses", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r813", "r934" ] }, "ntrb_SecuredBorrowingLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SecuredBorrowingLiabilityMember", "presentation": [ "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured borrowing liability [Member]", "verboseLabel": "Secured Borrowing Liability", "label": "Secured Borrowing Liability Member" } } }, "auth_ref": [] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r143", "r144", "r145", "r146", "r264", "r269", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r302", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r346", "r355", "r356", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r803", "r806", "r807", "r812", "r852", "r994", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1023", "r1024" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0", "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable", "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable0" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r164", "r166", "r169", "r171", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r300", "r301", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r684", "r685", "r686", "r752", "r754", "r758", "r765", "r772", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r790", "r821", "r836", "r837", "r838", "r839", "r841", "r842", "r843", "r844", "r851", "r860", "r950", "r994", "r996", "r997", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1023", "r1024" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://nutriband.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT REPORTING", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r146", "r264", "r268", "r269", "r270", "r271", "r272", "r285", "r287", "r288", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r302", "r802", "r804", "r805", "r806", "r808", "r809", "r810" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Performance to the GAAP Measure of Gross Profit [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingRevenueReconcilingItemLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0" ], "lang": { "en-us": { "role": { "label": "Schedule of Net Sales and Property and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r91" ] }, "us-gaap_SeparateAccountLiabilityWithdrawal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeparateAccountLiabilityWithdrawal", "crdr": "debit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Separate Account, Liability, Withdrawal", "documentation": "Amount of decrease in liability for separate account from withdrawal of funds." } } }, "auth_ref": [ "r1022" ] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A Preferred Stock [Member]", "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r887", "r888", "r949" ] }, "us-gaap_ServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ServiceMember", "presentation": [ "http://nutriband.com/role/ScheduleofDisaggregatesitsRevenuefromContractsTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Services [Member]", "label": "Service [Member]", "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service." } } }, "auth_ref": [ "r820" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation-options", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r462" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Volatility rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r461" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r463" ] }, "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableNumber", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Shares, Exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Number" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares, Outstanding, Beginning balance", "periodEndLabel": "Shares, Outstanding, Ending balance", "terseLabel": "Shares, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r442" ] }, "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumbers", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number Exercisable (in Shares)", "verboseLabel": "Weighted Average Exercise Price for Shares Exercisable", "documentation": "Number of share based compensation arrangement by share based payment award options exercisable numbers.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Numbers" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r442" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic Value, Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r455" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Shares, Expired/Cancelled", "negatedLabel": "Shares, Expired/Cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r447" ] }, "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrices", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Life, Expired/Cancelled", "documentation": "Remaining Life, Expired/Cancelled.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Prices" } } }, "auth_ref": [] }, "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGrantDateIntrinsicValue", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic Value, Granted", "documentation": "Sharebased compensation arrangement by sharebased payment award options grant in period grant date intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Period Grant Date Intrinsic Value" } } }, "auth_ref": [] }, "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInTrinsicValueExpiredCancelled": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInTrinsicValueExpiredCancelled", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic Value, Expired/Cancelled", "documentation": "Intrinsic Value, Expired/Cancelled.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grant In Trinsic Value Expired Cancelled" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Shares, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r444" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Intrinsic Value, Outstanding beginning balance", "periodEndLabel": "Intrinsic Value, Outstanding ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r44" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares, Outstanding beginning balance", "periodEndLabel": "Shares, Outstanding ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r440", "r441" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price for Shares Outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price", "documentation": "Change in the weighted average exercise price of options outstanding." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Exercise Price, Outstanding beginning balance", "periodEndLabel": "Exercise Price, Outstanding ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r440", "r441" ] }, "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice1", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0" ], "lang": { "en-us": { "role": { "periodStartLabel": "Exercise Price, Outstanding, Beginning balance", "periodEndLabel": "Exercise Price, Outstanding, Ending balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price1" } } }, "auth_ref": [] }, "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices": { "xbrltype": "perShareItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardRangeOfExercisePrices", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Range of Exercise Prices", "documentation": "Duration of long-term share based compensation arrangement by share based payment award range of exercise prices.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Range Of Exercise Prices" } } }, "auth_ref": [] }, "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisableWeightedAverageExercisePrice", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price for Shares Exercisable", "documentation": "The price per share based compensation arrangement by share based payment award warrants exercisable weighted average exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercisable Weighted Average Exercise Price" } } }, "auth_ref": [] }, "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIntrinsicValue", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic Value (in Dollars)", "documentation": "It represents intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Warrants Intrinsic Value" } } }, "auth_ref": [] }, "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingNumber", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number Outstanding (in Shares)", "documentation": "Number of share based compensation arrangement by share based payment award warrants outstanding number.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Number" } } }, "auth_ref": [] }, "ntrb_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price for Shares Outstanding", "documentation": "The price per share share based compensation arrangement by share based payment award warrants outstanding period increase decrease weighted average exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding Period Increase Decrease Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price, Exercised", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r445" ] }, "ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInRemainingLifeExercised": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInRemainingLifeExercised", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Life, Exercised", "documentation": "Duration of long-term share based compensation arrangements by share based payment award options exercises in remaining life exercised.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Remaining Life Exercised" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price, Expired/Cancelled", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r447" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price, Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r444" ] }, "ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingNumber1", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares, Outstanding beginning balance", "periodEndLabel": "Shares, Outstanding ending balance", "documentation": "The price per share based compensation arrangements by share based payment award options outstanding number1", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Number1" } } }, "auth_ref": [] }, "ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeExpiredCancelled": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeExpiredCancelled", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Life, Expired/Cancelled", "documentation": "Duration of long-term share based compensation arrangements by share based payment award options emaining life expired cancelled.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Remaining Life Expired Cancelled" } } }, "auth_ref": [] }, "ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeRemainingLifeGranted": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRemainingLifeRemainingLifeGranted", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Life, Granted", "documentation": "Remaining Life, Granted.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Remaining Life Remaining Life Granted" } } }, "auth_ref": [] }, "ntrb_ShareBasedCompensationArrangementsByShareBasedPaymentRemainingLifeExercised": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentRemainingLifeExercised", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Life, Exercised", "documentation": "Remaining Life, Exercised.", "label": "Share Based Compensation Arrangements By Share Based Payment Remaining Life Exercised" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r435", "r439", "r458", "r459", "r460", "r461", "r464", "r466", "r467", "r468", "r469" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r47" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r48" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number Exercisable", "verboseLabel": "Purchase warrant (in Shares)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number Outstanding", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": [ "r119", "r120" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Range of Exercise Prices", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r48" ] }, "ntrb_ShareBasedIntrinsicValueExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedIntrinsicValueExercised", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic Value, Exercised", "documentation": "The amount of share based intrinsic value exercised.", "label": "Share Based Intrinsic Value Exercised" } } }, "auth_ref": [] }, "ntrb_ShareBasedIntrinsicValueExpiredCancelled": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedIntrinsicValueExpiredCancelled", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic Value, Expired/Cancelled", "documentation": "Intrinsic Value, Expired/Cancelled.", "label": "Share Based Intrinsic Value Expired Cancelled" } } }, "auth_ref": [] }, "ntrb_ShareBasedPaymentArrangementIntrinsicValueExpiredCancelled": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "ShareBasedPaymentArrangementIntrinsicValueExpiredCancelled", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic Value, Expired/Cancelled", "documentation": "Share based payment arrangement intrinsic value expired.", "label": "Share Based Payment Arrangement Intrinsic Value Expired Cancelled" } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase shares (in Dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expire year", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r826" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r460" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "periodStartLabel": "Intrinsic Value, Outstanding, Beginning balance", "periodEndLabel": "Intrinsic Value, Outstanding, Ending balance", "terseLabel": "Intrinsic Value, Exercisable", "verboseLabel": "Intrinsic Value (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r44" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Life, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r44" ] }, "ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Life, Outstanding beginning balance", "documentation": "Duration of long-term share based compensation arangement by share based payment award options outstanding weighted average remaining contractual term.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Life, Outstanding, Beginning balance", "verboseLabel": "Remaining Life, Outstanding beginning balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r121" ] }, "ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAveragesRemainingContractualTerm2Granted": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAveragesRemainingContractualTerm2Granted", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Life, Granted", "documentation": "Remaining Life, Granted.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Averages Remaining Contractual Term2 Granted" } } }, "auth_ref": [] }, "ntrb_SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life(Years)", "verboseLabel": "Weighted Average Exercise Price for Shares Outstanding", "documentation": "Duration of long-term share based compensation arrangement by share based payment award warrants outstanding weighted average remaining contractual term2", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Warrants Outstanding Weighted Average Remaining Contractual Term2" } } }, "auth_ref": [] }, "ntrb_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic Value, Exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangements By Sharebased Payment Award Option Exercisable Intrinsic Value1" } } }, "auth_ref": [] }, "ntrb_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Life, Outstanding ending balance", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Sharebased Compensation Arrangements By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "ntrb_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining Life, Outstanding, Ending balance", "documentation": "Share-based compensation arrangement by share-based payment award, options, outstanding, weighted average remaining contractual term.", "label": "Sharebased Compensation Arrangements By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted Average Exercise Price for Shares Exercisable (in Dollars per share)", "terseLabel": "Weighted Average Exercise Price for Shares Exercisable", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth_ref": [ "r45" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price for Shares Outstanding (in Dollars per share)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth_ref": [ "r119", "r120" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life (Years)", "verboseLabel": "Weighted Average Life(Years)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r121" ] }, "ntrb_SharesHeldInCompanysEmployeeStockOptionPlanAfterAmendment": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SharesHeldInCompanysEmployeeStockOptionPlanAfterAmendment", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares of common stock (in Shares)", "documentation": "Represent the shares value of shares held in company's employee stock option plan after amendment.", "label": "Shares Held In Companys Employee Stock Option Plan After Amendment" } } }, "auth_ref": [] }, "ntrb_SharesHeldInCompanysEmployeeStockOptionPlanBeforeAmendment": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SharesHeldInCompanysEmployeeStockOptionPlanBeforeAmendment", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock option plan shares (in Shares)", "documentation": "Represent the share of held in company's employee stock option plan before amendment.", "label": "Shares Held In Companys Employee Stock Option Plan Before Amendment" } } }, "auth_ref": [] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in Shares)", "verboseLabel": "Shares issued", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r8" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prices per share (in Dollars per share)", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails", "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r64", "r939", "r940", "r941" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails", "http://nutriband.com/role/NotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r62", "r939", "r940", "r941" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r103", "r229" ] }, "ntrb_SonMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SonMember", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Son [Member]", "label": "Son Member" } } }, "auth_ref": [] }, "ntrb_SorrentoTherapeuticsIncAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SorrentoTherapeuticsIncAgreementMember", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sorrento Therapeutics Inc Agreement [Member]", "label": "Sorrento Therapeutics Inc Agreement Member" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable", "http://nutriband.com/role/ScheduleofSegmentPerformancetotheGAAPMeasureofGrossProfitTable0" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r143", "r144", "r145", "r146", "r194", "r264", "r269", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r283", "r284", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r295", "r296", "r297", "r302", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r346", "r349", "r355", "r356", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r803", "r806", "r807", "r812", "r852", "r994", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1023", "r1024" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r162", "r207", "r208", "r209", "r232", "r256", "r257", "r259", "r261", "r266", "r267", "r308", "r365", "r367", "r368", "r369", "r372", "r373", "r402", "r403", "r406", "r409", "r415", "r522", "r660", "r661", "r662", "r663", "r669", "r670", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r682", "r699", "r722", "r742", "r766", "r767", "r768", "r769", "r770", "r871", "r903", "r913" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/ShareholdersEquityType2or3", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r8", "r75", "r79", "r80", "r192", "r218", "r219", "r220", "r237", "r238", "r239", "r241", "r247", "r250", "r252", "r265", "r309", "r312", "r348", "r417", "r490", "r491", "r497", "r498", "r499", "r501", "r503", "r504", "r509", "r510", "r511", "r512", "r513", "r514", "r517", "r523", "r524", "r525", "r526", "r527", "r528", "r533", "r535", "r543", "r620", "r644", "r645", "r646", "r669", "r742" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0", "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable", "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable0" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r164", "r166", "r169", "r171", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r300", "r301", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r684", "r685", "r686", "r752", "r754", "r758", "r765", "r772", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r783", "r790", "r821", "r836", "r837", "r838", "r839", "r841", "r842", "r843", "r844", "r851", "r860", "r950", "r994", "r996", "r997", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021", "r1023", "r1024" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet", "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r237", "r238", "r239", "r265", "r535", "r563", "r658", "r682", "r691", "r692", "r693", "r694", "r695", "r696", "r699", "r702", "r703", "r704", "r705", "r706", "r708", "r709", "r710", "r711", "r714", "r715", "r716", "r717", "r718", "r720", "r723", "r724", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r742", "r861" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r189", "r253", "r434", "r872", "r873", "r911" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet", "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r237", "r238", "r239", "r265", "r303", "r535", "r563", "r658", "r682", "r691", "r692", "r693", "r694", "r695", "r696", "r699", "r702", "r703", "r704", "r705", "r706", "r708", "r709", "r710", "r711", "r714", "r715", "r716", "r717", "r718", "r720", "r723", "r724", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r742", "r861" ] }, "ntrb_StockIssuedDuringPeriodShareNotePayableAndInterestinShares": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockIssuedDuringPeriodShareNotePayableAndInterestinShares", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for note payable and interest (in Shares)", "documentation": "Issuance of common stock for note payable and interest shares.", "label": "Stock Issued During Period Share Note Payable And Interestin Shares" } } }, "auth_ref": [] }, "ntrb_StockIssuedDuringPeriodShareTreasuryStockAndWarrantsIssuedForTerminationAgreement": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockIssuedDuringPeriodShareTreasuryStockAndWarrantsIssuedForTerminationAgreement", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock and warrants issued for termination agreement (in Shares)", "documentation": "Treasury stock and warrants issued for termination agreement shares.", "label": "Stock Issued During Period Share Treasury Stock And Warrants Issued For Termination Agreement" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of common stock and warrants (in Shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r8", "r74", "r75", "r115", "r660", "r742", "r767" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares received (in Shares)", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase shares (in Shares)", "label": "Stock Issued During Period, Shares, Purchase of Assets", "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable", "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants (in Shares)", "verboseLabel": "Shares, Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r8", "r74", "r75", "r115", "r445" ] }, "ntrb_StockIssuedDuringPeriodSharesStockOptionsSharesExercised": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockIssuedDuringPeriodSharesStockOptionsSharesExercised", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Shares, Exercised", "documentation": "Number of shares stock issued during period shares stock options shares exercised.", "label": "Stock Issued During Period Shares Stock Options Shares Exercised" } } }, "auth_ref": [] }, "ntrb_StockIssuedDuringPeriodSharesTreasuryStockIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockIssuedDuringPeriodSharesTreasuryStockIssuedForServices", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock issued for services (in Shares)", "documentation": "Treasury stock issued for services.", "label": "Stock Issued During Period Shares Treasury Stock Issued For Services" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of common stock and warrants", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r8", "r74", "r75", "r115", "r669", "r742", "r767", "r867" ] }, "ntrb_StockIssuedDuringPeriodValueNotePayableAndInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockIssuedDuringPeriodValueNotePayableAndInterest", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for note payable and interest", "documentation": "Issuance of common stock for note payable and interest.", "label": "Stock Issued During Period Value Note Payable And Interest" } } }, "auth_ref": [] }, "ntrb_StockIssuedDuringPeriodValueReturnedInSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockIssuedDuringPeriodValueReturnedInSettlement", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock returned in settlement", "documentation": "Common stock returned in settlement.", "label": "Stock Issued During Period Value Returned In Settlement" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r8", "r75", "r79", "r80", "r115" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable" ], "lang": { "en-us": { "role": { "terseLabel": "Intrinsic Value, Exercised", "label": "Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)", "documentation": "Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit." } } }, "auth_ref": [] }, "ntrb_StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockIssuedDuringPeriodValueTreasuryStockAndWarrantsIssuedForTerminationAgreement", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock and warrants issued for termination agreement", "documentation": "Treasury stock and warrants issued for termination agreement.", "label": "Stock Issued During Period Value Treasury Stock And Warrants Issued For Termination Agreement" } } }, "auth_ref": [] }, "ntrb_StockIssuedDuringPeriodValueTreasuryStockIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockIssuedDuringPeriodValueTreasuryStockIssuedForServices", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock issued for services", "documentation": "Treasury stock issued for services.", "label": "Stock Issued During Period Value Treasury Stock Issued For Services" } } }, "auth_ref": [] }, "ntrb_StockIssuedDuringPeriodValueTreasuryStockRepurchased": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockIssuedDuringPeriodValueTreasuryStockRepurchased", "crdr": "credit", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock repurchased", "documentation": "Treasury stock repurchased.", "label": "Stock Issued During Period Value Treasury Stock Repurchased" } } }, "auth_ref": [] }, "ntrb_StockIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockIssuedForServices", "crdr": "debit", "presentation": [ "http://nutriband.com/role/ScheduleofDeferredTaxLiabilityandDeferredTaxAssetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Stock issued for services", "documentation": "The amount of Stock issued for services.", "label": "Stock Issued For Services" } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinOptionsOutstandingTable0", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheOptionsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Options [Member]", "verboseLabel": "Options Outstanding [Member]", "netLabel": "Equity Option [Member]", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r860" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase shares", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r8", "r74", "r75", "r115", "r663", "r742", "r769" ] }, "ntrb_StockRepurchasedDuringPeriodSharesTreasuryStockRepurchased": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockRepurchasedDuringPeriodSharesTreasuryStockRepurchased", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock repurchased (in Shares)", "label": "Stock Repurchased During Period Shares Treasury Stock Repurchased" } } }, "auth_ref": [] }, "ntrb_StockbasedCompensationwarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockbasedCompensationwarrants", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation-warrants", "documentation": "The amount of stock-based compensation-warrants.", "label": "Stockbased Compensationwarrants" } } }, "auth_ref": [] }, "ntrb_StockholderEquityNoteStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockholderEquityNoteStockSplit", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward stock split, description", "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.", "label": "Stockholder Equity Note Stock Split" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet", "http://nutriband.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders\u2019 Equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r75", "r79", "r80", "r106", "r701", "r719", "r743", "r744", "r835", "r868", "r905", "r926", "r973", "r1028" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity [Abstract]", "terseLabel": "STOCKHOLDERS\u2019 EQUITY:" } } }, "auth_ref": [] }, "ntrb_StockholdersEquityDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockholdersEquityDetailsLineItems", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity [Line Items]" } } }, "auth_ref": [] }, "ntrb_StockholdersEquityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "StockholdersEquityDetailsTable", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://nutriband.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS\u2019 EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r114", "r231", "r401", "r403", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r417", "r515", "r745", "r747", "r771" ] }, "us-gaap_StockholdersEquityNoteStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteStockSplit", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward stock split, description", "verboseLabel": "Forward stock split", "label": "Stockholders' Equity Note, Stock Split", "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements." } } }, "auth_ref": [ "r116" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forward stock split, description", "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r116" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r529", "r553" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r529", "r553" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r529", "r553" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "ntrb_SubsequentEventsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SubsequentEventsDetailsTable", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://nutriband.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r552", "r554" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails", "http://nutriband.com/role/StockholdersEquityDetails", "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "ntrb_SummaryofSignificantAccountingPoliciesDetailsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Line Items]" } } }, "auth_ref": [] }, "ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable", "presentation": [ "http://nutriband.com/role/ScheduleofPlantandEquipmentonStraightLineBasisOverEstimatedUsefulLifeofAssetsTable" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on Straight-Line Basis Over Estimated Useful Life of Assets [Table]" } } }, "auth_ref": [] }, "ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets [Line Items]" } } }, "auth_ref": [] }, "ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable", "presentation": [ "http://nutriband.com/role/ScheduleofPlantandEquipmentonaStraightLineBasisOvertheEstimatedUsefulLifeoftheAssetsTable" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of Plant and Equipment on a Straight-Line Basis Over the Estimated Useful Life of the Assets [Table]" } } }, "auth_ref": [] }, "ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofRevenuebyGeographicLocationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofRevenuebyGeographicLocationLineItems", "presentation": [ "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Revenue by Geographical Location [Line Items]" } } }, "auth_ref": [] }, "ntrb_SummaryofSignificantAccountingPoliciesDetailsScheduleofRevenuebyGeographicLocationTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofRevenuebyGeographicLocationTable", "presentation": [ "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable", "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable0" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of Revenue by Geographic Location [Table]" } } }, "auth_ref": [] }, "ntrb_SummaryofSignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "auth_ref": [] }, "ntrb_TIIJetServicesLDAMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "TIIJetServicesLDAMember", "presentation": [ "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TII Jet Services LDA [Member]", "label": "TIIJet Services LDAMember" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquitySharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquitySharesIssued", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued warrants (in Shares)", "label": "Temporary Equity, Shares Issued", "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r73" ] }, "ntrb_TerminationExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "TerminationExpenseMember", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination expense [Member]", "label": "Termination Expense Member" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails", "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": [ "r922", "r979" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails", "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]", "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "ntrb_TreasurySharesAndRecordedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "TreasurySharesAndRecordedCompensationExpense", "crdr": "debit", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares and recorded compensation expense (in Dollars)", "documentation": "The amount of treasury shares and recorded compensation expense.", "label": "Treasury Shares And Recorded Compensation Expense" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://nutriband.com/role/ShareholdersEquityType2or3", "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "verboseLabel": "Treasury Stock, Common [Member]", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r40" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r40" ] }, "ntrb_TreasuryStockIssuedForTerminationAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "TreasuryStockIssuedForTerminationAgreement", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock and warrants issued for termination agreement", "documentation": "The amount of treasury stock issued for termination agreement.", "label": "Treasury Stock Issued For Termination Agreement" } } }, "auth_ref": [] }, "ntrb_TreasuryStockPurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "TreasuryStockPurchase", "crdr": "debit", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock share purchase (in Dollars)", "documentation": "Purchase of stock purchase.", "label": "Treasury Stock Purchase" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://nutriband.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://nutriband.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock, value", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r40", "r41", "r75", "r79" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [ "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable", "http://nutriband.com/role/ScheduleofNetSalesandPropertyandEquipmentTable0", "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable", "http://nutriband.com/role/ScheduleofRevenuebyGeographicLocationTable0" ], "lang": { "en-us": { "role": { "terseLabel": "United States [Member]", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ntrb_UnauditedFinancialStatementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://nutriband.com/20240430", "localname": "UnauditedFinancialStatementsPolicyTextBlock", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Unaudited Financial Statements", "documentation": "Accounting policy for unaudited financial statements.", "label": "Unaudited Financial Statements Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://nutriband.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r24", "r25", "r26", "r150", "r151", "r153", "r154" ] }, "ntrb_WarehouseSpace": { "xbrltype": "integerItemType", "nsuri": "http://nutriband.com/20240430", "localname": "WarehouseSpace", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warehouse space", "documentation": "Warehouse space", "label": "Warehouse Space" } } }, "auth_ref": [] }, "us-gaap_WarrantExercisePriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantExercisePriceIncrease", "presentation": [ "http://nutriband.com/role/CommitmentsandContigenciesDetails", "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price per share (in Dollars per share)", "verboseLabel": "Warrants exercisable price (in Dollars per share)", "netLabel": "Exercise of price (in Dollars per share)", "label": "Warrant, Exercise Price, Increase", "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r416" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://nutriband.com/role/OptionsandWarrantsDetails", "http://nutriband.com/role/RelatedPartyTransactionsDetails", "http://nutriband.com/role/ScheduleofAdditionalInformationRelatingtotheWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofChangesinWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable", "http://nutriband.com/role/ScheduleofWarrantsExercisableTable", "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant [Member]", "verboseLabel": "Warrants [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r858", "r859", "r862", "r863", "r864", "r865" ] }, "ntrb_Warrants1Member": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "Warrants1Member", "presentation": [ "http://nutriband.com/role/StockholdersEquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants [Member]", "label": "Warrants1 Member" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://nutriband.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expire date", "label": "Warrants and Rights Outstanding, Maturity Date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r962", "r963", "r964" ] }, "ntrb_WarrantsNumberExercisableinShares": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "WarrantsNumberExercisableinShares", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number Exercisable (in Shares)", "documentation": "Warrant number of exercisable shares.", "label": "Warrants Number Exercisablein Shares" } } }, "auth_ref": [] }, "ntrb_WarrantsNumberOutstandinginShares": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "WarrantsNumberOutstandinginShares", "presentation": [ "http://nutriband.com/role/ScheduleofSummarizesAdditionalInformationRelatingtotheWarrantsOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number Outstanding (in Shares)", "documentation": "Warrant outstanding shares.", "label": "Warrants Number Outstandingin Shares" } } }, "auth_ref": [] }, "ntrb_WarrantsToPurchase": { "xbrltype": "sharesItemType", "nsuri": "http://nutriband.com/20240430", "localname": "WarrantsToPurchase", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants purchase (in Shares)", "documentation": "Warrants to purchase.", "label": "Warrants To Purchase" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares of common stock outstanding - diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r255", "r261" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares of common stock outstanding - basic (in Shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r254", "r261" ] }, "ntrb_WeightedAverageSharesOfCommonStockOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://nutriband.com/20240430", "localname": "WeightedAverageSharesOfCommonStockOutstandingAbstract", "presentation": [ "http://nutriband.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares of common stock outstanding", "label": "Weighted Average Shares Of Common Stock Outstanding Abstract" } } }, "auth_ref": [] }, "ntrb_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://nutriband.com/20240430", "localname": "WorkingCapital", "crdr": "credit", "presentation": [ "http://nutriband.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Working capital", "documentation": "Working capital is the amount of available capital that a company can readily use for day-to-day operations.", "label": "Working Capital" } } }, "auth_ref": [] }, "ntrb_amortizedOverPeriod": { "xbrltype": "durationItemType", "nsuri": "http://nutriband.com/20240430", "localname": "amortizedOverPeriod", "presentation": [ "http://nutriband.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized period", "documentation": "Duration of long-term amortized over period.", "label": "amortized Over Period" } } }, "auth_ref": [] }, "ntrb_newFiniteLivedIntangibleAssetsTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://nutriband.com/20240430", "localname": "newFiniteLivedIntangibleAssetsTwoMember", "presentation": [ "http://nutriband.com/role/ScheduleofIntangibleAssetsTable", "http://nutriband.com/role/ScheduleofIntangibleAssetsTable0" ], "lang": { "en-us": { "role": { "terseLabel": "Intellectual property and trademarks [Member]", "label": "new Finite Lived Intangible Assets Two Member" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(a)", "Paragraph": "4", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-13" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-14" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(14)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(15)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35", "Subparagraph": "(g)", "SubTopic": "235", "Topic": "932", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-35" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "SubTopic": "235", "Topic": "932", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-35A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Form 20-F", "Number": "Part II", "Section": "Item 18", "Subparagraph": "(Instruction 2)", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "M", "Paragraph": "Question 2", "Publisher": "SEC" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478609/920-350-50-4" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-35A" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-35A" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-25" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r791": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r795": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-34" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-7" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-7" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r871": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r872": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r873": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher": "SEC" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "6", "Subsection": "04", "Paragraph": "12", "Subparagraph": "(b)(1)", "Publisher": "SEC" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-16" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479048/940-320-50-1" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } }